"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Simple Family Members,Simple Family Member Jurisdictions,Extended Family Size,Extended Family Members,Extended Family Member Jurisdictions,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,EP,A1,EP 3711758 A1,175-848-266-125-914,2020-09-23,2020,EP 18878222 A,2018-11-13,KR 20170151248 A;;KR 2018013761 W,2017-11-14,"USE OF CARBAMATE COMPOUND FOR PREVENTING, ALLEVIATING OR TREATING ABSENCE SEIZURE OR EPILEPSY SHOWING ABSENCE SEIZURE","The present invention relates to a use of a carbamate compound represented by chemical formula 1, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof for preventing, alleviating or treating absence seizure or epilepsy showing absence seizure.",SK BIOPHARMACEUTICALS CO LTD,SHIN HYE WON,,https://lens.org/175-848-266-125-914,Patent Application,yes,0,0,27,095-418-251-758-452;;172-016-358-273-69X;;076-848-262-066-276;;135-481-838-122-470;;098-543-216-736-719;;086-571-364-434-926;;000-725-273-383-720;;056-496-205-069-225;;153-947-887-303-504;;058-375-562-836-105;;006-707-689-459-29X;;036-594-672-948-003;;175-848-266-125-914;;180-295-791-525-434;;030-642-208-724-01X;;099-848-387-400-56X;;015-109-212-500-52X;;026-234-878-168-692;;152-734-280-865-740;;011-181-861-380-530;;096-866-746-743-864;;043-369-112-902-472;;063-745-038-278-465;;141-748-827-420-509;;063-479-285-377-285;;080-616-656-930-540;;027-314-878-690-911,RU;;CA;;JP;;KR;;PT;;PL;;CN;;ES;;AU;;DK;;FI;;BR;;WO;;MX;;US;;IL;;EP,27,095-418-251-758-452;;172-016-358-273-69X;;076-848-262-066-276;;135-481-838-122-470;;098-543-216-736-719;;086-571-364-434-926;;000-725-273-383-720;;056-496-205-069-225;;153-947-887-303-504;;058-375-562-836-105;;006-707-689-459-29X;;036-594-672-948-003;;175-848-266-125-914;;180-295-791-525-434;;030-642-208-724-01X;;099-848-387-400-56X;;015-109-212-500-52X;;026-234-878-168-692;;152-734-280-865-740;;011-181-861-380-530;;096-866-746-743-864;;043-369-112-902-472;;063-745-038-278-465;;141-748-827-420-509;;063-479-285-377-285;;080-616-656-930-540;;027-314-878-690-911,RU;;CA;;JP;;KR;;PT;;PL;;CN;;ES;;AU;;DK;;FI;;BR;;WO;;MX;;US;;IL;;EP,0,A61K31/41;;A61P25/08;;A61K31/41;;A61K31/16;;A61P25/08;;A61K31/41;;A61K31/16;;A61P25/08;;A61K31/41,A61K31/41;;A61K31/16,,0,0,,,,ACTIVE
2,EP,B1,EP 3711758 B1,026-234-878-168-692,2024-03-27,2024,EP 18878222 A,2018-11-13,KR 20170151248 A;;KR 2018013761 W,2017-11-14,"USE OF CARBAMATE COMPOUND FOR PREVENTING, ALLEVIATING OR TREATING ABSENCE SEIZURE OR EPILEPSY SHOWING ABSENCE SEIZURE",,SK BIOPHARMACEUTICALS CO LTD,SHIN HYE WON,,https://lens.org/026-234-878-168-692,Granted Patent,yes,8,0,27,095-418-251-758-452;;172-016-358-273-69X;;076-848-262-066-276;;135-481-838-122-470;;098-543-216-736-719;;086-571-364-434-926;;000-725-273-383-720;;056-496-205-069-225;;153-947-887-303-504;;058-375-562-836-105;;006-707-689-459-29X;;036-594-672-948-003;;175-848-266-125-914;;180-295-791-525-434;;030-642-208-724-01X;;099-848-387-400-56X;;015-109-212-500-52X;;026-234-878-168-692;;152-734-280-865-740;;011-181-861-380-530;;096-866-746-743-864;;043-369-112-902-472;;063-745-038-278-465;;141-748-827-420-509;;063-479-285-377-285;;080-616-656-930-540;;027-314-878-690-911,RU;;CA;;JP;;KR;;PT;;PL;;CN;;ES;;AU;;DK;;FI;;BR;;WO;;MX;;US;;IL;;EP,27,095-418-251-758-452;;172-016-358-273-69X;;076-848-262-066-276;;135-481-838-122-470;;098-543-216-736-719;;086-571-364-434-926;;000-725-273-383-720;;056-496-205-069-225;;153-947-887-303-504;;058-375-562-836-105;;006-707-689-459-29X;;036-594-672-948-003;;175-848-266-125-914;;180-295-791-525-434;;030-642-208-724-01X;;099-848-387-400-56X;;015-109-212-500-52X;;026-234-878-168-692;;152-734-280-865-740;;011-181-861-380-530;;096-866-746-743-864;;043-369-112-902-472;;063-745-038-278-465;;141-748-827-420-509;;063-479-285-377-285;;080-616-656-930-540;;027-314-878-690-911,RU;;CA;;JP;;KR;;PT;;PL;;CN;;ES;;AU;;DK;;FI;;BR;;WO;;MX;;US;;IL;;EP,0,A61K31/41;;A61P25/08;;A61K31/41;;A61K31/16;;A61P25/08;;A61K31/41;;A61K31/16;;A61P25/08;;A61K31/41,A61K31/41;;A61K31/16;;A61P25/08;;A61P25/10,,16,16,036-449-495-631-839;;127-383-991-065-645;;053-279-259-339-315;;040-041-838-630-885;;033-810-217-802-066;;005-417-407-303-464;;092-409-304-367-057;;088-975-736-647-978;;104-868-911-812-235;;056-518-408-577-152;;004-001-377-853-979;;003-793-220-100-823;;008-387-721-476-405;;102-270-499-630-915;;061-442-537-366-127;;058-256-121-381-414,27505294;;10.1016/j.eplepsyres.2016.05.016;;10.1111/epi.13671;;28276064;;10.1016/b978-3-437-42523-3.00011-7;;29076416;;10.2174/1381612823666171024143541;;17304346;;10.1111/j.1535-7511.2007.00156.x;;pmc1797888;;26916017;;10.2174/1381612822666160226144200;;10.1038/nrd4126;;24052047;;23219031;;10.1016/j.eplepsyres.2012.10.001;;10.1007/978-1-4939-6774-2_19;;10.1016/j.eplepsyres.2015.01.001;;25769377;;10.2174/1381612823666170809100524;;28799516;;28017578;;10.1016/j.seizure.2016.11.022;;24635129;;pmc4027953;;10.1021/cb500108p;;pmc6112605;;28865303;;10.1016/j.eplepsyres.2017.08.013;;19337447;;pmc2646636;;10.2147/ndt.s1668;;20092980;;10.1016/j.eplepsyres.2009.12.005,"LÖSCHER WOLFGANG: ""Fit for purpose application of currently existing animal models in the discovery of novel epilepsy therapies"", EPILEPSY RESEARCH, ELSEVIER SCIENCE PUBLISHERS , AMSTERDAM, NL, vol. 126, 1 August 2016 (2016-08-01), pages 157 - 184, XP029709265, ISSN: 0920-1211, DOI: 10.1016/J.EPLEPSYRES.2016.05.016;;ROBERT S. FISHER; J. HELEN CROSS; CAROL D'SOUZA; JACQUELINE A. FRENCH; SHERYL R. HAUT; NORIMICHI HIGURASHI; EDOUARD HIRSCH; FLOOR : ""Instruction manual for the ILAE 2017 operational classification of seizure types"", EPILEPSIA, vol. 58, no. 4, 8 March 2017 (2017-03-08), New York , US , pages 531 - 542, XP071213725, ISSN: 0013-9580, DOI: 10.1111/epi.13671;;KLAUS AKTORIES , ULRICH FÖRSTERMANN , FRANZ HOFMANN , KLAUS STARKE: ""Allgemeine und spezielle Pharmakologie und Toxikologie"", 1 January 2013, ELSEVIER URBAN & FISCHER, ISBN: 978-3-437-42523-3, article T.J. FEUERSTEIN: ""Kapitel 11 - Antikonvulsiva, Konvulsiva – Pharmakotherapie der Epilepsien"", pages: 269 - 279, XP093252923, DOI: 10.1016/C2012-0-06299-0;;ESKIOGLOU ELISSAVET, PERRENOUD MATTHIEU P., RYVLIN PHILIPPE, NOVY JAN: ""Novel Treatment and New Drugs in Epilepsy Treatment"", CURRENT PHARMACEUTICAL DESIGN, vol. 23, no. 42, 15 February 2018 (2018-02-15), NL , pages 6389 - 6398, XP093252924, ISSN: 1381-6128, DOI: 10.2174/1381612823666171024143541;;CARL E STAFSTROM: "" Persistent Sodium Current and Its Role in Epilepsy"", EPILEPSY CURRENTS, vol. 7, no. 1, 1 January 2007 (2007-01-01), pages 15 - 22, XP055337014, DOI: 10.1111/j.1535-7511.2007.00156.x;;SHIKHA KUMARI, CHANDRA BHUSHAN MISHRA , MANISHA TIWARI: ""Polypharmacological Drugs in the Treatment of Epilepsy: The Comprehensive Review of Marketed and New Emerging Molecules"", CURRENT PHARMACEUTICAL DESIGN , vol. 22, no. 21, 1 January 2016 (2016-01-01), pages 3212 - 3225, XP093252928, ISSN: 1381-6128, DOI: 10.2174/1381612822666160226144200;;WOLFGANG LÖSCHER, HENRIK KLITGAARD, ROY E. TWYMAN, DIETER SCHMIDT: ""New avenues for anti-epileptic drug discovery and development"", NATURE REVIEWS DRUG DISCOVERY, vol. 12, no. 10, 1 October 2013 (2013-10-01), GB , pages 757 - 776, XP055253606, ISSN: 1474-1776, DOI: 10.1038/nrd4126;;BIALER, MEIR: ""Progress report on new antiepileptic drugs: A summary of the Eleventh Eilat Conference (EILAT XI)"", EPILEPSY RESEARCH, vol. 103, 1 January 2013 (2013-01-01), XP055691206, DOI: 10.1016/j.eplepsyres.2012.10.001;;MOHAMAD Z. KOUBEISSI, NABIL J. AZAR: ""Epilepsy Board Review"", 28 June 2017, SPRINGER, New York, ISBN: 978-1-4939-6772-8, article BASSEL ABOU-KHALIL: ""Other Pharmacological Therapies: Investigational Antiepileptic Drugs, Animal Models of Epilepsy, Hormonal Therapy, Immunotherapy"", pages: 241 - 245, XP093252936, DOI: 10.1007/978-1-4939-6774-2_19;;MEIR BIALER: ""Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII)"", EPILEPSY RESEARCH, vol. 111, 1 March 2015 (2015-03-01), NL , pages 85 - 141, XP055611172, ISSN: 0920-1211, DOI: 10.1016/j.eplepsyres.2015.01.001;;GAETANO ZACCARA, D. SCHMIDT: ""Antiepileptic Drugs in Clinical Development: Differentiate or Die?"", CURRENT PHARMACEUTICAL DESIGN, vol. 23, no. 37, 9 February 2018 (2018-02-09), NL , pages 5593 - 5605, XP055507491, ISSN: 1381-6128, DOI: 10.2174/1381612823666170809100524;;GOLYALA AMBICA; KWAN PATRICK: ""Drug development for refractory epilepsy: The past 25 years and beyond"", SEIZURE, vol. 44, 6 December 2016 (2016-12-06), GB , pages 147 - 156, XP029901803, ISSN: 1059-1311, DOI: 10.1016/j.seizure.2016.11.022;;JOHN GILCHRIST , STACEY DUTTON , MARCELO DIAZ-BUSTAMANTE , ANNIE MCPHERSON , NICOLAS OLIVARES , JEET KALIA , ANDREW ESCAYG ,FRANK : ""Na v 1.1 Modulation by a Novel Triazole Compound Attenuates Epileptic Seizures in Rodents"", ACS CHEMICAL BIOLOGY, vol. 9, no. 5, 16 May 2014 (2014-05-16), pages 1204 - 1212, XP055362820, ISSN: 1554-8929, DOI: 10.1021/cb500108p;;KANG JING-QIONG: ""Defects at the crossroads of GABAergic signaling in generalized genetic epilepsies"", EPILEPSY RESEARCH (AUTHOR MANUSCRIPT), vol. 137, 1 November 2017 (2017-11-01), NL , pages 1 - 24, XP093252943, ISSN: 0920-1211, DOI: 10.1016/j.eplepsyres.2017.08.013;;KENOU VAN RIJCKEVORSEL: ""Treatment of Lennox-Gastaut syndrome: overview and recent findings"", NEUROPSYCHIATRIC DISEASE AND TREATMENT, vol. 4, no. 6, 1 December 2008 (2008-12-01), pages 1001 - 1019, XP093252950, DOI: 10.2147/ndt.s1668;;OZLEM AKMAN , TAMER DEMIRALP , NURBAY ATES , FILIZ YILMAZ ONAT: ""Electroencephalographic differences between WAG/Rij and GAERS rat models of absence epilepsy"", EPILEPSY RESEARCH, vol. 89, no. 2-3, 1 May 2010 (2010-05-01), NL , pages 185 - 193, XP026996985, ISSN: 0920-1211, DOI: 10.1016/j.eplepsyres.2009.12.005",ACTIVE
3,JP,A,JP 2023085469 A,098-543-216-736-719,2023-06-20,2023,JP 2023061633 A,2023-04-05,JP 2020544727 A;;KR 20170151248 A;;KR 2018013761 W,2017-11-14,"USE OF CARBAMATE COMPOUND FOR PREVENTING, ALLEVIATING OR TREATING ABSENCE SEIZURE OR EPILEPSY SHOWING ABSENCE SEIZURE","To provide a medicine used for preventing, alleviating or treating absence seizure or epilepsy showing absence seizure.SOLUTION: The present invention relates to a medicine containing a carbamate compound of formula (1), or a pharmaceutically acceptable salt, a solvate or a hydrate thereof for preventing, alleviating or treating epilepsy showing absence seizure. The epilepsy showing absence seizures is selected from the group consisting of child absence epilepsy, epilepsy with myoclonic absence, juvenile absence epilepsy, juvenile myoclonic epilepsy, Jeavons syndrome (eyelid myoclonia with absence), and genetic generalized epilepsy with phantom absence.SELECTED DRAWING: None",SK BIOPHARMACEUTICALS CO LTD,SHIN HYE WON,,https://lens.org/098-543-216-736-719,Patent Application,no,0,0,27,095-418-251-758-452;;172-016-358-273-69X;;076-848-262-066-276;;135-481-838-122-470;;098-543-216-736-719;;086-571-364-434-926;;000-725-273-383-720;;056-496-205-069-225;;153-947-887-303-504;;058-375-562-836-105;;006-707-689-459-29X;;036-594-672-948-003;;175-848-266-125-914;;180-295-791-525-434;;030-642-208-724-01X;;099-848-387-400-56X;;015-109-212-500-52X;;026-234-878-168-692;;152-734-280-865-740;;011-181-861-380-530;;096-866-746-743-864;;043-369-112-902-472;;063-745-038-278-465;;141-748-827-420-509;;063-479-285-377-285;;080-616-656-930-540;;027-314-878-690-911,RU;;CA;;JP;;KR;;PT;;PL;;CN;;ES;;AU;;DK;;FI;;BR;;WO;;MX;;US;;IL;;EP,27,095-418-251-758-452;;172-016-358-273-69X;;076-848-262-066-276;;135-481-838-122-470;;098-543-216-736-719;;086-571-364-434-926;;000-725-273-383-720;;056-496-205-069-225;;153-947-887-303-504;;058-375-562-836-105;;006-707-689-459-29X;;036-594-672-948-003;;175-848-266-125-914;;180-295-791-525-434;;030-642-208-724-01X;;099-848-387-400-56X;;015-109-212-500-52X;;026-234-878-168-692;;152-734-280-865-740;;011-181-861-380-530;;096-866-746-743-864;;043-369-112-902-472;;063-745-038-278-465;;141-748-827-420-509;;063-479-285-377-285;;080-616-656-930-540;;027-314-878-690-911,RU;;CA;;JP;;KR;;PT;;PL;;CN;;ES;;AU;;DK;;FI;;BR;;WO;;MX;;US;;IL;;EP,0,A61K31/41;;A61P25/08;;A61K31/41;;A61K31/16;;A61P25/08;;A61K31/41;;A61K31/16;;A61P25/08;;A61K31/41,A61K31/41;;A61K9/08;;A61K9/10;;A61K9/14;;A61K9/16;;A61K9/20;;A61K9/48;;A61P25/08,,0,0,,,,ACTIVE
4,US,A1,US 2020/0352907 A1,096-866-746-743-864,2020-11-12,2020,US 201816763636 A,2018-11-13,KR 20170151248 A;;KR 2018013761 W,2017-11-14,"Use Of Carbamate Compound For Preventing, Alleviating Or Treating Absence Seizure Or Epilepsy Showing Absence Seizure","The present invention relates to a use of a carbamate compound represented by chemical formula 1, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof for preventing, alleviating or treating absence seizure or epilepsy showing absence seizure.",SK BIOPHARMACEUTICALS CO LTD,SHIN HYE WON,SK BIOPHARMACEUTICALS CO. LTD (2020-05-22),https://lens.org/096-866-746-743-864,Patent Application,yes,1,0,27,095-418-251-758-452;;172-016-358-273-69X;;076-848-262-066-276;;135-481-838-122-470;;098-543-216-736-719;;086-571-364-434-926;;000-725-273-383-720;;056-496-205-069-225;;153-947-887-303-504;;058-375-562-836-105;;006-707-689-459-29X;;036-594-672-948-003;;175-848-266-125-914;;180-295-791-525-434;;030-642-208-724-01X;;099-848-387-400-56X;;015-109-212-500-52X;;026-234-878-168-692;;152-734-280-865-740;;011-181-861-380-530;;096-866-746-743-864;;043-369-112-902-472;;063-745-038-278-465;;141-748-827-420-509;;063-479-285-377-285;;080-616-656-930-540;;027-314-878-690-911,RU;;CA;;JP;;KR;;PT;;PL;;CN;;ES;;AU;;DK;;FI;;BR;;WO;;MX;;US;;IL;;EP,27,095-418-251-758-452;;172-016-358-273-69X;;076-848-262-066-276;;135-481-838-122-470;;098-543-216-736-719;;086-571-364-434-926;;000-725-273-383-720;;056-496-205-069-225;;153-947-887-303-504;;058-375-562-836-105;;006-707-689-459-29X;;036-594-672-948-003;;175-848-266-125-914;;180-295-791-525-434;;030-642-208-724-01X;;099-848-387-400-56X;;015-109-212-500-52X;;026-234-878-168-692;;152-734-280-865-740;;011-181-861-380-530;;096-866-746-743-864;;043-369-112-902-472;;063-745-038-278-465;;141-748-827-420-509;;063-479-285-377-285;;080-616-656-930-540;;027-314-878-690-911,RU;;CA;;JP;;KR;;PT;;PL;;CN;;ES;;AU;;DK;;FI;;BR;;WO;;MX;;US;;IL;;EP,0,A61K31/41;;A61P25/08;;A61K31/41;;A61K31/16;;A61P25/08;;A61K31/41;;A61K31/16;;A61P25/08;;A61K31/41,A61K31/41;;A61P25/08,,6,5,102-270-499-630-915;;056-518-408-577-152;;008-387-721-476-405;;102-270-499-630-915;;061-442-537-366-127,pmc6112605;;10.1016/j.eplepsyres.2017.08.013;;28865303;;25769377;;10.1016/j.eplepsyres.2015.01.001;;10.1021/cb500108p;;24635129;;pmc4027953;;pmc6112605;;10.1016/j.eplepsyres.2017.08.013;;28865303;;19337447;;10.2147/ndt.s1668;;pmc2646636,"Kang (Epilepsy Research 137 (2017) 9–18, Available online 26 August 2017);;Rijckevorsel (Neuropsychiatr Dis Treat. 2008 Dec; 4(6): 1001–1019);;M. Bialer, et al. Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII), Epilepsy Research, 2015, V. 111, IS. 0920-1211, P. 85-141, doi.org/10.1016/j.eplepsyres.2015.01.001. (Year: 2015);;Gilchrist J, et al. Nav1.1 modulation by a novel triazole compound attenuates epileptic seizures in rodents. ACS Chem Biol. 2014 May 16;9(5):1204-12. doi: 10.1021/cb500108p. (Year: 2014);;J. Kang, Defects at the crossroads of GABAergic signaling in generalized genetic epilepsies, Epilepsy Research, 2017, Volume 137, Pages 9-18, ISSN 0920-1211, doi.org/10.1016/j.eplepsyres.2017.08.013. (Available online 26 August 2017). (Year: 2017);;V. Rijckevorsel K. Treatment of Lennox-Gastaut syndrome: overview and recent findings. Neuropsychiatr Dis Treat. 2008 Dec;4(6):1001-19. doi: 10.2147/ndt.s1668. (Year: 2008)",PENDING
5,TW,A,TW 201717929 A,010-950-856-027-860,2017-06-01,2017,TW 105116059 A,2016-05-23,KR 20150071996 A,2015-05-22,"Medicament comprising carisbamate, and its use for prevention, relief or treatment of pain or epilepsy","The present invention relates to a medicament comprising carisbamate, and its use for preventing, relieving or treating pain or epilepsy, in more detail, to a medicament and a pharmaceutical composition comprising at least one selected from gabapentin and pregabalin with carisbamate, and its use for preventing, relieving or treating pain or epilepsy.",SK BIOPHARMACEUTICALS CO LTD,YI HAN-JU;;HWANG SUN-GWAN;;JO MIN-JAE,,https://lens.org/010-950-856-027-860,Patent of Addition,no,0,0,3,010-950-856-027-860;;016-967-837-165-431;;103-855-602-445-639,KR;;WO;;TW,3,010-950-856-027-860;;016-967-837-165-431;;103-855-602-445-639,KR;;WO;;TW,0,A61K9/00;;A61K31/195;;A61K31/197;;A61K31/27;;A61K31/195;;A61K9/0019;;A61K9/0021;;A61K31/197;;A61K31/27,A61K31/195;;A61K31/197;;A61K31/27;;A61P25/04;;A61P25/08,,0,0,,,,PENDING
6,WO,A1,WO 2016/190638 A1,016-967-837-165-431,2016-12-01,2016,KR 2016005441 W,2016-05-23,KR 20150071996 A,2015-05-22,"MEDICAMENT COMPRISING CARISBAMATE, AND USE THEREOF FOR PREVENTION, ALLEVIATION OR TREATMENT OF PAIN OR EPILEPSY","The present invention relates to a medicament comprising carisbamate, and use thereof for prevention, alleviation or treatment of pain or epilepsy and, more specifically, relates to a medicament and a pharmaceutical composition comprising: carisbamate; and at least one selected from among gabapentin and pregabalin, and use thereof for treating pain or epilepsy.",SK BIOPHARMACEUTICALS CO LTD,YI HAN JU;;HWANG SUN GWAN;;JO MIN JAE,,https://lens.org/016-967-837-165-431,Patent Application,yes,2,4,3,010-950-856-027-860;;016-967-837-165-431;;103-855-602-445-639,KR;;WO;;TW,3,010-950-856-027-860;;016-967-837-165-431;;103-855-602-445-639,KR;;WO;;TW,0,A61K9/00;;A61K31/195;;A61K31/197;;A61K31/27;;A61K31/195;;A61K9/0019;;A61K9/0021;;A61K31/197;;A61K31/27,A61K31/195;;A61K9/00;;A61K31/197;;A61K31/27,,3,3,036-914-602-923-53X;;034-677-395-068-42X;;010-336-763-199-356,10.1111/papr.12080;;23692321;;17199023;;10.1016/j.nurt.2006.11.016;;pmc7479705;;19222595;;10.1111/j.1526-4610.2008.01326.x,"SMITH, T. MD ET AL.: ""Efficacy and Safety of Carisbamate in Patients with Diabetic Neuropathy or Postherpetic Neuralgia: Results from 3 Randomized, Double-Blind Placebo-Controlled Trials"", PAIN PRACT., vol. 14, no. 4, 2014, pages 332 - 342, XP055332726;;NOVAK, G. P. ET AL.: ""Carisbamate (RWJ-333369"", NEUROTHERAPEUTICS, vol. 4, no. 1, January 2007 (2007-01-01), pages 106 - 109, XP005735284;;CADY, R. K. MD ET AL.: ""Evaluation of Carisbamate for the Treatment of Migraine in a Randomized, Double-Blind Trial"", AMERICAN HEADACHE SOCIETY, vol. 49, no. 2, February 2009 (2009-02-01), pages 216 - 226, XP055332727",PENDING
7,KR,A,KR 20160137443 A,103-855-602-445-639,2016-11-30,2016,KR 20160062690 A,2016-05-23,KR 20150071996 A,2015-05-22,MEDICAMENT COMPRISING CARISBAMATE AND ITS USE FOR PREVENTION RELIEF OR TREATMENT OF PAIN OR EPILEPSY,"The present invention relates to a medicament comprising carisbamate, and uses for treatment of pain or epilepsy and, more specifically, to a medicament and a pharmaceutical composition comprising carisbamate and one or more selected from gabapentin and pregabalin, and to uses for treatment of pain or epilepsy.",SK BIOPHARMACEUTICALS CO LTD,YI HAN JU;;HWANG SUN GWAN;;JO MIN JAE,,https://lens.org/103-855-602-445-639,Patent Application,no,0,0,3,010-950-856-027-860;;016-967-837-165-431;;103-855-602-445-639,KR;;WO;;TW,3,010-950-856-027-860;;016-967-837-165-431;;103-855-602-445-639,KR;;WO;;TW,0,A61K9/00;;A61K31/195;;A61K31/197;;A61K31/27;;A61K31/195;;A61K9/0019;;A61K9/0021;;A61K31/197;;A61K31/27,A61K31/195;;A61K9/00;;A61K31/197;;A61K31/27,,0,0,,,,DISCONTINUED
8,CN,A,CN 111432812 A,058-375-562-836-105,2020-07-17,2020,CN 201880073833 A,2018-11-13,KR 20170151248 A;;KR 2018013761 W,2017-11-14,"USE OF CARBAMATE COMPOUND FOR PREVENTING, ALLEVIATING OR TREATING ABSENCE SEIZURE OR EPILEPSY SHOWING ABSENCE SEIZURE","The present invention relates to a use of a carbamate compound represented by chemical formula 1, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof for preventing, alleviating or treating absence seizure or epilepsy showing absence seizure.",SK BIOPHARMACEUTICALS CO LTD,SHIN HYE WON,,https://lens.org/058-375-562-836-105,Patent Application,no,3,1,27,095-418-251-758-452;;172-016-358-273-69X;;076-848-262-066-276;;135-481-838-122-470;;098-543-216-736-719;;086-571-364-434-926;;000-725-273-383-720;;056-496-205-069-225;;153-947-887-303-504;;058-375-562-836-105;;006-707-689-459-29X;;036-594-672-948-003;;175-848-266-125-914;;180-295-791-525-434;;030-642-208-724-01X;;099-848-387-400-56X;;015-109-212-500-52X;;026-234-878-168-692;;152-734-280-865-740;;011-181-861-380-530;;096-866-746-743-864;;043-369-112-902-472;;063-745-038-278-465;;141-748-827-420-509;;063-479-285-377-285;;080-616-656-930-540;;027-314-878-690-911,RU;;CA;;JP;;KR;;PT;;PL;;CN;;ES;;AU;;DK;;FI;;BR;;WO;;MX;;US;;IL;;EP,27,095-418-251-758-452;;172-016-358-273-69X;;076-848-262-066-276;;135-481-838-122-470;;098-543-216-736-719;;086-571-364-434-926;;000-725-273-383-720;;056-496-205-069-225;;153-947-887-303-504;;058-375-562-836-105;;006-707-689-459-29X;;036-594-672-948-003;;175-848-266-125-914;;180-295-791-525-434;;030-642-208-724-01X;;099-848-387-400-56X;;015-109-212-500-52X;;026-234-878-168-692;;152-734-280-865-740;;011-181-861-380-530;;096-866-746-743-864;;043-369-112-902-472;;063-745-038-278-465;;141-748-827-420-509;;063-479-285-377-285;;080-616-656-930-540;;027-314-878-690-911,RU;;CA;;JP;;KR;;PT;;PL;;CN;;ES;;AU;;DK;;FI;;BR;;WO;;MX;;US;;IL;;EP,0,A61K31/41;;A61P25/08;;A61K31/41;;A61K31/16;;A61P25/08;;A61K31/41;;A61K31/16;;A61P25/08;;A61K31/41,A61K31/41;;A61K31/16,,2,2,056-518-408-577-152;;003-793-220-100-823,25769377;;10.1016/j.eplepsyres.2015.01.001;;10.1016/j.seizure.2016.11.022;;28017578,"BIALER M, ET AL.: ""Progress report on new antiepileptic drugs: a summary of the Twelfth Eilat Conference (EILAT XII)"", 《EPILEPSY RESEARCH》;;GOLYALA A, KWAN P.: ""Drug development for refractory epilepsy: the past 25 years and beyond"", 《SEIZURE》",PENDING
9,CA,A1,CA 3081223 A1,056-496-205-069-225,2019-05-23,2019,CA 3081223 A,2018-11-13,KR 20170151248 A;;KR 2018013761 W,2017-11-14,"USE OF CARBAMATE COMPOUND FOR PREVENTING, ALLEVIATING OR TREATING ABSENCE SEIZURE OR EPILEPSY SHOWING ABSENCE SEIZURE","The present invention relates to a use of a carbamate compound represented by chemical formula 1, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof for preventing, alleviating or treating absence seizure or epilepsy showing absence seizure.",SK BIOPHARMACEUTICALS CO LTD,SHIN HYE WON,,https://lens.org/056-496-205-069-225,Patent Application,no,0,0,27,095-418-251-758-452;;172-016-358-273-69X;;076-848-262-066-276;;135-481-838-122-470;;098-543-216-736-719;;086-571-364-434-926;;000-725-273-383-720;;056-496-205-069-225;;153-947-887-303-504;;058-375-562-836-105;;006-707-689-459-29X;;036-594-672-948-003;;175-848-266-125-914;;180-295-791-525-434;;030-642-208-724-01X;;099-848-387-400-56X;;015-109-212-500-52X;;026-234-878-168-692;;152-734-280-865-740;;011-181-861-380-530;;096-866-746-743-864;;043-369-112-902-472;;063-745-038-278-465;;141-748-827-420-509;;063-479-285-377-285;;080-616-656-930-540;;027-314-878-690-911,RU;;CA;;JP;;KR;;PT;;PL;;CN;;ES;;AU;;DK;;FI;;BR;;WO;;MX;;US;;IL;;EP,27,095-418-251-758-452;;172-016-358-273-69X;;076-848-262-066-276;;135-481-838-122-470;;098-543-216-736-719;;086-571-364-434-926;;000-725-273-383-720;;056-496-205-069-225;;153-947-887-303-504;;058-375-562-836-105;;006-707-689-459-29X;;036-594-672-948-003;;175-848-266-125-914;;180-295-791-525-434;;030-642-208-724-01X;;099-848-387-400-56X;;015-109-212-500-52X;;026-234-878-168-692;;152-734-280-865-740;;011-181-861-380-530;;096-866-746-743-864;;043-369-112-902-472;;063-745-038-278-465;;141-748-827-420-509;;063-479-285-377-285;;080-616-656-930-540;;027-314-878-690-911,RU;;CA;;JP;;KR;;PT;;PL;;CN;;ES;;AU;;DK;;FI;;BR;;WO;;MX;;US;;IL;;EP,0,A61K31/41;;A61P25/08;;A61K31/41;;A61K31/16;;A61P25/08;;A61K31/41;;A61K31/16;;A61P25/08;;A61K31/41,A61K31/41;;A61K31/16,,0,0,,,,PENDING
10,MX,A,MX 2020004972 A,153-947-887-303-504,2020-08-24,2020,MX 2020004972 A,2018-11-13,KR 20170151248 A;;KR 2018013761 W,2017-11-14,"USE OF CARBAMATE COMPOUND FOR PREVENTING, ALLEVIATING OR TREATING ABSENCE SEIZURE OR EPILEPSY SHOWING ABSENCE SEIZURE.","The present invention relates to a use of a carbamate compound represented by chemical formula 1, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof for preventing, alleviating or treating absence seizure or epilepsy showing absence seizure.",SK BIOPHARMACEUTICALS CO LTD,SHIN HYE WON,,https://lens.org/153-947-887-303-504,Patent Application,no,0,0,27,095-418-251-758-452;;172-016-358-273-69X;;076-848-262-066-276;;135-481-838-122-470;;098-543-216-736-719;;086-571-364-434-926;;000-725-273-383-720;;056-496-205-069-225;;153-947-887-303-504;;058-375-562-836-105;;006-707-689-459-29X;;036-594-672-948-003;;175-848-266-125-914;;180-295-791-525-434;;030-642-208-724-01X;;099-848-387-400-56X;;015-109-212-500-52X;;026-234-878-168-692;;152-734-280-865-740;;011-181-861-380-530;;096-866-746-743-864;;043-369-112-902-472;;063-745-038-278-465;;141-748-827-420-509;;063-479-285-377-285;;080-616-656-930-540;;027-314-878-690-911,RU;;CA;;JP;;KR;;PT;;PL;;CN;;ES;;AU;;DK;;FI;;BR;;WO;;MX;;US;;IL;;EP,27,095-418-251-758-452;;172-016-358-273-69X;;076-848-262-066-276;;135-481-838-122-470;;098-543-216-736-719;;086-571-364-434-926;;000-725-273-383-720;;056-496-205-069-225;;153-947-887-303-504;;058-375-562-836-105;;006-707-689-459-29X;;036-594-672-948-003;;175-848-266-125-914;;180-295-791-525-434;;030-642-208-724-01X;;099-848-387-400-56X;;015-109-212-500-52X;;026-234-878-168-692;;152-734-280-865-740;;011-181-861-380-530;;096-866-746-743-864;;043-369-112-902-472;;063-745-038-278-465;;141-748-827-420-509;;063-479-285-377-285;;080-616-656-930-540;;027-314-878-690-911,RU;;CA;;JP;;KR;;PT;;PL;;CN;;ES;;AU;;DK;;FI;;BR;;WO;;MX;;US;;IL;;EP,0,A61K31/41;;A61P25/08;;A61K31/41;;A61K31/16;;A61P25/08;;A61K31/41;;A61K31/16;;A61P25/08;;A61K31/41,A61K31/41;;A61K31/16,,0,0,,,,PENDING
11,WO,A1,WO 2019/098628 A1,135-481-838-122-470,2019-05-23,2019,KR 2018013761 W,2018-11-13,KR 20170151248 A,2017-11-14,"USE OF CARBAMATE COMPOUND FOR PREVENTING, ALLEVIATING OR TREATING ABSENCE SEIZURE OR EPILEPSY SHOWING ABSENCE SEIZURE","The present invention relates to a use of a carbamate compound represented by chemical formula 1, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof for preventing, alleviating or treating absence seizure or epilepsy showing absence seizure.",SK BIOPHARMACEUTICALS CO LTD,SHIN HYE WON,,https://lens.org/135-481-838-122-470,Patent Application,yes,6,1,27,095-418-251-758-452;;172-016-358-273-69X;;076-848-262-066-276;;135-481-838-122-470;;098-543-216-736-719;;086-571-364-434-926;;000-725-273-383-720;;056-496-205-069-225;;153-947-887-303-504;;058-375-562-836-105;;006-707-689-459-29X;;036-594-672-948-003;;175-848-266-125-914;;180-295-791-525-434;;030-642-208-724-01X;;099-848-387-400-56X;;015-109-212-500-52X;;026-234-878-168-692;;152-734-280-865-740;;011-181-861-380-530;;096-866-746-743-864;;043-369-112-902-472;;063-745-038-278-465;;141-748-827-420-509;;063-479-285-377-285;;080-616-656-930-540;;027-314-878-690-911,RU;;CA;;JP;;KR;;PT;;PL;;CN;;ES;;AU;;DK;;FI;;BR;;WO;;MX;;US;;IL;;EP,27,095-418-251-758-452;;172-016-358-273-69X;;076-848-262-066-276;;135-481-838-122-470;;098-543-216-736-719;;086-571-364-434-926;;000-725-273-383-720;;056-496-205-069-225;;153-947-887-303-504;;058-375-562-836-105;;006-707-689-459-29X;;036-594-672-948-003;;175-848-266-125-914;;180-295-791-525-434;;030-642-208-724-01X;;099-848-387-400-56X;;015-109-212-500-52X;;026-234-878-168-692;;152-734-280-865-740;;011-181-861-380-530;;096-866-746-743-864;;043-369-112-902-472;;063-745-038-278-465;;141-748-827-420-509;;063-479-285-377-285;;080-616-656-930-540;;027-314-878-690-911,RU;;CA;;JP;;KR;;PT;;PL;;CN;;ES;;AU;;DK;;FI;;BR;;WO;;MX;;US;;IL;;EP,0,A61K31/41;;A61P25/08;;A61K31/41;;A61K31/16;;A61P25/08;;A61K31/41;;A61K31/16;;A61P25/08;;A61K31/41,A61K31/41;;A61K31/16,,12,12,056-518-408-577-152;;003-793-220-100-823;;036-473-105-155-17X;;016-533-196-567-191;;157-684-837-258-50X;;015-280-833-960-940;;020-329-241-682-903;;031-418-999-629-181;;015-981-831-612-485;;010-109-739-351-004;;073-122-292-552-855;;059-834-363-809-776,25769377;;10.1016/j.eplepsyres.2015.01.001;;10.1016/j.seizure.2016.11.022;;28017578;;pmc2924476;;10.1056/nejmoa0902014;;20200383;;10.1053/seiz.1999.0303;;10486298;;10.1016/j.jneumeth.2015.05.022;;26068173;;21093310;;10.1016/j.seizure.2010.10.011;;8402164;;10.1016/0006-8993(93)90421-i;;15795547;;10.1097/01.wnf.0000159955.87511.bc;;10.1038/sj.bjp.0706791;;16865096;;pmc1752009;;16337109;;10.1016/j.eplepsyres.2005.11.001;;12151117;;10.1016/s0920-1211(02)00068-2;;12575471,"BIALER, M. ET AL.: ""Progress Report on new Antiepileptic Drugs: A Summary of the Twelfth Eilat Conference (EILAT XII"", EPILEPSY RESEARCH, vol. 1, no. 11, 2015, pages 85 - 141, XP055608941;;GOLYALA, A. ET AL.: ""Drug Development for Refractory Epilepsy: The Past 25 Years and Beyond"", SEIZURE, vol. 44, January 2017 (2017-01-01), pages 147 - 156, XP029901803, DOI: doi:10.1016/j.seizure.2016.11.022;;GLAUSER ET AL.: ""Ethosuximide, Valproic Acid, and Lamotrigine in Childhood Absence Epilepsy"", NEW ENGLAND JOURNAL OF MEDICINE, vol. 362, no. 9, 2010, pages 790 - 9;;KNAKE ET AL.: ""Tiagabine-induced absence status in idiopathic generalized epilepsy"", EUROPEAN JOURNAL OF EPILEPSY, vol. 8, no. 5, 8 August 1999 (1999-08-08), pages 314 - 317;;DEPAULIS ET AL.: ""The genetic absence epilepsy rat from Strasbourg as a model to decipher the neuronal and network mechanisms of generalized idiopathic epilepsies"", J NEUROSCI METHODS, vol. 260, 15 February 2016 (2016-02-15), pages 159 - 74, XP029405999, DOI: 10.1016/j.jneumeth.2015.05.022;;DEDEURWAERDERE ET AL.: ""Fluctuating and constant valproate administration gives equivalent seizure control in rats with genetic and acquired epilepsy"", SEIZURE, vol. 20, no. 1, January 2011 (2011-01-01), pages 72 - 9, XP027570829;;NEHLIG ET AL.: ""Cerebral energy metabolism in rats with genetic absence epilepsy is not correlated with the pharmacological increase or suppression of spike-wave discharges"", BRAIN RES., vol. 618, no. 1, 30 July 1993 (1993-07-30), pages 1 - 8, XP024282154, DOI: 10.1016/0006-8993(93)90421-I;;WALLENGREN ET AL.: ""Aggravation of absence seizures by carbamazepine in a genetic rat model does not induce neuronal c-Fos activation"", CLIN NEUROPHARMACOL., vol. 28, no. 2, March 2005 (2005-03-01), pages 60 - 5;;GURBANOVA ET AL.: ""Effect of systemic and intracortical administration of phenytoin in two genetic models of absence epilepsy"", BR J PHARMACOL., vol. 148, no. 8, August 2006 (2006-08-01), pages 1076 - 82;;VARTANIAN ET AL.: ""Activity profile of pregabalin in rodent models of epilepsy and ataxia"", EPILEPSY RES., vol. 68, no. 3, March 2006 (2006-03-01), pages 189 - 205, XP025114989, DOI: 10.1016/j.eplepsyres.2005.11.001;;KLITGAARD ET AL.: ""Use of epileptic animals for adverse effect testing"", EPILEPSY RES., vol. 50, no. 1-2, June 2002 (2002-06-01), pages 55 - 65;;VAN LUIJTELAAR ELDRINKENBURG WHVAN RIJN CMCOENEN AM: ""Rat models of genetic absence epilepsy: what do EEG spike-wave discharges tell us about drug effects?"", METHODS FIND EXP CLIN PHARMACOL., vol. 24, no. D, 2002, pages 65 - 70",PENDING
12,AU,A1,AU 2018/367729 A1,030-642-208-724-01X,2020-05-21,2020,AU 2018/367729 A,2018-11-13,KR 20170151248 A;;KR 2018013761 W,2017-11-14,"Use of carbamate compound for preventing, alleviating or treating absence seizure or epilepsy showing absence seizure","The present invention relates to a use of a carbamate compound represented by chemical formula 1, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof for preventing, alleviating or treating absence seizure or epilepsy showing absence seizure.",SK BIOPHARMACEUTICALS CO LTD,SHIN HYE WON,,https://lens.org/030-642-208-724-01X,Patent Application,no,0,0,27,095-418-251-758-452;;172-016-358-273-69X;;076-848-262-066-276;;135-481-838-122-470;;098-543-216-736-719;;086-571-364-434-926;;000-725-273-383-720;;056-496-205-069-225;;153-947-887-303-504;;058-375-562-836-105;;006-707-689-459-29X;;036-594-672-948-003;;175-848-266-125-914;;180-295-791-525-434;;030-642-208-724-01X;;099-848-387-400-56X;;015-109-212-500-52X;;026-234-878-168-692;;152-734-280-865-740;;011-181-861-380-530;;096-866-746-743-864;;043-369-112-902-472;;063-745-038-278-465;;141-748-827-420-509;;063-479-285-377-285;;080-616-656-930-540;;027-314-878-690-911,RU;;CA;;JP;;KR;;PT;;PL;;CN;;ES;;AU;;DK;;FI;;BR;;WO;;MX;;US;;IL;;EP,27,095-418-251-758-452;;172-016-358-273-69X;;076-848-262-066-276;;135-481-838-122-470;;098-543-216-736-719;;086-571-364-434-926;;000-725-273-383-720;;056-496-205-069-225;;153-947-887-303-504;;058-375-562-836-105;;006-707-689-459-29X;;036-594-672-948-003;;175-848-266-125-914;;180-295-791-525-434;;030-642-208-724-01X;;099-848-387-400-56X;;015-109-212-500-52X;;026-234-878-168-692;;152-734-280-865-740;;011-181-861-380-530;;096-866-746-743-864;;043-369-112-902-472;;063-745-038-278-465;;141-748-827-420-509;;063-479-285-377-285;;080-616-656-930-540;;027-314-878-690-911,RU;;CA;;JP;;KR;;PT;;PL;;CN;;ES;;AU;;DK;;FI;;BR;;WO;;MX;;US;;IL;;EP,0,A61K31/41;;A61P25/08;;A61K31/41;;A61K31/16;;A61P25/08;;A61K31/41;;A61K31/16;;A61P25/08;;A61K31/41,A61K31/41;;A61K31/16,,0,0,,,,ACTIVE
13,AU,B2,AU 2018/367729 B2,152-734-280-865-740,2024-06-13,2024,AU 2018/367729 A,2018-11-13,KR 20170151248 A;;KR 2018013761 W,2017-11-14,"Use of carbamate compound for preventing, alleviating or treating absence seizure or epilepsy showing absence seizure","The present invention relates to a use of a carbamate compound represented by chemical formula 1, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof for preventing, alleviating or treating absence seizure or epilepsy showing absence seizure.",SK BIOPHARMACEUTICALS CO LTD,SHIN HYE WON,,https://lens.org/152-734-280-865-740,Granted Patent,no,0,0,27,095-418-251-758-452;;172-016-358-273-69X;;076-848-262-066-276;;135-481-838-122-470;;098-543-216-736-719;;086-571-364-434-926;;000-725-273-383-720;;056-496-205-069-225;;153-947-887-303-504;;058-375-562-836-105;;006-707-689-459-29X;;036-594-672-948-003;;175-848-266-125-914;;180-295-791-525-434;;030-642-208-724-01X;;099-848-387-400-56X;;015-109-212-500-52X;;026-234-878-168-692;;152-734-280-865-740;;011-181-861-380-530;;096-866-746-743-864;;043-369-112-902-472;;063-745-038-278-465;;141-748-827-420-509;;063-479-285-377-285;;080-616-656-930-540;;027-314-878-690-911,RU;;CA;;JP;;KR;;PT;;PL;;CN;;ES;;AU;;DK;;FI;;BR;;WO;;MX;;US;;IL;;EP,27,095-418-251-758-452;;172-016-358-273-69X;;076-848-262-066-276;;135-481-838-122-470;;098-543-216-736-719;;086-571-364-434-926;;000-725-273-383-720;;056-496-205-069-225;;153-947-887-303-504;;058-375-562-836-105;;006-707-689-459-29X;;036-594-672-948-003;;175-848-266-125-914;;180-295-791-525-434;;030-642-208-724-01X;;099-848-387-400-56X;;015-109-212-500-52X;;026-234-878-168-692;;152-734-280-865-740;;011-181-861-380-530;;096-866-746-743-864;;043-369-112-902-472;;063-745-038-278-465;;141-748-827-420-509;;063-479-285-377-285;;080-616-656-930-540;;027-314-878-690-911,RU;;CA;;JP;;KR;;PT;;PL;;CN;;ES;;AU;;DK;;FI;;BR;;WO;;MX;;US;;IL;;EP,0,A61K31/41;;A61P25/08;;A61K31/41;;A61K31/16;;A61P25/08;;A61K31/41;;A61K31/16;;A61P25/08;;A61K31/41,A61K31/41;;A61K31/16,,0,0,,,,ACTIVE
14,US,A1,US 2023/0293489 A1,143-294-121-284-524,2023-09-21,2023,US 202318134203 A,2023-04-13,US 202318134203 A;;US 202017037932 A;;US 201916348630 A;;KR 2019003294 W;;US 201862646043 P,2018-03-21,USE OF [(1R)-1-(2-CHLOROPHENYL)-2-(TETRAZOL-2-YL)ETHYL] CARBAMATE IN COMBINATION THERAPY,The present disclosure provides combination therapy using [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate (cenobamate) and one or more antiepileptic drugs for the prevention or treatment of a neurological disorder such as epilepsy.,SK BIOPHARMACEUTICALS CO LTD,KAMIN MARC;;VERNILLET LAURENT,,https://lens.org/143-294-121-284-524,Patent Application,yes,0,0,7,079-763-211-354-725;;143-294-121-284-524;;014-855-218-612-811;;041-178-417-286-063;;159-862-453-603-660;;082-511-235-306-637;;121-926-653-240-439,WO;;US;;EP,7,079-763-211-354-725;;143-294-121-284-524;;014-855-218-612-811;;041-178-417-286-063;;159-862-453-603-660;;082-511-235-306-637;;121-926-653-240-439,WO;;US;;EP,0,A61K31/515;;A61K31/19;;A61K31/4015;;A61K31/41;;A61K31/4166;;A61K31/53;;A61K31/55;;A61K45/06;;A61P25/00;;A61K31/41;;A61K31/4166;;A61K31/515;;A61K31/53;;A61K31/55;;A61P25/08,A61K31/41;;A61K31/4166;;A61K31/515;;A61K31/53;;A61K31/55;;A61P25/08,,0,0,,,,PENDING
15,EP,B1,EP 2214637 B1,093-752-459-993-321,2013-05-08,2013,EP 08843347 A,2008-10-31,IB 2008003331 W;;US 98414407 P,2007-10-31,STABILIZED PEDIATRIC SUSPENSION OF CARISBAMATE,,SK BIOPHARMACEUTICALS CO LTD,EMBRECHTS ROGER;;DE LEERSNIJDER CEDRIC,"SK BIOPHARMACEUTICALS CO., LTD (2012-04-11)",https://lens.org/093-752-459-993-321,Granted Patent,yes,1,0,45,159-516-822-737-188;;040-245-016-852-096;;040-396-512-596-78X;;136-179-622-675-024;;032-262-165-909-820;;023-012-761-894-962;;155-504-418-632-516;;121-405-562-545-17X;;144-325-189-916-052;;019-981-338-213-670;;073-883-683-736-009;;105-520-197-837-708;;013-201-034-883-247;;105-972-285-891-795;;151-893-743-218-93X;;094-149-172-560-22X;;034-012-308-776-30X;;022-521-355-363-284;;093-752-459-993-321;;151-344-301-196-639;;095-497-761-003-445;;072-033-840-567-492;;156-658-975-310-219;;007-013-520-063-978;;087-798-926-602-198;;169-513-077-811-155;;018-566-154-564-674;;004-901-672-182-825;;064-101-233-865-545;;140-581-159-677-430;;195-599-680-964-597;;180-692-465-797-580;;026-265-607-683-002;;111-092-477-236-068;;173-050-548-549-55X;;091-001-366-009-655;;165-184-116-879-794;;165-651-624-073-99X;;043-323-131-136-319;;144-274-517-083-663;;163-120-758-498-402;;182-497-281-003-263;;033-345-284-779-58X;;071-113-377-559-012;;001-681-502-396-600,CA;;EC;;KR;;PA;;ES;;NI;;TW;;US;;CO;;JP;;UY;;ZA;;CN;;PL;;CL;;MY;;CR;;AU;;BR;;EA;;MX;;WO;;PE;;AR;;EP;;IL,45,033-345-284-779-58X;;040-245-016-852-096;;040-396-512-596-78X;;159-516-822-737-188;;136-179-622-675-024;;032-262-165-909-820;;155-504-418-632-516;;121-405-562-545-17X;;144-325-189-916-052;;019-981-338-213-670;;073-883-683-736-009;;105-520-197-837-708;;013-201-034-883-247;;105-972-285-891-795;;151-893-743-218-93X;;094-149-172-560-22X;;034-012-308-776-30X;;022-521-355-363-284;;093-752-459-993-321;;151-344-301-196-639;;095-497-761-003-445;;072-033-840-567-492;;156-658-975-310-219;;007-013-520-063-978;;087-798-926-602-198;;169-513-077-811-155;;018-566-154-564-674;;004-901-672-182-825;;064-101-233-865-545;;140-581-159-677-430;;195-599-680-964-597;;180-692-465-797-580;;026-265-607-683-002;;111-092-477-236-068;;173-050-548-549-55X;;091-001-366-009-655;;165-184-116-879-794;;165-651-624-073-99X;;043-323-131-136-319;;144-274-517-083-663;;163-120-758-498-402;;182-497-281-003-263;;001-681-502-396-600;;071-113-377-559-012;;023-012-761-894-962,CA;;EC;;KR;;PA;;ES;;NI;;TW;;US;;CO;;JP;;UY;;ZA;;CN;;PL;;CL;;MY;;CR;;AU;;BR;;EA;;MX;;WO;;PE;;AR;;EP;;IL,0,A61K31/325;;A61K9/0095;;A61K31/27;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/14;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P29/00;;A61K31/325;;A61K9/0095;;A61K31/27;;A61K47/12;;A61K47/26;;A61K47/36;;A61K47/38,A61K9/00;;A61K31/27,,0,0,,,,ACTIVE
16,US,A1,US 2019/0365709 A1,079-763-211-354-725,2019-12-05,2019,US 201916348630 A,2019-03-21,US 201916348630 A;;US 201862646043 P;;KR 2019003294 W,2018-03-21,Use Of [(1R)-1-(2-Chlorophenyl)-2-(Tetrazol-2-YL)Ethyl] Carbamate In Combination Therapy,The present disclosure provides combination therapy using [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate (cenobamate) and one or more antiepileptic drugs for the prevention or treatment of a neurological disorder such as epilepsy.,SK BIOPHARMACEUTICALS CO LTD,KAMIN MARC;;VERNILLET LAURENT,SK BIOPHARMACEUTICALS CO. LTD (2019-04-25),https://lens.org/079-763-211-354-725,Patent Application,yes,0,0,7,079-763-211-354-725;;143-294-121-284-524;;014-855-218-612-811;;041-178-417-286-063;;159-862-453-603-660;;082-511-235-306-637;;121-926-653-240-439,WO;;US;;EP,7,079-763-211-354-725;;143-294-121-284-524;;014-855-218-612-811;;041-178-417-286-063;;159-862-453-603-660;;082-511-235-306-637;;121-926-653-240-439,WO;;US;;EP,0,A61K31/515;;A61K31/19;;A61K31/4015;;A61K31/41;;A61K31/4166;;A61K31/53;;A61K31/55;;A61K45/06;;A61P25/00;;A61K31/41;;A61K31/4166;;A61K31/515;;A61K31/53;;A61K31/55;;A61P25/08,A61K31/41;;A61K31/4166;;A61K31/515;;A61K31/53;;A61K31/55;;A61P25/08,,3,2,003-793-220-100-823;;020-651-645-217-966,10.1016/j.seizure.2016.11.022;;28017578;;10.1684/epd.2014.0714;;25515681,"Krauss Seizure freedom with YKP3089 as adjunctive therapy for refractory partial-onset seizure in double-blind placebo-controlled trial, Neurology, 2016, Vol. 86, 16 supplement, IDS;;Golyala Drug development for refractory epilepsy The past 25 years and beyond, Seizure, 2017, Vol. 44, pp 147-156;;Zaccara et al Interaction between antiepileptic drug, and between antiepileptic drugs and other drugs, Epileptic Disord. 2014, Vol. 36 no 4, pp 409-431, IDS",DISCONTINUED
17,WO,A1,WO 2019/182376 A1,159-862-453-603-660,2019-09-26,2019,KR 2019003294 W,2019-03-21,US 201862646043 P,2018-03-21,USE OF [(1R)-1-(2-CHLOROPHENYL)-2-(TETRAZOL-2-YL)ETHYL] CARBAMATE IN COMBINATION THERAPY,The present disclosure provides combination therapy using [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate (cenobamate) and one or more antiepileptic drugs for the prevention or treatment of a neurological disorder such as epilepsy.,SK BIOPHARMACEUTICALS CO LTD,KAMIN MARC;;VERNILLET LAURENT,,https://lens.org/159-862-453-603-660,Patent Application,yes,1,0,7,079-763-211-354-725;;143-294-121-284-524;;014-855-218-612-811;;041-178-417-286-063;;159-862-453-603-660;;082-511-235-306-637;;121-926-653-240-439,WO;;US;;EP,7,079-763-211-354-725;;143-294-121-284-524;;014-855-218-612-811;;041-178-417-286-063;;159-862-453-603-660;;082-511-235-306-637;;121-926-653-240-439,WO;;US;;EP,0,A61K31/515;;A61K31/41;;A61K31/55;;A61K31/4166;;A61P25/00;;A61K45/06;;A61K31/53;;A61K31/4015;;A61K31/19;;A61P25/08;;A61K31/41;;A61K31/4166;;A61K31/515;;A61K31/53;;A61K31/55,A61K31/41;;A61K31/4166;;A61K31/4196;;A61K31/515;;A61K31/55;;A61P25/00,,5,1,020-651-645-217-966,10.1684/epd.2014.0714;;25515681,"KIM SUN-YOUNG: ""Viva100] SK Biopharm' s new antiepileptic drug, 'Cenobamate' is about to be commercialized... It aims at 1 trillion won in annual sales, the world' s No. 1 'Vimpat"", VIVA 100 > HEALTH, 7 December 2017 (2017-12-07), pages 1 - 3, XP009523682, Retrieved from the Internet <URL:http://www.viva100.com/main/view.php?key=20171205010001659>;;GREGORY KRAUSS, JACQUELINE FRENCH, MARC KAMIN, PALANICHAMY ILANKUMARAN: ""Seizure freedom with YKP3089as adjunctive therapy for refractory partial-onset seizures in double-blind placebo- controlled trials (P2.019"", NEUROLOGY, vol. 86, no. 16, 4 April 2016 (2016-04-04), XP009523686, ISSN: 0028-3878;;GAETANO ZACCARA; EMILIO PERUCCA: ""Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs"", EPILEPTIC DISORDERS, vol. 16, no. 4, 31 December 2014 (2014-12-31), pages 409 - 431, XP055636311, ISSN: 1294-9361, DOI: 10.1684/epd.2014.0714;;VERNILLET, L.; KAMIN, M.: ""Drug-drug interactions between cenobamate and other antiepileptic drugs: Results from phase 1 studies with carbamazepine, phenobarbital, phenytoin, and divalproex sodium"", AMERICAN SOCIETY FOR CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 103, no. S1, 7 February 2018 (2018-02-07), Orlando, FL. , USA, pages S91 - S97, XP009523795, ISSN: 1532-6535;;See also references of EP 3768257A4",PENDING
18,US,B2,US 11654133 B2,041-178-417-286-063,2023-05-23,2023,US 202017037932 A,2020-09-30,US 202017037932 A;;US 201916348630 A;;KR 2019003294 W;;US 201862646043 P,2018-03-21,Use of [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate in combination therapy,The present disclosure provides combination therapy using [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate (cenobamate) and one or more antiepileptic drugs for the prevention or treatment of a neurological disorder such as epilepsy.,SK BIOPHARMACEUTICALS CO LTD,KAMIN MARC;;VERNILLET LAURENT,YAHOO AD TECH LLC (2021-11-02);;SK BIOPHARMACEUTICALS CO. LTD (2019-04-25),https://lens.org/041-178-417-286-063,Granted Patent,yes,1,0,7,079-763-211-354-725;;143-294-121-284-524;;014-855-218-612-811;;041-178-417-286-063;;159-862-453-603-660;;082-511-235-306-637;;121-926-653-240-439,WO;;US;;EP,7,079-763-211-354-725;;143-294-121-284-524;;014-855-218-612-811;;041-178-417-286-063;;159-862-453-603-660;;082-511-235-306-637;;121-926-653-240-439,WO;;US;;EP,0,A61K31/515;;A61K31/19;;A61K31/4015;;A61K31/41;;A61K31/4166;;A61K31/53;;A61K31/55;;A61K45/06;;A61P25/00;;A61K31/41;;A61K31/4166;;A61K31/515;;A61K31/53;;A61K31/55;;A61P25/08,A61K31/41;;A61K31/4166;;A61K31/515;;A61K31/53;;A61K31/55;;A61P25/08,,15,5,106-672-643-350-051;;004-001-377-853-979;;020-651-645-217-966;;047-209-982-725-265;;003-793-220-100-823,7227222;;10.2165/00003495-198121050-00005;;28799516;;10.2174/1381612823666170809100524;;10.1684/epd.2014.0714;;25515681;;17957935;;10.1016/j.seizure.2016.11.022;;28017578,"Reynolds, E. H., et al.; “Single Drug or Combination Therapy for Epilepsy?”, Drugs, 1981, vol. 21, pp. 374-382.;;Zaccara, G., et al.; “Antiepileptic Drugs in Clinical Development: Differentiate or Die?”, Current Pharmaceutical Design., 2017, vol. 23, pp. 5593-5605.;;Extended European Search Report from corresponding European Patent Application No. 19771303.5, dated Dec. 9, 2021.;;International Search Report from corresponding PCT Application No. PCT/KR2019/003294, dated Jul. 3, 2019.;;“[Viva100] SK Biopharm's new antiepileptic drug, ‘Cenobamate’ is about to be commercialized . . . It aims at 1 trillion won in annual sales, the world's No. 1 ‘Vimpat’.” Bridge Economic (Online newspaper), Dec. 7, 2017, pp. 1-3, Retrieved from <URL: http://www.viva100.com/main/view.php?key=20171205010001659>.;;Krauss, Gregory et al., “Seizure freedom with YKP3089as adjunctive therapy for refractory partial-onset seizures in double-blind placebo controlled trials (P2.019).” Neurology, 2016, vol. 86, Suppl. 16, Retrieved from <URL: https://n.neurology.org/content/86/16_Supplement/P2.019>.;;Zaccara, Gaetano et al., “Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs.” Epileptic Disorders, 2014, vol. 16, No. 4, pp. 409-431.;;Vernillet, L. et al., “Drug-drug interactions between Cenobamate and other antiepileptic drugs: Results from phase 1 studies with carbamazepine, phenobarbital, phenytoin, and divalproex sodium.” American Society for Clinical Pharmacology & Therapeutics, Abstracts of 2018 Annual Meeting; Mar. 21-24, 2018 (First published: Feb. 7, 2018), Orlando, FL., USA, pp. S5-S97.;;Sperling, M. R., et al.; “Safety of Cenobamate (YKP3089) as Adjunctive Treatment for Uncontrolled Partial (Focal) Seizures: Results From a Large, Phase 3, Multicenter, Open-Label Study”, Presented at the American Epilepsy Society Annual Meeting, Nov. 30-Dec. 4, 2018, New Orleans, LA, USA, poster.;;Kamin, M., et al.; “Time to Onset of Efficacy in Seizure Reduction With Cenobamate (YKP3089) in Patients With Uncontrolled Partial Seizures From Two Randomized Clinical Trials”, Presented at the American Epilepsy Society Annual Meeting, Nov. 30-Dec. 4, 2018, New Orleans, LA, USA, poster.;;Incecayir, T., et al.; “Bioavailability File: Lamotrigine”, FABAD J. Pharm. Sci., 31, pp. 163-179, 2006.;;Rojanasthien, N., et al.; “Effect of Doses on the Bioavailability of Phenytoin from a Prompt-Release and an Extended-Release Preparation: Single Dose Study”, J Med Assoc Thai 2007; 90 (9): 1883-93.;;Vernillet, L., et al.; “Drug-Drug Interactions Between Cenobamate and Other Antiepileptic Drugs: Results From Phase I Studies With Carbamazepine, Phenobarbital, Phenytoin, and Divalproex Sodium”, Presented at the Annual Meeting of the American Society for Clinical Pharmacology & Therapeutics (ASCPT 2018), Mar. 21-24, 2018, Orlando, FL., poster.;;Golyala et al., “Drug development for refractory epilepsy: The past 25 years and beyond”, Seizure, 2017, vol. 44, pp. 147-156.;;Office Action (Non-Final) from corresponding U.S. Appl. No. 16/348,630, dated Apr. 1, 2020.",ACTIVE
19,US,A1,US 2021/0008033 A1,082-511-235-306-637,2021-01-14,2021,US 202017037932 A,2020-09-30,US 202017037932 A;;US 201916348630 A;;KR 2019003294 W;;US 201862646043 P,2018-03-21,Use Of [(1R)-1-(2-Chlorophenyl)-2-(Tetrazol-2-YL)Ethyl] Carbamate In Combination Therapy,The present disclosure provides combination therapy using [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate (cenobamate) and one or more antiepileptic drugs for the prevention or treatment of a neurological disorder such as epilepsy.,SK BIOPHARMACEUTICALS CO LTD,KAMIN MARC;;VERNILLET LAURENT,YAHOO AD TECH LLC (2021-11-02);;SK BIOPHARMACEUTICALS CO. LTD (2019-04-25),https://lens.org/082-511-235-306-637,Patent Application,yes,0,0,7,079-763-211-354-725;;143-294-121-284-524;;014-855-218-612-811;;041-178-417-286-063;;159-862-453-603-660;;082-511-235-306-637;;121-926-653-240-439,WO;;US;;EP,7,079-763-211-354-725;;143-294-121-284-524;;014-855-218-612-811;;041-178-417-286-063;;159-862-453-603-660;;082-511-235-306-637;;121-926-653-240-439,WO;;US;;EP,0,A61K31/515;;A61K31/19;;A61K31/4015;;A61K31/41;;A61K31/4166;;A61K31/53;;A61K31/55;;A61K45/06;;A61P25/00;;A61K31/41;;A61K31/4166;;A61K31/515;;A61K31/53;;A61K31/55;;A61P25/08,A61K31/41;;A61K31/4166;;A61K31/515;;A61K31/53;;A61K31/55;;A61P25/08,,0,0,,,,ACTIVE
20,US,A1,US 2016/0008476 A1,001-681-502-396-600,2016-01-14,2016,US 201514858583 A,2015-09-18,US 201514858583 A;;US 201213570853 A;;US 25849008 A;;US 98414407 P,2007-10-31,STABILIZED PEDIATRIC SUSPENSION OF CARISBAMATE,"The present invention provides a stabilized pharmaceutical suspension of carisbamate for pediatric and adult use. More particularly, the suspension is stabilized with hypromellose (HPMC) to prevent crystal growth of the suspended particles and to prevent re-crystallization of the drug product with change in polymorphic form.",SK BIOPHARMACEUTICALS CO LTD,EMBRECHTS ROGER;;DE LEERSNIJDER CEDRIC,,https://lens.org/001-681-502-396-600,Patent Application,yes,1,6,45,159-516-822-737-188;;040-245-016-852-096;;040-396-512-596-78X;;136-179-622-675-024;;032-262-165-909-820;;023-012-761-894-962;;155-504-418-632-516;;121-405-562-545-17X;;144-325-189-916-052;;019-981-338-213-670;;073-883-683-736-009;;105-520-197-837-708;;013-201-034-883-247;;105-972-285-891-795;;151-893-743-218-93X;;094-149-172-560-22X;;034-012-308-776-30X;;022-521-355-363-284;;093-752-459-993-321;;151-344-301-196-639;;095-497-761-003-445;;072-033-840-567-492;;156-658-975-310-219;;007-013-520-063-978;;087-798-926-602-198;;169-513-077-811-155;;018-566-154-564-674;;004-901-672-182-825;;064-101-233-865-545;;140-581-159-677-430;;195-599-680-964-597;;180-692-465-797-580;;026-265-607-683-002;;111-092-477-236-068;;173-050-548-549-55X;;091-001-366-009-655;;165-184-116-879-794;;165-651-624-073-99X;;043-323-131-136-319;;144-274-517-083-663;;163-120-758-498-402;;182-497-281-003-263;;033-345-284-779-58X;;071-113-377-559-012;;001-681-502-396-600,CA;;EC;;KR;;PA;;ES;;NI;;TW;;US;;CO;;JP;;UY;;ZA;;CN;;PL;;CL;;MY;;CR;;AU;;BR;;EA;;MX;;WO;;PE;;AR;;EP;;IL,45,033-345-284-779-58X;;040-245-016-852-096;;040-396-512-596-78X;;159-516-822-737-188;;136-179-622-675-024;;032-262-165-909-820;;155-504-418-632-516;;121-405-562-545-17X;;144-325-189-916-052;;019-981-338-213-670;;073-883-683-736-009;;105-520-197-837-708;;013-201-034-883-247;;105-972-285-891-795;;151-893-743-218-93X;;094-149-172-560-22X;;034-012-308-776-30X;;022-521-355-363-284;;093-752-459-993-321;;151-344-301-196-639;;095-497-761-003-445;;072-033-840-567-492;;156-658-975-310-219;;007-013-520-063-978;;087-798-926-602-198;;169-513-077-811-155;;018-566-154-564-674;;004-901-672-182-825;;064-101-233-865-545;;140-581-159-677-430;;195-599-680-964-597;;180-692-465-797-580;;026-265-607-683-002;;111-092-477-236-068;;173-050-548-549-55X;;091-001-366-009-655;;165-184-116-879-794;;165-651-624-073-99X;;043-323-131-136-319;;144-274-517-083-663;;163-120-758-498-402;;182-497-281-003-263;;001-681-502-396-600;;071-113-377-559-012;;023-012-761-894-962,CA;;EC;;KR;;PA;;ES;;NI;;TW;;US;;CO;;JP;;UY;;ZA;;CN;;PL;;CL;;MY;;CR;;AU;;BR;;EA;;MX;;WO;;PE;;AR;;EP;;IL,0,A61K31/325;;A61K9/0095;;A61K31/27;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/14;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P29/00;;A61K31/325;;A61K9/0095;;A61K31/27;;A61K47/12;;A61K47/26;;A61K47/36;;A61K47/38,A61K47/36;;A61K31/325,,0,0,,,,DISCONTINUED
21,US,B2,US 12070448 B2,076-785-153-510-088,2024-08-27,2024,US 201917277856 A,2019-09-20,US 201917277856 A;;US 201862734406 P;;KR 2019012184 W,2018-09-21,"Use of carbamate compound for prevention, alleviation or treatment of status epilepticus","The present invention relates to a use for the purpose of preventing, alleviating, or treating status epilepticus by administering a medicament or pharmaceutical composition comprising a carbamate compound of chemical formula 1.",SK BIOPHARMACEUTICALS CO LTD,CHOI EUN JU;;SHIN HYE WON;;SHIN YU JIN,SK BIOPHARMACEUTICALS CO. LTD (2021-03-16),https://lens.org/076-785-153-510-088,Granted Patent,yes,7,0,11,095-192-663-747-961;;158-219-377-523-79X;;008-336-260-217-389;;011-174-825-787-178;;134-034-736-963-905;;196-674-732-660-194;;076-785-153-510-088;;069-900-525-135-010;;111-127-472-538-662;;003-906-004-716-306;;136-319-502-988-001,CA;;JP;;KR;;WO;;US;;CN;;EP,11,095-192-663-747-961;;158-219-377-523-79X;;008-336-260-217-389;;069-900-525-135-010;;196-674-732-660-194;;134-034-736-963-905;;076-785-153-510-088;;011-174-825-787-178;;111-127-472-538-662;;003-906-004-716-306;;136-319-502-988-001,CA;;JP;;KR;;WO;;US;;CN;;EP,0,A61P31/00;;A61P9/10;;A61K31/41;;A61P35/00;;A61P3/00;;A61K31/41;;A61P9/10;;A61P3/00;;A61P31/00;;A61P35/00;;A61P25/08;;A61K31/41,A61K31/41;;A61P25/08,,5,3,088-975-736-647-978;;056-518-408-577-152;;078-207-787-645-038,23219031;;10.1016/j.eplepsyres.2012.10.001;;25769377;;10.1016/j.eplepsyres.2015.01.001;;10.1212/wnl.86.16_supplement.p2.019,"M. Bialer et al., Epilepsy Research, 2013, vol. 103, pp. 2-30.;;Tenkan, Epilepsy Treatment Guideline, 2018, pp. 76-90.;;International Search Report from corresponding PCT Application No. PCT/KR2019/012184, dated Dec. 30, 2019.;;Bialer, M. et al. Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII). Epilepsy Research 2015, vol. 11I, pp. 85-141.;;Krauss, G. et al. Seizure Freedom with YKP3089 as Adjunctive Therapy for Refractory Partial-Onset Seizures in Double-Blind Placebo-Controlled Trials (P2, 019). Neurology.2016, vol. 86. 16 Supplement.",ACTIVE
22,US,A1,US 2021/0346348 A1,158-219-377-523-79X,2021-11-11,2021,US 201917277856 A,2019-09-20,US 201917277856 A;;US 201862734406 P;;KR 2019012184 W,2018-09-21,"USE OF CARBAMATE COMPOUND FOR PREVENTION, ALLEVIATION OR TREATMENT OF STATUS EPILEPTICUS","The present invention relates to a use for the purpose of preventing, alleviating, or treating status epilepticus by administering a medicament or pharmaceutical composition comprising a carbamate compound of chemical formula 1.",SK BIOPHARMACEUTICALS CO LTD,CHOI EUN JU;;SHIN HYE WON;;SHIN YU JIN,SK BIOPHARMACEUTICALS CO. LTD (2021-03-16),https://lens.org/158-219-377-523-79X,Patent Application,yes,3,0,11,095-192-663-747-961;;158-219-377-523-79X;;008-336-260-217-389;;011-174-825-787-178;;134-034-736-963-905;;196-674-732-660-194;;076-785-153-510-088;;069-900-525-135-010;;111-127-472-538-662;;003-906-004-716-306;;136-319-502-988-001,CA;;JP;;KR;;WO;;US;;CN;;EP,11,095-192-663-747-961;;158-219-377-523-79X;;008-336-260-217-389;;069-900-525-135-010;;196-674-732-660-194;;134-034-736-963-905;;076-785-153-510-088;;011-174-825-787-178;;111-127-472-538-662;;003-906-004-716-306;;136-319-502-988-001,CA;;JP;;KR;;WO;;US;;CN;;EP,0,A61P31/00;;A61P9/10;;A61K31/41;;A61P35/00;;A61P3/00;;A61K31/41;;A61P9/10;;A61P3/00;;A61P31/00;;A61P35/00;;A61P25/08;;A61K31/41,A61K31/41;;A61P25/08,,0,0,,,,ACTIVE
23,EP,A1,EP 3854392 A1,111-127-472-538-662,2021-07-28,2021,EP 19862522 A,2019-09-20,US 201862734406 P;;KR 2019012184 W,2018-09-21,"USE OF CARBAMATE COMPOUND FOR PREVENTION, ALLEVIATION, OR TREATMENT OF CONCURRENT SEIZURES","The present invention relates to a use for the purpose of preventing, alleviating, or treating status epilepticus by administering a medicament or pharmaceutical composition comprising a carbamate compound of chemical formula 1.",SK BIOPHARMACEUTICALS CO LTD,CHOI EUN JU;;SHIN HYE WON;;SHIN YU JIN,,https://lens.org/111-127-472-538-662,Patent Application,yes,0,0,11,095-192-663-747-961;;158-219-377-523-79X;;008-336-260-217-389;;011-174-825-787-178;;134-034-736-963-905;;196-674-732-660-194;;076-785-153-510-088;;069-900-525-135-010;;111-127-472-538-662;;003-906-004-716-306;;136-319-502-988-001,CA;;JP;;KR;;WO;;US;;CN;;EP,11,095-192-663-747-961;;158-219-377-523-79X;;008-336-260-217-389;;069-900-525-135-010;;196-674-732-660-194;;134-034-736-963-905;;076-785-153-510-088;;011-174-825-787-178;;111-127-472-538-662;;003-906-004-716-306;;136-319-502-988-001,CA;;JP;;KR;;WO;;US;;CN;;EP,0,A61P31/00;;A61P9/10;;A61K31/41;;A61P35/00;;A61P3/00;;A61K31/41;;A61P9/10;;A61P3/00;;A61P31/00;;A61P35/00;;A61P25/08;;A61K31/41,A61K31/41;;A61P3/00;;A61P9/10;;A61P31/00;;A61P35/00,,0,0,,,,PENDING
24,US,A1,US 2024/0366566 A1,003-906-004-716-306,2024-11-07,2024,US 202418777900 A,2024-07-19,US 202418777900 A;;US 202117277856 A;;KR 2019012184 W;;US 201862734406 P,2018-09-21,"USE OF CARBAMATE COMPOUND FOR PREVENTION, ALLEVIATION OR TREATMENT OF STATUS EPILEPTICUS","The present invention relates to a use for the purpose of preventing, alleviating, or treating status epilepticus by administering a medicament or pharmaceutical composition comprising a carbamate compound of chemical formula.",SK BIOPHARMACEUTICALS CO LTD,CHOI EUN JU;;SHIN HYE WON;;SHIN YU JIN,SK BIOPHARMACEUTICALS CO. LTD (2021-03-16),https://lens.org/003-906-004-716-306,Patent Application,yes,0,0,11,095-192-663-747-961;;158-219-377-523-79X;;008-336-260-217-389;;011-174-825-787-178;;134-034-736-963-905;;196-674-732-660-194;;076-785-153-510-088;;069-900-525-135-010;;111-127-472-538-662;;003-906-004-716-306;;136-319-502-988-001,CA;;JP;;KR;;WO;;US;;CN;;EP,11,095-192-663-747-961;;158-219-377-523-79X;;008-336-260-217-389;;069-900-525-135-010;;196-674-732-660-194;;134-034-736-963-905;;076-785-153-510-088;;011-174-825-787-178;;111-127-472-538-662;;003-906-004-716-306;;136-319-502-988-001,CA;;JP;;KR;;WO;;US;;CN;;EP,0,A61P31/00;;A61P9/10;;A61K31/41;;A61P35/00;;A61P3/00;;A61K31/41;;A61P9/10;;A61P3/00;;A61P31/00;;A61P35/00;;A61P25/08;;A61K31/41,A61K31/41;;A61P25/08,,0,0,,,,PENDING
25,US,B2,US 12070447 B2,095-049-103-255-780,2024-08-27,2024,US 201716468756 A,2017-12-14,KR 20160170389 A;;KR 2017014727 W,2016-12-14,Parenteral liquid preparation comprising carbamate compound,"The present invention relates to a parenteral liquid preparation containing, as active ingredients; a carbamate compound of chemical formula 1, an isomer thereof, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof; and a cyclodextrin derivative.",SK BIOPHARMACEUTICALS CO LTD,BAEK MYOUNG KI;;LEE JI HYE;;CHOI SO YOUNG,SK BIOPHARMACEUTICALS CO. LTD (2019-08-01),https://lens.org/095-049-103-255-780,Granted Patent,yes,5,0,30,060-923-564-159-175;;169-666-013-418-722;;084-296-444-876-55X;;041-798-041-171-74X;;079-780-444-625-21X;;050-316-334-099-640;;177-941-877-877-786;;128-343-568-859-560;;154-925-592-541-053;;113-768-574-798-142;;185-075-412-068-657;;094-097-745-734-265;;000-524-521-089-352;;047-394-776-275-766;;091-320-116-911-871;;106-496-612-257-196;;150-043-787-521-570;;003-852-561-431-88X;;185-757-584-499-89X;;167-469-769-765-999;;193-694-435-058-657;;143-802-406-793-830;;128-702-725-238-816;;032-481-162-424-369;;081-969-435-631-459;;061-310-025-264-528;;106-667-910-198-95X;;055-784-025-208-347;;095-049-103-255-780;;173-676-504-997-064,CA;;RU;;JP;;KR;;PT;;ZA;;PL;;CN;;CL;;ES;;AU;;DK;;BR;;WO;;MX;;US;;EP;;IL,30,060-923-564-159-175;;169-666-013-418-722;;084-296-444-876-55X;;041-798-041-171-74X;;079-780-444-625-21X;;050-316-334-099-640;;177-941-877-877-786;;128-343-568-859-560;;154-925-592-541-053;;113-768-574-798-142;;185-075-412-068-657;;094-097-745-734-265;;000-524-521-089-352;;047-394-776-275-766;;091-320-116-911-871;;106-496-612-257-196;;150-043-787-521-570;;003-852-561-431-88X;;185-757-584-499-89X;;167-469-769-765-999;;193-694-435-058-657;;143-802-406-793-830;;128-702-725-238-816;;032-481-162-424-369;;081-969-435-631-459;;061-310-025-264-528;;106-667-910-198-95X;;055-784-025-208-347;;095-049-103-255-780;;173-676-504-997-064,CA;;RU;;JP;;KR;;PT;;ZA;;PL;;CN;;CL;;ES;;AU;;DK;;BR;;WO;;MX;;US;;EP;;IL,0,A61K9/08;;A61K31/41;;A61K47/40;;A61K47/6951;;A61P25/00;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/34;;A61P3/04;;A61P9/10;;A61P21/02;;A61K9/08;;A61K31/325;;A61K31/41;;A61K9/0019;;A61K47/6951;;A61K31/4192;;A61P25/08;;A61K31/41;;A61K9/0019;;A61K31/4192;;A61K9/08;;A61P25/08;;A61K47/40;;A61K47/6951;;A61K31/325;;A61K47/69;;A61K9/08;;A61K47/40;;A61K9/0019;;A61K31/41;;A61K31/325;;A61K31/41;;A61K9/0019;;A61K9/08;;A61K47/69;;A61P25/08;;A61K9/0019;;A61K31/41;;A61K47/40,A61K31/41;;A61K9/00;;A61K9/19;;A61K47/40,,16,7,030-323-919-989-42X;;075-596-410-145-597;;063-549-821-197-773;;024-517-856-931-527;;014-486-629-729-140;;001-633-791-021-525;;078-207-787-645-038,20970964;;10.1016/j.eplepsyres.2010.09.001;;15032302;;10.1023/b:pham.0000016235.32639.23;;10.1056/nejm198211253072206;;7133084;;9040088;;10.1021/js960213f;;8923319;;10.1021/js960075u;;16109630;;10.1080/03639040500214738;;10.1212/wnl.86.16_supplement.p2.019,"Bender (Cyclodextrin Chemistry, Reactivity and Structure Comcepts in Organic Chemistry 6, Springer-Verlag Berlin Heidelberg New York 1978).;;Cavitron (Cavitron™ and Cavasol hydroxypropyl-β-cyclodextrins, Jul. 25, 2012, PC_11734_Cavitron_Cavasol.pdf (ashland.com)(hereinafter Cavitron)).;;Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy research. Dec. 1, 2010;92(2-3):89-124. (Year: 2010).;;Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharmaceutical research. Feb. 2004;21:201-30. (Year: 2004).;;Gershanik, J., et al.; “The Gasping Syndrome and Benzyl Alcohol Poisoning”, The New England Journal of Medicine, Nov. 25, 1982, vol. 307, No. 22, pp. 1384-1388.;;Irie, T., et al.; “Pharmaceutical Applications of Cyclodextrins. III. Toxicological Issues and Safety Evaluation”, Journal of Pharmaceutical Sciences, Feb. 1997, vol. 86, No. 2, pp. 147-162.;;Fairchild, E. J., et al.; “Registry of Toxic Effects of Chemical Substances”, 1977 Edition, vol. II. DHEW Publ. No.(NIOSH) 78-104-B. (English Abstract Only).;;International Search Report (ISR) from corresponding PCT Application No. PCT/KR2017/014727, mailed Feb. 28, 2018.;;Rajewski, R. A., et al; “Pharmaceutical Applications of Cyclodextrins. 2. In Vivo Drug Delivery”, Journal of Pharmaceutical Sciences, 1996, vol. 85, No. 11, pp. 1142-1169.;;Loscher, W., et al.; “New Injectable Aqueous Carbamazepine Solution Through Complexing with 2-Hydroxypropyl-β-Cyclodextrin: Tolerability and Pharmacokinetics After Intravenous Injection in Comparison to a Glycofurol-Based Formulation”, Epilepsia, 1995, vol. 36, No. 3, pp. 255-261.;;Gould, S., et al.; “2-Hydroxypropyl-β-cyclodextrin (HP-β-CD): a Toxicology Review”, Food and Chemical Toxicology, 2005, vol. 43, pp. 1451-1459.;;Holvoet, C., et al.; “Inclusion Complexation of Lorazepam with Different Cyclodextrins Suitable for Parenteral Use”, Drug Development and Industrial Pharmacy, 2005, vol. 31, pp. 567-575.;;Extended European Search Report, dated May 29, 2020 from corresponding European Patent Application No. 17880335.9.;;Duncan P Taylor: “YKP3089 (Epilepsy)—Poster”, May 24, 2013, XP055650994, Retrieved from the internet: URL:http://www.kddf.org/common/file/?idx=1417&fname=Bio_USA-Poster_10_YKP_3089.pdf [retrieved on—Dec. 9, 2019J].;;Examination Report from corresponding Australian Patent Application No. 2017374450, dated Oct. 28, 2022.;;Krauss, G., et al.; “Seizure Freedom with YKP3089 as Adjunctive Therapy for Refractory Partial-Onset Seizures in Double-Blind Placebo-Controlled Trials”, Neurology, 2016, vol. 86, 16 supplement, .3 pages.",ACTIVE
26,EP,B1,EP 3556349 B1,084-296-444-876-55X,2021-11-24,2021,EP 17880335 A,2017-12-14,KR 20160170389 A;;KR 2017014727 W,2016-12-14,PARENTERAL LIQUID PREPARATION COMPRISING CARBAMATE COMPOUND,,SK BIOPHARMACEUTICALS CO LTD,BAEK MYOUNG KI;;LEE JI HYE;;CHOI SO YOUNG,,https://lens.org/084-296-444-876-55X,Granted Patent,yes,2,0,30,060-923-564-159-175;;169-666-013-418-722;;084-296-444-876-55X;;041-798-041-171-74X;;079-780-444-625-21X;;050-316-334-099-640;;177-941-877-877-786;;128-343-568-859-560;;154-925-592-541-053;;113-768-574-798-142;;185-075-412-068-657;;094-097-745-734-265;;000-524-521-089-352;;047-394-776-275-766;;091-320-116-911-871;;106-496-612-257-196;;150-043-787-521-570;;003-852-561-431-88X;;185-757-584-499-89X;;167-469-769-765-999;;193-694-435-058-657;;143-802-406-793-830;;128-702-725-238-816;;032-481-162-424-369;;081-969-435-631-459;;061-310-025-264-528;;106-667-910-198-95X;;055-784-025-208-347;;095-049-103-255-780;;173-676-504-997-064,CA;;RU;;JP;;KR;;PT;;ZA;;PL;;CN;;CL;;ES;;AU;;DK;;BR;;WO;;MX;;US;;EP;;IL,30,060-923-564-159-175;;169-666-013-418-722;;084-296-444-876-55X;;041-798-041-171-74X;;079-780-444-625-21X;;050-316-334-099-640;;177-941-877-877-786;;128-343-568-859-560;;154-925-592-541-053;;113-768-574-798-142;;185-075-412-068-657;;094-097-745-734-265;;000-524-521-089-352;;047-394-776-275-766;;091-320-116-911-871;;106-496-612-257-196;;150-043-787-521-570;;003-852-561-431-88X;;185-757-584-499-89X;;167-469-769-765-999;;193-694-435-058-657;;143-802-406-793-830;;128-702-725-238-816;;032-481-162-424-369;;081-969-435-631-459;;061-310-025-264-528;;106-667-910-198-95X;;055-784-025-208-347;;095-049-103-255-780;;173-676-504-997-064,CA;;RU;;JP;;KR;;PT;;ZA;;PL;;CN;;CL;;ES;;AU;;DK;;BR;;WO;;MX;;US;;EP;;IL,0,A61K9/08;;A61K31/41;;A61K47/40;;A61K47/6951;;A61P25/00;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/34;;A61P3/04;;A61P9/10;;A61P21/02;;A61K9/08;;A61K31/325;;A61K31/41;;A61K9/0019;;A61K47/6951;;A61K31/4192;;A61P25/08;;A61K31/41;;A61K9/0019;;A61K31/4192;;A61K9/08;;A61P25/08;;A61K47/40;;A61K47/6951;;A61K31/325;;A61K47/69;;A61K9/08;;A61K47/40;;A61K9/0019;;A61K31/41;;A61K31/325;;A61K31/41;;A61K9/0019;;A61K9/08;;A61K47/69;;A61P25/08;;A61K9/0019;;A61K31/41;;A61K47/40,A61K9/08;;A61K31/4192;;A61K47/69,,9,0,,,"RAJEWSKI R A ET AL: ""PHARMACEUTICAL APPLICATIONS OF CYCLODEXTRINS. 2. IN VIVO DRUG DELIVERY"", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, US, vol. 85, no. 11, 1 November 1996 (1996-11-01), pages 1142-1169, XP000629515, ISSN: 0022-3549, DOI: 10.1021/JS960075U;;WOLFGANG LOSCHER ET AL: ""New Injectable Aqueous Carbamazepine Solution Through Complexing with 2-Hydroxypropyl-beta-Cyclodextrin: Tolerability and Pharmacokinetics After Intravenous Injection in Comparison to a Glycofurol-Based Formulation"", EPILEPSIA, vol. 36, no. 3, 1 March 1995 (1995-03-01), pages 255-261, XP055428288, NEW YORK, US ISSN: 0013-9580, DOI: 10.1111/j.1528-1157.1995.tb00993.x;;GOULD S ET AL: ""2-Hydroxypropyl-@b-cyclodextrin (HP-@b-CD): A toxicology review"", FOOD AND CHEMICAL TOXICOLOGY, PERGAMON, GB, vol. 43, no. 10, 1 October 2005 (2005-10-01), pages 1451-1459, XP004976497, ISSN: 0278-6915, DOI: 10.1016/J.FCT.2005.03.007;;CHANTAL HOLVOET ET AL: ""Inclusion Complexation of Lorazepam with Different Cyclodextrins Suitable for Parenteral Use"", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol. 31, no. 6, 1 January 2005 (2005-01-01), pages 567-575, XP055510488, US ISSN: 0363-9045, DOI: 10.1080/03639040500214738;;Duncan P Taylor: ""YKP3089 (Epilepsy) - Poster"", , 24 May 2013 (2013-05-24), XP055650994, Retrieved from the Internet: URL:http://www.kddf.org/common/file/?idx=1 417&fname=BIO_USA-Poster_10_YKP_3089.pdf [retrieved on 2019-12-09];;RAJEWSKI, R. A. ET AL.: 'Pharmaceutical Applications of Cyclodextrins. 2. In Vivo Drug Delivery' JOURNAL OF PHARMACEUTICAL SCIENCES vol. 85, no. 11, 1996, pages 1142 - 1169, XP000629515;;LOSCHER, W. ET AL.: 'New Injectable Aqueous Carbamazepine Solution Through Complexing with 2-Hydroxypropyl-13-Cyclodextrin: Tolerability and Pharmacokinetics After Intravenous Injection in Comparison to a Glycofurol-Based Formulation' EPILEPSIA vol. 36, no. 3, 1995, pages 255 - 261, XP055428288;;GOULD, S. ET AL.: '2-Hydroxypropyl-beta-cyclodextrin (HP-beta- CD ): a Toxicology Review' FOOD AND CHEMICAL TOXICOLOGY vol. 43, 2005, pages 1451 - 1459, XP004976497;;HOLVOET, C. ET AL.: 'Inclusion Complexation of Lorazepam with Different Cyclodextrins Suitable for Parenteral Use' DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY vol. 31, 2005, pages 567 - 575, XP055510488",ACTIVE
27,EP,A1,EP 3556349 A1,128-343-568-859-560,2019-10-23,2019,EP 17880335 A,2017-12-14,KR 20160170389 A;;KR 2017014727 W,2016-12-14,PARENTERAL LIQUID PREPARATION COMPRISING CARBAMATE COMPOUND,"The present invention relates to a parenteral liquid preparation containing, as active ingredients; a carbamate compound of chemical formula 1, an isomer thereof, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof; and a cyclodextrin derivative.",SK BIOPHARMACEUTICALS CO LTD,BAEK MYOUNG KI;;LEE JI HYE;;CHOI SO YOUNG,,https://lens.org/128-343-568-859-560,Patent Application,yes,0,1,30,060-923-564-159-175;;169-666-013-418-722;;084-296-444-876-55X;;041-798-041-171-74X;;079-780-444-625-21X;;050-316-334-099-640;;177-941-877-877-786;;128-343-568-859-560;;154-925-592-541-053;;113-768-574-798-142;;185-075-412-068-657;;094-097-745-734-265;;000-524-521-089-352;;047-394-776-275-766;;091-320-116-911-871;;106-496-612-257-196;;150-043-787-521-570;;003-852-561-431-88X;;185-757-584-499-89X;;167-469-769-765-999;;193-694-435-058-657;;143-802-406-793-830;;128-702-725-238-816;;032-481-162-424-369;;081-969-435-631-459;;061-310-025-264-528;;106-667-910-198-95X;;055-784-025-208-347;;095-049-103-255-780;;173-676-504-997-064,CA;;RU;;JP;;KR;;PT;;ZA;;PL;;CN;;CL;;ES;;AU;;DK;;BR;;WO;;MX;;US;;EP;;IL,30,060-923-564-159-175;;169-666-013-418-722;;084-296-444-876-55X;;041-798-041-171-74X;;079-780-444-625-21X;;050-316-334-099-640;;177-941-877-877-786;;128-343-568-859-560;;154-925-592-541-053;;113-768-574-798-142;;185-075-412-068-657;;094-097-745-734-265;;000-524-521-089-352;;047-394-776-275-766;;091-320-116-911-871;;106-496-612-257-196;;150-043-787-521-570;;003-852-561-431-88X;;185-757-584-499-89X;;167-469-769-765-999;;193-694-435-058-657;;143-802-406-793-830;;128-702-725-238-816;;032-481-162-424-369;;081-969-435-631-459;;061-310-025-264-528;;106-667-910-198-95X;;055-784-025-208-347;;095-049-103-255-780;;173-676-504-997-064,CA;;RU;;JP;;KR;;PT;;ZA;;PL;;CN;;CL;;ES;;AU;;DK;;BR;;WO;;MX;;US;;EP;;IL,0,A61K9/08;;A61K31/41;;A61K47/40;;A61K47/6951;;A61P25/00;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/34;;A61P3/04;;A61P9/10;;A61P21/02;;A61K9/08;;A61K31/325;;A61K31/41;;A61K9/0019;;A61K47/6951;;A61K31/4192;;A61P25/08;;A61K31/41;;A61K9/0019;;A61K31/4192;;A61K9/08;;A61P25/08;;A61K47/40;;A61K47/6951;;A61K31/325;;A61K47/69;;A61K9/08;;A61K47/40;;A61K9/0019;;A61K31/41;;A61K31/325;;A61K31/41;;A61K9/0019;;A61K9/08;;A61K47/69;;A61P25/08;;A61K9/0019;;A61K31/41;;A61K47/40,A61K9/08;;A61K9/00;;A61K31/325;;A61K31/41;;A61K47/40,,0,0,,,,ACTIVE
28,US,A1,US 2019/0314336 A1,055-784-025-208-347,2019-10-17,2019,US 201716468756 A,2017-12-14,KR 20160170389 A;;KR 2017014727 W,2016-12-14,PARENTERAL LIQUID PREPARATION COMPRISING CARBAMATE COMPOUND,"The present invention relates to a parenteral liquid preparation containing, as active ingredients; a carbamate compound of chemical formula 1, an isomer thereof, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof; and a cyclodextrin derivative.",SK BIOPHARMACEUTICALS CO LTD,BAEK MYOUNG KI;;LEE JI HYE;;CHOI SO YOUNG,SK BIOPHARMACEUTICALS CO. LTD (2019-08-01),https://lens.org/055-784-025-208-347,Patent Application,yes,0,0,30,060-923-564-159-175;;169-666-013-418-722;;084-296-444-876-55X;;041-798-041-171-74X;;079-780-444-625-21X;;050-316-334-099-640;;177-941-877-877-786;;128-343-568-859-560;;154-925-592-541-053;;113-768-574-798-142;;185-075-412-068-657;;094-097-745-734-265;;000-524-521-089-352;;047-394-776-275-766;;091-320-116-911-871;;106-496-612-257-196;;150-043-787-521-570;;003-852-561-431-88X;;185-757-584-499-89X;;167-469-769-765-999;;193-694-435-058-657;;143-802-406-793-830;;128-702-725-238-816;;032-481-162-424-369;;081-969-435-631-459;;061-310-025-264-528;;106-667-910-198-95X;;055-784-025-208-347;;095-049-103-255-780;;173-676-504-997-064,CA;;RU;;JP;;KR;;PT;;ZA;;PL;;CN;;CL;;ES;;AU;;DK;;BR;;WO;;MX;;US;;EP;;IL,30,060-923-564-159-175;;169-666-013-418-722;;084-296-444-876-55X;;041-798-041-171-74X;;079-780-444-625-21X;;050-316-334-099-640;;177-941-877-877-786;;128-343-568-859-560;;154-925-592-541-053;;113-768-574-798-142;;185-075-412-068-657;;094-097-745-734-265;;000-524-521-089-352;;047-394-776-275-766;;091-320-116-911-871;;106-496-612-257-196;;150-043-787-521-570;;003-852-561-431-88X;;185-757-584-499-89X;;167-469-769-765-999;;193-694-435-058-657;;143-802-406-793-830;;128-702-725-238-816;;032-481-162-424-369;;081-969-435-631-459;;061-310-025-264-528;;106-667-910-198-95X;;055-784-025-208-347;;095-049-103-255-780;;173-676-504-997-064,CA;;RU;;JP;;KR;;PT;;ZA;;PL;;CN;;CL;;ES;;AU;;DK;;BR;;WO;;MX;;US;;EP;;IL,0,A61K9/08;;A61K31/41;;A61K47/40;;A61K47/6951;;A61P25/00;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/34;;A61P3/04;;A61P9/10;;A61P21/02;;A61K9/08;;A61K31/325;;A61K31/41;;A61K9/0019;;A61K47/6951;;A61K31/4192;;A61P25/08;;A61K31/41;;A61K9/0019;;A61K31/4192;;A61K9/08;;A61P25/08;;A61K47/40;;A61K47/6951;;A61K31/325;;A61K47/69;;A61K9/08;;A61K47/40;;A61K9/0019;;A61K31/41;;A61K31/325;;A61K31/41;;A61K9/0019;;A61K9/08;;A61K47/69;;A61P25/08;;A61K9/0019;;A61K31/41;;A61K47/40,A61K31/41;;A61K9/00;;A61K47/40,,2,2,030-323-919-989-42X;;075-596-410-145-597,20970964;;10.1016/j.eplepsyres.2010.09.001;;15032302;;10.1023/b:pham.0000016235.32639.23,"Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy research. 2010 Dec 1;92(2-3):89-124. (Year: 2010);;Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharmaceutical research. 2004 Feb;21:201-30. (Year: 2004)",ACTIVE
29,US,B2,US 10201519 B2,033-345-284-779-58X,2019-02-12,2019,US 201715400676 A,2017-01-06,US 201715400676 A;;US 201514858583 A;;US 201213570853 A;;US 25849008 A;;US 98414407 P,2007-10-31,Stabilized pediatric suspension of carisbamate,"The present invention provides a stabilized pharmaceutical suspension of carisbamate for pediatric and adult use. More particularly, the suspension is stabilized with hypromellose (HFMC) to prevent crystal growth of the suspended particles and to prevent re-crystallization of the drug product with change in polymorphic form.",SK BIOPHARMACEUTICALS CO LTD,EMBRECHTS ROGER;;DE LEERSNIJDER CEDRIC,,https://lens.org/033-345-284-779-58X,Granted Patent,yes,9,0,45,159-516-822-737-188;;040-245-016-852-096;;040-396-512-596-78X;;136-179-622-675-024;;032-262-165-909-820;;023-012-761-894-962;;155-504-418-632-516;;121-405-562-545-17X;;144-325-189-916-052;;019-981-338-213-670;;073-883-683-736-009;;105-520-197-837-708;;013-201-034-883-247;;105-972-285-891-795;;151-893-743-218-93X;;094-149-172-560-22X;;034-012-308-776-30X;;022-521-355-363-284;;093-752-459-993-321;;151-344-301-196-639;;095-497-761-003-445;;072-033-840-567-492;;156-658-975-310-219;;007-013-520-063-978;;087-798-926-602-198;;169-513-077-811-155;;018-566-154-564-674;;004-901-672-182-825;;064-101-233-865-545;;140-581-159-677-430;;195-599-680-964-597;;180-692-465-797-580;;026-265-607-683-002;;111-092-477-236-068;;173-050-548-549-55X;;091-001-366-009-655;;165-184-116-879-794;;165-651-624-073-99X;;043-323-131-136-319;;144-274-517-083-663;;163-120-758-498-402;;182-497-281-003-263;;033-345-284-779-58X;;071-113-377-559-012;;001-681-502-396-600,CA;;EC;;KR;;PA;;ES;;NI;;TW;;US;;CO;;JP;;UY;;ZA;;CN;;PL;;CL;;MY;;CR;;AU;;BR;;EA;;MX;;WO;;PE;;AR;;EP;;IL,45,033-345-284-779-58X;;040-245-016-852-096;;040-396-512-596-78X;;159-516-822-737-188;;136-179-622-675-024;;032-262-165-909-820;;155-504-418-632-516;;121-405-562-545-17X;;144-325-189-916-052;;019-981-338-213-670;;073-883-683-736-009;;105-520-197-837-708;;013-201-034-883-247;;105-972-285-891-795;;151-893-743-218-93X;;094-149-172-560-22X;;034-012-308-776-30X;;022-521-355-363-284;;093-752-459-993-321;;151-344-301-196-639;;095-497-761-003-445;;072-033-840-567-492;;156-658-975-310-219;;007-013-520-063-978;;087-798-926-602-198;;169-513-077-811-155;;018-566-154-564-674;;004-901-672-182-825;;064-101-233-865-545;;140-581-159-677-430;;195-599-680-964-597;;180-692-465-797-580;;026-265-607-683-002;;111-092-477-236-068;;173-050-548-549-55X;;091-001-366-009-655;;165-184-116-879-794;;165-651-624-073-99X;;043-323-131-136-319;;144-274-517-083-663;;163-120-758-498-402;;182-497-281-003-263;;001-681-502-396-600;;071-113-377-559-012;;023-012-761-894-962,CA;;EC;;KR;;PA;;ES;;NI;;TW;;US;;CO;;JP;;UY;;ZA;;CN;;PL;;CL;;MY;;CR;;AU;;BR;;EA;;MX;;WO;;PE;;AR;;EP;;IL,0,A61K31/325;;A61K9/0095;;A61K31/27;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/14;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P29/00;;A61K31/325;;A61K9/0095;;A61K31/27;;A61K47/12;;A61K47/26;;A61K47/36;;A61K47/38,A61K31/27;;A61K9/00;;A61K31/325;;A61K47/12;;A61K47/26;;A61K47/36;;A61K47/38,,6,0,,,"Office Action (Restriction Requirement) dated Dec. 1, 2010 in U.S. Appl. No. 12/258,490.;;Office Action (Non-final) dated Dec. 21, 2011 in U.S. Appl. No. 12/258,490.;;Office Action (Non-final) dated Dec. 7, 2012 in U.S. Appl. No. 13/570,853.;;Office Action (Non-final) dated Oct. 6, 2014 in U.S. Appl. No. 13/570,853.;;Office Action (Non-final) dated Mar. 25, 2016 in U.S. Appl. No. 14/858,583.;;Office Action (Final) dated Oct. 7, 2016 in U.S. Appl. No. 14/858,583.",ACTIVE
30,US,A1,US 2017/0112798 A1,105-520-197-837-708,2017-04-27,2017,US 201715400676 A,2017-01-06,US 201715400676 A;;US 201514858583 A;;US 201213570853 A;;US 25849008 A;;US 98414407 P,2007-10-31,STABILIZED PEDIATRIC SUSPENSION OF CARISBAMATE,"The present invention provides a stabilized pharmaceutical suspension of carisbamate for pediatric and adult use. More particularly, the suspension is stabilized with hypromellose (HFMC) to prevent crystal growth of the suspended particles and to prevent re-crystallization of the drug product with change in polymorphic form.",SK BIOPHARMACEUTICALS CO LTD,EMBRECHTS ROGER;;DE LEERSNIJDER CEDRIC,,https://lens.org/105-520-197-837-708,Patent Application,yes,0,0,45,159-516-822-737-188;;040-245-016-852-096;;040-396-512-596-78X;;136-179-622-675-024;;032-262-165-909-820;;023-012-761-894-962;;155-504-418-632-516;;121-405-562-545-17X;;144-325-189-916-052;;019-981-338-213-670;;073-883-683-736-009;;105-520-197-837-708;;013-201-034-883-247;;105-972-285-891-795;;151-893-743-218-93X;;094-149-172-560-22X;;034-012-308-776-30X;;022-521-355-363-284;;093-752-459-993-321;;151-344-301-196-639;;095-497-761-003-445;;072-033-840-567-492;;156-658-975-310-219;;007-013-520-063-978;;087-798-926-602-198;;169-513-077-811-155;;018-566-154-564-674;;004-901-672-182-825;;064-101-233-865-545;;140-581-159-677-430;;195-599-680-964-597;;180-692-465-797-580;;026-265-607-683-002;;111-092-477-236-068;;173-050-548-549-55X;;091-001-366-009-655;;165-184-116-879-794;;165-651-624-073-99X;;043-323-131-136-319;;144-274-517-083-663;;163-120-758-498-402;;182-497-281-003-263;;033-345-284-779-58X;;071-113-377-559-012;;001-681-502-396-600,CA;;EC;;KR;;PA;;ES;;NI;;TW;;US;;CO;;JP;;UY;;ZA;;CN;;PL;;CL;;MY;;CR;;AU;;BR;;EA;;MX;;WO;;PE;;AR;;EP;;IL,45,033-345-284-779-58X;;040-245-016-852-096;;040-396-512-596-78X;;159-516-822-737-188;;136-179-622-675-024;;032-262-165-909-820;;155-504-418-632-516;;121-405-562-545-17X;;144-325-189-916-052;;019-981-338-213-670;;073-883-683-736-009;;105-520-197-837-708;;013-201-034-883-247;;105-972-285-891-795;;151-893-743-218-93X;;094-149-172-560-22X;;034-012-308-776-30X;;022-521-355-363-284;;093-752-459-993-321;;151-344-301-196-639;;095-497-761-003-445;;072-033-840-567-492;;156-658-975-310-219;;007-013-520-063-978;;087-798-926-602-198;;169-513-077-811-155;;018-566-154-564-674;;004-901-672-182-825;;064-101-233-865-545;;140-581-159-677-430;;195-599-680-964-597;;180-692-465-797-580;;026-265-607-683-002;;111-092-477-236-068;;173-050-548-549-55X;;091-001-366-009-655;;165-184-116-879-794;;165-651-624-073-99X;;043-323-131-136-319;;144-274-517-083-663;;163-120-758-498-402;;182-497-281-003-263;;001-681-502-396-600;;071-113-377-559-012;;023-012-761-894-962,CA;;EC;;KR;;PA;;ES;;NI;;TW;;US;;CO;;JP;;UY;;ZA;;CN;;PL;;CL;;MY;;CR;;AU;;BR;;EA;;MX;;WO;;PE;;AR;;EP;;IL,0,A61K31/325;;A61K9/0095;;A61K31/27;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/14;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P29/00;;A61K31/325;;A61K9/0095;;A61K31/27;;A61K47/12;;A61K47/26;;A61K47/36;;A61K47/38,A61K31/325;;A61K47/12;;A61K47/26;;A61K47/38,,0,0,,,,ACTIVE
31,EP,A4,EP 3711758 A4,063-479-285-377-285,2021-08-04,2021,EP 18878222 A,2018-11-13,KR 20170151248 A;;KR 2018013761 W,2017-11-14,"USE OF CARBAMATE COMPOUND FOR PREVENTING, ALLEVIATING OR TREATING ABSENCE SEIZURE OR EPILEPSY SHOWING ABSENCE SEIZURE",,SK BIOPHARMACEUTICALS CO LTD,SHIN HYE WON,,https://lens.org/063-479-285-377-285,Search Report,no,1,0,27,095-418-251-758-452;;172-016-358-273-69X;;076-848-262-066-276;;135-481-838-122-470;;098-543-216-736-719;;086-571-364-434-926;;000-725-273-383-720;;056-496-205-069-225;;153-947-887-303-504;;058-375-562-836-105;;006-707-689-459-29X;;036-594-672-948-003;;175-848-266-125-914;;180-295-791-525-434;;030-642-208-724-01X;;099-848-387-400-56X;;015-109-212-500-52X;;026-234-878-168-692;;152-734-280-865-740;;011-181-861-380-530;;096-866-746-743-864;;043-369-112-902-472;;063-745-038-278-465;;141-748-827-420-509;;063-479-285-377-285;;080-616-656-930-540;;027-314-878-690-911,RU;;CA;;JP;;KR;;PT;;PL;;CN;;ES;;AU;;DK;;FI;;BR;;WO;;MX;;US;;IL;;EP,27,095-418-251-758-452;;172-016-358-273-69X;;076-848-262-066-276;;135-481-838-122-470;;098-543-216-736-719;;086-571-364-434-926;;000-725-273-383-720;;056-496-205-069-225;;153-947-887-303-504;;058-375-562-836-105;;006-707-689-459-29X;;036-594-672-948-003;;175-848-266-125-914;;180-295-791-525-434;;030-642-208-724-01X;;099-848-387-400-56X;;015-109-212-500-52X;;026-234-878-168-692;;152-734-280-865-740;;011-181-861-380-530;;096-866-746-743-864;;043-369-112-902-472;;063-745-038-278-465;;141-748-827-420-509;;063-479-285-377-285;;080-616-656-930-540;;027-314-878-690-911,RU;;CA;;JP;;KR;;PT;;PL;;CN;;ES;;AU;;DK;;FI;;BR;;WO;;MX;;US;;IL;;EP,0,A61K31/41;;A61P25/08;;A61K31/41;;A61K31/16;;A61P25/08;;A61K31/41;;A61K31/16;;A61P25/08;;A61K31/41,A61K31/41;;A61K31/16;;A61P25/08;;A61P25/10,,3,2,088-975-736-647-978;;003-793-220-100-823,23219031;;10.1016/j.eplepsyres.2012.10.001;;10.1016/j.seizure.2016.11.022;;28017578,"MEIR BIALER ET AL: ""Progress report on new antiepileptic drugs: A summary of the Eleventh Eilat Conference (EILAT XI)"", EPILEPSY RESEARCH, vol. 103, no. 1, 1 January 2013 (2013-01-01), NL, pages 2 - 30, XP055691206, ISSN: 0920-1211, DOI: 10.1016/j.eplepsyres.2012.10.001;;GOLYALA AMBICA ET AL: ""Drug development for refractory epilepsy: The past 25 years and beyond"", SEIZURE, BAILLIERE TINDALL, LONDON, GB, vol. 44, 6 December 2016 (2016-12-06), pages 147 - 156, XP029901803, ISSN: 1059-1311, DOI: 10.1016/J.SEIZURE.2016.11.022;;See also references of WO 2019098628A1",ACTIVE
32,PT,T,PT 3711758 T,063-745-038-278-465,2024-04-22,2024,PT 18878222 T,2018-11-13,KR 20170151248 A,2017-11-14,"USE OF CARBAMATE COMPOUND FOR PREVENTING, ALLEVIATING OR TREATING ABSENCE SEIZURE OR EPILEPSY SHOWING ABSENCE SEIZURE",,SK BIOPHARMACEUTICALS CO LTD,,,https://lens.org/063-745-038-278-465,Patent Application,no,0,0,27,095-418-251-758-452;;172-016-358-273-69X;;076-848-262-066-276;;135-481-838-122-470;;098-543-216-736-719;;086-571-364-434-926;;000-725-273-383-720;;056-496-205-069-225;;153-947-887-303-504;;058-375-562-836-105;;006-707-689-459-29X;;036-594-672-948-003;;175-848-266-125-914;;180-295-791-525-434;;030-642-208-724-01X;;099-848-387-400-56X;;015-109-212-500-52X;;026-234-878-168-692;;152-734-280-865-740;;011-181-861-380-530;;096-866-746-743-864;;043-369-112-902-472;;063-745-038-278-465;;141-748-827-420-509;;063-479-285-377-285;;080-616-656-930-540;;027-314-878-690-911,RU;;CA;;JP;;KR;;PT;;PL;;CN;;ES;;AU;;DK;;FI;;BR;;WO;;MX;;US;;IL;;EP,27,095-418-251-758-452;;172-016-358-273-69X;;076-848-262-066-276;;135-481-838-122-470;;098-543-216-736-719;;086-571-364-434-926;;000-725-273-383-720;;056-496-205-069-225;;153-947-887-303-504;;058-375-562-836-105;;006-707-689-459-29X;;036-594-672-948-003;;175-848-266-125-914;;180-295-791-525-434;;030-642-208-724-01X;;099-848-387-400-56X;;015-109-212-500-52X;;026-234-878-168-692;;152-734-280-865-740;;011-181-861-380-530;;096-866-746-743-864;;043-369-112-902-472;;063-745-038-278-465;;141-748-827-420-509;;063-479-285-377-285;;080-616-656-930-540;;027-314-878-690-911,RU;;CA;;JP;;KR;;PT;;PL;;CN;;ES;;AU;;DK;;FI;;BR;;WO;;MX;;US;;IL;;EP,0,A61K31/41;;A61P25/08;;A61K31/41;;A61K31/16;;A61P25/08;;A61K31/41;;A61K31/16;;A61P25/08;;A61K31/41,A61K31/41;;A61K31/16,,0,0,,,,PENDING
33,PL,T3,PL 3711758 T3,095-418-251-758-452,2024-07-01,2024,PL 18878222 T,2018-11-13,KR 20170151248 A;;KR 2018013761 W,2017-11-14,"USE OF CARBAMATE COMPOUND FOR PREVENTING, ALLEVIATING OR TREATING ABSENCE SEIZURE OR EPILEPSY SHOWING ABSENCE SEIZURE",,SK BIOPHARMACEUTICALS CO LTD,SHIN HYE WON,,https://lens.org/095-418-251-758-452,Patent Application,no,0,0,27,095-418-251-758-452;;172-016-358-273-69X;;076-848-262-066-276;;135-481-838-122-470;;098-543-216-736-719;;086-571-364-434-926;;000-725-273-383-720;;056-496-205-069-225;;153-947-887-303-504;;058-375-562-836-105;;006-707-689-459-29X;;036-594-672-948-003;;175-848-266-125-914;;180-295-791-525-434;;030-642-208-724-01X;;099-848-387-400-56X;;015-109-212-500-52X;;026-234-878-168-692;;152-734-280-865-740;;011-181-861-380-530;;096-866-746-743-864;;043-369-112-902-472;;063-745-038-278-465;;141-748-827-420-509;;063-479-285-377-285;;080-616-656-930-540;;027-314-878-690-911,RU;;CA;;JP;;KR;;PT;;PL;;CN;;ES;;AU;;DK;;FI;;BR;;WO;;MX;;US;;IL;;EP,27,095-418-251-758-452;;172-016-358-273-69X;;076-848-262-066-276;;135-481-838-122-470;;098-543-216-736-719;;086-571-364-434-926;;000-725-273-383-720;;056-496-205-069-225;;153-947-887-303-504;;058-375-562-836-105;;006-707-689-459-29X;;036-594-672-948-003;;175-848-266-125-914;;180-295-791-525-434;;030-642-208-724-01X;;099-848-387-400-56X;;015-109-212-500-52X;;026-234-878-168-692;;152-734-280-865-740;;011-181-861-380-530;;096-866-746-743-864;;043-369-112-902-472;;063-745-038-278-465;;141-748-827-420-509;;063-479-285-377-285;;080-616-656-930-540;;027-314-878-690-911,RU;;CA;;JP;;KR;;PT;;PL;;CN;;ES;;AU;;DK;;FI;;BR;;WO;;MX;;US;;IL;;EP,0,A61K31/41;;A61P25/08;;A61K31/41;;A61K31/16;;A61P25/08;;A61K31/41;;A61K31/16;;A61P25/08;;A61K31/41,A61K31/41;;A61K31/16;;A61P25/08;;A61P25/10,,0,0,,,,PENDING
34,IL,B1,IL 274428 B1,086-571-364-434-926,2023-04-01,2023,IL 27442820 A,2020-05-04,KR 20170151248 A;;KR 2018013761 W,2017-11-14,"Use of carbamate compound for preventing, alleviating or treating absence seizure or epilepsy showing absence seizure",,SK BIOPHARMACEUTICALS CO LTD,,,https://lens.org/086-571-364-434-926,Unknown,no,1,0,27,095-418-251-758-452;;172-016-358-273-69X;;076-848-262-066-276;;135-481-838-122-470;;098-543-216-736-719;;086-571-364-434-926;;000-725-273-383-720;;056-496-205-069-225;;153-947-887-303-504;;058-375-562-836-105;;006-707-689-459-29X;;036-594-672-948-003;;175-848-266-125-914;;180-295-791-525-434;;030-642-208-724-01X;;099-848-387-400-56X;;015-109-212-500-52X;;026-234-878-168-692;;152-734-280-865-740;;011-181-861-380-530;;096-866-746-743-864;;043-369-112-902-472;;063-745-038-278-465;;141-748-827-420-509;;063-479-285-377-285;;080-616-656-930-540;;027-314-878-690-911,RU;;CA;;JP;;KR;;PT;;PL;;CN;;ES;;AU;;DK;;FI;;BR;;WO;;MX;;US;;IL;;EP,27,095-418-251-758-452;;172-016-358-273-69X;;076-848-262-066-276;;135-481-838-122-470;;098-543-216-736-719;;086-571-364-434-926;;000-725-273-383-720;;056-496-205-069-225;;153-947-887-303-504;;058-375-562-836-105;;006-707-689-459-29X;;036-594-672-948-003;;175-848-266-125-914;;180-295-791-525-434;;030-642-208-724-01X;;099-848-387-400-56X;;015-109-212-500-52X;;026-234-878-168-692;;152-734-280-865-740;;011-181-861-380-530;;096-866-746-743-864;;043-369-112-902-472;;063-745-038-278-465;;141-748-827-420-509;;063-479-285-377-285;;080-616-656-930-540;;027-314-878-690-911,RU;;CA;;JP;;KR;;PT;;PL;;CN;;ES;;AU;;DK;;FI;;BR;;WO;;MX;;US;;IL;;EP,0,A61K31/41;;A61P25/08;;A61K31/41;;A61K31/16;;A61P25/08;;A61K31/41;;A61K31/16;;A61P25/08;;A61K31/41,A61K31/16;;A61K31/41;;A61P25/08,,1,1,056-518-408-577-152,25769377;;10.1016/j.eplepsyres.2015.01.001,"BIALER, M. ET AL:., PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS: A SUMMARY OF THE TWELFTH EILAT CONFERENCE (EILAT XII), 19 January 2015 (2015-01-19)",PENDING
35,FI,T3,FI 3711758 T3,043-369-112-902-472,2024-05-13,2024,FI 18878222 T,2018-11-13,KR 20170151248 A;;KR 2018013761 W,2017-11-14,"USE OF CARBAMATE COMPOUND FOR PREVENTING, ALLEVIATING OR TREATING ABSENCE SEIZURE OR EPILEPSY SHOWING ABSENCE SEIZURE",,SK BIOPHARMACEUTICALS CO LTD,SHIN HYE WON,,https://lens.org/043-369-112-902-472,Unknown,no,0,0,27,095-418-251-758-452;;172-016-358-273-69X;;076-848-262-066-276;;135-481-838-122-470;;098-543-216-736-719;;086-571-364-434-926;;000-725-273-383-720;;056-496-205-069-225;;153-947-887-303-504;;058-375-562-836-105;;006-707-689-459-29X;;036-594-672-948-003;;175-848-266-125-914;;180-295-791-525-434;;030-642-208-724-01X;;099-848-387-400-56X;;015-109-212-500-52X;;026-234-878-168-692;;152-734-280-865-740;;011-181-861-380-530;;096-866-746-743-864;;043-369-112-902-472;;063-745-038-278-465;;141-748-827-420-509;;063-479-285-377-285;;080-616-656-930-540;;027-314-878-690-911,RU;;CA;;JP;;KR;;PT;;PL;;CN;;ES;;AU;;DK;;FI;;BR;;WO;;MX;;US;;IL;;EP,27,095-418-251-758-452;;172-016-358-273-69X;;076-848-262-066-276;;135-481-838-122-470;;098-543-216-736-719;;086-571-364-434-926;;000-725-273-383-720;;056-496-205-069-225;;153-947-887-303-504;;058-375-562-836-105;;006-707-689-459-29X;;036-594-672-948-003;;175-848-266-125-914;;180-295-791-525-434;;030-642-208-724-01X;;099-848-387-400-56X;;015-109-212-500-52X;;026-234-878-168-692;;152-734-280-865-740;;011-181-861-380-530;;096-866-746-743-864;;043-369-112-902-472;;063-745-038-278-465;;141-748-827-420-509;;063-479-285-377-285;;080-616-656-930-540;;027-314-878-690-911,RU;;CA;;JP;;KR;;PT;;PL;;CN;;ES;;AU;;DK;;FI;;BR;;WO;;MX;;US;;IL;;EP,0,A61K31/41;;A61P25/08;;A61K31/41;;A61K31/16;;A61P25/08;;A61K31/41;;A61K31/16;;A61P25/08;;A61K31/41,A61K31/41;;A61K31/16;;A61P25/08;;A61P25/10,,0,0,,,,PENDING
36,AU,A1,AU 2019/341357 A1,193-541-220-154-003,2021-04-08,2021,AU 2019/341357 A,2019-09-20,KR 20180113956 A;;KR 2019012257 W,2018-09-21,"Compound containing oxadiazole, and pharmaceutical composition containing same",Disclosed in the present invention is an oxadiazole compound and pharmaceutically useful salts thereof. The compound and pharmaceutically useful salts thereof are especially suitable for the treatment of nervous system diseases such as epilepsy.,SK BIOPHARMACEUTICALS CO LTD,RYU CHOON HO;;HAN MIN SOO;;YOON YEO JIN;;KIM YU JIN;;LEE KA EUN;;LEE JU YOUNG;;JUNG MYUNG JIN;;BAEK EUN HEE;;SHIN YU JIN;;CHOI EUN JU;;KANG YOUNG SOON;;KIM YONG SOO;;SONG YEA MI;;KIM JIN SUNG;;LIM HEE JEONG,,https://lens.org/193-541-220-154-003,Patent Application,no,0,0,27,073-783-627-753-21X;;105-837-788-983-833;;193-541-220-154-003;;064-483-078-063-206;;002-871-334-804-591;;119-330-995-364-475;;086-131-270-248-699;;129-312-539-027-444;;157-483-232-156-761;;042-106-055-997-426;;193-011-693-177-215;;026-738-323-595-585;;155-353-465-515-595;;014-035-127-988-051;;196-391-965-699-401;;036-830-218-723-965;;168-613-521-890-497;;143-369-275-856-779;;126-626-178-763-712;;019-976-038-731-541;;169-396-880-557-539;;175-151-470-083-993;;199-474-098-614-213;;019-255-876-702-360;;062-373-315-232-174;;183-911-754-561-669;;097-435-805-189-392,CA;;JP;;KR;;ZA;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,27,073-783-627-753-21X;;105-837-788-983-833;;193-541-220-154-003;;064-483-078-063-206;;002-871-334-804-591;;119-330-995-364-475;;086-131-270-248-699;;129-312-539-027-444;;157-483-232-156-761;;042-106-055-997-426;;193-011-693-177-215;;026-738-323-595-585;;155-353-465-515-595;;014-035-127-988-051;;196-391-965-699-401;;036-830-218-723-965;;168-613-521-890-497;;143-369-275-856-779;;126-626-178-763-712;;019-976-038-731-541;;169-396-880-557-539;;175-151-470-083-993;;199-474-098-614-213;;019-255-876-702-360;;062-373-315-232-174;;183-911-754-561-669;;097-435-805-189-392,CA;;JP;;KR;;ZA;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,0,C07D271/10;;A61K31/4245;;A61P25/08;;C07D271/06;;A61K31/4245;;A61P25/00;;C07D271/10;;C07D271/10;;A61K31/4245;;A61P25/00;;A61P25/08;;A61K31/4245;;C07D271/10,C07D271/10;;A61K31/4245;;A61P25/00,,0,0,,,,ACTIVE
37,IL,A,IL 274428 A,076-848-262-066-276,2020-06-30,2020,IL 27442820 A,2020-05-04,KR 20170151248 A;;KR 2018013761 W,2017-11-14,"Use of carbamate compound for preventing, alleviating or treating absence seizure or epilepsy showing absence seizure",,SK BIOPHARMACEUTICALS CO LTD,,,https://lens.org/076-848-262-066-276,Patent Application,no,0,0,27,095-418-251-758-452;;172-016-358-273-69X;;076-848-262-066-276;;135-481-838-122-470;;098-543-216-736-719;;086-571-364-434-926;;000-725-273-383-720;;056-496-205-069-225;;153-947-887-303-504;;058-375-562-836-105;;006-707-689-459-29X;;036-594-672-948-003;;175-848-266-125-914;;180-295-791-525-434;;030-642-208-724-01X;;099-848-387-400-56X;;015-109-212-500-52X;;026-234-878-168-692;;152-734-280-865-740;;011-181-861-380-530;;096-866-746-743-864;;043-369-112-902-472;;063-745-038-278-465;;141-748-827-420-509;;063-479-285-377-285;;080-616-656-930-540;;027-314-878-690-911,RU;;CA;;JP;;KR;;PT;;PL;;CN;;ES;;AU;;DK;;FI;;BR;;WO;;MX;;US;;IL;;EP,27,095-418-251-758-452;;172-016-358-273-69X;;076-848-262-066-276;;135-481-838-122-470;;098-543-216-736-719;;086-571-364-434-926;;000-725-273-383-720;;056-496-205-069-225;;153-947-887-303-504;;058-375-562-836-105;;006-707-689-459-29X;;036-594-672-948-003;;175-848-266-125-914;;180-295-791-525-434;;030-642-208-724-01X;;099-848-387-400-56X;;015-109-212-500-52X;;026-234-878-168-692;;152-734-280-865-740;;011-181-861-380-530;;096-866-746-743-864;;043-369-112-902-472;;063-745-038-278-465;;141-748-827-420-509;;063-479-285-377-285;;080-616-656-930-540;;027-314-878-690-911,RU;;CA;;JP;;KR;;PT;;PL;;CN;;ES;;AU;;DK;;FI;;BR;;WO;;MX;;US;;IL;;EP,0,A61K31/41;;A61P25/08;;A61K31/41;;A61K31/16;;A61P25/08;;A61K31/41;;A61K31/16;;A61P25/08;;A61K31/41,,,0,0,,,,PENDING
38,TW,A,TW 202023547 A,062-373-315-232-174,2020-07-01,2020,TW 108133837 A,2019-09-19,KR 20180113956 A,2018-09-21,Compound having oxadiazole and pharmaceutical composition containing the same,Disclosed are oxadiazole compounds and pharmaceutically acceptable salts thereof. The compounds and pharmaceutically acceptable salts thereof are specifically suitable for the treatment of neurological diseases such as epilepsy.,SK BIOPHARMACEUTICALS CO LTD,RYU CHOON-HO;;HAN MIN-SOO;;YOON YEO-JIN;;KIM YU-JIN;;LEE KA-EUN;;LEE JU-YOUNG;;JUNG MYUNG-JIN;;BAEK EUN-HEE;;SHIN YU-JIN;;CHOI EUN-JU;;KANG YOUNG-SOON;;KIM YONG-SOO;;SONG YEA-MI;;KIM JIN-SUNG;;LIM HEE-JEONG,,https://lens.org/062-373-315-232-174,Patent of Addition,no,0,0,27,073-783-627-753-21X;;105-837-788-983-833;;193-541-220-154-003;;064-483-078-063-206;;002-871-334-804-591;;119-330-995-364-475;;086-131-270-248-699;;129-312-539-027-444;;157-483-232-156-761;;042-106-055-997-426;;193-011-693-177-215;;026-738-323-595-585;;155-353-465-515-595;;014-035-127-988-051;;196-391-965-699-401;;036-830-218-723-965;;168-613-521-890-497;;143-369-275-856-779;;126-626-178-763-712;;019-976-038-731-541;;169-396-880-557-539;;175-151-470-083-993;;199-474-098-614-213;;019-255-876-702-360;;062-373-315-232-174;;183-911-754-561-669;;097-435-805-189-392,CA;;JP;;KR;;ZA;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,27,073-783-627-753-21X;;105-837-788-983-833;;193-541-220-154-003;;064-483-078-063-206;;002-871-334-804-591;;119-330-995-364-475;;086-131-270-248-699;;129-312-539-027-444;;157-483-232-156-761;;042-106-055-997-426;;193-011-693-177-215;;026-738-323-595-585;;155-353-465-515-595;;014-035-127-988-051;;196-391-965-699-401;;036-830-218-723-965;;168-613-521-890-497;;143-369-275-856-779;;126-626-178-763-712;;019-976-038-731-541;;169-396-880-557-539;;175-151-470-083-993;;199-474-098-614-213;;019-255-876-702-360;;062-373-315-232-174;;183-911-754-561-669;;097-435-805-189-392,CA;;JP;;KR;;ZA;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,0,C07D271/10;;A61K31/4245;;A61P25/08;;C07D271/06;;A61K31/4245;;A61P25/00;;C07D271/10;;C07D271/10;;A61K31/4245;;A61P25/00;;A61P25/08;;A61K31/4245;;C07D271/10,A61K31/4245;;C07D271/10,,0,0,,,,ACTIVE
39,CA,A1,CA 3112700 A1,036-830-218-723-965,2020-03-26,2020,CA 3112700 A,2019-09-20,KR 20180113956 A;;KR 2019012257 W,2018-09-21,"COMPOUND CONTAINING OXADIAZOLE, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME",Disclosed in the present invention is an oxadiazole compound and pharmaceutically useful salts thereof. The compound and pharmaceutically useful salts thereof are especially suitable for the treatment of nervous system diseases such as epilepsy.,SK BIOPHARMACEUTICALS CO LTD,RYU CHOON HO;;HAN MIN SOO;;YOON YEO JIN;;KIM YU JIN;;LEE KA EUN;;LEE JU YOUNG;;JUNG MYUNG JIN;;BAEK EUN HEE;;SHIN YU JIN;;CHOI EUN JU;;KANG YOUNG SOON;;KIM YONG SOO;;SONG YEA MI;;KIM JIN SUNG;;LIM HEE JEONG,,https://lens.org/036-830-218-723-965,Patent Application,no,0,0,27,073-783-627-753-21X;;105-837-788-983-833;;193-541-220-154-003;;064-483-078-063-206;;002-871-334-804-591;;119-330-995-364-475;;086-131-270-248-699;;129-312-539-027-444;;157-483-232-156-761;;042-106-055-997-426;;193-011-693-177-215;;026-738-323-595-585;;155-353-465-515-595;;014-035-127-988-051;;196-391-965-699-401;;036-830-218-723-965;;168-613-521-890-497;;143-369-275-856-779;;126-626-178-763-712;;019-976-038-731-541;;169-396-880-557-539;;175-151-470-083-993;;199-474-098-614-213;;019-255-876-702-360;;062-373-315-232-174;;183-911-754-561-669;;097-435-805-189-392,CA;;JP;;KR;;ZA;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,27,073-783-627-753-21X;;105-837-788-983-833;;193-541-220-154-003;;064-483-078-063-206;;002-871-334-804-591;;119-330-995-364-475;;086-131-270-248-699;;129-312-539-027-444;;157-483-232-156-761;;042-106-055-997-426;;193-011-693-177-215;;026-738-323-595-585;;155-353-465-515-595;;014-035-127-988-051;;196-391-965-699-401;;036-830-218-723-965;;168-613-521-890-497;;143-369-275-856-779;;126-626-178-763-712;;019-976-038-731-541;;169-396-880-557-539;;175-151-470-083-993;;199-474-098-614-213;;019-255-876-702-360;;062-373-315-232-174;;183-911-754-561-669;;097-435-805-189-392,CA;;JP;;KR;;ZA;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,0,C07D271/10;;A61K31/4245;;A61P25/08;;C07D271/06;;A61K31/4245;;A61P25/00;;C07D271/10;;C07D271/10;;A61K31/4245;;A61P25/00;;A61P25/08;;A61K31/4245;;C07D271/10,C07D271/10;;A61K31/4245;;A61P25/00,,0,0,,,,PENDING
40,IL,B2,IL 274428 B2,006-707-689-459-29X,2023-08-01,2023,IL 27442820 A,2020-05-04,KR 20170151248 A;;KR 2018013761 W,2017-11-14,"Use of carbamate compound for preventing, alleviating or treating absence seizure or epilepsy showing absence seizure",,SK BIOPHARMACEUTICALS CO LTD,,,https://lens.org/006-707-689-459-29X,Unknown,no,1,0,27,095-418-251-758-452;;172-016-358-273-69X;;076-848-262-066-276;;135-481-838-122-470;;098-543-216-736-719;;086-571-364-434-926;;000-725-273-383-720;;056-496-205-069-225;;153-947-887-303-504;;058-375-562-836-105;;006-707-689-459-29X;;036-594-672-948-003;;175-848-266-125-914;;180-295-791-525-434;;030-642-208-724-01X;;099-848-387-400-56X;;015-109-212-500-52X;;026-234-878-168-692;;152-734-280-865-740;;011-181-861-380-530;;096-866-746-743-864;;043-369-112-902-472;;063-745-038-278-465;;141-748-827-420-509;;063-479-285-377-285;;080-616-656-930-540;;027-314-878-690-911,RU;;CA;;JP;;KR;;PT;;PL;;CN;;ES;;AU;;DK;;FI;;BR;;WO;;MX;;US;;IL;;EP,27,095-418-251-758-452;;172-016-358-273-69X;;076-848-262-066-276;;135-481-838-122-470;;098-543-216-736-719;;086-571-364-434-926;;000-725-273-383-720;;056-496-205-069-225;;153-947-887-303-504;;058-375-562-836-105;;006-707-689-459-29X;;036-594-672-948-003;;175-848-266-125-914;;180-295-791-525-434;;030-642-208-724-01X;;099-848-387-400-56X;;015-109-212-500-52X;;026-234-878-168-692;;152-734-280-865-740;;011-181-861-380-530;;096-866-746-743-864;;043-369-112-902-472;;063-745-038-278-465;;141-748-827-420-509;;063-479-285-377-285;;080-616-656-930-540;;027-314-878-690-911,RU;;CA;;JP;;KR;;PT;;PL;;CN;;ES;;AU;;DK;;FI;;BR;;WO;;MX;;US;;IL;;EP,0,A61K31/41;;A61P25/08;;A61K31/41;;A61K31/16;;A61P25/08;;A61K31/41;;A61K31/16;;A61P25/08;;A61K31/41,A61K31/16;;A61K31/41;;A61P25/08,,1,1,056-518-408-577-152,25769377;;10.1016/j.eplepsyres.2015.01.001,"BIALER, M. ET AL:., PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS: A SUMMARY OF THE TWELFTH EILAT CONFERENCE (EILAT XII), 19 January 2015 (2015-01-19)",PENDING
41,CN,A,CN 113272285 A,073-783-627-753-21X,2021-08-17,2021,CN 201980076515 A,2019-09-20,KR 20180113956 A;;KR 2019012257 W,2018-09-21,"COMPOUND CONTAINING OXADIAZOLE, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME",Disclosed in the present invention is an oxadiazole compound and pharmaceutically useful salts thereof. The compound and pharmaceutically useful salts thereof are especially suitable for the treatment of nervous system diseases such as epilepsy.,SK BIOPHARMACEUTICALS CO LTD,RYU CHOON-HO;;HAN MIN-SOO;;YOON YEO-JIN;;KIM YU-JIN;;LEE KA-EUN;;LEE JU-YOUNG;;JUNG MYUNG-JIN;;BAEK EUN-HEE;;SHIN YU-JIN;;CHOI EUN-JU;;KANG YOUNG-SOON;;KIM YONG-SOO;;SONG YEA-MI;;KIM JIN-SUNG;;LIM HEE-JEONG,,https://lens.org/073-783-627-753-21X,Patent Application,no,5,0,27,073-783-627-753-21X;;105-837-788-983-833;;193-541-220-154-003;;064-483-078-063-206;;002-871-334-804-591;;119-330-995-364-475;;086-131-270-248-699;;129-312-539-027-444;;157-483-232-156-761;;042-106-055-997-426;;193-011-693-177-215;;026-738-323-595-585;;155-353-465-515-595;;014-035-127-988-051;;196-391-965-699-401;;036-830-218-723-965;;168-613-521-890-497;;143-369-275-856-779;;126-626-178-763-712;;019-976-038-731-541;;169-396-880-557-539;;175-151-470-083-993;;199-474-098-614-213;;019-255-876-702-360;;062-373-315-232-174;;183-911-754-561-669;;097-435-805-189-392,CA;;JP;;KR;;ZA;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,27,073-783-627-753-21X;;105-837-788-983-833;;193-541-220-154-003;;064-483-078-063-206;;002-871-334-804-591;;119-330-995-364-475;;086-131-270-248-699;;129-312-539-027-444;;157-483-232-156-761;;042-106-055-997-426;;193-011-693-177-215;;026-738-323-595-585;;155-353-465-515-595;;014-035-127-988-051;;196-391-965-699-401;;036-830-218-723-965;;168-613-521-890-497;;143-369-275-856-779;;126-626-178-763-712;;019-976-038-731-541;;169-396-880-557-539;;175-151-470-083-993;;199-474-098-614-213;;019-255-876-702-360;;062-373-315-232-174;;183-911-754-561-669;;097-435-805-189-392,CA;;JP;;KR;;ZA;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,0,C07D271/10;;A61K31/4245;;A61P25/08;;C07D271/06;;A61K31/4245;;A61P25/00;;C07D271/10;;C07D271/10;;A61K31/4245;;A61P25/00;;A61P25/08;;A61K31/4245;;C07D271/10,C07D271/10;;A61K31/4245;;A61P25/00,,1,0,,,"MEIR BIALER 等: ""Progress report on new antiepileptic drugs:A summary of the Eigth Eilat Conference(EILAT VIII)""",PENDING
42,MX,A,MX 2021003204 A,169-396-880-557-539,2021-05-27,2021,MX 2021003204 A,2019-09-20,KR 20180113956 A;;KR 2019012257 W,2018-09-21,"COMPOUND CONTAINING OXADIAZOLE, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME.",Disclosed in the present invention is an oxadiazole compound and pharmaceutically useful salts thereof. The compound and pharmaceutically useful salts thereof are especially suitable for the treatment of nervous system diseases such as epilepsy.,SK BIOPHARMACEUTICALS CO LTD,LEE JU YOUNG;;HAN MIN SOO;;KANG YOUNG SOON;;SHIN YU JIN;;CHOI EUN JU;;RYU CHOON HO;;YOON YEO JIN;;KIM YU JIN;;LEE KA EUN;;JUNG MYUNG JIN;;BAEK EUN HEE;;KIM YONG SOO;;SONG YEA MI;;KIM JIN SUNG;;LIM HEE JEONG,,https://lens.org/169-396-880-557-539,Patent Application,no,0,0,27,073-783-627-753-21X;;105-837-788-983-833;;193-541-220-154-003;;064-483-078-063-206;;002-871-334-804-591;;119-330-995-364-475;;086-131-270-248-699;;129-312-539-027-444;;157-483-232-156-761;;042-106-055-997-426;;193-011-693-177-215;;026-738-323-595-585;;155-353-465-515-595;;014-035-127-988-051;;196-391-965-699-401;;036-830-218-723-965;;168-613-521-890-497;;143-369-275-856-779;;126-626-178-763-712;;019-976-038-731-541;;169-396-880-557-539;;175-151-470-083-993;;199-474-098-614-213;;019-255-876-702-360;;062-373-315-232-174;;183-911-754-561-669;;097-435-805-189-392,CA;;JP;;KR;;ZA;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,27,073-783-627-753-21X;;105-837-788-983-833;;193-541-220-154-003;;064-483-078-063-206;;002-871-334-804-591;;119-330-995-364-475;;086-131-270-248-699;;129-312-539-027-444;;157-483-232-156-761;;042-106-055-997-426;;193-011-693-177-215;;026-738-323-595-585;;155-353-465-515-595;;014-035-127-988-051;;196-391-965-699-401;;036-830-218-723-965;;168-613-521-890-497;;143-369-275-856-779;;126-626-178-763-712;;019-976-038-731-541;;169-396-880-557-539;;175-151-470-083-993;;199-474-098-614-213;;019-255-876-702-360;;062-373-315-232-174;;183-911-754-561-669;;097-435-805-189-392,CA;;JP;;KR;;ZA;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,0,C07D271/10;;A61K31/4245;;A61P25/08;;C07D271/06;;A61K31/4245;;A61P25/00;;C07D271/10;;C07D271/10;;A61K31/4245;;A61P25/00;;A61P25/08;;A61K31/4245;;C07D271/10,A61K31/4245;;A61P25/00;;C07D271/10,,0,0,,,,PENDING
43,WO,A1,WO 2020/060299 A1,126-626-178-763-712,2020-03-26,2020,KR 2019012257 W,2019-09-20,KR 20180113956 A,2018-09-21,"COMPOUND CONTAINING OXADIAZOLE, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME",Disclosed in the present invention is an oxadiazole compound and pharmaceutically useful salts thereof. The compound and pharmaceutically useful salts thereof are especially suitable for the treatment of nervous system diseases such as epilepsy.,SK BIOPHARMACEUTICALS CO LTD,RYU CHOON HO;;HAN MIN SOO;;YOON YEO JIN;;KIM YU JIN;;LEE KA EUN;;LEE JU YOUNG;;JUNG MYUNG JIN;;BAEK EUN HEE;;SHIN YU JIN;;CHOI EUN JU;;KANG YOUNG SOON;;KIM YONG SOO;;SONG YEA MI;;KIM JIN SUNG;;LIM HEE JEONG,,https://lens.org/126-626-178-763-712,Patent Application,yes,7,0,27,073-783-627-753-21X;;105-837-788-983-833;;193-541-220-154-003;;064-483-078-063-206;;002-871-334-804-591;;119-330-995-364-475;;086-131-270-248-699;;129-312-539-027-444;;157-483-232-156-761;;042-106-055-997-426;;193-011-693-177-215;;026-738-323-595-585;;155-353-465-515-595;;014-035-127-988-051;;196-391-965-699-401;;036-830-218-723-965;;168-613-521-890-497;;143-369-275-856-779;;126-626-178-763-712;;019-976-038-731-541;;169-396-880-557-539;;175-151-470-083-993;;199-474-098-614-213;;019-255-876-702-360;;062-373-315-232-174;;183-911-754-561-669;;097-435-805-189-392,CA;;JP;;KR;;ZA;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,27,073-783-627-753-21X;;105-837-788-983-833;;193-541-220-154-003;;064-483-078-063-206;;002-871-334-804-591;;119-330-995-364-475;;086-131-270-248-699;;129-312-539-027-444;;157-483-232-156-761;;042-106-055-997-426;;193-011-693-177-215;;026-738-323-595-585;;155-353-465-515-595;;014-035-127-988-051;;196-391-965-699-401;;036-830-218-723-965;;168-613-521-890-497;;143-369-275-856-779;;126-626-178-763-712;;019-976-038-731-541;;169-396-880-557-539;;175-151-470-083-993;;199-474-098-614-213;;019-255-876-702-360;;062-373-315-232-174;;183-911-754-561-669;;097-435-805-189-392,CA;;JP;;KR;;ZA;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,0,C07D271/10;;A61K31/4245;;A61P25/08;;C07D271/06;;A61K31/4245;;A61P25/00;;C07D271/10;;C07D271/10;;A61K31/4245;;A61P25/00;;A61P25/08;;A61K31/4245;;C07D271/10,C07D271/10;;A61K31/4245;;A61P25/00,,2,1,056-518-408-577-152,25769377;;10.1016/j.eplepsyres.2015.01.001,"BIALER, M. ET AL.: ""Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (ESLAT XII"", EPILEPSY RESEARCH., vol. 111, 2015, pages 85 - 141, XP055611172, DOI: 10.1016/j.eplepsyres.2015.01.001;;See also references of EP 3854788A4",PENDING
44,AU,B2,AU 2019/341357 B2,168-613-521-890-497,2023-03-02,2023,AU 2019/341357 A,2019-09-20,KR 20180113956 A;;KR 2019012257 W,2018-09-21,"Compound containing oxadiazole, and pharmaceutical composition containing same",Disclosed in the present invention is an oxadiazole compound and pharmaceutically useful salts thereof. The compound and pharmaceutically useful salts thereof are especially suitable for the treatment of nervous system diseases such as epilepsy.,SK BIOPHARMACEUTICALS CO LTD,RYU CHOON HO;;HAN MIN SOO;;YOON YEO JIN;;KIM YU JIN;;LEE KA EUN;;LEE JU YOUNG;;JUNG MYUNG JIN;;BAEK EUN HEE;;SHIN YU JIN;;CHOI EUN JU;;KANG YOUNG SOON;;KIM YONG SOO;;SONG YEA MI;;KIM JIN SUNG;;LIM HEE JEONG,,https://lens.org/168-613-521-890-497,Granted Patent,no,2,0,27,073-783-627-753-21X;;105-837-788-983-833;;193-541-220-154-003;;064-483-078-063-206;;002-871-334-804-591;;119-330-995-364-475;;086-131-270-248-699;;129-312-539-027-444;;157-483-232-156-761;;042-106-055-997-426;;193-011-693-177-215;;026-738-323-595-585;;155-353-465-515-595;;014-035-127-988-051;;196-391-965-699-401;;036-830-218-723-965;;168-613-521-890-497;;143-369-275-856-779;;126-626-178-763-712;;019-976-038-731-541;;169-396-880-557-539;;175-151-470-083-993;;199-474-098-614-213;;019-255-876-702-360;;062-373-315-232-174;;183-911-754-561-669;;097-435-805-189-392,CA;;JP;;KR;;ZA;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,27,073-783-627-753-21X;;105-837-788-983-833;;193-541-220-154-003;;064-483-078-063-206;;002-871-334-804-591;;119-330-995-364-475;;086-131-270-248-699;;129-312-539-027-444;;157-483-232-156-761;;042-106-055-997-426;;193-011-693-177-215;;026-738-323-595-585;;155-353-465-515-595;;014-035-127-988-051;;196-391-965-699-401;;036-830-218-723-965;;168-613-521-890-497;;143-369-275-856-779;;126-626-178-763-712;;019-976-038-731-541;;169-396-880-557-539;;175-151-470-083-993;;199-474-098-614-213;;019-255-876-702-360;;062-373-315-232-174;;183-911-754-561-669;;097-435-805-189-392,CA;;JP;;KR;;ZA;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,0,C07D271/10;;A61K31/4245;;A61P25/08;;C07D271/06;;A61K31/4245;;A61P25/00;;C07D271/10;;C07D271/10;;A61K31/4245;;A61P25/00;;A61P25/08;;A61K31/4245;;C07D271/10,C07D271/10;;A61K31/4245;;A61P25/00,,1,1,056-518-408-577-152,25769377;;10.1016/j.eplepsyres.2015.01.001,"BIALER, M. ET AL.: ""Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference ESLAT XII"", EPILEPSY RESEARCH, 2015, vol. 111, pages 85 - 141",ACTIVE
45,US,A1,US 2024/0374568 A1,047-394-776-275-766,2024-11-14,2024,US 202418779456 A,2024-07-22,US 202418779456 A;;KR 20160170389 A;;US 201916468756 A;;KR 2017014727 W,2016-12-14,PARENTERAL LIQUID PREPARATION COMPRISING CARBAMATE COMPOUND,"The present invention relates to a parenteral liquid preparation containing, as active ingredients; a carbamate compound of chemical formula 1, an isomer thereof, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof; and a cyclodextrin derivative.",SK BIOPHARMACEUTICALS CO LTD,BAEK MYOUNG KI;;LEE JI HYE;;CHOI SO YOUNG,SK BIOPHARMACEUTICALS CO. LTD (2019-08-01),https://lens.org/047-394-776-275-766,Patent Application,yes,0,0,30,060-923-564-159-175;;169-666-013-418-722;;084-296-444-876-55X;;041-798-041-171-74X;;079-780-444-625-21X;;050-316-334-099-640;;177-941-877-877-786;;128-343-568-859-560;;154-925-592-541-053;;113-768-574-798-142;;185-075-412-068-657;;094-097-745-734-265;;000-524-521-089-352;;047-394-776-275-766;;091-320-116-911-871;;106-496-612-257-196;;150-043-787-521-570;;003-852-561-431-88X;;185-757-584-499-89X;;167-469-769-765-999;;193-694-435-058-657;;143-802-406-793-830;;128-702-725-238-816;;032-481-162-424-369;;081-969-435-631-459;;061-310-025-264-528;;106-667-910-198-95X;;055-784-025-208-347;;095-049-103-255-780;;173-676-504-997-064,CA;;RU;;JP;;KR;;PT;;ZA;;PL;;CN;;CL;;ES;;AU;;DK;;BR;;WO;;MX;;US;;EP;;IL,30,060-923-564-159-175;;169-666-013-418-722;;084-296-444-876-55X;;041-798-041-171-74X;;079-780-444-625-21X;;050-316-334-099-640;;177-941-877-877-786;;128-343-568-859-560;;154-925-592-541-053;;113-768-574-798-142;;185-075-412-068-657;;094-097-745-734-265;;000-524-521-089-352;;047-394-776-275-766;;091-320-116-911-871;;106-496-612-257-196;;150-043-787-521-570;;003-852-561-431-88X;;185-757-584-499-89X;;167-469-769-765-999;;193-694-435-058-657;;143-802-406-793-830;;128-702-725-238-816;;032-481-162-424-369;;081-969-435-631-459;;061-310-025-264-528;;106-667-910-198-95X;;055-784-025-208-347;;095-049-103-255-780;;173-676-504-997-064,CA;;RU;;JP;;KR;;PT;;ZA;;PL;;CN;;CL;;ES;;AU;;DK;;BR;;WO;;MX;;US;;EP;;IL,0,A61K9/08;;A61K31/41;;A61K47/40;;A61K47/6951;;A61P25/00;;A61P25/06;;A61P25/08;;A61P25/14;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/34;;A61P3/04;;A61P9/10;;A61P21/02;;A61K9/08;;A61K31/325;;A61K31/41;;A61K9/0019;;A61K47/6951;;A61K31/4192;;A61P25/08;;A61K31/41;;A61K9/0019;;A61K31/4192;;A61K9/08;;A61P25/08;;A61K47/40;;A61K47/6951;;A61K31/325;;A61K47/69;;A61K9/08;;A61K47/40;;A61K9/0019;;A61K31/41;;A61K31/325;;A61K31/41;;A61K9/0019;;A61K9/08;;A61K47/69;;A61P25/08;;A61K9/0019;;A61K31/41;;A61K47/40,A61K31/41;;A61K9/00;;A61K47/40,,0,0,,,,PENDING
46,AU,B2,AU 2006/237798 B2,017-987-040-851-615,2012-07-12,2012,AU 2006/237798 A,2006-04-21,US 67453005 P;;KR 2006001523 W,2005-04-22,Neurotherapeutic azole compounds,"Azole compounds containing carbamoyl group and pharmaceutically useful salts thereof are described. The compounds are effective anticonvulsants which are used in the treatment of disorders of the central nervous system, especially as anxiety, depression, convulsion, epilepsy, migraine, bipolar disorder, drug abuse, smoking, ADHD, obesity, sleep disorder, neuropathic pain, stroke, cognitive impairment, neurodegeneration, stroke and muscle spasm.",SK BIOPHARMACEUTICALS CO LTD,KU BON-CHUL;;IM DAE-JOONG;;KANG YOUNG-SUN;;YI HAN-JU;;SHIN YU-JIN;;LEE EUN-HO;;KIM CHOON-GIL;;CHOI YONG-MOON;;LEE HYUN-SEOK,"SK BIOPHARMACEUTICALS CO., LTD. (2012-02-09)",https://lens.org/017-987-040-851-615,Granted Patent,no,1,0,34,016-822-368-774-981;;196-754-367-480-282;;025-132-948-117-281;;019-469-508-277-771;;157-657-824-512-659;;122-254-729-268-807;;180-232-893-065-231;;017-987-040-851-615;;000-680-957-729-597;;006-920-412-140-801;;139-527-526-424-169;;069-474-687-657-162;;083-286-225-706-598;;056-745-581-271-210;;067-295-709-373-878;;013-963-816-145-602;;194-960-877-543-401;;029-305-540-871-019;;042-360-756-119-232;;101-617-645-457-318;;018-793-095-827-904;;161-520-181-401-177;;104-338-199-379-619;;077-980-256-736-311;;000-732-844-264-860;;067-331-391-354-92X;;134-514-719-844-835;;178-238-990-495-618;;190-616-138-405-656;;142-903-062-833-312;;034-768-583-874-799;;179-653-074-541-863;;075-627-671-506-61X;;099-025-001-215-146,CA;;RU;;KR;;JP;;PT;;ZA;;CN;;NL;;PL;;ES;;MY;;TW;;AU;;DK;;BR;;FI;;MX;;WO;;US;;AR;;EP,34,016-822-368-774-981;;196-754-367-480-282;;025-132-948-117-281;;019-469-508-277-771;;157-657-824-512-659;;122-254-729-268-807;;180-232-893-065-231;;017-987-040-851-615;;000-680-957-729-597;;006-920-412-140-801;;139-527-526-424-169;;069-474-687-657-162;;083-286-225-706-598;;056-745-581-271-210;;067-295-709-373-878;;013-963-816-145-602;;194-960-877-543-401;;029-305-540-871-019;;042-360-756-119-232;;101-617-645-457-318;;018-793-095-827-904;;161-520-181-401-177;;104-338-199-379-619;;077-980-256-736-311;;000-732-844-264-860;;067-331-391-354-92X;;134-514-719-844-835;;178-238-990-495-618;;190-616-138-405-656;;142-903-062-833-312;;034-768-583-874-799;;179-653-074-541-863;;075-627-671-506-61X;;099-025-001-215-146,CA;;RU;;KR;;JP;;PT;;ZA;;CN;;NL;;PL;;ES;;MY;;TW;;AU;;DK;;BR;;FI;;MX;;WO;;US;;AR;;EP,0,C07D249/04;;C07D257/04;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/06;;A61P21/00;;A61P25/00;;A61P25/06;;A61P25/08;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/34;;A61P29/00;;A61P3/04;;A61P9/10;;C07D257/04;;A61K31/4192;;C07D257/04;;C07D401/12;;C07D401/14;;C07D249/04;;C07D403/12;;C07D405/06,C07D257/04,,1,1,035-230-547-171-641,10.1021/cr950066q;;11848856,"PATANI, G. et al., Chemical Reviews, 1996, vol. 96, pages 3147-3176",ACTIVE
47,MY,A,MY 148589 A,179-653-074-541-863,2013-05-15,2013,MY PI20061865 A,2006-04-24,US 67453005 P,2005-04-22,NEUROTHERAPEUTIC AZOLE COMPOUNDS,"AZOLE COMPOUNDS CONTAINING CARBAMOYL GROUP AND PHARMACEUTICALLY USEFUL SALTS THEREOF ARE DESCRIBED. THE COMPOUNDS ARE EFFECTIVE ANTICONVULSANTS WHICH ARE USED IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM, ESPECIALLY AS ANXIETY, DEPRESSION, CONVULSION, EPILEPSY, MIGRAINE, BIPOLAR DISORDER, DRUG ABUSE, SMOKING, ADHD, OBESITY, SLEEP DISORDER, NEUROPATHIC PAIN, STROKE, COGNITIVE IMPAIRMENT, NEURODEGENERATION, STROKE AND MUSCLE SPASM.",SK BIOPHARMACEUTICALS CO LTD,MOON CHOI YONG;;GIL KIM CHOON;;SUN KANG YOUNG;;JU YI HAN;;SEOK LEE HYUN;;CHUL KU BON;;HO LEE EUN;;JOONG IM DAE;;JIN SHIN YU,,https://lens.org/179-653-074-541-863,Granted Patent,no,0,0,34,016-822-368-774-981;;196-754-367-480-282;;025-132-948-117-281;;019-469-508-277-771;;157-657-824-512-659;;122-254-729-268-807;;180-232-893-065-231;;017-987-040-851-615;;000-680-957-729-597;;006-920-412-140-801;;139-527-526-424-169;;069-474-687-657-162;;083-286-225-706-598;;056-745-581-271-210;;067-295-709-373-878;;013-963-816-145-602;;194-960-877-543-401;;029-305-540-871-019;;042-360-756-119-232;;101-617-645-457-318;;018-793-095-827-904;;161-520-181-401-177;;104-338-199-379-619;;077-980-256-736-311;;000-732-844-264-860;;067-331-391-354-92X;;134-514-719-844-835;;178-238-990-495-618;;190-616-138-405-656;;142-903-062-833-312;;034-768-583-874-799;;179-653-074-541-863;;075-627-671-506-61X;;099-025-001-215-146,CA;;RU;;KR;;JP;;PT;;ZA;;CN;;NL;;PL;;ES;;MY;;TW;;AU;;DK;;BR;;FI;;MX;;WO;;US;;AR;;EP,34,016-822-368-774-981;;196-754-367-480-282;;025-132-948-117-281;;019-469-508-277-771;;157-657-824-512-659;;122-254-729-268-807;;180-232-893-065-231;;017-987-040-851-615;;000-680-957-729-597;;006-920-412-140-801;;139-527-526-424-169;;069-474-687-657-162;;083-286-225-706-598;;056-745-581-271-210;;067-295-709-373-878;;013-963-816-145-602;;194-960-877-543-401;;029-305-540-871-019;;042-360-756-119-232;;101-617-645-457-318;;018-793-095-827-904;;161-520-181-401-177;;104-338-199-379-619;;077-980-256-736-311;;000-732-844-264-860;;067-331-391-354-92X;;134-514-719-844-835;;178-238-990-495-618;;190-616-138-405-656;;142-903-062-833-312;;034-768-583-874-799;;179-653-074-541-863;;075-627-671-506-61X;;099-025-001-215-146,CA;;RU;;KR;;JP;;PT;;ZA;;CN;;NL;;PL;;ES;;MY;;TW;;AU;;DK;;BR;;FI;;MX;;WO;;US;;AR;;EP,0,C07D257/04;;A61P3/04;;A61P9/10;;A61P21/00;;A61P25/00;;A61P25/06;;A61P25/08;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/34;;A61P29/00;;C07D249/04;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/06;;C07D257/04;;A61K31/4192;;C07D257/04;;C07D249/04;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/06,A61K31/445,,0,0,,,,ACTIVE
48,US,A1,US 2021/0115001 A1,014-035-127-988-051,2021-04-22,2021,US 201916613659 A,2019-09-20,KR 20180113956 A;;KR 2019012257 W,2018-09-21,Compound Having Oxadiazole And Pharmaceutical Composition Containing The Same,Disclosed are oxadiazole compounds and pharmaceutically acceptable salts thereof. The compounds and pharmaceutically acceptable salts thereof are specifically suitable for the treatment of neurological diseases such as epilepsy.,SK BIOPHARMACEUTICALS CO LTD,RYU CHOON HO;;HAN MIN SOO;;YOON YEO JIN;;KIM YU JIN;;LEE KA EUN;;LEE JU YOUNG;;JUNG MYUNG JIN;;BAEK EUN HEE;;SHIN YU JIN;;CHOI EUN JU;;KANG YOUNG SOON;;KIM YONG SOO;;SONG YEA MI;;KIM JIN SUNG;;LIM HEE JEONG,SK BIOPHARMACEUTICALS CO. LTD (2019-11-13),https://lens.org/014-035-127-988-051,Patent Application,yes,0,0,27,073-783-627-753-21X;;105-837-788-983-833;;193-541-220-154-003;;064-483-078-063-206;;002-871-334-804-591;;119-330-995-364-475;;086-131-270-248-699;;129-312-539-027-444;;157-483-232-156-761;;042-106-055-997-426;;193-011-693-177-215;;026-738-323-595-585;;155-353-465-515-595;;014-035-127-988-051;;196-391-965-699-401;;036-830-218-723-965;;168-613-521-890-497;;143-369-275-856-779;;126-626-178-763-712;;019-976-038-731-541;;169-396-880-557-539;;175-151-470-083-993;;199-474-098-614-213;;019-255-876-702-360;;062-373-315-232-174;;183-911-754-561-669;;097-435-805-189-392,CA;;JP;;KR;;ZA;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,27,073-783-627-753-21X;;105-837-788-983-833;;193-541-220-154-003;;064-483-078-063-206;;002-871-334-804-591;;119-330-995-364-475;;086-131-270-248-699;;129-312-539-027-444;;157-483-232-156-761;;042-106-055-997-426;;193-011-693-177-215;;026-738-323-595-585;;155-353-465-515-595;;014-035-127-988-051;;196-391-965-699-401;;036-830-218-723-965;;168-613-521-890-497;;143-369-275-856-779;;126-626-178-763-712;;019-976-038-731-541;;169-396-880-557-539;;175-151-470-083-993;;199-474-098-614-213;;019-255-876-702-360;;062-373-315-232-174;;183-911-754-561-669;;097-435-805-189-392,CA;;JP;;KR;;ZA;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,0,C07D271/10;;A61K31/4245;;A61P25/08;;C07D271/06;;A61K31/4245;;A61P25/00;;C07D271/10;;C07D271/10;;A61K31/4245;;A61P25/00;;A61P25/08;;A61K31/4245;;C07D271/10,C07D271/10;;A61K31/4245;;A61P25/08,,0,0,,,,ACTIVE
49,US,A1,US 2022/0024886 A1,199-474-098-614-213,2022-01-27,2022,US 202117327928 A,2021-05-24,US 202117327928 A;;KR 20180113956 A;;US 201916613659 A;;KR 2019012257 W,2018-09-21,COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME,Disclosed are oxadiazole compounds and pharmaceutically acceptable salts thereof. The compounds and pharmaceutically acceptable salts thereof are specifically suitable for the treatment of neurological diseases such as epilepsy.,SK BIOPHARMACEUTICALS CO LTD,RYU CHOON HO;;HAN MIN SOO;;YOON YEO JIN;;KIM YU JIN;;LEE KA EUN;;LEE JU YOUNG;;JUNG MYUNG JIN;;BAEK EUN HEE;;SHIN YU JIN;;CHOI EUN JU;;KANG YOUNG SOON;;KIM YONG SOO;;SONG YEA MI;;KIM JIN SUNG;;LIM HEE JEONG,SK BIOPHARMACEUTICALS CO. LTD (2019-11-13),https://lens.org/199-474-098-614-213,Patent Application,yes,0,0,27,073-783-627-753-21X;;105-837-788-983-833;;193-541-220-154-003;;064-483-078-063-206;;002-871-334-804-591;;119-330-995-364-475;;086-131-270-248-699;;129-312-539-027-444;;157-483-232-156-761;;042-106-055-997-426;;193-011-693-177-215;;026-738-323-595-585;;155-353-465-515-595;;014-035-127-988-051;;196-391-965-699-401;;036-830-218-723-965;;168-613-521-890-497;;143-369-275-856-779;;126-626-178-763-712;;019-976-038-731-541;;169-396-880-557-539;;175-151-470-083-993;;199-474-098-614-213;;019-255-876-702-360;;062-373-315-232-174;;183-911-754-561-669;;097-435-805-189-392,CA;;JP;;KR;;ZA;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,27,073-783-627-753-21X;;105-837-788-983-833;;193-541-220-154-003;;064-483-078-063-206;;002-871-334-804-591;;119-330-995-364-475;;086-131-270-248-699;;129-312-539-027-444;;157-483-232-156-761;;042-106-055-997-426;;193-011-693-177-215;;026-738-323-595-585;;155-353-465-515-595;;014-035-127-988-051;;196-391-965-699-401;;036-830-218-723-965;;168-613-521-890-497;;143-369-275-856-779;;126-626-178-763-712;;019-976-038-731-541;;169-396-880-557-539;;175-151-470-083-993;;199-474-098-614-213;;019-255-876-702-360;;062-373-315-232-174;;183-911-754-561-669;;097-435-805-189-392,CA;;JP;;KR;;ZA;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,0,C07D271/10;;A61K31/4245;;A61P25/08;;C07D271/06;;A61K31/4245;;A61P25/00;;C07D271/10;;C07D271/10;;A61K31/4245;;A61P25/00;;A61P25/08;;A61K31/4245;;C07D271/10,C07D271/10;;A61K31/4245;;A61P25/08,,0,0,,,,ACTIVE
50,US,B2,US 11053208 B2,064-483-078-063-206,2021-07-06,2021,US 201916613659 A,2019-09-20,KR 20180113956 A;;KR 2019012257 W,2018-09-21,Compound having oxadiazole and pharmaceutical composition containing the same,Disclosed are oxadiazole compounds and pharmaceutically acceptable salts thereof. The compounds and pharmaceutically acceptable salts thereof are specifically suitable for the treatment of neurological diseases such as epilepsy.,SK BIOPHARMACEUTICALS CO LTD,RYU CHOON HO;;HAN MIN SOO;;YOON YEO JIN;;KIM YU JIN;;LEE KA EUN;;LEE JU YOUNG;;JUNG MYUNG JIN;;BAEK EUN HEE;;SHIN YU JIN;;CHOI EUN JU;;KANG YOUNG SOON;;KIM YONG SOO;;SONG YEA MI;;KIM JIN SUNG;;LIM HEE JEONG,SK BIOPHARMACEUTICALS CO. LTD (2019-11-13),https://lens.org/064-483-078-063-206,Granted Patent,yes,4,0,27,073-783-627-753-21X;;105-837-788-983-833;;193-541-220-154-003;;064-483-078-063-206;;002-871-334-804-591;;119-330-995-364-475;;086-131-270-248-699;;129-312-539-027-444;;157-483-232-156-761;;042-106-055-997-426;;193-011-693-177-215;;026-738-323-595-585;;155-353-465-515-595;;014-035-127-988-051;;196-391-965-699-401;;036-830-218-723-965;;168-613-521-890-497;;143-369-275-856-779;;126-626-178-763-712;;019-976-038-731-541;;169-396-880-557-539;;175-151-470-083-993;;199-474-098-614-213;;019-255-876-702-360;;062-373-315-232-174;;183-911-754-561-669;;097-435-805-189-392,CA;;JP;;KR;;ZA;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,27,073-783-627-753-21X;;105-837-788-983-833;;193-541-220-154-003;;064-483-078-063-206;;002-871-334-804-591;;119-330-995-364-475;;086-131-270-248-699;;129-312-539-027-444;;157-483-232-156-761;;042-106-055-997-426;;193-011-693-177-215;;026-738-323-595-585;;155-353-465-515-595;;014-035-127-988-051;;196-391-965-699-401;;036-830-218-723-965;;168-613-521-890-497;;143-369-275-856-779;;126-626-178-763-712;;019-976-038-731-541;;169-396-880-557-539;;175-151-470-083-993;;199-474-098-614-213;;019-255-876-702-360;;062-373-315-232-174;;183-911-754-561-669;;097-435-805-189-392,CA;;JP;;KR;;ZA;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,0,C07D271/10;;A61K31/4245;;A61P25/08;;C07D271/06;;A61K31/4245;;A61P25/00;;C07D271/10;;C07D271/10;;A61K31/4245;;A61P25/00;;A61P25/08;;A61K31/4245;;C07D271/10,A61P25/18;;A61K31/41;;A61K31/4245;;A61P25/08;;C07D271/10,,0,0,,,,ACTIVE
51,US,A1,US 2021/0085646 A1,021-105-149-319-638,2021-03-25,2021,US 201716469268 A,2017-12-14,KR 20160170434 A;;KR 2017014731 W,2016-12-14,Orally Disintegrated Tablet Comprising Carbamate Compound,"The present invention relates to an orally disintegrated tablet and a method for producing same, the tablet containing a carbamate compound of chemical formula 1, an isomer thereof, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof, as an active ingredient.",SK BIOPHARMACEUTICALS CO LTD,BAEK MYOUNG KI;;CHOI SO YOUNG;;LEE JI HYE,SK BIOPHARMACEUTICALS CO. LTD (2019-08-01),https://lens.org/021-105-149-319-638,Patent Application,yes,0,1,13,086-911-683-460-054;;021-105-149-319-638;;119-653-520-550-182;;057-652-801-265-773;;167-283-766-670-374;;034-950-914-504-241;;041-271-659-050-156;;139-279-258-584-683;;176-935-090-943-789;;120-855-124-037-45X;;067-756-178-675-314;;156-622-690-296-666;;180-777-341-695-040,CA;;JP;;KR;;WO;;US;;CN;;ES;;EP,13,086-911-683-460-054;;021-105-149-319-638;;119-653-520-550-182;;057-652-801-265-773;;167-283-766-670-374;;034-950-914-504-241;;041-271-659-050-156;;139-279-258-584-683;;176-935-090-943-789;;120-855-124-037-45X;;067-756-178-675-314;;156-622-690-296-666;;180-777-341-695-040,CA;;JP;;KR;;WO;;US;;CN;;ES;;EP,0,A61K31/16;;A61K31/41;;A61K9/0056;;A61K9/2027;;A61P25/08;;A61P25/06;;A61P25/24;;A61K9/0056;;A61K31/41;;A61K31/16;;A61K47/26;;A61K47/30;;A61K9/0056;;A61K9/2018;;A61K9/2027;;A61K9/2054;;A61K9/2059;;A61K31/41,A61K31/41;;A61K9/00;;A61K9/20,,0,0,,,,PENDING
52,EP,A1,EP 3556345 A1,167-283-766-670-374,2019-10-23,2019,EP 17879982 A,2017-12-14,KR 20160170434 A;;KR 2017014731 W,2016-12-14,ORALLY DISINTEGRATED TABLET COMPRISING CARBAMATE COMPOUND,"The present invention relates to an orally disintegrated tablet and a method for producing same, the tablet containing a carbamate compound of chemical formula 1, an isomer thereof, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof, as an active ingredient.",SK BIOPHARMACEUTICALS CO LTD,BAEK MYOUNG KI;;CHOI SO YOUNG;;LEE JI HYE,,https://lens.org/167-283-766-670-374,Patent Application,yes,0,1,13,086-911-683-460-054;;021-105-149-319-638;;119-653-520-550-182;;057-652-801-265-773;;167-283-766-670-374;;034-950-914-504-241;;041-271-659-050-156;;139-279-258-584-683;;176-935-090-943-789;;120-855-124-037-45X;;067-756-178-675-314;;156-622-690-296-666;;180-777-341-695-040,CA;;JP;;KR;;WO;;US;;CN;;ES;;EP,13,086-911-683-460-054;;021-105-149-319-638;;119-653-520-550-182;;057-652-801-265-773;;167-283-766-670-374;;034-950-914-504-241;;041-271-659-050-156;;139-279-258-584-683;;176-935-090-943-789;;120-855-124-037-45X;;067-756-178-675-314;;156-622-690-296-666;;180-777-341-695-040,CA;;JP;;KR;;WO;;US;;CN;;ES;;EP,0,A61K31/16;;A61K31/41;;A61K9/0056;;A61K9/2027;;A61P25/08;;A61P25/06;;A61P25/24;;A61K9/0056;;A61K31/41;;A61K31/16;;A61K47/26;;A61K47/30;;A61K9/0056;;A61K9/2018;;A61K9/2027;;A61K9/2054;;A61K9/2059;;A61K31/41,A61K31/16;;A61K9/00;;A61K31/41;;A61K47/26;;A61K47/30,,0,0,,,,ACTIVE
53,EP,A1,EP 3854788 A1,119-330-995-364-475,2021-07-28,2021,EP 19863530 A,2019-09-20,KR 20180113956 A;;KR 2019012257 W,2018-09-21,"COMPOUND CONTAINING OXADIAZOLE, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME",Disclosed in the present invention is an oxadiazole compound and pharmaceutically useful salts thereof. The compound and pharmaceutically useful salts thereof are espicially suitable for the treatment of nervous system diseases such as epilepsy.,SK BIOPHARMACEUTICALS CO LTD,RYU CHOON HO;;HAN MIN SOO;;YOON YEO JIN;;KIM YU JIN;;LEE KA EUN;;LEE JU YOUNG;;JUNG MYUNG JIN;;BAEK EUN HEE;;SHIN YU JIN;;CHOI EUN JU;;KANG YOUNG SOON;;KIM YONG SOO;;SONG YEA MI;;KIM JIN SUNG;;LIM HEE JEONG,,https://lens.org/119-330-995-364-475,Patent Application,yes,0,0,27,073-783-627-753-21X;;105-837-788-983-833;;193-541-220-154-003;;064-483-078-063-206;;002-871-334-804-591;;119-330-995-364-475;;086-131-270-248-699;;129-312-539-027-444;;157-483-232-156-761;;042-106-055-997-426;;193-011-693-177-215;;026-738-323-595-585;;155-353-465-515-595;;014-035-127-988-051;;196-391-965-699-401;;036-830-218-723-965;;168-613-521-890-497;;143-369-275-856-779;;126-626-178-763-712;;019-976-038-731-541;;169-396-880-557-539;;175-151-470-083-993;;199-474-098-614-213;;019-255-876-702-360;;062-373-315-232-174;;183-911-754-561-669;;097-435-805-189-392,CA;;JP;;KR;;ZA;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,27,073-783-627-753-21X;;105-837-788-983-833;;193-541-220-154-003;;064-483-078-063-206;;002-871-334-804-591;;119-330-995-364-475;;086-131-270-248-699;;129-312-539-027-444;;157-483-232-156-761;;042-106-055-997-426;;193-011-693-177-215;;026-738-323-595-585;;155-353-465-515-595;;014-035-127-988-051;;196-391-965-699-401;;036-830-218-723-965;;168-613-521-890-497;;143-369-275-856-779;;126-626-178-763-712;;019-976-038-731-541;;169-396-880-557-539;;175-151-470-083-993;;199-474-098-614-213;;019-255-876-702-360;;062-373-315-232-174;;183-911-754-561-669;;097-435-805-189-392,CA;;JP;;KR;;ZA;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,0,C07D271/10;;A61K31/4245;;A61P25/08;;C07D271/06;;A61K31/4245;;A61P25/00;;C07D271/10;;C07D271/10;;A61K31/4245;;A61P25/00;;A61P25/08;;A61K31/4245;;C07D271/10,C07D271/10;;A61K31/4245;;A61P25/00,,0,0,,,,PENDING
54,US,B2,US 12145914 B2,042-106-055-997-426,2024-11-19,2024,US 202318155924 A,2023-01-18,US 202318155924 A;;KR 20180113956 A;;US 202117327928 A;;US 201916613659 A;;KR 2019012257 W,2018-09-21,Compound having oxadiazole and pharmaceutical composition containing the same,Disclosed are oxadiazole compounds and pharmaceutically acceptable salts thereof. The compounds and pharmaceutically acceptable salts thereof are specifically suitable for the treatment of neurological diseases such as epilepsy.,SK BIOPHARMACEUTICALS CO LTD,RYU CHOON HO;;HAN MIN SOO;;YOON YEO JIN;;KIM YU JIN;;LEE KA EUN;;LEE JU YOUNG;;JUNG MYUNG JIN;;BAEK EUN HEE;;SHIN YU JIN;;CHOI EUN JU;;KANG YOUNG SOON;;KIM YONG SOO;;SONG YEA MI;;KIM JIN SUNG;;LIM HEE JEONG,SK BIOPHARMACEUTICALS CO. LTD (2019-11-13),https://lens.org/042-106-055-997-426,Granted Patent,yes,9,0,27,073-783-627-753-21X;;105-837-788-983-833;;193-541-220-154-003;;064-483-078-063-206;;002-871-334-804-591;;119-330-995-364-475;;086-131-270-248-699;;129-312-539-027-444;;157-483-232-156-761;;042-106-055-997-426;;193-011-693-177-215;;026-738-323-595-585;;155-353-465-515-595;;014-035-127-988-051;;196-391-965-699-401;;036-830-218-723-965;;168-613-521-890-497;;143-369-275-856-779;;126-626-178-763-712;;019-976-038-731-541;;169-396-880-557-539;;175-151-470-083-993;;199-474-098-614-213;;019-255-876-702-360;;062-373-315-232-174;;183-911-754-561-669;;097-435-805-189-392,CA;;JP;;KR;;ZA;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,27,073-783-627-753-21X;;105-837-788-983-833;;193-541-220-154-003;;064-483-078-063-206;;002-871-334-804-591;;119-330-995-364-475;;086-131-270-248-699;;129-312-539-027-444;;157-483-232-156-761;;042-106-055-997-426;;193-011-693-177-215;;026-738-323-595-585;;155-353-465-515-595;;014-035-127-988-051;;196-391-965-699-401;;036-830-218-723-965;;168-613-521-890-497;;143-369-275-856-779;;126-626-178-763-712;;019-976-038-731-541;;169-396-880-557-539;;175-151-470-083-993;;199-474-098-614-213;;019-255-876-702-360;;062-373-315-232-174;;183-911-754-561-669;;097-435-805-189-392,CA;;JP;;KR;;ZA;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,0,C07D271/10;;A61K31/4245;;A61P25/08;;C07D271/06;;A61K31/4245;;A61P25/00;;C07D271/10;;C07D271/10;;A61K31/4245;;A61P25/00;;A61P25/08;;A61K31/4245;;C07D271/10,C07D271/10;;A61K31/4245;;A61P25/08,,3,0,,,"Extended European Search Report from corresponding European Patent Application No. 19863530.2, dated May 18, 2022.;;Office Action (Non-Final) from corresponding U.S. Appl. No. 17/327,928, dated Jul. 5, 2022.;;Notice of Allowance from corresponding U.S. Appl. No. 17/327,928, dated Nov. 23, 2022.",ACTIVE
55,US,B2,US 11603358 B2,175-151-470-083-993,2023-03-14,2023,US 202117327928 A,2021-05-24,US 202117327928 A;;KR 20180113956 A;;US 201916613659 A;;KR 2019012257 W,2018-09-21,Compound having oxadiazole and pharmaceutical composition containing the same,Disclosed are oxadiazole compounds and pharmaceutically acceptable salts thereof. The compounds and pharmaceutically acceptable salts thereof are specifically suitable for the treatment of neurological diseases such as epilepsy.,SK BIOPHARMACEUTICALS CO LTD,RYU CHOON HO;;HAN MIN SOO;;YOON YEO JIN;;KIM YU JIN;;LEE KA EUN;;LEE JU YOUNG;;JUNG MYUNG JIN;;BAEK EUN HEE;;SHIN YU JIN;;CHOI EUN JU;;KANG YOUNG SOON;;KIM YONG SOO;;SONG YEA MI;;KIM JIN SUNG;;LIM HEE JEONG,SK BIOPHARMACEUTICALS CO. LTD (2019-11-13),https://lens.org/175-151-470-083-993,Granted Patent,yes,9,0,27,073-783-627-753-21X;;105-837-788-983-833;;193-541-220-154-003;;064-483-078-063-206;;002-871-334-804-591;;119-330-995-364-475;;086-131-270-248-699;;129-312-539-027-444;;157-483-232-156-761;;042-106-055-997-426;;193-011-693-177-215;;026-738-323-595-585;;155-353-465-515-595;;014-035-127-988-051;;196-391-965-699-401;;036-830-218-723-965;;168-613-521-890-497;;143-369-275-856-779;;126-626-178-763-712;;019-976-038-731-541;;169-396-880-557-539;;175-151-470-083-993;;199-474-098-614-213;;019-255-876-702-360;;062-373-315-232-174;;183-911-754-561-669;;097-435-805-189-392,CA;;JP;;KR;;ZA;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,27,073-783-627-753-21X;;105-837-788-983-833;;193-541-220-154-003;;064-483-078-063-206;;002-871-334-804-591;;119-330-995-364-475;;086-131-270-248-699;;129-312-539-027-444;;157-483-232-156-761;;042-106-055-997-426;;193-011-693-177-215;;026-738-323-595-585;;155-353-465-515-595;;014-035-127-988-051;;196-391-965-699-401;;036-830-218-723-965;;168-613-521-890-497;;143-369-275-856-779;;126-626-178-763-712;;019-976-038-731-541;;169-396-880-557-539;;175-151-470-083-993;;199-474-098-614-213;;019-255-876-702-360;;062-373-315-232-174;;183-911-754-561-669;;097-435-805-189-392,CA;;JP;;KR;;ZA;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,0,C07D271/10;;A61K31/4245;;A61P25/08;;C07D271/06;;A61K31/4245;;A61P25/00;;C07D271/10;;C07D271/10;;A61K31/4245;;A61P25/00;;A61P25/08;;A61K31/4245;;C07D271/10,C07D271/10;;A61K31/4245;;A61P25/08,,1,0,,,"Extended European Search Report from corresponding European Patent Application No. 19863530.2, dated May 18, 2022.",ACTIVE
56,US,A1,US 2023/0150955 A1,105-837-788-983-833,2023-05-18,2023,US 202318155924 A,2023-01-18,US 202318155924 A;;KR 20180113956 A;;US 202117327928 A;;US 201916613659 A;;KR 2019012257 W,2018-09-21,COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME,Disclosed are oxadiazole compounds and pharmaceutically acceptable salts thereof. The compounds and pharmaceutically acceptable salts thereof are specifically suitable for the treatment of neurological diseases such as epilepsy.,SK BIOPHARMACEUTICALS CO LTD,RYU CHOON HO;;HAN MIN SOO;;YOON YEO JIN;;KIM YU JIN;;LEE KA EUN;;LEE JU YOUNG;;JUNG MYUNG JIN;;BAEK EUN HEE;;SHIN YU JIN;;CHOI EUN JU;;KANG YOUNG SOON;;KIM YONG SOO;;SONG YEA MI;;KIM JIN SUNG;;LIM HEE JANG,SK BIOPHARMACEUTICALS CO. LTD (2019-11-13),https://lens.org/105-837-788-983-833,Patent Application,yes,0,0,27,073-783-627-753-21X;;105-837-788-983-833;;193-541-220-154-003;;064-483-078-063-206;;002-871-334-804-591;;119-330-995-364-475;;086-131-270-248-699;;129-312-539-027-444;;157-483-232-156-761;;042-106-055-997-426;;193-011-693-177-215;;026-738-323-595-585;;155-353-465-515-595;;014-035-127-988-051;;196-391-965-699-401;;036-830-218-723-965;;168-613-521-890-497;;143-369-275-856-779;;126-626-178-763-712;;019-976-038-731-541;;169-396-880-557-539;;175-151-470-083-993;;199-474-098-614-213;;019-255-876-702-360;;062-373-315-232-174;;183-911-754-561-669;;097-435-805-189-392,CA;;JP;;KR;;ZA;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,27,073-783-627-753-21X;;105-837-788-983-833;;193-541-220-154-003;;064-483-078-063-206;;002-871-334-804-591;;119-330-995-364-475;;086-131-270-248-699;;129-312-539-027-444;;157-483-232-156-761;;042-106-055-997-426;;193-011-693-177-215;;026-738-323-595-585;;155-353-465-515-595;;014-035-127-988-051;;196-391-965-699-401;;036-830-218-723-965;;168-613-521-890-497;;143-369-275-856-779;;126-626-178-763-712;;019-976-038-731-541;;169-396-880-557-539;;175-151-470-083-993;;199-474-098-614-213;;019-255-876-702-360;;062-373-315-232-174;;183-911-754-561-669;;097-435-805-189-392,CA;;JP;;KR;;ZA;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,0,C07D271/10;;A61K31/4245;;A61P25/08;;C07D271/06;;A61K31/4245;;A61P25/00;;C07D271/10;;C07D271/10;;A61K31/4245;;A61P25/00;;A61P25/08;;A61K31/4245;;C07D271/10,C07D271/10;;A61K31/4245;;A61P25/08,,0,0,,,,ACTIVE
57,US,A1,US 2025/0034101 A1,086-131-270-248-699,2025-01-30,2025,US 202418911634 A,2024-10-10,US 202418911634 A;;KR 20180113956 A;;US 202318155924 A;;US 202117327928 A;;US 201916613659 A;;KR 2019012257 W,2018-09-21,COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME,Disclosed are oxadiazole compounds and pharmaceutically acceptable salts thereof. The compounds and pharmaceutically acceptable salts thereof are specifically suitable for the treatment of neurological diseases such as epilepsy.,SK BIOPHARMACEUTICALS CO LTD,RYU CHOON HO;;HAN MIN SOO;;YOON YEO JIN;;KIM YU JIN;;LEE KA EUN;;LEE JU YOUNG;;JUNG MYUNG JIN;;BAEK EUN HEE;;SHIN YU JIN;;CHOI EUN JU;;KANG YOUNG SOON;;KIM YONG SOO;;SONG YEA MI;;KIM JIN SUNG;;LIM HEE JEONG,SK BIOPHARMACEUTICALS CO. LTD (2019-11-13),https://lens.org/086-131-270-248-699,Patent Application,yes,0,0,27,073-783-627-753-21X;;105-837-788-983-833;;193-541-220-154-003;;064-483-078-063-206;;002-871-334-804-591;;119-330-995-364-475;;086-131-270-248-699;;129-312-539-027-444;;157-483-232-156-761;;042-106-055-997-426;;193-011-693-177-215;;026-738-323-595-585;;155-353-465-515-595;;014-035-127-988-051;;196-391-965-699-401;;036-830-218-723-965;;168-613-521-890-497;;143-369-275-856-779;;126-626-178-763-712;;019-976-038-731-541;;169-396-880-557-539;;175-151-470-083-993;;199-474-098-614-213;;019-255-876-702-360;;062-373-315-232-174;;183-911-754-561-669;;097-435-805-189-392,CA;;JP;;KR;;ZA;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,27,073-783-627-753-21X;;105-837-788-983-833;;193-541-220-154-003;;064-483-078-063-206;;002-871-334-804-591;;119-330-995-364-475;;086-131-270-248-699;;129-312-539-027-444;;157-483-232-156-761;;042-106-055-997-426;;193-011-693-177-215;;026-738-323-595-585;;155-353-465-515-595;;014-035-127-988-051;;196-391-965-699-401;;036-830-218-723-965;;168-613-521-890-497;;143-369-275-856-779;;126-626-178-763-712;;019-976-038-731-541;;169-396-880-557-539;;175-151-470-083-993;;199-474-098-614-213;;019-255-876-702-360;;062-373-315-232-174;;183-911-754-561-669;;097-435-805-189-392,CA;;JP;;KR;;ZA;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,0,C07D271/10;;A61K31/4245;;A61P25/08;;C07D271/06;;A61K31/4245;;A61P25/00;;C07D271/10;;C07D271/10;;A61K31/4245;;A61P25/00;;A61P25/08;;A61K31/4245;;C07D271/10,C07D271/10;;A61K31/4245;;A61P25/08,,0,0,,,,PENDING
58,EP,B1,EP 3556345 B1,180-777-341-695-040,2021-09-22,2021,EP 17879982 A,2017-12-14,KR 20160170434 A;;KR 2017014731 W,2016-12-14,ORALLY DISINTEGRATED TABLET COMPRISING CARBAMATE COMPOUND,,SK BIOPHARMACEUTICALS CO LTD,BAEK MYOUNG KI;;CHOI SO YOUNG;;LEE JI HYE,,https://lens.org/180-777-341-695-040,Granted Patent,yes,8,0,13,086-911-683-460-054;;021-105-149-319-638;;119-653-520-550-182;;057-652-801-265-773;;167-283-766-670-374;;034-950-914-504-241;;041-271-659-050-156;;139-279-258-584-683;;176-935-090-943-789;;120-855-124-037-45X;;067-756-178-675-314;;156-622-690-296-666;;180-777-341-695-040,CA;;JP;;KR;;WO;;US;;CN;;ES;;EP,13,086-911-683-460-054;;021-105-149-319-638;;119-653-520-550-182;;057-652-801-265-773;;167-283-766-670-374;;034-950-914-504-241;;041-271-659-050-156;;139-279-258-584-683;;176-935-090-943-789;;120-855-124-037-45X;;067-756-178-675-314;;156-622-690-296-666;;180-777-341-695-040,CA;;JP;;KR;;WO;;US;;CN;;ES;;EP,0,A61K31/16;;A61K31/41;;A61K9/0056;;A61K9/2027;;A61P25/08;;A61P25/06;;A61P25/24;;A61K9/0056;;A61K31/41;;A61K31/16;;A61K47/26;;A61K47/30;;A61K9/0056;;A61K9/2018;;A61K9/2027;;A61K9/2054;;A61K9/2059;;A61K31/41,A61K9/20;;A61K31/16;;A61K31/41;;A61P25/06;;A61P25/08;;A61P25/24,,1,0,,,"MEIR BIALER ET AL: ""Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII)"", EPILEPSY RESEARCH., vol. 111, 1 March 2015 (2015-03-01), pages 85-141, XP055611172, NL ISSN: 0920-1211, DOI: 10.1016/j.eplepsyres.2015.01.001",ACTIVE
59,WO,A1,WO 2024/201420 A1,196-156-694-738-180,2024-10-03,2024,IB 2024053115 W,2024-03-29,US 202363493526 P,2023-03-31,MIRNA-484 INHIBITORS AND USES THEREOF,"The present disclosure includes the use of a miR-484 inhibitor for treating a disease or disorder associated with the increased level of miR-484. In some aspects, the miR-484 inhibitor is capable of reducing the expression of a gene and/or protein associated with miR-484.",BIORCHESTRA CO LTD;;SK BIOPHARMACEUTICALS CO LTD,JANG HA NA;;RYU JIN-HYEOB;;LIM JONGYEOB;;JUNG YEON-JOO;;PARK YOUNG JIN;;KIM INSUN;;LIM YU NA;;KANG HOWON;;JOUNG CHANMI;;CHOI EUNJU;;PARK AH HYUNG;;YOOK CHAEHYUN;;CHO SEOKHWAN;;SHIN YUJIN;;GIL SO-YOUNG,,https://lens.org/196-156-694-738-180,Patent Application,yes,4,0,1,196-156-694-738-180,WO,1,196-156-694-738-180,WO,151,A61P25/08;;C12N15/113;;A61K31/7105;;C12N2310/113;;C12N2310/315;;C12N2310/335;;C12N2310/3341;;C12N2310/141;;C12N2310/341;;A61K45/06,C12N15/113;;A61K31/7105;;A61K48/00;;A61P25/08,,1,1,030-037-321-392-672,pmc7082931;;32192507;;10.1186/s13000-020-00946-8,"LI YING, LIU YUSONG, YAO JIE, LI RUI, FAN XIAOCHENG: ""Downregulation of miR-484 is associated with poor prognosis and tumor progression of gastric cancer"", DIAGNOSTIC PATHOLOGY, BIOMED CENTRAL LTD, LO, vol. 15, no. 1, 1 December 2020 (2020-12-01), Lo , XP093216126, ISSN: 1746-1596, DOI: 10.1186/s13000-020-00946-8",PENDING
60,US,A1,US 2023/0157947 A1,104-663-707-039-450,2023-05-25,2023,US 202318157953 A,2023-01-23,US 202318157953 A;;KR 20190151556 A;;US 202217778450 A;;KR 2020016427 W,2019-11-22,ORAL PHARMACEUTICAL COMPOSITION COMPRISING CARBAMATE COMPOUND AND PREPARATION METHOD THEREFOR,"The present invention relates to an oral pharmaceutical composition comprising a carbamate compound of chemical formula 1, an isomer thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof as an active ingredient, and a preparation method therefor.",SK BIOPHARMACEUTICALS CO LTD,LEE JI HYE;;CHOI SO YOUNG,SK BIOPHARMACEUTICALS CO. LTD (2022-07-04),https://lens.org/104-663-707-039-450,Patent Application,yes,0,2,15,059-896-407-577-57X;;031-355-534-300-807;;120-537-913-593-666;;104-663-707-039-450;;104-085-871-564-327;;122-796-985-905-779;;189-093-197-879-645;;111-879-041-878-966;;171-539-093-331-861;;195-295-276-338-102;;040-851-159-981-899;;019-155-279-352-94X;;051-540-720-579-362;;007-960-770-399-381;;091-762-929-559-455,CA;;JP;;KR;;CN;;CL;;AU;;BR;;MX;;WO;;US;;CO;;EP;;IL,15,059-896-407-577-57X;;031-355-534-300-807;;120-537-913-593-666;;104-663-707-039-450;;104-085-871-564-327;;122-796-985-905-779;;189-093-197-879-645;;111-879-041-878-966;;171-539-093-331-861;;195-295-276-338-102;;040-851-159-981-899;;019-155-279-352-94X;;051-540-720-579-362;;007-960-770-399-381;;091-762-929-559-455,CA;;JP;;KR;;CN;;CL;;AU;;BR;;MX;;WO;;US;;CO;;EP;;IL,0,A61P25/08;;A61K9/2027;;A61K9/205;;A61K9/2054;;A61K9/2826;;A61K9/2866;;A61K31/41;;A61K31/41;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/48;;A61P25/08;;A61K9/14;;A61K9/0053;;A61K9/20;;A61K31/41;;A61P25/08;;A61K9/0053;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2059;;A61K9/2077;;A61K9/2095;;A61K31/41,A61K9/00;;A61K9/20;;A61K31/41,,0,0,,,,PENDING
61,US,A1,US 2023/0013175 A1,153-444-631-916-345,2023-01-19,2023,US 202217826289 A,2022-05-27,US 202217826289 A;;US 202163194276 P,2021-05-28,ORAL AQUEOUS SUSPENSION FORMULATION COMPRISING CARBAMATE COMPOUND,"The present disclosure relates to an aqueous formulation comprising as an active ingredient a carbamate compound of Formula 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof, poloxamer, and an aqueous carrier, wherein the aqueous formulation is in the form of a suspension formulation.",SK BIOPHARMACEUTICALS CO LTD,PENDSE PRAVADA;;BOMMANA MURALI M;;NOH REGINA H;;PEGAN AUGUSTIN;;WEBB TRAVIS JOHN;;MAXWELL JEJUAN,SK BIOPHARMACEUTICALS CO. LTD (2022-08-03),https://lens.org/153-444-631-916-345,Patent Application,yes,2,0,15,111-109-197-313-573;;042-997-463-397-886;;105-565-454-473-183;;172-668-392-503-27X;;187-819-716-849-841;;123-252-227-422-840;;138-488-033-596-813;;180-817-471-897-998;;181-506-206-725-878;;091-318-187-324-348;;010-971-791-330-780;;153-444-631-916-345;;174-159-569-741-677;;151-542-428-514-670;;141-237-207-332-458,CA;;JP;;KR;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,15,111-109-197-313-573;;042-997-463-397-886;;105-565-454-473-183;;172-668-392-503-27X;;187-819-716-849-841;;123-252-227-422-840;;138-488-033-596-813;;180-817-471-897-998;;181-506-206-725-878;;091-318-187-324-348;;010-971-791-330-780;;153-444-631-916-345;;174-159-569-741-677;;151-542-428-514-670;;141-237-207-332-458,CA;;JP;;KR;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,0,A61K47/10;;A61K9/10;;A61K47/02;;A61K31/41;;A61K47/36;;A61P25/00;;A61K47/38;;A61K9/0095;;A61K31/41;;A61K9/0095;;A61K9/10;;A61K47/02;;A61K47/10;;A61K47/32;;A61K47/36;;A61K47/38;;A61P25/00;;A61K9/0095;;A61K47/34;;A61K47/02;;A61K47/38;;A61K47/32;;A61K31/41;;A61P25/00;;A61K9/10;;A61K31/41;;A61K47/02;;A61K47/10;;A61K47/32;;A61K47/38,A61K31/41;;A61K9/10;;A61K47/02;;A61K47/10;;A61K47/32;;A61K47/38,,0,0,,,,ACTIVE
62,US,B2,US 9566268 B2,059-818-577-811-185,2017-02-14,2017,US 201615231382 A,2016-08-08,US 201615231382 A;;KR 20120125516 A;;US 201514441277 A;;KR 2013010088 W,2012-11-07,Solid dispersions of insoluble drug and preparation method thereof,"The present invention relates to a solid dispersion characterized in that it comprises carbamic acid 3-(4-benzyloxy-phenyl)-isoxazol-5-ylmethyl ester as an active ingredient and a water-soluble polymer having a glass transition temperature lower than the melting point of the active ingredient as a carrier, and it is prepared via melt extrusion. The solid dispersion of the present invention remarkably increases the solubility and dissolution rate of the active ingredient which is an insoluble drug to efficiently improve the bioavailability when it is orally administered.",SK BIOPHARMACEUTICALS CO LTD,BAEK MYOUNG KI;;PEGAN AUGUSTIN,SK BIOPHARMACEUTICALS CO. LTD (2015-04-29),https://lens.org/059-818-577-811-185,Granted Patent,yes,8,0,30,128-620-442-386-588;;028-343-319-786-633;;184-988-190-580-830;;047-396-290-600-150;;034-164-982-258-945;;084-719-226-983-455;;159-256-564-500-664;;137-858-336-936-060;;015-789-677-099-344;;034-768-311-267-012;;158-063-407-607-233;;077-346-478-004-062;;012-993-406-841-921;;144-214-810-400-133;;009-016-496-340-563;;077-664-040-242-553;;059-818-577-811-185;;142-180-585-070-83X;;171-736-899-421-471;;137-408-508-367-59X;;030-714-980-956-369;;035-123-234-357-441;;070-848-719-776-254;;109-855-883-873-055;;107-181-894-552-82X;;185-072-571-289-680;;186-704-426-793-951;;088-325-414-156-864;;096-015-093-763-44X;;123-899-487-200-838,RU;;CA;;JP;;KR;;TR;;CN;;PL;;ES;;AU;;BR;;WO;;MX;;US;;HK;;EP,30,128-620-442-386-588;;028-343-319-786-633;;184-988-190-580-830;;047-396-290-600-150;;034-164-982-258-945;;084-719-226-983-455;;159-256-564-500-664;;137-858-336-936-060;;015-789-677-099-344;;034-768-311-267-012;;158-063-407-607-233;;077-346-478-004-062;;012-993-406-841-921;;144-214-810-400-133;;009-016-496-340-563;;077-664-040-242-553;;059-818-577-811-185;;142-180-585-070-83X;;171-736-899-421-471;;137-408-508-367-59X;;030-714-980-956-369;;035-123-234-357-441;;070-848-719-776-254;;109-855-883-873-055;;107-181-894-552-82X;;185-072-571-289-680;;186-704-426-793-951;;088-325-414-156-864;;096-015-093-763-44X;;123-899-487-200-838,RU;;CA;;JP;;KR;;TR;;CN;;PL;;ES;;AU;;BR;;WO;;MX;;US;;HK;;EP,0,A61K9/146;;A61K31/42;;C07D261/08;;A61K9/2027;;C07D261/08;;A61K9/146;;A61K9/2027;;A61K47/32;;A61K31/42;;A61P25/00;;A61P25/28;;A61K47/34;;A61K47/30;;A61K31/42;;C07D261/08;;A61K9/0053;;A61K9/141;;A61K9/146;;A61K9/20;;A61K31/42;;A61K47/00;;A61K47/30;;A61K2121/00;;C07D261/08;;A61K9/146;;A61K9/2027;;B01F23/66;;B01F23/81;;B01F35/90;;B01F27/40;;B01F2035/99;;B01F2101/22;;A61K31/42;;A61K9/10;;A61K47/32;;A61K9/0053;;A61K9/2031,A61K31/42;;A61K9/00;;A61K9/14;;A61K9/20;;B01F23/80,,4,1,196-137-673-224-806,10.1021/cen-v081n008.p032,"International Search Report (ISR) dated Feb. 20, 2014 in PCT/KR2013/010088 published as WO 2014/073889.;;John Wiley & Sons, Inc., (2002). Kirk-Othmer Encyclopedia of chemical technology copyright ©. Article Online Posting Date: Aug. 16, 2002.;;Rouhi (2003). ""The right stuff, from research and developments to the clinic, getting rug crystals right is full of pitfalls"". Chemical & Engineering News. pp. 32-35.;;(Jun. 2012). Vitamin E TPGS and Food Grade.",ACTIVE
63,EP,B1,EP 2215040 B1,068-256-620-485-587,2016-06-01,2016,EP 08840130 A,2008-10-18,IB 2008003300 W;;US 98087707 P,2007-10-18,PROCESS FOR PREPARING (S) 2-(2-CHLOROPHENYL)-2-HYDROXY-ETHYL CARBAMATE,,SK BIOPHARMACEUTICALS CO LTD,PORSTMANN FRANK;;MEIER THOMAS,"SK BIOPHARMACEUTICALS CO., LTD (2011-10-05)",https://lens.org/068-256-620-485-587,Granted Patent,yes,5,0,29,033-517-476-026-505;;118-879-148-133-977;;165-601-565-097-733;;155-278-235-628-335;;029-251-821-784-13X;;048-943-987-274-881;;118-392-519-155-16X;;060-407-829-547-86X;;141-884-521-063-971;;176-663-951-385-496;;181-625-099-650-760;;153-366-641-673-243;;169-074-310-922-408;;040-357-274-079-936;;074-537-058-333-735;;078-081-675-008-965;;174-652-114-633-927;;056-184-092-020-405;;184-244-634-272-82X;;068-256-620-485-587;;024-881-781-734-633;;080-839-254-433-371;;153-510-183-234-844;;056-342-346-700-242;;095-558-766-355-681;;005-219-751-158-57X;;007-944-099-914-972;;183-637-187-109-043;;129-531-301-965-801,CA;;EC;;KR;;JP;;PA;;ZA;;UY;;CN;;CL;;NI;;CR;;TW;;AU;;BR;;WO;;EA;;MX;;PE;;US;;CO;;AR;;IL;;EP,29,033-517-476-026-505;;118-879-148-133-977;;165-601-565-097-733;;155-278-235-628-335;;029-251-821-784-13X;;048-943-987-274-881;;118-392-519-155-16X;;060-407-829-547-86X;;141-884-521-063-971;;176-663-951-385-496;;181-625-099-650-760;;153-366-641-673-243;;169-074-310-922-408;;040-357-274-079-936;;074-537-058-333-735;;078-081-675-008-965;;174-652-114-633-927;;056-184-092-020-405;;184-244-634-272-82X;;068-256-620-485-587;;024-881-781-734-633;;080-839-254-433-371;;153-510-183-234-844;;056-342-346-700-242;;095-558-766-355-681;;005-219-751-158-57X;;007-944-099-914-972;;183-637-187-109-043;;129-531-301-965-801,CA;;EC;;KR;;JP;;PA;;ZA;;UY;;CN;;CL;;NI;;CR;;TW;;AU;;BR;;WO;;EA;;MX;;PE;;US;;CO;;AR;;IL;;EP,0,C07C269/06;;A61P25/00;;A61P25/08;;C07C41/48;;C07C67/08;;C07C67/31;;Y02P20/55;;C07C269/06;;C07C41/48;;C07C67/08;;C07C67/31,C07C67/08;;C07C41/48;;C07C43/315;;C07C67/31;;C07C69/732;;C07C269/06;;C07C271/12,,0,0,,,,ACTIVE
64,WO,A1,WO 2022/250499 A1,111-109-197-313-573,2022-12-01,2022,KR 2022007581 W,2022-05-27,US 202163194276 P,2021-05-28,ORAL AQUEOUS SUSPENSION FORMULATIONS COMPRISING CARBAMATE COMPOUND,"The present disclosure relates to an aqueous formulation comprising as an active ingredient a carbamate compound of Formula 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof, poloxamer, and an aqueous carrier, wherein the aqueous formulation is in the form of a suspension formulation.",SK BIOPHARMACEUTICALS CO LTD,PENDSE PRAVADA;;BOMMANA MURALI M;;NOH REGINA H;;PEGAN AUGUSTIN;;WEBB TRAVIS JOHN;;MAXWELL JEJUAN,,https://lens.org/111-109-197-313-573,Patent Application,yes,3,1,15,111-109-197-313-573;;042-997-463-397-886;;105-565-454-473-183;;172-668-392-503-27X;;187-819-716-849-841;;123-252-227-422-840;;138-488-033-596-813;;180-817-471-897-998;;181-506-206-725-878;;091-318-187-324-348;;010-971-791-330-780;;153-444-631-916-345;;174-159-569-741-677;;151-542-428-514-670;;141-237-207-332-458,CA;;JP;;KR;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,15,111-109-197-313-573;;042-997-463-397-886;;105-565-454-473-183;;172-668-392-503-27X;;187-819-716-849-841;;123-252-227-422-840;;138-488-033-596-813;;180-817-471-897-998;;181-506-206-725-878;;091-318-187-324-348;;010-971-791-330-780;;153-444-631-916-345;;174-159-569-741-677;;151-542-428-514-670;;141-237-207-332-458,CA;;JP;;KR;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,0,A61K47/10;;A61K9/10;;A61K47/02;;A61K31/41;;A61K47/36;;A61P25/00;;A61K47/38;;A61K9/0095;;A61K31/41;;A61K9/0095;;A61K9/10;;A61K47/02;;A61K47/10;;A61K47/32;;A61K47/36;;A61K47/38;;A61P25/00;;A61K9/0095;;A61K47/34;;A61K47/02;;A61K47/38;;A61K47/32;;A61K31/41;;A61P25/00;;A61K9/10;;A61K31/41;;A61K47/02;;A61K47/10;;A61K47/32;;A61K47/38,A61K9/08;;A61K9/00;;A61K9/10;;A61K31/41;;A61K47/02;;A61K47/10;;A61K47/36;;A61K47/38;;A61P25/00,,2,2,104-393-614-814-49X;;089-318-292-992-557,32328931;;pmc7221039;;10.1007/s40268-020-00305-4;;32087001;;10.1002/cpdd.769,"FERRARI LOUIS, NISMAN ARKADY, PEGAN AUGUSTIN, URSINO JORDAN: ""An Ex Vivo Evaluation of Cenobamate Administered via Enteral Tubes"", DRUGS IN R&D, ADIS INTERNATIONAL LTD , NZL, vol. 20, no. 2, 1 June 2020 (2020-06-01), pages 125 - 133, XP093008475, ISSN: 1174-5886, DOI: 10.1007/s40268-020-00305-4;;VERNILLET LAURENT, STEPHEN A. GREENE, MARC KAMIN: ""Pharmacokinetics of cenobamate: results from single and multiple oral ascending-dose studies in healthy subjects"", CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, vol. 9, no. 4, 22 February 2020 (2020-02-22), pages 428 - 443, XP093008494, DOI: 10.1002/cpdd.769",PENDING
65,EP,B1,EP 2566475 B1,034-852-710-631-338,2019-12-11,2019,EP 11777560 A,2011-05-03,KR 20100041436 A;;KR 2011003318 W,2010-05-03,PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURON OR NEURODEGENERATION,,SK BIOPHARMACEUTICALS CO LTD,PARK CHEOL HYOUNG;;MIN HYE KYUNG;;PARK IN SUK;;LIM MI JUNG;;LEE JI WON;;CHUNG JIN YONG;;YOON YEO JIN;;PARK JOO YOUNG,,https://lens.org/034-852-710-631-338,Granted Patent,yes,12,0,29,083-039-858-242-705;;112-978-299-565-262;;167-510-528-540-117;;030-396-572-256-67X;;005-606-654-973-855;;044-160-932-409-906;;179-167-967-243-034;;105-588-674-891-784;;083-927-741-654-410;;181-093-802-766-315;;115-475-254-140-257;;033-176-141-122-359;;001-137-200-928-772;;100-201-254-946-24X;;128-594-256-312-773;;034-852-710-631-338;;173-997-219-171-383;;030-774-362-450-39X;;077-722-933-911-999;;013-924-370-730-345;;191-530-673-964-029;;163-910-907-096-308;;013-649-920-355-110;;135-196-887-792-996;;054-286-540-912-656;;103-278-855-304-829;;056-912-353-242-800;;179-903-799-833-766;;137-947-736-509-345,CA;;RU;;KR;;JP;;BR;;WO;;MX;;CN;;US;;ES;;EP;;AU,29,083-039-858-242-705;;112-978-299-565-262;;167-510-528-540-117;;030-396-572-256-67X;;005-606-654-973-855;;044-160-932-409-906;;179-167-967-243-034;;105-588-674-891-784;;083-927-741-654-410;;181-093-802-766-315;;115-475-254-140-257;;033-176-141-122-359;;001-137-200-928-772;;100-201-254-946-24X;;128-594-256-312-773;;034-852-710-631-338;;173-997-219-171-383;;030-774-362-450-39X;;077-722-933-911-999;;013-924-370-730-345;;191-530-673-964-029;;163-910-907-096-308;;013-649-920-355-110;;135-196-887-792-996;;054-286-540-912-656;;103-278-855-304-829;;056-912-353-242-800;;179-903-799-833-766;;137-947-736-509-345,CA;;RU;;KR;;JP;;BR;;WO;;MX;;CN;;US;;ES;;EP;;AU,0,C07D261/08;;A61K31/4196;;A61K31/4245;;A61K31/433;;A61P9/10;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P27/02;;A61P31/00;;A61P43/00;;A61K31/4196;;A61K31/4245;;A61K31/433;;A61K2121/00;;A61K31/4196;;A61K31/42;;A61K31/4245;;A61K31/433;;A61P25/00;;A61P25/28;;C07D261/08;;A61K31/4196;;A61K31/4245;;A61K31/433,A61K31/4196;;A61K31/4245;;A61K31/433;;A61P25/00,,1,0,,,"VELIKORODOV A V ET AL: ""Synthesis and cardiovascular activity of some azaheterocycles with carbamate groups"", PHARMACEUTICAL CHEMISTRY JOURNAL, KLUWER ACADEMIC PUBLISHERS-CONSULTANTS BUREAU, NE, vol. 40, no. 4, 1 April 2006 (2006-04-01), pages 182-185, XP019437027, ISSN: 1573-9031, DOI: 10.1007/S11094-006-0087-6",ACTIVE
66,EP,A1,EP 4049662 A1,153-229-645-863-908,2022-08-31,2022,EP 20879398 A,2020-10-21,KR 20190130384 A;;KR 2020014399 W,2019-10-21,"USE OF IMIDAZOPYRIMIDINE OR IMIDAZOTRIAZINE COMPOUNDS FOR PREVENTION, ALLEVIATION, OR TREATMENT OF COGNITIVE DISORDERS, OR FOR IMPROVING COGNITIVE FUNCTION","The present invention relates to a use of imidazopyrimidine or imidazotriazine compounds of Chemical Formula 1, or pharmaceutically acceptable salts, solvates, or hydrates thereof, for preventing, alleviating or treating cognitive disorder or for improving enhancing cognitive function.",SK BIOPHARMACEUTICALS CO LTD,JOUNG CHAN MI;;CHUNG JIN YONG,,https://lens.org/153-229-645-863-908,Patent Application,yes,0,0,16,077-536-142-327-957;;108-774-037-689-362;;161-705-084-860-911;;060-993-941-597-730;;062-861-871-789-62X;;067-980-138-998-73X;;016-672-531-762-884;;153-229-645-863-908;;007-748-899-917-604;;005-743-877-393-023;;167-448-531-137-72X;;018-434-201-700-33X;;085-702-557-106-137;;025-234-759-849-763;;093-432-465-174-901;;149-554-640-917-203,CA;;KR;;JP;;ZA;;CN;;CL;;AU;;BR;;WO;;MX;;US;;EP;;IL,16,077-536-142-327-957;;108-774-037-689-362;;161-705-084-860-911;;060-993-941-597-730;;062-861-871-789-62X;;067-980-138-998-73X;;016-672-531-762-884;;153-229-645-863-908;;007-748-899-917-604;;005-743-877-393-023;;167-448-531-137-72X;;018-434-201-700-33X;;085-702-557-106-137;;025-234-759-849-763;;093-432-465-174-901;;149-554-640-917-203,CA;;KR;;JP;;ZA;;CN;;CL;;AU;;BR;;WO;;MX;;US;;EP;;IL,0,A61K31/519;;A61K31/53;;A61K45/06;;A61P25/28;;C07D487/04;;A61K31/131;;A61K31/4458;;A61K31/473;;A61K31/27;;A61K31/198;;A61K31/519;;A61K31/53;;A61P25/28;;C07D487/04;;A61P25/28;;A61K31/519;;A61K31/53,A61K31/519;;A61K31/131;;A61K31/4458;;A61K31/53;;A61K45/06;;A61P25/28;;C07D487/04,,0,0,,,,PENDING
67,US,A1,US 2016/0346258 A1,070-848-719-776-254,2016-12-01,2016,US 201615231382 A,2016-08-08,US 201615231382 A;;KR 20120125516 A;;US 201514441277 A;;KR 2013010088 W,2012-11-07,SOLID DISPERSIONS OF INSOLUBLE DRUG AND PREPARATION METHOD THEREOF,"The present invention relates to a solid dispersion characterized in that it comprises carbamic acid 3-(4-benzyloxy-phenyl)-isoxazol-5-ylmethyl ester as an active ingredient and a water-soluble polymer having a glass transition temperature lower than the melting point of the active ingredient as a carrier, and it is prepared via melt extrusion. The solid dispersion of the present invention remarkably increases the solubility and dissolution rate of the active ingredient which is an insoluble drug to efficiently improve the bioavailability when it is orally administered.",SK BIOPHARMACEUTICALS CO LTD,BAEK MYOUNG KI;;PEGAN AUGUSTIN,SK BIOPHARMACEUTICALS CO. LTD (2015-04-29),https://lens.org/070-848-719-776-254,Patent Application,yes,0,0,30,128-620-442-386-588;;028-343-319-786-633;;184-988-190-580-830;;047-396-290-600-150;;034-164-982-258-945;;084-719-226-983-455;;159-256-564-500-664;;137-858-336-936-060;;015-789-677-099-344;;034-768-311-267-012;;158-063-407-607-233;;077-346-478-004-062;;012-993-406-841-921;;144-214-810-400-133;;009-016-496-340-563;;077-664-040-242-553;;059-818-577-811-185;;142-180-585-070-83X;;171-736-899-421-471;;137-408-508-367-59X;;030-714-980-956-369;;035-123-234-357-441;;070-848-719-776-254;;109-855-883-873-055;;107-181-894-552-82X;;185-072-571-289-680;;186-704-426-793-951;;088-325-414-156-864;;096-015-093-763-44X;;123-899-487-200-838,RU;;CA;;JP;;KR;;TR;;CN;;PL;;ES;;AU;;BR;;WO;;MX;;US;;HK;;EP,30,128-620-442-386-588;;028-343-319-786-633;;184-988-190-580-830;;047-396-290-600-150;;034-164-982-258-945;;084-719-226-983-455;;159-256-564-500-664;;137-858-336-936-060;;015-789-677-099-344;;034-768-311-267-012;;158-063-407-607-233;;077-346-478-004-062;;012-993-406-841-921;;144-214-810-400-133;;009-016-496-340-563;;077-664-040-242-553;;059-818-577-811-185;;142-180-585-070-83X;;171-736-899-421-471;;137-408-508-367-59X;;030-714-980-956-369;;035-123-234-357-441;;070-848-719-776-254;;109-855-883-873-055;;107-181-894-552-82X;;185-072-571-289-680;;186-704-426-793-951;;088-325-414-156-864;;096-015-093-763-44X;;123-899-487-200-838,RU;;CA;;JP;;KR;;TR;;CN;;PL;;ES;;AU;;BR;;WO;;MX;;US;;HK;;EP,0,A61K9/146;;A61K31/42;;C07D261/08;;A61K9/2027;;C07D261/08;;A61K9/146;;A61K9/2027;;A61K47/32;;A61K31/42;;A61P25/00;;A61P25/28;;A61K47/34;;A61K47/30;;A61K31/42;;C07D261/08;;A61K9/0053;;A61K9/141;;A61K9/146;;A61K9/20;;A61K31/42;;A61K47/00;;A61K47/30;;A61K2121/00;;C07D261/08;;A61K9/146;;A61K9/2027;;B01F23/66;;B01F23/81;;B01F35/90;;B01F27/40;;B01F2035/99;;B01F2101/22;;A61K31/42;;A61K9/10;;A61K47/32;;A61K9/0053;;A61K9/2031,A61K31/42;;A61K9/00;;A61K9/14;;A61K9/20;;B01F23/80,,0,0,,,,ACTIVE
68,US,B2,US 9161913 B2,165-651-624-073-99X,2015-10-20,2015,US 201213570853 A,2012-08-09,US 201213570853 A;;US 25849008 A;;US 98414407 P,2007-10-31,Stabilized pediatric suspension of carisbamate,"The present invention provides a stabilized pharmaceutical suspension of carisbamate for pediatric and adult use. More particularly, the suspension is stabilized with hypromellose (HPMC) to prevent crystal growth of the suspended particles and to prevent re-crystallization of the drug product with change in polymorphic form.",EMBRECHTS ROGER;;DE LEERSNIJDER CEDRIC;;SK BIOPHARMACEUTICALS CO LTD,EMBRECHTS ROGER;;DE LEERSNIJDER CEDRIC,,https://lens.org/165-651-624-073-99X,Granted Patent,yes,7,2,45,159-516-822-737-188;;040-245-016-852-096;;040-396-512-596-78X;;136-179-622-675-024;;032-262-165-909-820;;023-012-761-894-962;;155-504-418-632-516;;121-405-562-545-17X;;144-325-189-916-052;;019-981-338-213-670;;073-883-683-736-009;;105-520-197-837-708;;013-201-034-883-247;;105-972-285-891-795;;151-893-743-218-93X;;094-149-172-560-22X;;034-012-308-776-30X;;022-521-355-363-284;;093-752-459-993-321;;151-344-301-196-639;;095-497-761-003-445;;072-033-840-567-492;;156-658-975-310-219;;007-013-520-063-978;;087-798-926-602-198;;169-513-077-811-155;;018-566-154-564-674;;004-901-672-182-825;;064-101-233-865-545;;140-581-159-677-430;;195-599-680-964-597;;180-692-465-797-580;;026-265-607-683-002;;111-092-477-236-068;;173-050-548-549-55X;;091-001-366-009-655;;165-184-116-879-794;;165-651-624-073-99X;;043-323-131-136-319;;144-274-517-083-663;;163-120-758-498-402;;182-497-281-003-263;;033-345-284-779-58X;;071-113-377-559-012;;001-681-502-396-600,CA;;EC;;KR;;PA;;ES;;NI;;TW;;US;;CO;;JP;;UY;;ZA;;CN;;PL;;CL;;MY;;CR;;AU;;BR;;EA;;MX;;WO;;PE;;AR;;EP;;IL,45,033-345-284-779-58X;;040-245-016-852-096;;040-396-512-596-78X;;159-516-822-737-188;;136-179-622-675-024;;032-262-165-909-820;;155-504-418-632-516;;121-405-562-545-17X;;144-325-189-916-052;;019-981-338-213-670;;073-883-683-736-009;;105-520-197-837-708;;013-201-034-883-247;;105-972-285-891-795;;151-893-743-218-93X;;094-149-172-560-22X;;034-012-308-776-30X;;022-521-355-363-284;;093-752-459-993-321;;151-344-301-196-639;;095-497-761-003-445;;072-033-840-567-492;;156-658-975-310-219;;007-013-520-063-978;;087-798-926-602-198;;169-513-077-811-155;;018-566-154-564-674;;004-901-672-182-825;;064-101-233-865-545;;140-581-159-677-430;;195-599-680-964-597;;180-692-465-797-580;;026-265-607-683-002;;111-092-477-236-068;;173-050-548-549-55X;;091-001-366-009-655;;165-184-116-879-794;;165-651-624-073-99X;;043-323-131-136-319;;144-274-517-083-663;;163-120-758-498-402;;182-497-281-003-263;;001-681-502-396-600;;071-113-377-559-012;;023-012-761-894-962,CA;;EC;;KR;;PA;;ES;;NI;;TW;;US;;CO;;JP;;UY;;ZA;;CN;;PL;;CL;;MY;;CR;;AU;;BR;;EA;;MX;;WO;;PE;;AR;;EP;;IL,0,A61K31/325;;A61K9/0095;;A61K31/27;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/14;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P29/00;;A61K31/325;;A61K9/0095;;A61K31/27;;A61K47/12;;A61K47/26;;A61K47/36;;A61K47/38,A61K31/27;;A61K9/00,,0,0,,,,ACTIVE
69,US,A1,US 2015/0283243 A1,144-214-810-400-133,2015-10-08,2015,US 201314441277 A,2013-11-07,KR 20120125516 A;;KR 2013010088 W,2012-11-07,SOLID DISPERSIONS OF INSOLUBLE DRUG AND PREPARATION METHOD THEREOF,"The present invention relates to a solid dispersion characterized in that it comprises carbamic acid 3-(4-ben-zyloxy-phenyl)-isoxazol-5-ylmethyl ester as an active ingredient and a water-soluble polymer having a glass transition temperature lower than the melting point of the active ingredient as a carrier, and it is prepared via melt extrusion. The solid dispersion of the present invention remarkably increases the solubility and dissolution rate of the active ingredient which is an insoluble drug to efficiently improve the bioavailability when it is orally administered.",SK BIOPHARMACEUTICALS CO LTD;;SK BIOPHARMACEUTICALS CO LTD A CORP,BAEK MYOUNG KI;;PEGAN AUGUSTIN,SK BIOPHARMACEUTICALS CO. LTD (2015-04-29),https://lens.org/144-214-810-400-133,Patent Application,yes,3,1,30,128-620-442-386-588;;028-343-319-786-633;;184-988-190-580-830;;047-396-290-600-150;;034-164-982-258-945;;084-719-226-983-455;;159-256-564-500-664;;137-858-336-936-060;;015-789-677-099-344;;034-768-311-267-012;;158-063-407-607-233;;077-346-478-004-062;;012-993-406-841-921;;144-214-810-400-133;;009-016-496-340-563;;077-664-040-242-553;;059-818-577-811-185;;142-180-585-070-83X;;171-736-899-421-471;;137-408-508-367-59X;;030-714-980-956-369;;035-123-234-357-441;;070-848-719-776-254;;109-855-883-873-055;;107-181-894-552-82X;;185-072-571-289-680;;186-704-426-793-951;;088-325-414-156-864;;096-015-093-763-44X;;123-899-487-200-838,RU;;CA;;JP;;KR;;TR;;CN;;PL;;ES;;AU;;BR;;WO;;MX;;US;;HK;;EP,30,128-620-442-386-588;;028-343-319-786-633;;184-988-190-580-830;;047-396-290-600-150;;034-164-982-258-945;;084-719-226-983-455;;159-256-564-500-664;;137-858-336-936-060;;015-789-677-099-344;;034-768-311-267-012;;158-063-407-607-233;;077-346-478-004-062;;012-993-406-841-921;;144-214-810-400-133;;009-016-496-340-563;;077-664-040-242-553;;059-818-577-811-185;;142-180-585-070-83X;;171-736-899-421-471;;137-408-508-367-59X;;030-714-980-956-369;;035-123-234-357-441;;070-848-719-776-254;;109-855-883-873-055;;107-181-894-552-82X;;185-072-571-289-680;;186-704-426-793-951;;088-325-414-156-864;;096-015-093-763-44X;;123-899-487-200-838,RU;;CA;;JP;;KR;;TR;;CN;;PL;;ES;;AU;;BR;;WO;;MX;;US;;HK;;EP,0,A61K9/146;;A61K31/42;;C07D261/08;;A61K9/2027;;C07D261/08;;A61K9/146;;A61K9/2027;;A61K47/32;;A61K31/42;;A61P25/00;;A61P25/28;;A61K47/34;;A61K47/30;;A61K31/42;;C07D261/08;;A61K9/0053;;A61K9/141;;A61K9/146;;A61K9/20;;A61K31/42;;A61K47/00;;A61K47/30;;A61K2121/00;;C07D261/08;;A61K9/146;;A61K9/2027;;B01F23/66;;B01F23/81;;B01F35/90;;B01F27/40;;B01F2035/99;;B01F2101/22;;A61K31/42;;A61K9/10;;A61K47/32;;A61K9/0053;;A61K9/2031,A61K47/32;;A61K9/10;;A61K31/42;;B01F23/80,,4,1,196-137-673-224-806,10.1021/cen-v081n008.p032,"Kirk-Othmer Encyclopedia of Chemical Technology Copyright © 2002 by John Wiley & Sons, Inc., pp. 95-147, Article Online Posting Date: August 16, 2002;;Ullmann's Encyclopedia of Industrial Chemistry, Copyright © 2002 by Wiley-VCH Verlag GmbH & Co. KGaA , pp. 1-51;;Rouhi, ""The Right Stuff, from research and development to the clinic, getting drug crystals right is full of pitfalls"", Chemical & Engineering News, February 24, 2003, pp. 32-35;;Vitamin E TPGS NF and Food Grade, June 20012",ACTIVE
70,US,B2,US 8263652 B2,136-179-622-675-024,2012-09-11,2012,US 25849008 A,2008-10-27,US 25849008 A;;US 98414407 P,2007-10-31,Stabilized pediatric suspension of carisbamate,"The present invention provides a stabilized pharmaceutical suspension of carisbamate for pediatric and adult use. More particularly, the suspension is stabilized with hypromellose (HPMC) to prevent crystal growth of the suspended particles and to prevent re-crystallization of the drug product with change in polymorphic form.",EMBRECHTS ROGER;;DE LEERSNIJDER CEDRIC;;SK BIOPHARMACEUTICALS CO LTD,EMBRECHTS ROGER;;DE LEERSNIJDER CEDRIC,JANSSEN PHARMACEUTICA N.V (2008-03-05);;SK BIOPHARMACEUTICALS CO. LTD (2011-03-30),https://lens.org/136-179-622-675-024,Granted Patent,yes,2,3,45,159-516-822-737-188;;040-245-016-852-096;;040-396-512-596-78X;;136-179-622-675-024;;032-262-165-909-820;;023-012-761-894-962;;155-504-418-632-516;;121-405-562-545-17X;;144-325-189-916-052;;019-981-338-213-670;;073-883-683-736-009;;105-520-197-837-708;;013-201-034-883-247;;105-972-285-891-795;;151-893-743-218-93X;;094-149-172-560-22X;;034-012-308-776-30X;;022-521-355-363-284;;093-752-459-993-321;;151-344-301-196-639;;095-497-761-003-445;;072-033-840-567-492;;156-658-975-310-219;;007-013-520-063-978;;087-798-926-602-198;;169-513-077-811-155;;018-566-154-564-674;;004-901-672-182-825;;064-101-233-865-545;;140-581-159-677-430;;195-599-680-964-597;;180-692-465-797-580;;026-265-607-683-002;;111-092-477-236-068;;173-050-548-549-55X;;091-001-366-009-655;;165-184-116-879-794;;165-651-624-073-99X;;043-323-131-136-319;;144-274-517-083-663;;163-120-758-498-402;;182-497-281-003-263;;033-345-284-779-58X;;071-113-377-559-012;;001-681-502-396-600,CA;;EC;;KR;;PA;;ES;;NI;;TW;;US;;CO;;JP;;UY;;ZA;;CN;;PL;;CL;;MY;;CR;;AU;;BR;;EA;;MX;;WO;;PE;;AR;;EP;;IL,45,033-345-284-779-58X;;040-245-016-852-096;;040-396-512-596-78X;;159-516-822-737-188;;136-179-622-675-024;;032-262-165-909-820;;155-504-418-632-516;;121-405-562-545-17X;;144-325-189-916-052;;019-981-338-213-670;;073-883-683-736-009;;105-520-197-837-708;;013-201-034-883-247;;105-972-285-891-795;;151-893-743-218-93X;;094-149-172-560-22X;;034-012-308-776-30X;;022-521-355-363-284;;093-752-459-993-321;;151-344-301-196-639;;095-497-761-003-445;;072-033-840-567-492;;156-658-975-310-219;;007-013-520-063-978;;087-798-926-602-198;;169-513-077-811-155;;018-566-154-564-674;;004-901-672-182-825;;064-101-233-865-545;;140-581-159-677-430;;195-599-680-964-597;;180-692-465-797-580;;026-265-607-683-002;;111-092-477-236-068;;173-050-548-549-55X;;091-001-366-009-655;;165-184-116-879-794;;165-651-624-073-99X;;043-323-131-136-319;;144-274-517-083-663;;163-120-758-498-402;;182-497-281-003-263;;001-681-502-396-600;;071-113-377-559-012;;023-012-761-894-962,CA;;EC;;KR;;PA;;ES;;NI;;TW;;US;;CO;;JP;;UY;;ZA;;CN;;PL;;CL;;MY;;CR;;AU;;BR;;EA;;MX;;WO;;PE;;AR;;EP;;IL,0,A61K31/325;;A61K9/0095;;A61K31/27;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/14;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/28;;A61P29/00;;A61K31/325;;A61K9/0095;;A61K31/27;;A61K47/12;;A61K47/26;;A61K47/36;;A61K47/38,A61K31/27,514/489,0,0,,,,ACTIVE
71,US,B2,US 12226399 B2,187-819-716-849-841,2025-02-18,2025,US 202217826289 A,2022-05-27,US 202217826289 A;;US 202163194276 P,2021-05-28,Oral aqueous suspension formulation comprising carbamate compound,"The present disclosure relates to an aqueous formulation comprising as an active ingredient a carbamate compound of Formula 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof, poloxamer, and an aqueous carrier, wherein the aqueous formulation is in the form of a suspension formulation.",SK BIOPHARMACEUTICALS CO LTD,PENDSE PRAVADA;;BOMMANA MURALI M;;NOH REGINA H;;PEGAN AUGUSTIN;;WEBB TRAVIS JOHN;;MAXWELL JEJUAN,SK BIOPHARMACEUTICALS CO. LTD (2022-08-03),https://lens.org/187-819-716-849-841,Granted Patent,yes,5,0,15,111-109-197-313-573;;042-997-463-397-886;;105-565-454-473-183;;172-668-392-503-27X;;187-819-716-849-841;;123-252-227-422-840;;138-488-033-596-813;;180-817-471-897-998;;181-506-206-725-878;;091-318-187-324-348;;010-971-791-330-780;;153-444-631-916-345;;174-159-569-741-677;;151-542-428-514-670;;141-237-207-332-458,CA;;JP;;KR;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,15,111-109-197-313-573;;042-997-463-397-886;;105-565-454-473-183;;172-668-392-503-27X;;187-819-716-849-841;;123-252-227-422-840;;138-488-033-596-813;;180-817-471-897-998;;181-506-206-725-878;;091-318-187-324-348;;010-971-791-330-780;;153-444-631-916-345;;174-159-569-741-677;;151-542-428-514-670;;141-237-207-332-458,CA;;JP;;KR;;CN;;CL;;TW;;AU;;BR;;WO;;MX;;US;;AR;;EP;;IL,0,A61K47/10;;A61K9/10;;A61K47/02;;A61K31/41;;A61K47/36;;A61P25/00;;A61K47/38;;A61K9/0095;;A61K31/41;;A61K9/0095;;A61K9/10;;A61K47/02;;A61K47/10;;A61K47/32;;A61K47/36;;A61K47/38;;A61P25/00;;A61K9/0095;;A61K47/34;;A61K47/02;;A61K47/38;;A61K47/32;;A61K31/41;;A61P25/00;;A61K9/10;;A61K31/41;;A61K47/02;;A61K47/10;;A61K47/32;;A61K47/38,A61K31/41;;A61K9/10;;A61K47/02;;A61K47/10;;A61K47/32;;A61K47/34;;A61K47/36;;A61K47/38;;A61P25/00,,0,0,,,,ACTIVE
72,US,B2,US 9290464 B2,054-286-540-912-656,2016-03-22,2016,US 201414337628 A,2014-07-22,US 201414337628 A;;KR 20100041436 A;;US 201213695809 A;;KR 2011003318 W,2010-05-03,Pharmaceutical composition for inhibiting apoptosis of neuron or neurodegeneration,Provided is a pharmaceutical composition for inhibiting apoptosis of neurons or neurodegeneration. The pharmaceutical composition effectively prevents or treats diseases related to apoptosis of neurons or neurodegeneration.,SK BIOPHARMACEUTICALS CO LTD,PARK CHEOL HYOUNG;;MIN HYE KYUNG;;PARK IN SUK;;LIM MI JUNG;;LEE JI WON;;CHUNG JIN YONG;;YOON YEO JIN;;PARK JOO YOUNG,,https://lens.org/054-286-540-912-656,Granted Patent,yes,15,0,29,083-039-858-242-705;;112-978-299-565-262;;167-510-528-540-117;;030-396-572-256-67X;;005-606-654-973-855;;044-160-932-409-906;;179-167-967-243-034;;105-588-674-891-784;;083-927-741-654-410;;181-093-802-766-315;;115-475-254-140-257;;033-176-141-122-359;;001-137-200-928-772;;100-201-254-946-24X;;128-594-256-312-773;;034-852-710-631-338;;173-997-219-171-383;;030-774-362-450-39X;;077-722-933-911-999;;013-924-370-730-345;;191-530-673-964-029;;163-910-907-096-308;;013-649-920-355-110;;135-196-887-792-996;;054-286-540-912-656;;103-278-855-304-829;;056-912-353-242-800;;179-903-799-833-766;;137-947-736-509-345,CA;;RU;;KR;;JP;;BR;;WO;;MX;;CN;;US;;ES;;EP;;AU,29,083-039-858-242-705;;112-978-299-565-262;;167-510-528-540-117;;030-396-572-256-67X;;005-606-654-973-855;;044-160-932-409-906;;179-167-967-243-034;;105-588-674-891-784;;083-927-741-654-410;;181-093-802-766-315;;115-475-254-140-257;;033-176-141-122-359;;001-137-200-928-772;;100-201-254-946-24X;;128-594-256-312-773;;034-852-710-631-338;;173-997-219-171-383;;030-774-362-450-39X;;077-722-933-911-999;;013-924-370-730-345;;191-530-673-964-029;;163-910-907-096-308;;013-649-920-355-110;;135-196-887-792-996;;054-286-540-912-656;;103-278-855-304-829;;056-912-353-242-800;;179-903-799-833-766;;137-947-736-509-345,CA;;RU;;KR;;JP;;BR;;WO;;MX;;CN;;US;;ES;;EP;;AU,0,C07D261/08;;A61K31/4196;;A61K31/4245;;A61K31/433;;A61P9/10;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P27/02;;A61P31/00;;A61P43/00;;A61K31/4196;;A61K31/4245;;A61K31/433;;A61K2121/00;;A61K31/4196;;A61K31/42;;A61K31/4245;;A61K31/433;;A61P25/00;;A61P25/28;;C07D261/08;;A61K31/4196;;A61K31/4245;;A61K31/433,A61K31/42;;A61K31/41;;A61K31/4196;;A61K31/4245;;A61K31/425;;A61K31/433;;C07D261/08,,45,41,014-940-369-418-721;;059-772-259-790-672;;003-442-169-604-000;;062-784-033-080-439;;082-752-597-106-197;;000-592-134-863-138;;044-031-150-189-426;;079-487-506-039-265;;007-184-165-866-448;;005-962-605-901-91X;;023-664-658-989-49X;;053-881-431-566-061;;031-924-029-481-368;;002-642-713-148-310;;100-925-308-977-978;;018-052-409-408-975;;095-570-487-792-864;;125-442-892-352-782;;028-585-517-362-171;;039-899-380-419-069;;001-984-489-498-626;;019-425-317-169-116;;122-079-859-330-191;;072-445-148-605-027;;087-509-537-522-158;;097-453-736-173-440;;019-121-815-747-473;;009-501-675-949-701;;004-366-945-590-823;;074-555-246-495-925;;014-531-661-219-036;;011-004-785-493-826;;022-437-410-146-855;;016-068-174-873-998;;025-601-771-249-260;;026-023-618-909-247;;062-139-337-054-262;;023-338-367-652-578;;065-356-303-160-104;;019-755-188-269-314;;077-840-643-698-250,10.1634/stemcells.2006-0223;;16990586;;10.1002/chin.200423235;;11588183;;pmc6763865;;10.1523/jneurosci.21-20-08108.2001;;12031278;;10.1016/s0361-9230(01)00775-4;;10.1006/exnr.2002.8033;;12504889;;7689641;;10.1111/j.1471-4159.1993.tb03633.x;;16787833;;10.1007/bf03033786;;10.1002/ana.20624;;16178023;;10.1016/j.jns.2009.02.008;;10.1016/0361-9230(91)90242-c;;1826461;;10.1111/j.1582-4934.2003.tb00225.x;;pmc6741335;;14594549;;14964686;;10.1080/14734220310004289;;10.1016/s0165-0173(98)00046-0;;9974149;;pmc6762498;;10.1523/jneurosci.21-10-j0001.2001;;11319241;;10.1056/nejmra022366;;12672865;;9013391;;10.1007/bf01291788;;pmc4514105;;10.1111/j.1582-4934.2008.00402.x;;18624755;;10.1101/gad.13.15.1899;;10444588;;12729576;;10.1016/s0006-291x(03)00614-4;;9157311;;10.1016/0306-4522(95)00571-4;;17468299;;10.1124/jpet.106.118034;;pmc6786015;;9952406;;10.1523/jneurosci.19-04-01284.1999;;12200198;;10.1016/s0892-0362(02)00221-0;;11253364;;10.1038/35040009;;10.1038/nrn1886;;16552414;;pmc3710114;;9875735;;10.1097/00001756-199812010-00034;;9581757;;10.1016/s0896-6273(00)81004-1;;10.1016/0306-4522(95)00066-r;;7675192;;9827592;;9613716;;10.1002/mds.870131306;;12671216;;10.1016/0306-4522(94)90605-x;;7516500;;10.1007/s10863-005-6590-8;;16167175;;pmc2570496;;9409726;;10.1016/s0006-8993(97)00941-4;;10.1016/s0892-0362(02)00222-2;;12200192;;10.1111/j.1471-4159.1993.tb13610.x;;8376979;;10.1007/s11094-006-0087-6;;10.2165/00023210-200519090-00001;;16142989;;10.1038/nrn1883;;16552415;;10.1016/s0896-6273(03)00601-9;;14556717;;10683571;;10.1016/s0306-4522(99)00567-9;;17056129;;10.1016/j.tips.2006.10.004,"Kimura et al. Stem Cells 25 (2007) 115-124.;;Gfesser, et al. (2004) ""Structure-activity relationships of non-imidazole H3 receptor ligands. Part 3: 5-Substituted 3-phenyl-1,2,4-oxadiazoles as potent antagonists."" Bioorganic & Medicinal Chemistry Letters, 14:673-676.;;Akerud, et al., ""Neuroprotection through Delivery of Glial Cell Line-Derived Neurotrophic Factor by Neural Stem Cells in a Mouse Model of Parkinson's Disease."", The Journal of Neuroscience, 21:8108-8118, 2001.;;Alberch, et al., ""Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington's Disease."" Brain Research Bulletin, 57:817-822, 2002.;;Armentero, et al. ""Dopamine Receptor Agonists Mediate Neuroprotection in Malonate-Induced Striatal Lesion in the Rat."" Experimental Neurology, 178:301-305.;;Beal, et al. ""Age-Dependent Striatal Excitotoxic Lesions Produced by the Endogenous Mitochondrial Inhibitor Malonate."" J. Neurochem. 61:1147-1150, 1993.;;Beal, et al., Neuroprotective and Neurorestorative Strategies for Neuronal Injury., Neurotoxicity Research, 2:71-84, 2000.;;Beal, ""Mitochondria Take Center Stage in Aging and Neurodegeneration."", Ann. Neurol., 58:495-505, 2005.;;Beal, ""Mitochondrial dysfunction in neurodegenerative diseases and stroke: Neuroprotective strategies."", Journal of Neurological Sciences, 283:240-320, 2009.;;Behl, et al., ""Serial Review: Causes and Consequences of Oxidative Stress in Alzheimer's Disease."" Free radical Biology & Medicine, 33(2): 182-191, 2002.;;Berger, et al., ""Retrograde Degeneration of Nitrostriatal Neurons Induced by Instrastriatal 6-Hydroxydopamine Injection in Rats."", Brain Res., 26:301-307, 1991.;;Burlacu, ""Regulation of apoptosis by Bcl-2 family proteins."" J. Cell Mol. Med., 7:249-257, 2003.;;Canu, et al, ""In vitro cultured neurons for molecular studies correlating apoptosis with events related to Alzheimer disease."", Cerebellum, 2:270-278, 2003.;;Cassarino, et al., ""An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration."", Brain Res Review, 29(1):1-25, 1999.;;Chen, et al., ""Neuroprotection by Caffeine and A2A Adenosine Receptor Inactivation in a model of Parkinson's Disease."", J. Neurosci., 21:RC143, 2001.;;Friedlander, ""Apoptosis and Caspases in Neurodegenerative Diseases."", The New England Journal of Medicine, 348(14):1365-1375, 2003.;;Gerlach, et al., ""Animal models of Parkinson's Disease: an empirical comparison with the phenomenology of the disease in man."", J. Neural Trasm., 103:987-1041.;;Gorman, ""Neuronal cell death in neurodegenerative diseases: recurring themes around protein handling."", Journal of Cellular and Molecular Medicine, 12:2263-2280, 2008.;;Gross, et al., ""BCL-2 family members and the mitochondria in apoptosis."" Genes and Development, 13:1899-1911, 1999.;;Kroemer, ""Mitochondrial control of apoptosis: an introduction."" Biochem Biophys Res Commun., 304(3):433-435, 2003.;;Lee, et al., ""Dopaminergic Neuronal Degeneration and Motor Impairments Following Axon Terminal Lesion by Intrastriatal 6-Hydroxydopamine in the Rat."", Neurosci., 72:641-653, 1996.;;Lin, et al., ""Neuroprotection by Small Molecule Activators of the Nerve Growth Factor Receptor."", The Journal of Pharmacology and Experimental Therapeutics, 322:59-69, 2007.;;Lotharius, et al., ""Distinct Mechanisms Underlie Neurotoxin-Mediated Cell Death in Cultured Dopaminergic Neurons."", J. Neurosci., 19:1284-1293, 1999.;;Maruyama, et al., ""Neuroprotection by propargylamines in Parkinson's disease Suppression of apoptosis and induction of prosurvival genes."", Neurotoxicology and Teratolgy, 24:675-682, 2002.;;Mattson, ""Apoptosis in Neurodegenerative Disorders."" Nature Reviews Molecular Cell Biology, 1:120-130, 2000.;;Mattson, et al., ""Ageing and neuronal vulnerability."" Nat. Rev. Neurosci., 7:278-294, 2006.;;Monopoli, et al., ""Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats."", Neuro Report, 9:3955-3959, 1998.;;Nagahara, et al., ""Neuroprotective effects of brain-deprived neurotrophic factor in rodent and primate models of Alzheimer's Disease."", Narure medicine.;;Pettmann, et al., ""Neruonal Cell Death"" Neuron., 20:633-647, 1998.;;Przedborski, et al., ""Dose-Dependent Lesions of the Dopaminergic Nigrostriatal Pathway Induced by Intrastriatal Injection of 6-Hydroxydopamine."", Neurosci., 67:631-647, 1995.;;Przedborski, et al., ""Mechanisms of MPTP Toxicity."", Mov. Disord., 13:35-38, 1998.;;Przedborski, et al., ""The parkinsonian toxin MPTP: action and mechanism."" Restor. Neurol. Neurosci., 16:135-142, 2000.;;Sauer, et al., ""Progressive Degeneration of Nigrostriatal Dopamine Neurons Following Instrstriatal Terminal Lesions with 6-Hydroxydopamine: A Combined Retrograde Tracing and Immunocytochemical Study in the Rat."", Neurosci., 59:401-415, 1994.;;Soane, et al., ""Inhibition of Mitochondrial Neural Cell Death Pathways by Protein Transduction of Bcl-2 Family Proteins."", Journal of Bioenergetics and Biomembranes, 37:179-190, 2005.;;Sonsalla, et al. ""Inhibition of striatal energy metabolism produces cell loss in the ipsilateral substantia nigra."", Brain Res., 773:223-226, 1997.;;Speciale, ""MPTP Insights into parkinsonian neurodegeneration."" Neurotoxicol. Teratol. 24:607-620, 2002.;;Tipton, et al., ""Advances in Our Understanding of the Mechanisms of the Neurotoxicity of MPTP and Related Compounds."", J. Neurochem., 61:1191-1206, 1993.;;Velikorodov, et al., ""Synthesis and Cardiovascular Activity of Some Azaheterocycles with Carbamate Groups."", Pharmaceutical Chemistry Journal, vol. 40, No. 4, 182-185, 2006.;;Wu, et al., ""Treatment of Parkinson's' Disease What's on the Horizon?"", CNS Drugs, 19:723, 2005.;;Youdim, et al., ""The therapeutic potential of monoamine oxidase inhibitors."" Nat. Rev. Neurosci., 7:295-309, 2006.;;Yuan, et al., ""Diversity in the Mechanisms of Neuronal Cell Death."" Neuron, 40:401-413, 2003.;;Zeevalk, et al., ""Oxidative Stress During Energy Impairment in Mesencephalic Cultures is not a Downstream Consequence of a Secondary Excitotoxicity."", Neuroscience, 96:309-316, 2000.;;Zhang, et al., ""Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease."" TRENDS in Pharmaceutical Sciences, 27:619-625, 2006.;;PCT/KR2011/003318 International Search Report dated Jan. 10, 2012 (3 pgs.).;;The extended European Search Report issued in EP 11777560.1, dated Feb. 13, 2014.",ACTIVE
73,US,B2,US 9068207 B2,034-404-087-195-992,2015-06-30,2015,US 201313776964 A,2013-02-26,US 201313776964 A;;US 90426710 A;;US 25186709 P,2009-10-15,Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester,"Disclosed is a method for the preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl esters, comprising the enantioselective enzyme reduction of a 1-aryl-2-tetrazolyl-ethyl ketone to form a (R)-1-aryl-2-tetrazolyl-ethyl alcohol and the carbamation of said alcohol.",SK BIOPHARMACEUTICALS CO LTD;;SK BIOPHARMACEUTICALS CO LTD,LIM SANG CHUL;;UHM MOO YONG;;LEE DAE WON;;KIM HUI HO;;LEE DONG HO;;LEE HYUN SEOK,,https://lens.org/034-404-087-195-992,Granted Patent,yes,87,0,34,016-197-744-023-399;;038-532-396-776-768;;117-360-948-134-305;;100-961-428-414-334;;126-300-092-826-786;;010-230-015-612-963;;055-058-684-385-949;;034-404-087-195-992;;085-485-945-533-853;;193-170-982-419-952;;151-820-942-918-798;;094-952-948-890-748;;095-655-236-166-570;;118-596-803-384-538;;072-679-912-699-324;;114-195-532-650-52X;;109-515-102-992-078;;041-488-748-194-116;;069-796-278-488-670;;136-889-561-047-716;;011-196-245-292-379;;121-249-289-774-323;;105-513-255-591-588;;026-150-348-487-268;;118-470-678-781-636;;149-849-678-101-400;;171-411-424-337-617;;115-870-633-855-244;;037-806-165-788-023;;193-394-402-499-566;;155-040-750-977-927;;044-652-973-822-810;;182-096-519-644-558;;157-158-332-478-988,CA;;RU;;KR;;JP;;ZA;;HU;;CN;;PL;;CL;;MY;;ES;;AU;;BR;;WO;;MX;;US;;HK;;EP;;IL,34,016-197-744-023-399;;038-532-396-776-768;;117-360-948-134-305;;100-961-428-414-334;;126-300-092-826-786;;010-230-015-612-963;;055-058-684-385-949;;034-404-087-195-992;;085-485-945-533-853;;193-170-982-419-952;;151-820-942-918-798;;094-952-948-890-748;;095-655-236-166-570;;118-596-803-384-538;;072-679-912-699-324;;114-195-532-650-52X;;109-515-102-992-078;;041-488-748-194-116;;069-796-278-488-670;;136-889-561-047-716;;011-196-245-292-379;;121-249-289-774-323;;105-513-255-591-588;;026-150-348-487-268;;118-470-678-781-636;;149-849-678-101-400;;171-411-424-337-617;;115-870-633-855-244;;037-806-165-788-023;;193-394-402-499-566;;155-040-750-977-927;;044-652-973-822-810;;182-096-519-644-558;;157-158-332-478-988,CA;;RU;;KR;;JP;;ZA;;HU;;CN;;PL;;CL;;MY;;ES;;AU;;BR;;WO;;MX;;US;;HK;;EP;;IL,8,A61P25/00;;C07D257/04;;C07D257/06;;A61K31/41;;C12P17/12;;C12P17/10;;C07D257/04,C12P17/10;;C07D257/04,,10,4,010-680-137-385-664;;139-582-685-904-567;;001-580-232-559-357;;005-903-507-321-057,10.1016/j.tet.2007.12.020;;10.1016/j.tetasy.2008.12.035;;19251421;;10.1016/j.bmc.2009.02.004;;10.1016/s0957-4166(01)00020-9,"Hobuss et al. (2008) ""Catalytic enantioselective borane reduction of arylketones with pinene-derived amino alcohols,"" Tetrahedron, 64(8):1635-1640.;;Matsuda, T. et al. (2009) ""Recent progress in biocatalysis for asymmetric oxidation and reduction."" Tetrahedron: Asymmetry. 20(5):513-557.;;Rostom et al., (2009) ""Azole antimicrobial pharmacophore-based tetrazoles: Synthesis and biological evaluation as potential antimicrobial and anticonvulsant agents,"" Bioorganic & Medicinal Chemistry 17:2410-2422.;;Yadav et al., (2001) ""A facile synthesis of (R)-(-)-2-azido-1-arylethanols from 2-azido-1-arylketones using baker's yeast,"" Tetrahedron: Asymmetry, 12(1):63-67.;;European Search Opinion mailed Oct. 22, 2012 from the European Patent Office in the corresponding European Patent Application No. 09846577.6.;;International Search Report and Written Opinion mailed on Apr. 28, 2010 in the corresponding PCT Application No. PCT/KR2009/005906.;;International Search Report and Written Opinion mailed on Jul. 11, 2011 in the related PCT Application No. PCT/KR2010/007069.;;Office Action dated Jan. 31, 2012 issued in U.S. Appl. No. 12/578,709.;;Office Action dated May 18, 2012 issued in U.S. Appl. No. 12/904,267.;;Office Action dated Jun. 29, 2012 issued in U.S. Appl. No. 12/578,709.",ACTIVE
74,US,A1,US 2014/0350062 A1,115-475-254-140-257,2014-11-27,2014,US 201414337628 A,2014-07-22,US 201414337628 A;;KR 20100041436 A;;US 201213695809 A;;KR 2011003318 W,2010-05-03,PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURON OR NEURODEGENERATION,Provided is a pharmaceutical composition for inhibiting apoptosis of neurons or neurodegeneration. The pharmaceutical composition effectively prevents or treats diseases related to apoptosis of neurons or neurodegeneration.,SK BIOPHARMACEUTICALS CO LTD,PARK CHEOL HYOUNG;;MIN HYE KYUNG;;PARK IN SUK;;LIM MI JUNG;;LEE JI WON;;CHUNG JIN YONG;;YOON YEO JIN;;PARK JOO YOUNG,,https://lens.org/115-475-254-140-257,Patent Application,yes,0,1,29,083-039-858-242-705;;112-978-299-565-262;;167-510-528-540-117;;030-396-572-256-67X;;005-606-654-973-855;;044-160-932-409-906;;179-167-967-243-034;;105-588-674-891-784;;083-927-741-654-410;;181-093-802-766-315;;115-475-254-140-257;;033-176-141-122-359;;001-137-200-928-772;;100-201-254-946-24X;;128-594-256-312-773;;034-852-710-631-338;;173-997-219-171-383;;030-774-362-450-39X;;077-722-933-911-999;;013-924-370-730-345;;191-530-673-964-029;;163-910-907-096-308;;013-649-920-355-110;;135-196-887-792-996;;054-286-540-912-656;;103-278-855-304-829;;056-912-353-242-800;;179-903-799-833-766;;137-947-736-509-345,CA;;RU;;KR;;JP;;BR;;WO;;MX;;CN;;US;;ES;;EP;;AU,29,083-039-858-242-705;;112-978-299-565-262;;167-510-528-540-117;;030-396-572-256-67X;;005-606-654-973-855;;044-160-932-409-906;;179-167-967-243-034;;105-588-674-891-784;;083-927-741-654-410;;181-093-802-766-315;;115-475-254-140-257;;033-176-141-122-359;;001-137-200-928-772;;100-201-254-946-24X;;128-594-256-312-773;;034-852-710-631-338;;173-997-219-171-383;;030-774-362-450-39X;;077-722-933-911-999;;013-924-370-730-345;;191-530-673-964-029;;163-910-907-096-308;;013-649-920-355-110;;135-196-887-792-996;;054-286-540-912-656;;103-278-855-304-829;;056-912-353-242-800;;179-903-799-833-766;;137-947-736-509-345,CA;;RU;;KR;;JP;;BR;;WO;;MX;;CN;;US;;ES;;EP;;AU,0,C07D261/08;;A61K31/4196;;A61K31/4245;;A61K31/433;;A61P9/10;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P27/02;;A61P31/00;;A61P43/00;;A61K31/4196;;A61K31/4245;;A61K31/433;;A61K2121/00;;A61K31/4196;;A61K31/42;;A61K31/4245;;A61K31/433;;A61P25/00;;A61P25/28;;C07D261/08;;A61K31/4196;;A61K31/4245;;A61K31/433,C07D261/08,514/378,1,1,014-940-369-418-721,10.1634/stemcells.2006-0223;;16990586,Kimura et al. Stem Cells 25 (2007) 115-124.,ACTIVE
75,EP,B1,EP 1879873 B1,157-657-824-512-659,2013-10-09,2013,EP 06768472 A,2006-04-21,KR 2006001523 W;;US 67453005 P,2005-04-22,NEUROTHERAPEUTIC AZOLE COMPOUNDS,,SK BIOPHARMACEUTICALS CO LTD,CHOI YONG-MOON;;KIM CHOON-GIL;;KANG YOUNG-SUN;;YI HAN-JU;;LEE HYUN-SEOK;;KU BON-CHUL;;LEE EUN-HO;;IM DAE-JOONG;;SHIN YU-JIN,"SK BIOPHARMACEUTICALS CO., LTD., KR (2018-12-14);;SK BIOPHARMACEUTICALS CO., LTD. (2012-03-14)",https://lens.org/157-657-824-512-659,Granted Patent,yes,1,0,34,016-822-368-774-981;;196-754-367-480-282;;025-132-948-117-281;;019-469-508-277-771;;157-657-824-512-659;;122-254-729-268-807;;180-232-893-065-231;;017-987-040-851-615;;000-680-957-729-597;;006-920-412-140-801;;139-527-526-424-169;;069-474-687-657-162;;083-286-225-706-598;;056-745-581-271-210;;067-295-709-373-878;;013-963-816-145-602;;194-960-877-543-401;;029-305-540-871-019;;042-360-756-119-232;;101-617-645-457-318;;018-793-095-827-904;;161-520-181-401-177;;104-338-199-379-619;;077-980-256-736-311;;000-732-844-264-860;;067-331-391-354-92X;;134-514-719-844-835;;178-238-990-495-618;;190-616-138-405-656;;142-903-062-833-312;;034-768-583-874-799;;179-653-074-541-863;;075-627-671-506-61X;;099-025-001-215-146,CA;;RU;;KR;;JP;;PT;;ZA;;CN;;NL;;PL;;ES;;MY;;TW;;AU;;DK;;BR;;FI;;MX;;WO;;US;;AR;;EP,34,016-822-368-774-981;;196-754-367-480-282;;025-132-948-117-281;;019-469-508-277-771;;157-657-824-512-659;;122-254-729-268-807;;180-232-893-065-231;;017-987-040-851-615;;000-680-957-729-597;;006-920-412-140-801;;139-527-526-424-169;;069-474-687-657-162;;083-286-225-706-598;;056-745-581-271-210;;067-295-709-373-878;;013-963-816-145-602;;194-960-877-543-401;;029-305-540-871-019;;042-360-756-119-232;;101-617-645-457-318;;018-793-095-827-904;;161-520-181-401-177;;104-338-199-379-619;;077-980-256-736-311;;000-732-844-264-860;;067-331-391-354-92X;;134-514-719-844-835;;178-238-990-495-618;;190-616-138-405-656;;142-903-062-833-312;;034-768-583-874-799;;179-653-074-541-863;;075-627-671-506-61X;;099-025-001-215-146,CA;;RU;;KR;;JP;;PT;;ZA;;CN;;NL;;PL;;ES;;MY;;TW;;AU;;DK;;BR;;FI;;MX;;WO;;US;;AR;;EP,0,C07D257/04;;A61P3/04;;A61P9/10;;A61P21/00;;A61P25/00;;A61P25/06;;A61P25/08;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/34;;A61P29/00;;C07D249/04;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/06;;C07D257/04;;A61K31/4192;;C07D257/04;;C07D249/04;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/06,C07D249/04;;C07D257/04;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/06,,1,0,,,"ARZU KARAKURT ET AL.: 'Synthesis of some 1-(2-naphthyl)-2-(imidazole-1-yl)ethanone oxime and oxime ether derivatives and their anticonvulsant and antimicrobial activities' EUR. J. MED. CHEM. vol. 36, 2001, pages 421 - 433, XP004372854",ACTIVE
76,US,A1,US 2017/0105973 A1,186-704-426-793-951,2017-04-20,2017,US 201615394481 A,2016-12-29,US 201615394481 A;;KR 20120125516 A;;US 201615231382 A;;US 201514441277 A;;KR 2013010088 W,2012-11-07,SOLID DISPERSIONS OF INSOLUBLE DRUG AND PREPARATION METHOD THEREOF,"The present invention relates to a solid dispersion characterized in that it comprises carbamic acid 3-(4-benzyloxy-phenyl)-isoxazol-5-ylmethyl ester as an active ingredient and a water-soluble polymer having a glass transition temperature lower than the melting point of the active ingredient as a carrier, and it is prepared via melt extrusion. The solid dispersion of the present invention remarkably increases the solubility and dissolution rate of the active ingredient which is an insoluble drug to efficiently improve the bioavailability when it is orally administered.",SK BIOPHARMACEUTICALS CO LTD,BAEK MYOUNG KI;;PEGAN AUGUSTIN,SK BIOPHARMACEUTICALS CO. LTD (2015-04-29),https://lens.org/186-704-426-793-951,Patent Application,yes,3,0,30,128-620-442-386-588;;028-343-319-786-633;;184-988-190-580-830;;047-396-290-600-150;;034-164-982-258-945;;084-719-226-983-455;;159-256-564-500-664;;137-858-336-936-060;;015-789-677-099-344;;034-768-311-267-012;;158-063-407-607-233;;077-346-478-004-062;;012-993-406-841-921;;144-214-810-400-133;;009-016-496-340-563;;077-664-040-242-553;;059-818-577-811-185;;142-180-585-070-83X;;171-736-899-421-471;;137-408-508-367-59X;;030-714-980-956-369;;035-123-234-357-441;;070-848-719-776-254;;109-855-883-873-055;;107-181-894-552-82X;;185-072-571-289-680;;186-704-426-793-951;;088-325-414-156-864;;096-015-093-763-44X;;123-899-487-200-838,RU;;CA;;JP;;KR;;TR;;CN;;PL;;ES;;AU;;BR;;WO;;MX;;US;;HK;;EP,30,128-620-442-386-588;;028-343-319-786-633;;184-988-190-580-830;;047-396-290-600-150;;034-164-982-258-945;;084-719-226-983-455;;159-256-564-500-664;;137-858-336-936-060;;015-789-677-099-344;;034-768-311-267-012;;158-063-407-607-233;;077-346-478-004-062;;012-993-406-841-921;;144-214-810-400-133;;009-016-496-340-563;;077-664-040-242-553;;059-818-577-811-185;;142-180-585-070-83X;;171-736-899-421-471;;137-408-508-367-59X;;030-714-980-956-369;;035-123-234-357-441;;070-848-719-776-254;;109-855-883-873-055;;107-181-894-552-82X;;185-072-571-289-680;;186-704-426-793-951;;088-325-414-156-864;;096-015-093-763-44X;;123-899-487-200-838,RU;;CA;;JP;;KR;;TR;;CN;;PL;;ES;;AU;;BR;;WO;;MX;;US;;HK;;EP,0,A61K9/146;;A61K31/42;;C07D261/08;;A61K9/2027;;C07D261/08;;A61K9/146;;A61K9/2027;;A61K47/32;;A61K31/42;;A61P25/00;;A61P25/28;;A61K47/34;;A61K47/30;;A61K31/42;;C07D261/08;;A61K9/0053;;A61K9/141;;A61K9/146;;A61K9/20;;A61K31/42;;A61K47/00;;A61K47/30;;A61K2121/00;;C07D261/08;;A61K9/146;;A61K9/2027;;B01F23/66;;B01F23/81;;B01F35/90;;B01F27/40;;B01F2035/99;;B01F2101/22;;A61K31/42;;A61K9/10;;A61K47/32;;A61K9/0053;;A61K9/2031,A61K31/42;;A61K9/00;;A61K9/20;;B01F23/80,,1,0,,,"Vitamin E TPGS NF and Food Grade, June 20012",ACTIVE
77,WO,A1,WO 2014/073889 A1,184-988-190-580-830,2014-05-15,2014,KR 2013010088 W,2013-11-07,KR 20120125516 A,2012-11-07,SOLID DISPERSIONS OF INSOLUBLE DRUG AND PREPARATION METHOD THEREOF,"The present invention relates to a solid dispersion characterized in that it comprises carbamic acid 3-(4-benzyloxy-phenyl)-isoxazol-5-ylmethyl ester as an active ingredient and a water-soluble polymer having a glass transition temperature lower than the melting point of the active ingredient as a carrier, and it is prepared via melt extrusion. The solid dispersion of the present invention remarkably increases the solubility and dissolution rate of the active ingredient which is an insoluble drug to efficiently improve the bioavailability when it is orally administered.",SK BIOPHARMACEUTICALS CO LTD,BAEK MYOUNG KI;;PEGAN AUGUSTIN,,https://lens.org/184-988-190-580-830,Patent Application,yes,4,1,30,128-620-442-386-588;;028-343-319-786-633;;184-988-190-580-830;;047-396-290-600-150;;034-164-982-258-945;;084-719-226-983-455;;159-256-564-500-664;;137-858-336-936-060;;015-789-677-099-344;;034-768-311-267-012;;158-063-407-607-233;;077-346-478-004-062;;012-993-406-841-921;;144-214-810-400-133;;009-016-496-340-563;;077-664-040-242-553;;059-818-577-811-185;;142-180-585-070-83X;;171-736-899-421-471;;137-408-508-367-59X;;030-714-980-956-369;;035-123-234-357-441;;070-848-719-776-254;;109-855-883-873-055;;107-181-894-552-82X;;185-072-571-289-680;;186-704-426-793-951;;088-325-414-156-864;;096-015-093-763-44X;;123-899-487-200-838,RU;;CA;;JP;;KR;;TR;;CN;;PL;;ES;;AU;;BR;;WO;;MX;;US;;HK;;EP,30,128-620-442-386-588;;028-343-319-786-633;;184-988-190-580-830;;047-396-290-600-150;;034-164-982-258-945;;084-719-226-983-455;;159-256-564-500-664;;137-858-336-936-060;;015-789-677-099-344;;034-768-311-267-012;;158-063-407-607-233;;077-346-478-004-062;;012-993-406-841-921;;144-214-810-400-133;;009-016-496-340-563;;077-664-040-242-553;;059-818-577-811-185;;142-180-585-070-83X;;171-736-899-421-471;;137-408-508-367-59X;;030-714-980-956-369;;035-123-234-357-441;;070-848-719-776-254;;109-855-883-873-055;;107-181-894-552-82X;;185-072-571-289-680;;186-704-426-793-951;;088-325-414-156-864;;096-015-093-763-44X;;123-899-487-200-838,RU;;CA;;JP;;KR;;TR;;CN;;PL;;ES;;AU;;BR;;WO;;MX;;US;;HK;;EP,0,A61K9/146;;A61K31/42;;C07D261/08;;A61K9/2027;;C07D261/08;;A61K9/146;;A61K9/2027;;A61K47/32;;A61K31/42;;A61P25/00;;A61P25/28;;A61K47/34;;A61K47/30;;A61K31/42;;C07D261/08;;A61K9/0053;;A61K9/141;;A61K9/146;;A61K9/20;;A61K31/42;;A61K47/00;;A61K47/30;;A61K2121/00;;C07D261/08;;A61K9/146;;A61K9/2027;;B01F23/66;;B01F23/81;;B01F35/90;;B01F27/40;;B01F2035/99;;B01F2101/22;;A61K31/42;;A61K9/10;;A61K47/32;;A61K9/0053;;A61K9/2031,C07D261/08;;A61K31/42;;A61P25/00;;B01F23/80,,1,0,,,See also references of EP 2917188A4,PENDING
78,EP,A1,EP 4062906 A1,031-355-534-300-807,2022-09-28,2022,EP 20888989 A,2020-11-20,KR 20190151556 A;;KR 2020016427 W,2019-11-22,ORAL PHARMACEUTICAL COMPOSITION COMPRISING CARBAMATE COMPOUND AND PREPARATION METHOD THEREFOR,"The present invention relates to an oral pharmaceutical composition comprising a carbamate compound of chemical formula 1, an isomer thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof as an active ingredient, and a preparation method therefor.",SK BIOPHARMACEUTICALS CO LTD,LEE JI HYE;;CHOI SO YOUNG,,https://lens.org/031-355-534-300-807,Patent Application,yes,0,1,15,059-896-407-577-57X;;031-355-534-300-807;;120-537-913-593-666;;104-663-707-039-450;;104-085-871-564-327;;122-796-985-905-779;;189-093-197-879-645;;111-879-041-878-966;;171-539-093-331-861;;195-295-276-338-102;;040-851-159-981-899;;019-155-279-352-94X;;051-540-720-579-362;;007-960-770-399-381;;091-762-929-559-455,CA;;JP;;KR;;CN;;CL;;AU;;BR;;MX;;WO;;US;;CO;;EP;;IL,15,059-896-407-577-57X;;031-355-534-300-807;;120-537-913-593-666;;104-663-707-039-450;;104-085-871-564-327;;122-796-985-905-779;;189-093-197-879-645;;111-879-041-878-966;;171-539-093-331-861;;195-295-276-338-102;;040-851-159-981-899;;019-155-279-352-94X;;051-540-720-579-362;;007-960-770-399-381;;091-762-929-559-455,CA;;JP;;KR;;CN;;CL;;AU;;BR;;MX;;WO;;US;;CO;;EP;;IL,0,A61P25/08;;A61K9/2027;;A61K9/205;;A61K9/2054;;A61K9/2826;;A61K9/2866;;A61K31/41;;A61K31/41;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/48;;A61P25/08;;A61K9/14;;A61K9/0053;;A61K9/20;;A61K31/41;;A61P25/08;;A61K9/0053;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2059;;A61K9/2077;;A61K9/2095;;A61K31/41,A61K9/14;;A61K9/00;;A61K9/20;;A61K9/48;;A61K31/41;;A61P25/08,,0,0,,,,PENDING
79,EP,B1,EP 3556363 B1,151-665-941-023-960,2024-03-06,2024,EP 17880053 A,2017-12-14,KR 20160170227 A;;KR 2017014733 W,2016-12-14,"USE OF CARBAMATE COMPOUND FOR PREVENTION, ALLEVIATION OR TREATMENT OF PRURITUS",,SK BIOPHARMACEUTICALS CO LTD,PANG MIN HEE,,https://lens.org/151-665-941-023-960,Granted Patent,yes,7,0,9,015-014-893-363-388;;034-157-084-476-822;;151-168-414-290-357;;028-782-664-139-423;;064-904-250-830-490;;125-218-992-359-416;;014-779-227-870-570;;151-665-941-023-960;;114-926-704-672-909,KR;;WO;;US;;ES;;EP,9,015-014-893-363-388;;151-168-414-290-357;;034-157-084-476-822;;028-782-664-139-423;;064-904-250-830-490;;125-218-992-359-416;;014-779-227-870-570;;151-665-941-023-960;;114-926-704-672-909,KR;;WO;;US;;ES;;EP,0,A61K31/325;;A61K31/41;;A61P17/04;;A61K31/41;;A61K31/325;;A61P17/04;;A61K31/41,A61K31/41;;A61P17/04,,1,0,,,"FRANK LIEBEL ET AL: ""Anti-inflammatory and anti-itch activity of sertaconazole nitrate"", ARCHIVES OF DERMATOLOGICAL RESEARCH ; FOUNDED IN 1869 AS ARCHIV FÜR DERMATOLOGIE UND SYPHILIS, SPRINGER, BERLIN, DE, vol. 298, no. 4, 26 July 2006 (2006-07-26) , pages 191-199, XP019426276, ISSN: 1432-069X, DOI: 10.1007/S00403-006-0679-8",ACTIVE
80,EP,B1,EP 2086524 B1,123-043-173-950-187,2014-11-05,2014,EP 07833718 A,2007-10-31,KR 2007005410 W;;US 59976706 A,2006-11-15,TRANSNASAL ANTICONVULSIVE PHARMACEUTICAL COMPOSITION,,SK BIOPHARMACEUTICALS CO LTD,KIM KWON HO;;KAUR PARAMJEET;;JO JAE HOON;;BAEK MYOUNG KI;;YUK YEO JOO,"SK BIOPHARMACEUTICALS CO., LTD. (2012-02-22)",https://lens.org/123-043-173-950-187,Granted Patent,yes,6,0,17,065-289-310-786-263;;123-043-173-950-187;;075-157-304-373-401;;143-823-608-435-76X;;037-633-295-507-530;;137-415-120-336-856;;027-817-772-777-490;;063-392-812-099-343;;069-034-684-789-566;;094-595-098-363-518;;103-346-130-136-030;;060-919-597-122-860;;188-775-426-528-796;;048-923-818-204-024;;147-450-226-623-307;;009-407-159-374-39X;;137-589-457-598-608,DK;;CA;;JP;;KR;;MX;;WO;;US;;CN;;ES;;EP,17,065-289-310-786-263;;123-043-173-950-187;;075-157-304-373-401;;143-823-608-435-76X;;037-633-295-507-530;;137-415-120-336-856;;027-817-772-777-490;;063-392-812-099-343;;069-034-684-789-566;;094-595-098-363-518;;103-346-130-136-030;;060-919-597-122-860;;188-775-426-528-796;;048-923-818-204-024;;147-450-226-623-307;;009-407-159-374-39X;;137-589-457-598-608,DK;;CA;;JP;;KR;;MX;;WO;;US;;CN;;ES;;EP,0,A61K31/5513;;A61P21/02;;A61P25/08;;A61K47/14;;A61K9/107;;A61K31/5513;;A61K31/5513,A61K9/72;;A61K31/5513;;A61K47/10;;A61K47/14;;A61P21/02,,2,0,,,"LINDHARDT K. ET AL.: 'Intranasal bioavailability of diazepam in sheep correlated to rabbit and man' INTERNATIONAL JOURNAL OF PHARMACEUTICS vol. 231, no. 1, 2002, pages 67 - 72, XP008109948;;LI L. ET AL.: 'Rapid-onset intranasal delivery of anticonvulsants: pharmacokinetics and pharmacodynamic evaluation in rabbits' INTERNATIONAL JOURNAL OF PHARMACEUTICS vol. 199, no. 1, 2000, pages 65 - 76, XP008109947",ACTIVE
81,US,A1,US 2023/0000763 A1,122-796-985-905-779,2023-01-05,2023,US 202017778450 A,2020-11-20,KR 20190151556 A;;KR 2020016427 W,2019-11-22,ORAL PHARMACEUTICAL COMPOSITION COMPRISING CARBAMATE COMPOUND AND PREPARATION METHOD THEREFOR,"The present invention relates to an oral pharmaceutical composition comprising a carbamate compound of chemical formula 1, an isomer thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof as an active ingredient, and a preparation method therefor.",SK BIOPHARMACEUTICALS CO LTD,LEE JI HYE;;CHOI SO YOUNG,SK BIOPHARMACEUTICALS CO. LTD (2022-07-04),https://lens.org/122-796-985-905-779,Patent Application,yes,0,0,15,059-896-407-577-57X;;031-355-534-300-807;;120-537-913-593-666;;104-663-707-039-450;;104-085-871-564-327;;122-796-985-905-779;;189-093-197-879-645;;111-879-041-878-966;;171-539-093-331-861;;195-295-276-338-102;;040-851-159-981-899;;019-155-279-352-94X;;051-540-720-579-362;;007-960-770-399-381;;091-762-929-559-455,CA;;JP;;KR;;CN;;CL;;AU;;BR;;MX;;WO;;US;;CO;;EP;;IL,15,059-896-407-577-57X;;031-355-534-300-807;;120-537-913-593-666;;104-663-707-039-450;;104-085-871-564-327;;122-796-985-905-779;;189-093-197-879-645;;111-879-041-878-966;;171-539-093-331-861;;195-295-276-338-102;;040-851-159-981-899;;019-155-279-352-94X;;051-540-720-579-362;;007-960-770-399-381;;091-762-929-559-455,CA;;JP;;KR;;CN;;CL;;AU;;BR;;MX;;WO;;US;;CO;;EP;;IL,0,A61P25/08;;A61K9/2027;;A61K9/205;;A61K9/2054;;A61K9/2826;;A61K9/2866;;A61K31/41;;A61K31/41;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/48;;A61P25/08;;A61K9/14;;A61K9/0053;;A61K9/20;;A61K31/41;;A61P25/08;;A61K9/0053;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/2059;;A61K9/2077;;A61K9/2095;;A61K31/41,A61K9/00;;A61K9/20;;A61K31/41,,0,0,,,,PENDING
82,US,B2,US 9724335 B2,047-396-290-600-150,2017-08-08,2017,US 201615394481 A,2016-12-29,US 201615394481 A;;KR 20120125516 A;;US 201615231382 A;;US 201514441277 A;;KR 2013010088 W,2012-11-07,Solid dispersions of insoluble drug and preparation method thereof,"The present invention relates to a solid dispersion characterized in that it comprises carbamic acid 3-(4-benzyloxy-phenyl)-isoxazol-5-ylmethyl ester as an active ingredient and a water-soluble polymer having a glass transition temperature lower than the melting point of the active ingredient as a carrier, and it is prepared via melt extrusion. The solid dispersion of the present invention remarkably increases the solubility and dissolution rate of the active ingredient which is an insoluble drug to efficiently improve the bioavailability when it is orally administered.",SK BIOPHARMACEUTICALS CO LTD,BAEK MYOUNG KI;;PEGAN AUGUSTIN,SK BIOPHARMACEUTICALS CO. LTD (2015-04-29),https://lens.org/047-396-290-600-150,Granted Patent,yes,9,0,30,128-620-442-386-588;;028-343-319-786-633;;184-988-190-580-830;;047-396-290-600-150;;034-164-982-258-945;;084-719-226-983-455;;159-256-564-500-664;;137-858-336-936-060;;015-789-677-099-344;;034-768-311-267-012;;158-063-407-607-233;;077-346-478-004-062;;012-993-406-841-921;;144-214-810-400-133;;009-016-496-340-563;;077-664-040-242-553;;059-818-577-811-185;;142-180-585-070-83X;;171-736-899-421-471;;137-408-508-367-59X;;030-714-980-956-369;;035-123-234-357-441;;070-848-719-776-254;;109-855-883-873-055;;107-181-894-552-82X;;185-072-571-289-680;;186-704-426-793-951;;088-325-414-156-864;;096-015-093-763-44X;;123-899-487-200-838,RU;;CA;;JP;;KR;;TR;;CN;;PL;;ES;;AU;;BR;;WO;;MX;;US;;HK;;EP,30,128-620-442-386-588;;028-343-319-786-633;;184-988-190-580-830;;047-396-290-600-150;;034-164-982-258-945;;084-719-226-983-455;;159-256-564-500-664;;137-858-336-936-060;;015-789-677-099-344;;034-768-311-267-012;;158-063-407-607-233;;077-346-478-004-062;;012-993-406-841-921;;144-214-810-400-133;;009-016-496-340-563;;077-664-040-242-553;;059-818-577-811-185;;142-180-585-070-83X;;171-736-899-421-471;;137-408-508-367-59X;;030-714-980-956-369;;035-123-234-357-441;;070-848-719-776-254;;109-855-883-873-055;;107-181-894-552-82X;;185-072-571-289-680;;186-704-426-793-951;;088-325-414-156-864;;096-015-093-763-44X;;123-899-487-200-838,RU;;CA;;JP;;KR;;TR;;CN;;PL;;ES;;AU;;BR;;WO;;MX;;US;;HK;;EP,0,A61K9/146;;A61K31/42;;C07D261/08;;A61K9/2027;;C07D261/08;;A61K9/146;;A61K9/2027;;A61K47/32;;A61K31/42;;A61P25/00;;A61P25/28;;A61K47/34;;A61K47/30;;A61K31/42;;C07D261/08;;A61K9/0053;;A61K9/141;;A61K9/146;;A61K9/20;;A61K31/42;;A61K47/00;;A61K47/30;;A61K2121/00;;C07D261/08;;A61K9/146;;A61K9/2027;;B01F23/66;;B01F23/81;;B01F35/90;;B01F27/40;;B01F2035/99;;B01F2101/22;;A61K31/42;;A61K9/10;;A61K47/32;;A61K9/0053;;A61K9/2031,A61K31/42;;A61K9/00;;A61K9/10;;A61K9/14;;A61K9/20;;A61K47/32;;B01F23/80;;C07D261/08,,6,1,196-137-673-224-806,10.1021/cen-v081n008.p032,"Vitamin E TPGS NF and Food Grade, Jun. 2012.;;International Search Report (ISR) dated Feb. 20, 2014 in PCT/KR2013/010088 published as WO 2014/073889.;;Kirk-Othmer Encyclopedia of Chemical Technology Copyright© 2002 by John Wiley & Sons, Inc., pp. 94-147, Article Online Posting Date: Aug. 16, 2002.;;Rouhi, (2003) “The right stuff, from research and developments to the clinic, getting rug crystals right is full of pitfalls”. Chemical & Engineering News. pp. 32-35.;;Ullmann's Encyclopedia of Industrial Chemistry, Copyright© 2002 by Wiley-VCH Verlag GmbH & Co. KGaA, pp. 1-51.;;Vitamin E TPGS and Food Grade, Jun. 2012.",ACTIVE
83,US,B2,US 9439970 B2,028-343-319-786-633,2016-09-13,2016,US 201314441277 A,2013-11-07,KR 20120125516 A;;KR 2013010088 W,2012-11-07,Solid dispersions of insoluble drug and preparation method thereof,"The present invention relates to a solid dispersion characterized in that it comprises carbamic acid 3-(4-benzyloxy-phenyl)-isoxazol-5-ylmethyl ester as an active ingredient and a water-soluble polymer having a glass transition temperature lower than the melting point of the active ingredient as a carrier, and it is prepared via melt extrusion. The solid dispersion of the present invention remarkably increases the solubility and dissolution rate of the active ingredient which is an insoluble drug to efficiently improve the bioavailability when it is orally administered.",SK BIOPHARMACEUTICALS CO LTD,BAEK MYOUNG KI;;PEGAN AUGUSTIN,SK BIOPHARMACEUTICALS CO. LTD (2015-04-29),https://lens.org/028-343-319-786-633,Granted Patent,yes,9,0,30,128-620-442-386-588;;028-343-319-786-633;;184-988-190-580-830;;047-396-290-600-150;;034-164-982-258-945;;084-719-226-983-455;;159-256-564-500-664;;137-858-336-936-060;;015-789-677-099-344;;034-768-311-267-012;;158-063-407-607-233;;077-346-478-004-062;;012-993-406-841-921;;144-214-810-400-133;;009-016-496-340-563;;077-664-040-242-553;;059-818-577-811-185;;142-180-585-070-83X;;171-736-899-421-471;;137-408-508-367-59X;;030-714-980-956-369;;035-123-234-357-441;;070-848-719-776-254;;109-855-883-873-055;;107-181-894-552-82X;;185-072-571-289-680;;186-704-426-793-951;;088-325-414-156-864;;096-015-093-763-44X;;123-899-487-200-838,RU;;CA;;JP;;KR;;TR;;CN;;PL;;ES;;AU;;BR;;WO;;MX;;US;;HK;;EP,30,128-620-442-386-588;;028-343-319-786-633;;184-988-190-580-830;;047-396-290-600-150;;034-164-982-258-945;;084-719-226-983-455;;159-256-564-500-664;;137-858-336-936-060;;015-789-677-099-344;;034-768-311-267-012;;158-063-407-607-233;;077-346-478-004-062;;012-993-406-841-921;;144-214-810-400-133;;009-016-496-340-563;;077-664-040-242-553;;059-818-577-811-185;;142-180-585-070-83X;;171-736-899-421-471;;137-408-508-367-59X;;030-714-980-956-369;;035-123-234-357-441;;070-848-719-776-254;;109-855-883-873-055;;107-181-894-552-82X;;185-072-571-289-680;;186-704-426-793-951;;088-325-414-156-864;;096-015-093-763-44X;;123-899-487-200-838,RU;;CA;;JP;;KR;;TR;;CN;;PL;;ES;;AU;;BR;;WO;;MX;;US;;HK;;EP,0,A61K9/146;;A61K31/42;;C07D261/08;;A61K9/2027;;C07D261/08;;A61K9/146;;A61K9/2027;;A61K47/32;;A61K31/42;;A61P25/00;;A61P25/28;;A61K47/34;;A61K47/30;;A61K31/42;;C07D261/08;;A61K9/0053;;A61K9/141;;A61K9/146;;A61K9/20;;A61K31/42;;A61K47/00;;A61K47/30;;A61K2121/00;;C07D261/08;;A61K9/146;;A61K9/2027;;B01F23/66;;B01F23/81;;B01F35/90;;B01F27/40;;B01F2035/99;;B01F2101/22;;A61K31/42;;A61K9/10;;A61K47/32;;A61K9/0053;;A61K9/2031,A61K47/32;;A61K9/10;;A61K9/14;;A61K9/20;;A61K31/42;;B01F23/80;;C07D261/08,,5,1,196-137-673-224-806,10.1021/cen-v081n008.p032,"Kirk-Othmer Encyclopedia of Chemical Technology Copyright © 2002 by John Wiley & Sons, Inc., pp. 95-147, Article Online Posting Date: Aug. 16, 2002.;;Ullmann's Encyclopedia of Industrial Chemistry, Copyright © 2002 by Wiley-VCH Verlag GmbH & Co. KGaA , pp. 1-51.;;Rouhi, ""The Right Stuff, from research and development to the clinic, getting drug crystals right is full of pitfalls"", Chemical & Engineering News, Feb. 24, 2003, pp. 32-35.;;Vitamin E TPGS NF and Food Grade, Jun. 20012.;;International Search Report (ISR) dated Feb. 20, 2014 in PCT/KR2013/010088 published as WO 2014/073889.",ACTIVE
84,EP,B1,EP 2282721 B1,151-134-450-146-568,2018-02-14,2018,EP 09746768 A,2009-05-14,KR 2009002567 W;;KR 20080044481 A,2008-05-14,TRANSNASAL ANTICONVULSIVE PHARMACEUTICAL COMPOSITION COMPRISING POORLY SOLUBLE ANTICONVULSANT,,SK BIOPHARMACEUTICALS CO LTD,BAEK MYOUNG-KI;;JO JAE-HOON;;CHANG HYE-JIN,"SK BIOPHARMACEUTICALS CO., LTD. (2012-02-22)",https://lens.org/151-134-450-146-568,Granted Patent,yes,5,0,27,015-260-595-433-249;;175-803-753-292-77X;;083-887-966-342-967;;051-851-931-919-484;;195-187-617-647-635;;028-580-651-802-219;;137-926-056-618-190;;148-479-644-508-251;;108-289-621-162-448;;170-037-002-773-044;;120-564-706-346-359;;025-611-607-754-416;;040-895-886-524-090;;008-778-568-715-497;;052-871-813-367-118;;151-420-699-494-581;;000-082-259-582-671;;057-673-283-798-053;;025-300-968-868-330;;123-511-837-475-53X;;113-986-052-059-962;;097-083-913-770-591;;073-058-413-730-651;;088-077-507-443-969;;151-134-450-146-568;;141-156-788-913-116;;157-535-423-454-616,CA;;KR;;JP;;MX;;WO;;CN;;US;;ES;;EP;;AU,27,015-260-595-433-249;;175-803-753-292-77X;;083-887-966-342-967;;051-851-931-919-484;;195-187-617-647-635;;028-580-651-802-219;;137-926-056-618-190;;148-479-644-508-251;;108-289-621-162-448;;170-037-002-773-044;;120-564-706-346-359;;025-611-607-754-416;;040-895-886-524-090;;008-778-568-715-497;;052-871-813-367-118;;151-420-699-494-581;;000-082-259-582-671;;057-673-283-798-053;;025-300-968-868-330;;123-511-837-475-53X;;113-986-052-059-962;;097-083-913-770-591;;073-058-413-730-651;;088-077-507-443-969;;151-134-450-146-568;;141-156-788-913-116;;157-535-423-454-616,CA;;KR;;JP;;MX;;WO;;CN;;US;;ES;;EP;;AU,0,A61K9/0043;;A61K31/5513;;A61K47/08;;A61K47/14;;A61K47/26;;A61K31/5513;;A61K9/0043;;A61K47/26;;A61K47/44;;A61P25/08;;Y02A50/30;;A61K9/08;;A61K47/08;;A61K31/5513;;A61K9/0043;;A61K47/26;;A61K47/44;;Y02A50/30,A61K9/08;;A61K31/19;;A61K31/325;;A61K31/5513;;A61P25/08,,3,0,,,"LIANLI LI, INDRANIL NANDI,KWON H KIM: ""Development of an ethyl laurate-based microemulsion for rapid-onset intranasal delivery of diazepam"", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 237, no. 1-2, 22 April 2002 (2002-04-22), pages 77-85, XP008165238,;;KAUR P ET AL: ""Pharmacokinetics and brain uptake of diazepam after intravenous and intranasal administration in rats and rabbits"", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 364, no. 1, 19 November 2008 (2008-11-19), pages 27-35, XP025562416, ISSN: 0378-5173, DOI: 10.1016/J.IJPHARM.2008.07.030 [retrieved on 2008-08-06];;KIM, K.H. ET AL.: 'Rapid-onset intranasal delivery of anticonvulsants: pharmacokinetic and pharmacodynamic evaluation in rabbits' INTERNATIONAL JOURNAL OF PHARMACEUTICS vol. 199, 2000, pages 65 - 76, XP008109947",ACTIVE
85,EP,B1,EP 2917188 B1,137-858-336-936-060,2018-08-01,2018,EP 13854140 A,2013-11-07,KR 20120125516 A;;KR 2013010088 W,2012-11-07,SOLID DISPERSIONS OF INSOLUBLE DRUG AND PREPARATION METHOD THEREOF,,SK BIOPHARMACEUTICALS CO LTD,BAEK MYOUNG KI;;PEGAN AUGUSTIN,"SK BIOPHARMACEUTICALS CO., LTD. (2018-08-29)",https://lens.org/137-858-336-936-060,Granted Patent,yes,6,0,30,128-620-442-386-588;;028-343-319-786-633;;184-988-190-580-830;;047-396-290-600-150;;034-164-982-258-945;;084-719-226-983-455;;159-256-564-500-664;;137-858-336-936-060;;015-789-677-099-344;;034-768-311-267-012;;158-063-407-607-233;;077-346-478-004-062;;012-993-406-841-921;;144-214-810-400-133;;009-016-496-340-563;;077-664-040-242-553;;059-818-577-811-185;;142-180-585-070-83X;;171-736-899-421-471;;137-408-508-367-59X;;030-714-980-956-369;;035-123-234-357-441;;070-848-719-776-254;;109-855-883-873-055;;107-181-894-552-82X;;185-072-571-289-680;;186-704-426-793-951;;088-325-414-156-864;;096-015-093-763-44X;;123-899-487-200-838,RU;;CA;;JP;;KR;;TR;;CN;;PL;;ES;;AU;;BR;;WO;;MX;;US;;HK;;EP,30,128-620-442-386-588;;028-343-319-786-633;;184-988-190-580-830;;047-396-290-600-150;;034-164-982-258-945;;084-719-226-983-455;;159-256-564-500-664;;137-858-336-936-060;;015-789-677-099-344;;034-768-311-267-012;;158-063-407-607-233;;077-346-478-004-062;;012-993-406-841-921;;144-214-810-400-133;;009-016-496-340-563;;077-664-040-242-553;;059-818-577-811-185;;142-180-585-070-83X;;171-736-899-421-471;;137-408-508-367-59X;;030-714-980-956-369;;035-123-234-357-441;;070-848-719-776-254;;109-855-883-873-055;;107-181-894-552-82X;;185-072-571-289-680;;186-704-426-793-951;;088-325-414-156-864;;096-015-093-763-44X;;123-899-487-200-838,RU;;CA;;JP;;KR;;TR;;CN;;PL;;ES;;AU;;BR;;WO;;MX;;US;;HK;;EP,0,A61K9/146;;A61K31/42;;C07D261/08;;A61K9/2027;;C07D261/08;;A61K9/146;;A61K9/2027;;A61K47/32;;A61K31/42;;A61P25/00;;A61P25/28;;A61K47/34;;A61K47/30;;A61K31/42;;C07D261/08;;A61K9/0053;;A61K9/141;;A61K9/146;;A61K9/20;;A61K31/42;;A61K47/00;;A61K47/30;;A61K2121/00;;C07D261/08;;A61K9/146;;A61K9/2027;;B01F23/66;;B01F23/81;;B01F35/90;;B01F27/40;;B01F2035/99;;B01F2101/22;;A61K31/42;;A61K9/10;;A61K47/32;;A61K9/0053;;A61K9/2031,A61K9/20;;A61K9/10;;A61K9/14;;A61K31/42;;A61K47/32;;B01F23/80,,0,0,,,,ACTIVE
86,US,B2,US 11236054 B2,079-050-031-512-204,2022-02-01,2022,US 202016803039 A,2020-02-27,US 202016803039 A;;US 201916662547 A,2019-10-24,Method for preparing aryl 2-tetrazol-1-yl keto with improved selectivity,The present disclosure relates to a method for preparing aryl 2-tetrazol-2-yl ketone of the following Formula 1a with improved selectivity:wherein R1 and R2 are the same as defined herein.,SK BIOPHARMACEUTICALS CO LTD,LEE KYUWOONG;;CHA KYUNGMI;;YEOM SUYEON;;WOO JISEON,SK BIOPHARMACEUTICALS CO. LTD (2019-10-24),https://lens.org/079-050-031-512-204,Granted Patent,yes,4,1,4,152-813-639-166-248;;054-411-109-545-166;;137-576-535-269-074;;079-050-031-512-204,US,19,179-972-736-650-806;;128-259-863-037-867;;143-901-200-900-497;;157-657-411-184-300;;104-155-908-855-189;;053-463-657-502-878;;137-576-535-269-074;;152-813-639-166-248;;153-933-616-519-621;;064-607-628-090-228;;078-654-278-638-803;;079-050-031-512-204;;181-990-683-813-886;;041-306-109-656-855;;054-411-109-545-166;;169-356-576-120-707;;111-147-706-510-960;;103-991-078-024-470;;117-171-380-090-553,CA;;JP;;KR;;ZA;;CN;;CL;;AU;;BR;;MX;;WO;;US;;EP;;IL,0,C07D257/04;;C07D257/04,C07D257/04,,3,2,109-717-209-034-203;;160-732-385-174-277,10.1248/cpb.30.3450;;10.1039/p19860001157,"Aoyama, T. and Shioiri, T. (1982) “New methods and reagents in organic synthesis, 31, 1) lithium trimethylsilyldiazomethane: A new synthon for the preparation of tetrazoles.” Chem. Pharm. Bull., 30(9):3450-3452.;;Moderhack, D. and Lembcke, A. (1986) “Synthesis and Properties of Tetrazolium N-Phenacylides.” Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 7:1157-1163.;;Notice of Allowance, dated Nov. 27, 2019 issued in U.S. Appl. No. 16/662,547.",ACTIVE
87,US,A1,US 2018/0221383 A1,051-851-931-919-484,2018-08-09,2018,US 201815943203 A,2018-04-02,US 201815943203 A;;KR 20080044481 A;;US 201314060989 A;;US 94056310 A;;KR 2009002567 W,2008-05-14,Transnasal Anticonvulsive Pharmaceutical Composition Comprising Poorly Soluble Anticonvulsant,"There is provided a transnasal anticonvulsive pharmaceutical composition including a poorly soluble anticonvulsant. The anticonvulsive pharmaceutical composition comprising a poorly soluble anticonvulsant as an active component, which is transnasally spray-administered, comprises diethylene glycol monoethyl ether and fatty acid ester, wherein the fatty acid ester is selected from the group consisting of caprylocaproyl polyoxylglyceride, isopropyl palmitate, oleoyl polyoxylglyceride, sorbitan monolaurate 20, methyl laurate, ethyl laurate and polysorbate 20. Also, the anticonvulsive pharmaceutical composition comprising a poorly soluble anticonvulsant as an active component, which is transnasally spray-administered, comprises diethylene glycol monoethyl ether, fatty acid ester, methylpyrrolidone, water and alcohol. Therefore, the transnasal anticonvulsive pharmaceutical composition may be useful to highly enhance the bioavailability of the poorly soluble anticonvulsant. Also, the transnasal anticonvulsive pharmaceutical composition may be useful to allow the poorly soluble anticonvulsant to show the improved viscosity and/or enhanced solubility in order to effectively deliver the poorly soluble anticonvulsant at a therapeutic dose.",SK BIOPHARMACEUTICALS CO LTD,BAEK MYOUNG-KI;;JO JAE-HOON;;CHANG HYE-JIN,SK HOLDINGS CO. LTD (2010-11-17);;SK BIOPHARMACEUTICALS CO. LTD (2011-10-04),https://lens.org/051-851-931-919-484,Patent Application,yes,0,0,27,015-260-595-433-249;;175-803-753-292-77X;;083-887-966-342-967;;051-851-931-919-484;;195-187-617-647-635;;028-580-651-802-219;;137-926-056-618-190;;148-479-644-508-251;;108-289-621-162-448;;170-037-002-773-044;;120-564-706-346-359;;025-611-607-754-416;;040-895-886-524-090;;008-778-568-715-497;;052-871-813-367-118;;151-420-699-494-581;;000-082-259-582-671;;057-673-283-798-053;;025-300-968-868-330;;123-511-837-475-53X;;113-986-052-059-962;;097-083-913-770-591;;073-058-413-730-651;;088-077-507-443-969;;151-134-450-146-568;;141-156-788-913-116;;157-535-423-454-616,CA;;KR;;JP;;MX;;WO;;CN;;US;;ES;;EP;;AU,27,015-260-595-433-249;;175-803-753-292-77X;;083-887-966-342-967;;051-851-931-919-484;;195-187-617-647-635;;028-580-651-802-219;;137-926-056-618-190;;148-479-644-508-251;;108-289-621-162-448;;170-037-002-773-044;;120-564-706-346-359;;025-611-607-754-416;;040-895-886-524-090;;008-778-568-715-497;;052-871-813-367-118;;151-420-699-494-581;;000-082-259-582-671;;057-673-283-798-053;;025-300-968-868-330;;123-511-837-475-53X;;113-986-052-059-962;;097-083-913-770-591;;073-058-413-730-651;;088-077-507-443-969;;151-134-450-146-568;;141-156-788-913-116;;157-535-423-454-616,CA;;KR;;JP;;MX;;WO;;CN;;US;;ES;;EP;;AU,0,A61K9/0043;;A61K31/5513;;A61K47/08;;A61K47/14;;A61K47/26;;A61K31/5513;;A61K9/0043;;A61K47/26;;A61K47/44;;A61P25/08;;Y02A50/30;;A61K9/08;;A61K47/08;;A61K31/5513;;A61K9/0043;;A61K47/26;;A61K47/44;;Y02A50/30,A61K31/5513;;A61K9/00;;A61K47/26;;A61K47/44,,0,0,,,,DISCONTINUED
88,US,B2,US 9962392 B2,008-778-568-715-497,2018-05-08,2018,US 201314060989 A,2013-10-23,US 201314060989 A;;KR 20080044481 A;;US 94056310 A;;KR 2009002567 W,2008-05-14,Transnasal anticonvulsive pharmaceutical composition comprising poorly soluble anticonvulsant,"There is provided a transnasal anticonvulsive pharmaceutical composition including a poorly soluble anticonvulsant. The anticonvulsive pharmaceutical composition comprising a poorly soluble anticonvulsant as an active component, which is transnasally spray-administered, comprises diethylene glycol monoethyl ether and fatty acid ester, wherein the fatty acid ester is selected from the group consisting of caprylocaproyl polyoxylglyceride, isopropyl palmitate, oleoyl polyoxylglyceride, sorbitan monolaurate 20, methyl laurate, ethyl laurate, and polysorbate 20. Also, the anticonvulsive pharmaceutical composition comprising a poorly soluble anticonvulsant as an active component, which is transnasally spray-administered, comprises diethylene glycol monoethyl ether, fatty acid ester, methylpyrrolidone, water and alcohol. Therefore, the transnasal anticonvulsive pharmaceutical composition may be useful to highly enhance the bioavailability of the poorly soluble anticonvulsant. Also, the transnasal anticonvulsive pharmaceutical composition may be useful to allow the poorly soluble anticonvulsant to show the improved viscosity and/or enhanced solubility in order to effectively deliver the poorly soluble anticonvulsant at a therapeutic dose.",SK BIOPHARMACEUTICALS CO LTD,BAEK MYOUNG-KI;;JO JAE-HOON;;CHANG HYE-JIN,SK HOLDINGS CO. LTD (2010-11-17);;SK BIOPHARMACEUTICALS CO. LTD (2011-10-04),https://lens.org/008-778-568-715-497,Granted Patent,yes,35,0,27,015-260-595-433-249;;175-803-753-292-77X;;083-887-966-342-967;;051-851-931-919-484;;195-187-617-647-635;;028-580-651-802-219;;137-926-056-618-190;;148-479-644-508-251;;108-289-621-162-448;;170-037-002-773-044;;120-564-706-346-359;;025-611-607-754-416;;040-895-886-524-090;;008-778-568-715-497;;052-871-813-367-118;;151-420-699-494-581;;000-082-259-582-671;;057-673-283-798-053;;025-300-968-868-330;;123-511-837-475-53X;;113-986-052-059-962;;097-083-913-770-591;;073-058-413-730-651;;088-077-507-443-969;;151-134-450-146-568;;141-156-788-913-116;;157-535-423-454-616,CA;;KR;;JP;;MX;;WO;;CN;;US;;ES;;EP;;AU,27,015-260-595-433-249;;175-803-753-292-77X;;083-887-966-342-967;;051-851-931-919-484;;195-187-617-647-635;;028-580-651-802-219;;137-926-056-618-190;;148-479-644-508-251;;108-289-621-162-448;;170-037-002-773-044;;120-564-706-346-359;;025-611-607-754-416;;040-895-886-524-090;;008-778-568-715-497;;052-871-813-367-118;;151-420-699-494-581;;000-082-259-582-671;;057-673-283-798-053;;025-300-968-868-330;;123-511-837-475-53X;;113-986-052-059-962;;097-083-913-770-591;;073-058-413-730-651;;088-077-507-443-969;;151-134-450-146-568;;141-156-788-913-116;;157-535-423-454-616,CA;;KR;;JP;;MX;;WO;;CN;;US;;ES;;EP;;AU,0,A61K9/0043;;A61K31/5513;;A61K47/08;;A61K47/14;;A61K47/26;;A61K31/5513;;A61K9/0043;;A61K47/26;;A61K47/44;;A61P25/08;;Y02A50/30;;A61K9/08;;A61K47/08;;A61K31/5513;;A61K9/0043;;A61K47/26;;A61K47/44;;Y02A50/30,A61K9/08;;A61K9/00;;A61K31/5513;;A61K47/26;;A61K47/44,,10,7,029-810-493-102-90X;;116-628-295-591-733;;054-365-565-010-646;;000-118-339-456-327;;024-868-940-428-718;;019-477-232-707-725;;019-095-725-805-311,16091994;;10.1007/s11095-005-7391-9;;18760341;;10.1016/j.ijpharm.2008.07.030;;10.1016/0378-5173(89)90337-2;;10794928;;10.1016/s0378-5173(00)00373-2;;10.1016/s0378-5173(02)00029-7;;11955806;;11719015;;10.1016/s0378-5173(01)00872-9;;10.1016/0378-5173(80)90017-4,"Guo et al., “The effect of formulation variables and breathing patterns on the site of nasal deposition in an anatomically correct model,” Pharm. Res. 22:1871 (2005).;;Kaur et al., “Pharmacokinetics and brain uptake of diazepam after intravenous and intranasal administration in rats and rabbits,” Int. J. Pharm. 364:27 (2008).;;International Search Report and Written Opinion Corresponding to International Application No. PCT/US2012/031453; dated Sep. 26, 2012.;;International Search Report and Written Opinion Corresponding to International Application No. PCT/KR2009/002567; dated Dec. 22, 2009.;;Lau et al., “Absorption of diazepam and lorazepam following intranasal administration,” Int. J. Pharm. 54:171 (1989).;;Li et al., “Rapid-onset intranasal delivery of anticonvulsants: pharmacokinetic and pharmacodynamic evaluation in rabbits,” Int. J. Pharm. 199:65 (2000).;;Li et al., “Development of an ethyl laurate-based microemulsion for rapid-onset intranasal delivery of diazepam,” Int. J. Pharm. 237:77 (2002).;;Lindhardt et al., “Intranasal bioavailability of diazepam in sheep correlated to rabbit and man,” Int. J. Pharm. 231:67-72 (2002).;;Moolenaar et al., “Biopharmaceutics of rectal administration of drugs in man IX. Comparative biopharmaceutics of diazepam after single rectal, oral, intramuscular and intravenous administration in man,” Int. J. Pharm. 5:127 (1980).;;Extended European Search Report corresponding to European Application No. 12763553.0 dated Aug. 25, 2014.",ACTIVE
89,US,A1,US 2014/0051690 A1,157-535-423-454-616,2014-02-20,2014,US 201314060989 A,2013-10-23,US 201314060989 A;;KR 20080044481 A;;US 94056310 A;;KR 2009002567 W,2008-05-14,Transnasal Anticonvulsive Pharmaceutical Composition Comprising Poorly Soluble Anticonvulsant,"There is provided a transnasal anticonvulsive pharmaceutical composition including a poorly soluble anticonvulsant. The anticonvulsive pharmaceutical composition comprising a poorly soluble anticonvulsant as an active component, which is transnasally spray-administered, comprises diethylene glycol monoethyl ether and fatty acid ester, wherein the fatty acid ester is selected from the group consisting of caprylocaproyl polyoxylglyceride, isopropyl palmitate, oleoyl polyoxylglyceride, sorbitan monolaurate 20, methyl laurate, ethyl laurate, and polysorbate 20. Also, the anticonvulsive pharmaceutical composition comprising a poorly soluble anticonvulsant as an active component, which is transnasally spray-administered, comprises diethylene glycol monoethyl ether, fatty acid ester, methylpyrrolidone, water and alcohol. Therefore, the transnasal anticonvulsive pharmaceutical composition may be useful to highly enhance the bioavailability of the poorly soluble anticonvulsant. Also, the transnasal anticonvulsive pharmaceutical composition may be useful to allow the poorly soluble anticonvulsant to show the improved viscosity and/or enhanced solubility in order to effectively deliver the poorly soluble anticonvulsant at a therapeutic dose.",SK BIOPHARMACEUTICALS CO LTD,BAEK MYOUNG-KI;;JO JAE-HOON;;CHANG HYE-JIN,SK HOLDINGS CO. LTD (2010-11-17);;SK BIOPHARMACEUTICALS CO. LTD (2011-10-04),https://lens.org/157-535-423-454-616,Patent Application,yes,1,1,27,015-260-595-433-249;;175-803-753-292-77X;;083-887-966-342-967;;051-851-931-919-484;;195-187-617-647-635;;028-580-651-802-219;;137-926-056-618-190;;148-479-644-508-251;;108-289-621-162-448;;170-037-002-773-044;;120-564-706-346-359;;025-611-607-754-416;;040-895-886-524-090;;008-778-568-715-497;;052-871-813-367-118;;151-420-699-494-581;;000-082-259-582-671;;057-673-283-798-053;;025-300-968-868-330;;123-511-837-475-53X;;113-986-052-059-962;;097-083-913-770-591;;073-058-413-730-651;;088-077-507-443-969;;151-134-450-146-568;;141-156-788-913-116;;157-535-423-454-616,CA;;KR;;JP;;MX;;WO;;CN;;US;;ES;;EP;;AU,27,015-260-595-433-249;;175-803-753-292-77X;;083-887-966-342-967;;051-851-931-919-484;;195-187-617-647-635;;028-580-651-802-219;;137-926-056-618-190;;148-479-644-508-251;;108-289-621-162-448;;170-037-002-773-044;;120-564-706-346-359;;025-611-607-754-416;;040-895-886-524-090;;008-778-568-715-497;;052-871-813-367-118;;151-420-699-494-581;;000-082-259-582-671;;057-673-283-798-053;;025-300-968-868-330;;123-511-837-475-53X;;113-986-052-059-962;;097-083-913-770-591;;073-058-413-730-651;;088-077-507-443-969;;151-134-450-146-568;;141-156-788-913-116;;157-535-423-454-616,CA;;KR;;JP;;MX;;WO;;CN;;US;;ES;;EP;;AU,0,A61K9/0043;;A61K31/5513;;A61K47/08;;A61K47/14;;A61K47/26;;A61K31/5513;;A61K9/0043;;A61K47/26;;A61K47/44;;A61P25/08;;Y02A50/30;;A61K9/08;;A61K47/08;;A61K31/5513;;A61K9/0043;;A61K47/26;;A61K47/44;;Y02A50/30,A61K31/5513;;A61K9/00,514/221,0,0,,,,ACTIVE
90,US,B1,US 10611737 B1,152-813-639-166-248,2020-04-07,2020,US 201916662547 A,2019-10-24,US 201916662547 A,2019-10-24,Method for preparing aryl 2-tetrazol-2-yl ketone with improved selectivity,The present disclosure relates to a method for preparing aryl 2-tetrazol-2-yl ketone of the following Formula 1a with improved selectivity: wherein R 1 and R 2 are the same as defined herein.,SK BIOPHARMACEUTICALS CO LTD,LEE KYUWOONG;;CHA KYUNGMI;;YEOM SUYEON;;WOO JISEON,SK BIOPHARMACEUTICALS CO. LTD (2019-10-24),https://lens.org/152-813-639-166-248,Granted Patent,yes,2,1,4,152-813-639-166-248;;054-411-109-545-166;;137-576-535-269-074;;079-050-031-512-204,US,19,179-972-736-650-806;;128-259-863-037-867;;143-901-200-900-497;;157-657-411-184-300;;104-155-908-855-189;;053-463-657-502-878;;137-576-535-269-074;;152-813-639-166-248;;153-933-616-519-621;;064-607-628-090-228;;078-654-278-638-803;;079-050-031-512-204;;181-990-683-813-886;;041-306-109-656-855;;054-411-109-545-166;;169-356-576-120-707;;111-147-706-510-960;;103-991-078-024-470;;117-171-380-090-553,CA;;JP;;KR;;ZA;;CN;;CL;;AU;;BR;;MX;;WO;;US;;EP;;IL,0,C07D257/04;;C07D257/04,C07D257/04,,2,2,160-732-385-174-277;;109-717-209-034-203,10.1039/p19860001157;;10.1248/cpb.30.3450,"Moderhack, D. and Lembcke, A. (1986) “Synthesis and Properties of Tetrazolium N-Phenacylides. ”Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 7:1157-1163.;;Aoyama, T. and Shioiri, T. (1982) “New methods and reagents in organic synthesis, 31, 1) lithium trimethylsilyldiazomethane: A new synthon for the preparation of tetrazoles.” Chem. Pharm. Bull., 30(9):3450-3452.",ACTIVE
91,US,A1,US 2022/0112167 A1,137-576-535-269-074,2022-04-14,2022,US 202117555801 A,2021-12-20,US 202117555801 A;;US 202016803039 A;;US 201916662547 A,2019-10-24,Method For Preparing Aryl 2-Tetrazol-1-Yl Keto With Improved Selectivity,The present disclosure relates to a method for preparing aryl 2-tetrazol-2-yl ketone of the following Formula 1a with improved selectivity:wherein R1 and R2 are the same as defined herein.,SK BIOPHARMACEUTICALS CO LTD,LEE KYUWOONG;;CHA KYUNGMI;;YEOM SUYEON;;WOO JISEON,SK BIOPHARMACEUTICALS CO. LTD (2019-10-24),https://lens.org/137-576-535-269-074,Patent Application,yes,1,0,4,152-813-639-166-248;;054-411-109-545-166;;137-576-535-269-074;;079-050-031-512-204,US,19,179-972-736-650-806;;128-259-863-037-867;;143-901-200-900-497;;157-657-411-184-300;;104-155-908-855-189;;053-463-657-502-878;;137-576-535-269-074;;152-813-639-166-248;;153-933-616-519-621;;064-607-628-090-228;;078-654-278-638-803;;079-050-031-512-204;;181-990-683-813-886;;041-306-109-656-855;;054-411-109-545-166;;169-356-576-120-707;;111-147-706-510-960;;103-991-078-024-470;;117-171-380-090-553,CA;;JP;;KR;;ZA;;CN;;CL;;AU;;BR;;MX;;WO;;US;;EP;;IL,0,C07D257/04;;C07D257/04,C07D257/04,,0,0,,,,PENDING
92,US,A1,US 2021/0122719 A1,054-411-109-545-166,2021-04-29,2021,US 202016803039 A,2020-02-27,US 202016803039 A;;US 201916662547 A,2019-10-24,Method For Preparing Aryl 2-Tetrazol-1-Yl Keto With Improved Selectivity,The present disclosure relates to a method for preparing aryl 2-tetrazol-2-yl ketone of the following Formula 1a with improved selectivity: wherein R 1 and R 2 are the same as defined herein.,SK BIOPHARMACEUTICALS CO LTD,LEE KYUWOONG;;CHA KYUNGMI;;YEOM SUYEON;;WOO JISEON,SK BIOPHARMACEUTICALS CO. LTD (2019-10-24),https://lens.org/054-411-109-545-166,Patent Application,yes,0,0,4,152-813-639-166-248;;054-411-109-545-166;;137-576-535-269-074;;079-050-031-512-204,US,19,179-972-736-650-806;;128-259-863-037-867;;143-901-200-900-497;;157-657-411-184-300;;104-155-908-855-189;;053-463-657-502-878;;137-576-535-269-074;;152-813-639-166-248;;153-933-616-519-621;;064-607-628-090-228;;078-654-278-638-803;;079-050-031-512-204;;181-990-683-813-886;;041-306-109-656-855;;054-411-109-545-166;;169-356-576-120-707;;111-147-706-510-960;;103-991-078-024-470;;117-171-380-090-553,CA;;JP;;KR;;ZA;;CN;;CL;;AU;;BR;;MX;;WO;;US;;EP;;IL,0,C07D257/04;;C07D257/04,C07D257/04,,0,0,,,,ACTIVE
93,US,A1,US 2022/0370461 A1,077-536-142-327-957,2022-11-24,2022,US 202017770686 A,2020-10-21,KR 20190130384 A;;KR 2020014399 W,2019-10-21,"USE OF IMIDAZOPYRIMIDINE OR IMIDAZOTRIAZINE COMPOUNDS FOR PREVENTION, ALLEVIATION, OR TREATMENT OF COGNITIVE DISORDERS, OR FOR IMPROVING COGNITIVE FUNCTION","The present invention relates to a use of imidazopyrimidine or imidazotriazine compounds of Chemical Formula 1, or pharmaceutically acceptable salts, solvates, or hydrates thereof, for preventing, alleviating or treating cognitive disorder or for improving enhancing cognitive function.",SK BIOPHARMACEUTICALS CO LTD,JOUNG CHAN MI;;CHUNG JIN YONG,SK BIOPHARMACEUTICALS CO. LTD (2022-05-10),https://lens.org/077-536-142-327-957,Patent Application,yes,4,0,16,077-536-142-327-957;;108-774-037-689-362;;161-705-084-860-911;;060-993-941-597-730;;062-861-871-789-62X;;067-980-138-998-73X;;016-672-531-762-884;;153-229-645-863-908;;007-748-899-917-604;;005-743-877-393-023;;167-448-531-137-72X;;018-434-201-700-33X;;085-702-557-106-137;;025-234-759-849-763;;093-432-465-174-901;;149-554-640-917-203,CA;;KR;;JP;;ZA;;CN;;CL;;AU;;BR;;WO;;MX;;US;;EP;;IL,16,077-536-142-327-957;;108-774-037-689-362;;161-705-084-860-911;;060-993-941-597-730;;062-861-871-789-62X;;067-980-138-998-73X;;016-672-531-762-884;;153-229-645-863-908;;007-748-899-917-604;;005-743-877-393-023;;167-448-531-137-72X;;018-434-201-700-33X;;085-702-557-106-137;;025-234-759-849-763;;093-432-465-174-901;;149-554-640-917-203,CA;;KR;;JP;;ZA;;CN;;CL;;AU;;BR;;WO;;MX;;US;;EP;;IL,0,A61K31/519;;A61K31/53;;A61K45/06;;A61P25/28;;C07D487/04;;A61K31/131;;A61K31/4458;;A61K31/473;;A61K31/27;;A61K31/198;;A61K31/519;;A61K31/53;;A61P25/28;;C07D487/04;;A61P25/28;;A61K31/519;;A61K31/53,A61K31/519;;A61K31/53;;A61P25/28,,1,1,029-844-915-312-305,pmc2718545;;10.1097/wad.0b013e31816653bc;;18580597,"Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord. 2008 Jul-Sep;22(3):209-21. doi: 10.1097/WAD.0b013e31816653bc. PMID: 18580597; PMCID: PMC2718545. (Year: 2008)",PENDING
94,WO,A1,WO 2021/080380 A1,117-171-380-090-553,2021-04-29,2021,KR 2020014599 W,2020-10-23,US 201916662547 A;;KR 20190133120 A,2019-10-24,METHOD FOR PREPARING ARYL 2-TETRAZOL-2-YL KETONE WITH IMPROVED SELECTIVITY,The present disclosure relates to a method for preparing aryl 2-tetrazol-2-yl ketone of Formula 1a with improved selectivity.,SK BIOPHARMACEUTICALS CO LTD,LEE KYU WOONG;;CHA KYUNG MI;;YEOM SU YEON;;WOO JI SEON,,https://lens.org/117-171-380-090-553,Patent Application,yes,2,0,15,179-972-736-650-806;;128-259-863-037-867;;143-901-200-900-497;;157-657-411-184-300;;104-155-908-855-189;;053-463-657-502-878;;153-933-616-519-621;;064-607-628-090-228;;078-654-278-638-803;;181-990-683-813-886;;041-306-109-656-855;;169-356-576-120-707;;111-147-706-510-960;;103-991-078-024-470;;117-171-380-090-553,CA;;JP;;KR;;BR;;ZA;;MX;;WO;;CN;;CL;;EP;;IL;;AU,19,179-972-736-650-806;;128-259-863-037-867;;143-901-200-900-497;;157-657-411-184-300;;104-155-908-855-189;;053-463-657-502-878;;137-576-535-269-074;;152-813-639-166-248;;153-933-616-519-621;;064-607-628-090-228;;078-654-278-638-803;;079-050-031-512-204;;181-990-683-813-886;;041-306-109-656-855;;054-411-109-545-166;;169-356-576-120-707;;111-147-706-510-960;;103-991-078-024-470;;117-171-380-090-553,CA;;JP;;KR;;ZA;;CN;;CL;;AU;;BR;;MX;;WO;;US;;EP;;IL,0,C07D257/04;;C07D257/04;;A61P3/04;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;C07D257/04;;C07D257/04,C07D257/04,,4,3,042-106-154-723-850;;001-580-232-559-357;;023-125-617-138-207,10.1134/s1070428014060219;;19251421;;10.1016/j.bmc.2009.02.004;;pmc3320663;;10.1002/cmdc.201100420;;22162199,"KRYLOV A. S., DOGADINA A. V., TRIFONOV R. E.: ""5-phenyl-2H-tetrazol-2-ylmethyl ketones in the synthesis of tetrazolylalkanols and tetrazolyl(hydroxy)alkylphosphonates"", RUSSIAN JOURNAL OF ORGANIC CHEMISTRY., M A I K NAUKA - INTERPERIODICA, RU, vol. 50, no. 6, 1 June 2014 (2014-06-01), RU, pages 892 - 894, XP055805727, ISSN: 1070-4280, DOI: 10.1134/S1070428014060219;;ROSTOM, S.A.F. ; ASHOUR, H.M.A. ; RAZIK, H.A.A.E. ; FATTAH, A.E.F.H.A.E. ; EL-DIN, N.N.: ""Azole antimicrobial pharmacophore-based tetrazoles: Synthesis and biological evaluation as potential antimicrobial and anticonvulsant agents"", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 17, no. 6, 15 March 2009 (2009-03-15), AMSTERDAM, NL, pages 2410 - 2422, XP025981938, ISSN: 0968-0896, DOI: 10.1016/j.bmc.2009.02.004;;DANIEL SPINKS, LEAH S. TORRIE, STEPHEN THOMPSON, JUSTIN R. HARRISON, JULIE A. FREARSON, KEVIN D. READ, ALAN H. FAIRLAMB, PAUL G. W: ""Design, Synthesis and Biological Evaluation of Trypanosoma brucei Trypanothione Synthetase Inhibitors"", CHEMMEDCHEM, WILEY-VCH, vol. 7, no. 1, 2 January 2012 (2012-01-02), pages 95 - 106, XP055168733, ISSN: 18607179, DOI: 10.1002/cmdc.201100420;;See also references of EP 4048658A4",PENDING
95,EP,B1,EP 2248799 B1,121-242-319-872-767,2015-05-20,2015,EP 10174144 A,2002-12-19,EP 02793127 A;;US 41808402 P;;EP 01205097 A;;EP 10174144 A,2001-12-21,PROCESS FOR PREPARING 2-(SUBSTITUTED PHENYL)-2-HYDROXY-ETHYL CARBAMATES,,SK BIOPHARMACEUTICALS CO LTD,OTTEN THOMAS;;REY MAX DI;;KOREY DANIEL,"SK BIOPHARMACEUTICALS CO., LTD (2012-03-14)",https://lens.org/121-242-319-872-767,Granted Patent,yes,4,0,35,084-311-959-161-935;;123-810-607-666-306;;097-130-261-395-392;;154-228-420-463-569;;029-272-872-668-73X;;167-398-186-216-44X;;042-530-660-564-349;;010-926-356-444-430;;075-105-449-709-952;;092-483-553-653-252;;172-776-532-414-761;;143-357-104-338-67X;;015-069-459-390-55X;;175-838-657-880-117;;035-532-720-872-761;;048-184-040-497-981;;131-561-317-439-899;;012-905-421-929-822;;124-759-396-651-299;;045-416-559-431-998;;031-818-141-345-084;;045-570-492-527-770;;178-782-120-422-57X;;072-101-204-528-881;;193-525-952-660-796;;150-876-789-700-827;;121-242-319-872-767;;172-989-004-851-49X;;030-660-084-286-693;;032-839-976-942-089;;165-391-490-798-830;;195-193-317-151-014;;092-432-842-476-635;;128-037-857-837-231;;029-486-850-639-560,CA;;BG;;CZ;;JP;;KR;;HU;;CN;;PL;;MY;;NZ;;EE;;TW;;AU;;SK;;HR;;BR;;WO;;MX;;AR;;EP;;IL;;NO,43,084-311-959-161-935;;123-810-607-666-306;;097-130-261-395-392;;142-997-084-001-760;;029-272-872-668-73X;;154-228-420-463-569;;033-187-420-315-739;;167-398-186-216-44X;;008-888-460-031-306;;042-530-660-564-349;;010-926-356-444-430;;083-089-350-559-360;;075-105-449-709-952;;092-483-553-653-252;;172-776-532-414-761;;175-838-657-880-117;;143-357-104-338-67X;;178-577-182-837-866;;015-069-459-390-55X;;035-532-720-872-761;;048-184-040-497-981;;131-561-317-439-899;;012-905-421-929-822;;031-818-141-345-084;;045-416-559-431-998;;124-759-396-651-299;;152-158-270-462-451;;072-101-204-528-881;;178-782-120-422-57X;;193-525-952-660-796;;045-570-492-527-770;;091-173-990-595-302;;150-876-789-700-827;;092-432-842-476-635;;195-193-317-151-014;;030-660-084-286-693;;032-839-976-942-089;;165-391-490-798-830;;121-242-319-872-767;;172-989-004-851-49X;;128-037-857-837-231;;020-428-984-575-07X;;029-486-850-639-560,CA;;BG;;CZ;;KR;;JP;;ZA;;HU;;CN;;PL;;MY;;NZ;;EE;;TW;;AU;;SK;;HR;;BR;;EA;;WO;;MX;;AR;;EP;;IL;;NO,0,C07B2200/07;;C07B2200/13;;C07C43/1786;;C07C69/734;;C07C271/12;;C07C271/12;;A61K31/325;;C07B2200/13,C07C269/04;;C07B53/00;;C07C269/06;;C07C/;;C07C33/46;;C07C43/178;;C07C69/734;;C07C69/757;;C07C271/12;;C07C271/16,,0,0,,,,EXPIRED
96,EP,B1,EP 2488505 B1,085-485-945-533-853,2015-02-25,2015,EP 10823619 A,2010-10-15,US 25186709 P;;KR 2010007069 W,2009-10-15,METHOD FOR PREPARATION OF CARBAMIC ACID (R)-1-ARYL-2-TETRAZOLYL-ETHYL ESTER,,SK BIOPHARMACEUTICALS CO LTD,LIM SANG CHUL;;UHM MOO YONG;;LEE DAE WON;;KIM HUI HO;;LEE DONG HO;;LEE HYUN SEOK,,https://lens.org/085-485-945-533-853,Granted Patent,yes,4,0,34,016-197-744-023-399;;038-532-396-776-768;;117-360-948-134-305;;100-961-428-414-334;;126-300-092-826-786;;010-230-015-612-963;;055-058-684-385-949;;034-404-087-195-992;;085-485-945-533-853;;193-170-982-419-952;;151-820-942-918-798;;094-952-948-890-748;;095-655-236-166-570;;118-596-803-384-538;;072-679-912-699-324;;114-195-532-650-52X;;109-515-102-992-078;;041-488-748-194-116;;069-796-278-488-670;;136-889-561-047-716;;011-196-245-292-379;;121-249-289-774-323;;105-513-255-591-588;;026-150-348-487-268;;118-470-678-781-636;;149-849-678-101-400;;171-411-424-337-617;;115-870-633-855-244;;037-806-165-788-023;;193-394-402-499-566;;155-040-750-977-927;;044-652-973-822-810;;182-096-519-644-558;;157-158-332-478-988,CA;;RU;;KR;;JP;;ZA;;HU;;CN;;PL;;CL;;MY;;ES;;AU;;BR;;WO;;MX;;US;;HK;;EP;;IL,34,016-197-744-023-399;;038-532-396-776-768;;117-360-948-134-305;;100-961-428-414-334;;126-300-092-826-786;;010-230-015-612-963;;055-058-684-385-949;;034-404-087-195-992;;085-485-945-533-853;;193-170-982-419-952;;151-820-942-918-798;;094-952-948-890-748;;095-655-236-166-570;;118-596-803-384-538;;072-679-912-699-324;;114-195-532-650-52X;;109-515-102-992-078;;041-488-748-194-116;;069-796-278-488-670;;136-889-561-047-716;;011-196-245-292-379;;121-249-289-774-323;;105-513-255-591-588;;026-150-348-487-268;;118-470-678-781-636;;149-849-678-101-400;;171-411-424-337-617;;115-870-633-855-244;;037-806-165-788-023;;193-394-402-499-566;;155-040-750-977-927;;044-652-973-822-810;;182-096-519-644-558;;157-158-332-478-988,CA;;RU;;KR;;JP;;ZA;;HU;;CN;;PL;;CL;;MY;;ES;;AU;;BR;;WO;;MX;;US;;HK;;EP;;IL,0,A61P25/00;;C07D257/04;;C07D257/06;;A61K31/41;;C12P17/12;;C12P17/10;;C07D257/04,C07D257/04,,2,0,,,"MATSUDA T ET AL: ""Recent progress in biocatalysis for asymmetric oxidation and reduction"", TETRAHEDRON ASYMMETRY, PERGAMON PRESS LTD, OXFORD, GB, vol. 20, no. 5, 25 March 2009 (2009-03-25) , pages 513-557, XP026088241, ISSN: 0957-4166, DOI: 10.1016/J.TETASY.2008.12.035 [retrieved on 2009-04-15];;SHERIF A.F. ROSTOM ET AL.: 'Azole antimicrobial pharmacophore-based tetrazoles: Synthesis and biological evaluation as potential antimicrobial and anticonvulsant agents' BIOORGANIC & MEDICINAL CHEMISTRY vol. 1, no. 6, 15 March 2009, ISSN 0968-0896 pages 2410 - 2422",ACTIVE
97,US,A1,US 2015/0252398 A1,193-394-402-499-566,2015-09-10,2015,US 201514719728 A,2015-05-22,US 201514719728 A;;US 201313776964 A;;US 90426710 A;;US 25186709 P,2009-10-15,METHOD FOR PREPARATION OF CARBAMIC ACID (R)-1-ARYL-2-TETRAZOLYL-ETHYL ESTER,"Disclosed is a method for the preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl esters, comprising the enantioselective enzyme reduction of a 1-aryl-2-tetrazolyl-ethyl ketone to form a (R)-1-aryl-2-tetrazolyl-ethyl alcohol and the carbamation of said alcohol.",SK BIOPHARMACEUTICALS CO LTD,LIM SANG CHUL;;UHM MOO YONG;;LEE DAE WON;;KIM HUI HO;;LEE DONG HO;;LEE HYUN SEOK,,https://lens.org/193-394-402-499-566,Patent Application,yes,0,1,34,016-197-744-023-399;;038-532-396-776-768;;117-360-948-134-305;;100-961-428-414-334;;126-300-092-826-786;;010-230-015-612-963;;055-058-684-385-949;;034-404-087-195-992;;085-485-945-533-853;;193-170-982-419-952;;151-820-942-918-798;;094-952-948-890-748;;095-655-236-166-570;;118-596-803-384-538;;072-679-912-699-324;;114-195-532-650-52X;;109-515-102-992-078;;041-488-748-194-116;;069-796-278-488-670;;136-889-561-047-716;;011-196-245-292-379;;121-249-289-774-323;;105-513-255-591-588;;026-150-348-487-268;;118-470-678-781-636;;149-849-678-101-400;;171-411-424-337-617;;115-870-633-855-244;;037-806-165-788-023;;193-394-402-499-566;;155-040-750-977-927;;044-652-973-822-810;;182-096-519-644-558;;157-158-332-478-988,CA;;RU;;KR;;JP;;ZA;;HU;;CN;;PL;;CL;;MY;;ES;;AU;;BR;;WO;;MX;;US;;HK;;EP;;IL,34,016-197-744-023-399;;038-532-396-776-768;;117-360-948-134-305;;100-961-428-414-334;;126-300-092-826-786;;010-230-015-612-963;;055-058-684-385-949;;034-404-087-195-992;;085-485-945-533-853;;193-170-982-419-952;;151-820-942-918-798;;094-952-948-890-748;;095-655-236-166-570;;118-596-803-384-538;;072-679-912-699-324;;114-195-532-650-52X;;109-515-102-992-078;;041-488-748-194-116;;069-796-278-488-670;;136-889-561-047-716;;011-196-245-292-379;;121-249-289-774-323;;105-513-255-591-588;;026-150-348-487-268;;118-470-678-781-636;;149-849-678-101-400;;171-411-424-337-617;;115-870-633-855-244;;037-806-165-788-023;;193-394-402-499-566;;155-040-750-977-927;;044-652-973-822-810;;182-096-519-644-558;;157-158-332-478-988,CA;;RU;;KR;;JP;;ZA;;HU;;CN;;PL;;CL;;MY;;ES;;AU;;BR;;WO;;MX;;US;;HK;;EP;;IL,8,A61P25/00;;C07D257/04;;C07D257/06;;A61K31/41;;C12P17/12;;C12P17/10;;C07D257/04,C12P17/10,,0,0,,,,ACTIVE
98,US,A1,US 2014/0073018 A1,109-515-102-992-078,2014-03-13,2014,US 201313776964 A,2013-02-26,US 201313776964 A;;US 90426710 A;;US 25186709 P,2009-10-15,Method for Preparation of Carbamic Acid (R)-1-Aryl-2 Tetrazolyl-Ethyl Ester,"Disclosed is a method for the preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl esters, comprising the enantioselective enzyme reduction of a 1-aryl-2-tetrazolyl-ethyl ketone to form a (R)-1-aryl-2-tetrazolyl-ethyl alcohol and the carbamation of said alcohol.",SK BIOPHARMACEUTICALS CO LTD,LIM SANG CHUL;;UHM MOO YONG;;LEE DAE WON;;KIM HUI HO;;LEE DONG HO;;LEE HYUN SEOK,,https://lens.org/109-515-102-992-078,Patent Application,yes,2,1,34,016-197-744-023-399;;038-532-396-776-768;;117-360-948-134-305;;100-961-428-414-334;;126-300-092-826-786;;010-230-015-612-963;;055-058-684-385-949;;034-404-087-195-992;;085-485-945-533-853;;193-170-982-419-952;;151-820-942-918-798;;094-952-948-890-748;;095-655-236-166-570;;118-596-803-384-538;;072-679-912-699-324;;114-195-532-650-52X;;109-515-102-992-078;;041-488-748-194-116;;069-796-278-488-670;;136-889-561-047-716;;011-196-245-292-379;;121-249-289-774-323;;105-513-255-591-588;;026-150-348-487-268;;118-470-678-781-636;;149-849-678-101-400;;171-411-424-337-617;;115-870-633-855-244;;037-806-165-788-023;;193-394-402-499-566;;155-040-750-977-927;;044-652-973-822-810;;182-096-519-644-558;;157-158-332-478-988,CA;;RU;;KR;;JP;;ZA;;HU;;CN;;PL;;CL;;MY;;ES;;AU;;BR;;WO;;MX;;US;;HK;;EP;;IL,34,016-197-744-023-399;;038-532-396-776-768;;117-360-948-134-305;;100-961-428-414-334;;126-300-092-826-786;;010-230-015-612-963;;055-058-684-385-949;;034-404-087-195-992;;085-485-945-533-853;;193-170-982-419-952;;151-820-942-918-798;;094-952-948-890-748;;095-655-236-166-570;;118-596-803-384-538;;072-679-912-699-324;;114-195-532-650-52X;;109-515-102-992-078;;041-488-748-194-116;;069-796-278-488-670;;136-889-561-047-716;;011-196-245-292-379;;121-249-289-774-323;;105-513-255-591-588;;026-150-348-487-268;;118-470-678-781-636;;149-849-678-101-400;;171-411-424-337-617;;115-870-633-855-244;;037-806-165-788-023;;193-394-402-499-566;;155-040-750-977-927;;044-652-973-822-810;;182-096-519-644-558;;157-158-332-478-988,CA;;RU;;KR;;JP;;ZA;;HU;;CN;;PL;;CL;;MY;;ES;;AU;;BR;;WO;;MX;;US;;HK;;EP;;IL,8,A61P25/00;;C07D257/04;;C07D257/06;;A61K31/41;;C12P17/12;;C12P17/10;;C07D257/04,C12P17/10,435/121,0,0,,,,ACTIVE
99,US,B2,US 9434970 B2,114-195-532-650-52X,2016-09-06,2016,US 201514719728 A,2015-05-22,US 201514719728 A;;US 201313776964 A;;US 90426710 A;;US 25186709 P,2009-10-15,Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester,"Disclosed is a method for the preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl esters, comprising the enantioselective enzyme reduction of a 1-aryl-2-tetrazolyl-ethyl ketone to form a (R)-1-aryl-2-tetrazolyl-ethyl alcohol and the carbamation of said alcohol.",SK BIOPHARMACEUTICALS CO LTD,LIM SANG CHUL;;UHM MOO YONG;;LEE DAE WON;;KIM HUI HO;;LEE DONG HO;;LEE HYUN SEOK,,https://lens.org/114-195-532-650-52X,Granted Patent,yes,88,1,34,016-197-744-023-399;;038-532-396-776-768;;117-360-948-134-305;;100-961-428-414-334;;126-300-092-826-786;;010-230-015-612-963;;055-058-684-385-949;;034-404-087-195-992;;085-485-945-533-853;;193-170-982-419-952;;151-820-942-918-798;;094-952-948-890-748;;095-655-236-166-570;;118-596-803-384-538;;072-679-912-699-324;;114-195-532-650-52X;;109-515-102-992-078;;041-488-748-194-116;;069-796-278-488-670;;136-889-561-047-716;;011-196-245-292-379;;121-249-289-774-323;;105-513-255-591-588;;026-150-348-487-268;;118-470-678-781-636;;149-849-678-101-400;;171-411-424-337-617;;115-870-633-855-244;;037-806-165-788-023;;193-394-402-499-566;;155-040-750-977-927;;044-652-973-822-810;;182-096-519-644-558;;157-158-332-478-988,CA;;RU;;KR;;JP;;ZA;;HU;;CN;;PL;;CL;;MY;;ES;;AU;;BR;;WO;;MX;;US;;HK;;EP;;IL,34,016-197-744-023-399;;038-532-396-776-768;;117-360-948-134-305;;100-961-428-414-334;;126-300-092-826-786;;010-230-015-612-963;;055-058-684-385-949;;034-404-087-195-992;;085-485-945-533-853;;193-170-982-419-952;;151-820-942-918-798;;094-952-948-890-748;;095-655-236-166-570;;118-596-803-384-538;;072-679-912-699-324;;114-195-532-650-52X;;109-515-102-992-078;;041-488-748-194-116;;069-796-278-488-670;;136-889-561-047-716;;011-196-245-292-379;;121-249-289-774-323;;105-513-255-591-588;;026-150-348-487-268;;118-470-678-781-636;;149-849-678-101-400;;171-411-424-337-617;;115-870-633-855-244;;037-806-165-788-023;;193-394-402-499-566;;155-040-750-977-927;;044-652-973-822-810;;182-096-519-644-558;;157-158-332-478-988,CA;;RU;;KR;;JP;;ZA;;HU;;CN;;PL;;CL;;MY;;ES;;AU;;BR;;WO;;MX;;US;;HK;;EP;;IL,8,A61P25/00;;C07D257/04;;C07D257/06;;A61K31/41;;C12P17/12;;C12P17/10;;C07D257/04,C12P17/10;;C07D257/04,,16,4,010-680-137-385-664;;139-582-685-904-567;;001-580-232-559-357;;005-903-507-321-057,10.1016/j.tet.2007.12.020;;10.1016/j.tetasy.2008.12.035;;19251421;;10.1016/j.bmc.2009.02.004;;10.1016/s0957-4166(01)00020-9,"Hobuss et al. (2008) ""Catalytic enantioselective borane reduction of arylketones with pinene-derived amino alcohols,"" Tetrahedron, 64(8):1635-1640.;;Matsuda, T. et al. (2009) ""Recent progress in biocatalysis for asymmetric oxidation and reduction."" Tetrahedron: Asymmetry. 20(5):513-557.;;Rostom et al., (2009) ""Azole antimicrobial pharmacophore-based tetrazoles: Synthesis and biological evaluation as potential antimicrobial and anticonvulsant agents,"" Bioorganic & Medicinal Chemistry 17:2410-2422.;;Yadav et al., (2001) ""A facile synthesis of (R)-(-)-2-azido-1-arylethanols from 2-azido-1-arylketones using baker's yeast,"" Tetrahedron: Asymmetry, 12(1):63-67.;;Extended European Search Opinion dated Oct. 22, 2012 in the corresponding European Patent Application No. 09846577.6.;;International Search Report and Written Opinion dated Apr. 28, 2010 in the corresponding PCT Application No. PCT/KR2009/005906.;;International Search Report and Written Opinion dated Jul. 11, 2011 in the related PCT Application No. PCT/KR2010/007069.;;Office Action dated Nov. 3, 2011 issued in U.S. Appl. No. 12/578,709.;;Office Action dated Jan. 31, 2012 issued in U.S. Appl. No. 12/578,709.;;Office Action dated Apr. 19, 2012 issued in U.S. Appl. No. 12/904,267.;;Office Action dated May 18, 2012 issued in U.S. Appl. No. 12/904,267.;;Office Action dated Jun. 29, 2012 issued in U.S. Appl. No. 12/578,709.;;Notice of Allowance and Fees Due dated Jan. 3, 2013 issued in U.S. Appl. No. 12/904,267.;;Notice of Allowance and Fees Due dated Feb. 7, 2013 issued in U.S. Appl. No. 12/904,267.;;Notice of Allowance and Fees Due dated May 31, 2013 issued in U.S. Appl. No. 12/578,709.;;Notice of Allowance and Fees Due dated Feb. 25, 2015 issued in U.S. Appl. No. 13/776,964.",ACTIVE
100,EP,B1,EP 2445890 B1,081-782-803-753-24X,2015-05-06,2015,EP 09846577 A,2009-10-14,KR 2009005906 W;;KR 20090055576 A,2009-06-22,METHOD FOR PREPARATION OF CARBAMIC ACID (R)-1-ARYL-2-TETRAZOLYL-ETHYL ESTER,,SK BIOPHARMACEUTICALS CO LTD,LIM SANG CHUL;;UHM MOO YONG;;CHO NAHM RYUNE;;LEE DAE WON;;LEE JU YOUNG;;KIM HUI HO;;LEE DONG HO;;LEE HYUN SEOK;;LEE SE II,,https://lens.org/081-782-803-753-24X,Granted Patent,yes,3,2,28,007-555-136-346-451;;158-653-493-805-69X;;168-903-366-391-350;;060-834-915-468-988;;054-191-736-617-817;;047-587-052-154-169;;146-543-770-179-090;;187-264-533-757-139;;090-700-469-438-627;;195-978-189-312-759;;133-378-285-197-342;;081-782-803-753-24X;;132-439-277-743-024;;057-725-855-822-461;;012-511-230-387-803;;072-608-951-910-067;;099-311-434-759-20X;;046-065-801-072-546;;184-576-115-196-504;;069-876-936-965-214;;084-572-481-959-985;;139-626-924-540-871;;123-980-927-505-01X;;162-862-772-618-366;;192-577-110-026-922;;084-186-970-132-131;;140-397-656-885-695;;001-508-602-639-922,RU;;CA;;JP;;KR;;ZA;;CN;;PL;;CL;;MY;;ES;;AU;;BR;;MX;;WO;;US;;EP;;IL,28,007-555-136-346-451;;158-653-493-805-69X;;168-903-366-391-350;;060-834-915-468-988;;054-191-736-617-817;;047-587-052-154-169;;146-543-770-179-090;;187-264-533-757-139;;090-700-469-438-627;;195-978-189-312-759;;133-378-285-197-342;;081-782-803-753-24X;;132-439-277-743-024;;057-725-855-822-461;;012-511-230-387-803;;072-608-951-910-067;;099-311-434-759-20X;;046-065-801-072-546;;184-576-115-196-504;;069-876-936-965-214;;084-572-481-959-985;;139-626-924-540-871;;123-980-927-505-01X;;162-862-772-618-366;;192-577-110-026-922;;084-186-970-132-131;;140-397-656-885-695;;001-508-602-639-922,RU;;CA;;JP;;KR;;ZA;;CN;;PL;;CL;;MY;;ES;;AU;;BR;;MX;;WO;;US;;EP;;IL,0,C07D257/04;;C12P17/10;;C07D257/06;;C07D413/12;;C12P17/12;;C07D257/04;;C12P17/10,C07D257/06,,2,0,,,"HOBUSZ ET AL: ""Catalytic enantioselective borane reduction of arylketones with pinene-derived amino alcohols"", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 64, no. 8, 14 December 2007 (2007-12-14), pages 1635-1640, XP022424493, ISSN: 0040-4020, DOI: 10.1016/J.TET.2007.12.020;;YADAV J S ET AL: ""A facile synthesis of (R)-(-)-2-azido-1-arylethanols from 2-azido-1-arylketones using baker's yeast"", TETRAHEDRON ASYMMETRY, PERGAMON PRESS LTD, OXFORD, GB, vol. 12, no. 1, 5 February 2001 (2001-02-05), pages 63-67, XP004229364, ISSN: 0957-4166, DOI: 10.1016/S0957-4166(01)00020-9",ACTIVE
101,EP,B1,EP 1928451 B1,090-569-071-311-350,2011-12-28,2011,EP 05775692 A,2005-07-26,US 2005/0026439 W,2005-07-26,METHODS FOR TREATING SUBSTANCE-RELATED DISORDERS,,SK BIOPHARMACEUTICALS CO LTD,PLATA-SALAMAN CARLOS R;;ZHAO BOYU;;TWYMAN ROY E,"SK BIOPHARMACEUTICALS CO., LTD (2011-10-05)",https://lens.org/090-569-071-311-350,Granted Patent,yes,4,0,21,105-192-163-541-239;;134-020-851-035-648;;180-924-000-952-106;;024-751-188-275-450;;016-383-533-535-529;;040-061-733-114-911;;083-707-604-623-680;;134-858-865-556-902;;065-870-977-280-737;;064-406-578-678-128;;108-753-104-645-026;;021-061-934-001-770;;090-569-071-311-350;;122-425-652-704-802;;107-991-640-620-989;;060-941-128-034-244;;168-716-459-078-087;;129-377-480-420-846;;034-394-102-210-702;;047-081-051-154-505;;119-897-038-546-75X,CA;;KR;;JP;;AT;;CN;;ES;;AU;;BR;;EA;;WO;;IL;;EP;;NO,22,105-192-163-541-239;;134-020-851-035-648;;180-924-000-952-106;;024-751-188-275-450;;016-383-533-535-529;;040-061-733-114-911;;083-707-604-623-680;;134-858-865-556-902;;065-870-977-280-737;;064-406-578-678-128;;108-753-104-645-026;;021-061-934-001-770;;090-569-071-311-350;;168-716-459-078-087;;122-425-652-704-802;;107-991-640-620-989;;060-941-128-034-244;;122-707-430-092-463;;129-377-480-420-846;;034-394-102-210-702;;047-081-051-154-505;;119-897-038-546-75X,CA;;KR;;JP;;AT;;CN;;ES;;NZ;;AU;;BR;;EA;;WO;;IL;;EP;;NO,0,A61K31/325;;A61P15/10;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;A61P43/00;;A61K31/325,A61K31/325,,0,0,,,,ACTIVE
102,EP,B1,EP 1971600 B1,048-370-293-026-124,2013-08-21,2013,EP 06835537 A,2006-12-28,KR 2006005837 W;;KR 20050135247 A;;KR 20060135390 A,2005-12-30,ISOXAZOLE DERIVATIVES AND USE THEREOF,,SK BIOPHARMACEUTICALS CO LTD,CHO JEONG WOO;;CHOI SANG RAK;;HWANG SUN GWAN;;CHO KYUNG CHUL;;BAE SUNG JIN;;KOO TAE SUNG,"SK BIOPHARMACEUTICALS CO., LTD. (2012-02-22)",https://lens.org/048-370-293-026-124,Granted Patent,yes,4,0,11,086-802-411-620-47X;;105-300-638-607-197;;025-168-386-092-522;;048-370-293-026-124;;174-543-524-318-548;;180-028-851-411-441;;127-112-755-845-549;;078-127-951-586-595;;148-204-255-059-656;;141-256-840-629-613;;090-386-661-530-519,KR;;JP;;WO;;US;;ES;;EP,11,086-802-411-620-47X;;174-543-524-318-548;;105-300-638-607-197;;048-370-293-026-124;;025-168-386-092-522;;180-028-851-411-441;;127-112-755-845-549;;078-127-951-586-595;;148-204-255-059-656;;141-256-840-629-613;;090-386-661-530-519,KR;;JP;;WO;;US;;ES;;EP,0,C07D413/04;;A61P3/04;;A61P3/10;;A61P7/00;;A61P9/00;;A61P17/14;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07D413/12;;C07D413/14;;C07D413/04;;C07D413/12;;C07D413/14;;C07D413/04;;C07D413/12;;C07D413/14,C07D413/14;;A61K31/42;;A61K31/4439,,2,0,,,"DUMAS J. ET AL.: 'Discovery of a new class of p38 kinase inhibitors' BIOORGANIC & MEDICINAL CHEMISTRY LETTERS vol. 10, 2000, pages 2047 - 2050, XP004208308;;PAE A. ET AL.: 'Synthesis and in vitro activity of new oxazolidinone antibacterial agents having substituted isoxazoles' BIOORGANIC & MEDICINAL CHEMISTRY vol. 9, no. 18, 1999, pages 2678 - 2684, XP003015387",ACTIVE
103,US,A1,US 2023/0338295 A1,162-629-133-790-943,2023-10-26,2023,US 202118019856 A,2021-08-06,KR 20200098589 A;;KR 2021010391 W,2020-08-06,"SOLID ORAL COMPOSITION COMPRISING CARBAMATE COMPOUND, AND PREPARATION METHOD THEREFOR","The present application relates to a solid oral preparation and a preparation method therefor, the preparation comprising granules, which comprise: as an active ingredient, a carbamate compound of chemical formula 1, or a pharmaceutically acceptable salt, an isomer, solvate or a hydrate thereof; a diluent; and a binder.",SK BIOPHARMACEUTICALS CO LTD,LEE JI HYE;;CHOI SO YOUNG;;KIM SANG JIN;;YANG YUN HEE,SK BIOPHARMACEUTICALS CO. LTD (2023-03-07),https://lens.org/162-629-133-790-943,Patent Application,yes,0,0,14,186-689-989-699-456;;099-013-292-546-341;;023-992-460-826-460;;168-363-351-489-684;;033-660-380-040-080;;137-403-608-831-721;;087-409-300-858-384;;162-629-133-790-943;;033-013-188-448-894;;081-824-751-235-813;;136-364-925-210-480;;141-583-179-569-985;;032-157-856-354-989;;097-063-225-075-669,CA;;KR;;JP;;CN;;CL;;AU;;BR;;WO;;MX;;US;;CO;;EP;;IL,14,186-689-989-699-456;;099-013-292-546-341;;023-992-460-826-460;;168-363-351-489-684;;033-660-380-040-080;;162-629-133-790-943;;087-409-300-858-384;;033-013-188-448-894;;137-403-608-831-721;;081-824-751-235-813;;136-364-925-210-480;;141-583-179-569-985;;032-157-856-354-989;;097-063-225-075-669,CA;;KR;;JP;;CN;;CL;;AU;;BR;;WO;;MX;;US;;CO;;EP;;IL,0,A61K31/41;;A61P25/00;;A61K9/2054;;A61K9/2018;;A61K9/2077;;A61K31/41;;A61P25/00;;A61K9/20;;A61K9/00;;A61K9/20;;A61K31/41;;A61P25/00;;A61K9/2027;;A61K9/2054;;A61K9/2077;;A61K9/2095;;A61K31/41,A61K9/20;;A61K31/41,,0,0,,,,PENDING
104,EP,A1,EP 4193987 A1,033-013-188-448-894,2023-06-14,2023,EP 21852199 A,2021-08-06,KR 20200098589 A;;KR 2021010391 W,2020-08-06,"SOLID ORAL COMPOSITION COMPRISING CARBAMATE COMPOUND, AND PREPARATION METHOD THEREFOR","The present application relates to a solid oral preparation and a preparation method therefor, the preparation comprising granules, which comprise: as an active ingredient, a carbamate compound of chemical formula 1, or a pharmaceutically acceptable salt, an isomer, solvate or a hydrate thereof; a diluent; and a binder.",SK BIOPHARMACEUTICALS CO LTD,LEE JI HYE;;CHOI SO YOUNG;;KIM SANG JIN;;YANG YUN HEE,,https://lens.org/033-013-188-448-894,Patent Application,yes,0,0,14,186-689-989-699-456;;099-013-292-546-341;;023-992-460-826-460;;168-363-351-489-684;;033-660-380-040-080;;137-403-608-831-721;;087-409-300-858-384;;162-629-133-790-943;;033-013-188-448-894;;081-824-751-235-813;;136-364-925-210-480;;141-583-179-569-985;;032-157-856-354-989;;097-063-225-075-669,CA;;KR;;JP;;CN;;CL;;AU;;BR;;WO;;MX;;US;;CO;;EP;;IL,14,186-689-989-699-456;;099-013-292-546-341;;023-992-460-826-460;;168-363-351-489-684;;033-660-380-040-080;;162-629-133-790-943;;087-409-300-858-384;;033-013-188-448-894;;137-403-608-831-721;;081-824-751-235-813;;136-364-925-210-480;;141-583-179-569-985;;032-157-856-354-989;;097-063-225-075-669,CA;;KR;;JP;;CN;;CL;;AU;;BR;;WO;;MX;;US;;CO;;EP;;IL,0,A61K31/41;;A61P25/00;;A61K9/2054;;A61K9/2018;;A61K9/2077;;A61K31/41;;A61P25/00;;A61K9/20;;A61K9/00;;A61K9/20;;A61K31/41;;A61P25/00;;A61K9/2027;;A61K9/2054;;A61K9/2077;;A61K9/2095;;A61K31/41,A61K9/00;;A61K9/20;;A61K31/41;;A61P25/00,,0,0,,,,PENDING
105,WO,A1,WO 2022/260484 A1,042-362-798-819-439,2022-12-15,2022,KR 2022008238 W,2022-06-10,US 202163209463 P,2021-06-11,METHODS FOR TREATING AUTISM SPECTRUM DISORDERS (ASD),"The present disclosure relates generally to methods of treating autism spectrum disorders (ASD), using a compound of Formula (I).",SK BIOPHARMACEUTICALS CO LTD,CHUNG JIN YONG;;CHO SEOK HWAN;;LEE HYUN SEOK;;KANG HO WON;;KWAK YONG DO;;JO MIN JAE,,https://lens.org/042-362-798-819-439,Patent Application,yes,4,0,6,134-609-150-463-748;;060-648-609-873-61X;;104-451-252-149-981;;174-192-293-170-66X;;010-584-163-358-424;;042-362-798-819-439,KR;;JP;;WO;;CN;;US;;EP,6,134-609-150-463-748;;060-648-609-873-61X;;174-192-293-170-66X;;104-451-252-149-981;;010-584-163-358-424;;042-362-798-819-439,KR;;JP;;WO;;US;;CN;;EP,0,A61P25/18;;A61K31/27;;A61K31/27;;A61P25/18;;A61P25/00;;A61K31/27,A61K31/27;;A61P25/18,,1,1,063-545-337-862-956,10.1002/ebch.804;;21874125;;pmc3160736,"REIERSEN ANGELA M., HANDEN BENJAMIN: ""Commentary on ‘Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)’"", EVIDENCE-BASED CHILD HEALTH: A COCHRANE REVIEW JOURNAL, JOHN WILEY & SONS, GB, vol. 6, no. 4, 1 July 2011 (2011-07-01), GB , pages 1082 - 1085, XP093014263, ISSN: 1557-6272, DOI: 10.1002/ebch.786",PENDING
106,US,A1,US 2024/0261248 A1,174-192-293-170-66X,2024-08-08,2024,US 202218565188 A,2022-06-10,US 202218565188 A;;US 202163209463 P;;KR 2022008238 W,2021-06-11,METHODS FOR TREATING AUTISM SPECTRUM DISORDERS (ASD),"The present disclosure relates generally to methods of treating autism spectrum disorders (ASD), using a compound of Formula (I).",SK BIOPHARMACEUTICALS CO LTD,CHUNG JIN YONG;;CHO SEOK HWAN;;LEE HYUN SEOK;;KANG HO WON;;KWAK YONG DO;;JO MIN JAE,SK BIOPHARMACEUTICALS CO. LTD (2023-11-20),https://lens.org/174-192-293-170-66X,Patent Application,yes,0,0,6,134-609-150-463-748;;060-648-609-873-61X;;104-451-252-149-981;;174-192-293-170-66X;;010-584-163-358-424;;042-362-798-819-439,KR;;JP;;WO;;CN;;US;;EP,6,134-609-150-463-748;;060-648-609-873-61X;;174-192-293-170-66X;;104-451-252-149-981;;010-584-163-358-424;;042-362-798-819-439,KR;;JP;;WO;;US;;CN;;EP,0,A61P25/18;;A61K31/27;;A61K31/27;;A61P25/18;;A61P25/00;;A61K31/27,A61K31/27;;A61P25/00,,0,0,,,,PENDING
107,EP,B1,EP 2668185 B1,088-227-008-969-940,2016-11-23,2016,EP 12739548 A,2012-01-30,KR 20110008962 A;;KR 2012000652 W,2011-01-28,PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES,,SK BIOPHARMACEUTICALS CO LTD,MAENG CHEOL YOUNG;;JANG YOUNG KOO;;CHA SU BONG;;SHIN HYE WON;;JOUNG CHAN MI;;YI EUN JUNG,,https://lens.org/088-227-008-969-940,Granted Patent,yes,3,0,38,160-480-516-887-544;;183-766-785-119-795;;160-096-087-153-799;;099-303-326-630-265;;051-707-988-629-545;;149-102-626-714-234;;101-580-233-424-02X;;044-324-660-024-436;;102-040-318-042-150;;007-323-109-150-557;;137-515-039-683-971;;189-311-118-248-822;;062-832-256-786-926;;050-248-377-994-31X;;088-227-008-969-940;;157-104-881-167-142;;152-586-696-716-747;;035-204-582-504-764;;161-532-728-723-347;;036-183-174-524-762;;107-439-176-766-714;;180-020-553-513-144;;048-244-289-031-230;;055-337-448-583-566;;078-468-980-971-420;;118-444-082-208-16X;;186-169-532-756-87X;;010-744-547-429-455;;018-173-814-634-256;;118-637-540-893-40X;;062-326-391-883-33X;;002-242-574-877-309;;122-108-042-351-860;;175-203-797-197-070;;043-935-753-398-011;;161-082-200-130-505;;143-337-255-827-237;;111-560-504-700-722,CA;;RU;;KR;;JP;;ZA;;CN;;PL;;CL;;ES;;AU;;BR;;MX;;WO;;US;;HK;;EP,38,160-480-516-887-544;;183-766-785-119-795;;160-096-087-153-799;;099-303-326-630-265;;051-707-988-629-545;;149-102-626-714-234;;101-580-233-424-02X;;044-324-660-024-436;;102-040-318-042-150;;007-323-109-150-557;;137-515-039-683-971;;189-311-118-248-822;;062-832-256-786-926;;050-248-377-994-31X;;088-227-008-969-940;;157-104-881-167-142;;152-586-696-716-747;;035-204-582-504-764;;161-532-728-723-347;;036-183-174-524-762;;107-439-176-766-714;;180-020-553-513-144;;048-244-289-031-230;;055-337-448-583-566;;078-468-980-971-420;;118-444-082-208-16X;;186-169-532-756-87X;;010-744-547-429-455;;018-173-814-634-256;;118-637-540-893-40X;;062-326-391-883-33X;;002-242-574-877-309;;122-108-042-351-860;;175-203-797-197-070;;043-935-753-398-011;;161-082-200-130-505;;143-337-255-827-237;;111-560-504-700-722,CA;;RU;;KR;;JP;;ZA;;CN;;PL;;CL;;ES;;AU;;BR;;MX;;WO;;US;;HK;;EP,0,A61K31/439;;A61K31/497;;C07D453/02;;A61K31/4709;;A61K31/4725;;A61P25/00;;A61P25/18;;A61P25/28;;A61P43/00;;A61P25/28;;A61K9/0053;;A61K31/439;;C07D453/02;;A61K31/444;;A61K31/4748;;C07D471/08;;C07D453/02;;A61K31/439;;A61K31/497;;A61K9/0053;;A61K31/4709;;A61K31/4725,C07D471/08;;A61K31/4748;;A61P25/00;;C07D417/14,,1,0,,,"STEPHEN W. WRIGHT, ANTHONY A. CARLO, MAYNARD D. CAR ET AL.: ""Anilinoquinazoline inhibitors of fructose 1,6-bisphosphatase bind at a novel allosteric site: Synthesis, in vitro characterization, and X-ray crystallography"", J. MED. CHEM., vol. 45, 26 July 2002 (2002-07-26), pages 3865-3877, XP002719804,",ACTIVE
108,US,B2,US 10456385 B2,160-096-087-153-799,2019-10-29,2019,US 201815987550 A,2018-05-23,US 201815987550 A;;KR 20110008962 A;;US 201614997754 A;;US 201414581482 A;;US 201313980821 A;;KR 2012000652 W,2011-01-28,Pharmaceutical composition comprising pyridone derivatives,"A pyridone derivative compound and a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof, and a preventive or therapeutic pharmaceutical composition for cognitive disorders that includes the pyridone derivative compound or a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof.",SK BIOPHARMACEUTICALS CO LTD,MAENG CHEOL YOUNG;;JANG YOUNG KOO;;CHA SU BONG;;SHIN HYE WON;;JOUNG CHAN MI;;YI EUN JUNG,,https://lens.org/160-096-087-153-799,Granted Patent,yes,10,1,38,160-480-516-887-544;;183-766-785-119-795;;160-096-087-153-799;;099-303-326-630-265;;051-707-988-629-545;;149-102-626-714-234;;101-580-233-424-02X;;044-324-660-024-436;;102-040-318-042-150;;007-323-109-150-557;;137-515-039-683-971;;189-311-118-248-822;;062-832-256-786-926;;050-248-377-994-31X;;088-227-008-969-940;;157-104-881-167-142;;152-586-696-716-747;;035-204-582-504-764;;161-532-728-723-347;;036-183-174-524-762;;107-439-176-766-714;;180-020-553-513-144;;048-244-289-031-230;;055-337-448-583-566;;078-468-980-971-420;;118-444-082-208-16X;;186-169-532-756-87X;;010-744-547-429-455;;018-173-814-634-256;;118-637-540-893-40X;;062-326-391-883-33X;;002-242-574-877-309;;122-108-042-351-860;;175-203-797-197-070;;043-935-753-398-011;;161-082-200-130-505;;143-337-255-827-237;;111-560-504-700-722,CA;;RU;;KR;;JP;;ZA;;CN;;PL;;CL;;ES;;AU;;BR;;MX;;WO;;US;;HK;;EP,38,160-480-516-887-544;;183-766-785-119-795;;160-096-087-153-799;;099-303-326-630-265;;051-707-988-629-545;;149-102-626-714-234;;101-580-233-424-02X;;044-324-660-024-436;;102-040-318-042-150;;007-323-109-150-557;;137-515-039-683-971;;189-311-118-248-822;;062-832-256-786-926;;050-248-377-994-31X;;088-227-008-969-940;;157-104-881-167-142;;152-586-696-716-747;;035-204-582-504-764;;161-532-728-723-347;;036-183-174-524-762;;107-439-176-766-714;;180-020-553-513-144;;048-244-289-031-230;;055-337-448-583-566;;078-468-980-971-420;;118-444-082-208-16X;;186-169-532-756-87X;;010-744-547-429-455;;018-173-814-634-256;;118-637-540-893-40X;;062-326-391-883-33X;;002-242-574-877-309;;122-108-042-351-860;;175-203-797-197-070;;043-935-753-398-011;;161-082-200-130-505;;143-337-255-827-237;;111-560-504-700-722,CA;;RU;;KR;;JP;;ZA;;CN;;PL;;CL;;ES;;AU;;BR;;MX;;WO;;US;;HK;;EP,0,A61K31/439;;A61K31/497;;C07D453/02;;A61K31/4709;;A61K31/4725;;A61P25/00;;A61P25/18;;A61P25/28;;A61P43/00;;A61P25/28;;A61K9/0053;;A61K31/439;;C07D453/02;;A61K31/444;;A61K31/4748;;C07D471/08;;C07D453/02;;A61K31/439;;A61K31/497;;A61K9/0053;;A61K31/4709;;A61K31/4725,A61K31/439;;A61K9/00;;A61K31/4709;;A61K31/4725;;A61K31/497;;C07D453/02,,42,24,065-153-423-956-107;;020-158-334-451-22X;;004-396-584-821-792;;030-533-626-812-36X;;025-322-934-414-08X;;025-667-632-630-530;;024-690-242-284-803;;052-959-294-068-381;;044-334-094-970-696;;009-550-404-283-996;;085-851-440-777-139;;013-471-544-328-120;;102-675-895-745-525;;004-071-370-575-885;;025-899-980-994-317;;037-132-026-628-144;;001-736-805-176-66X;;026-235-388-838-897;;040-108-145-486-132;;045-698-625-863-798;;051-514-658-283-00X;;073-287-437-765-057;;040-507-343-438-914;;011-407-639-113-73X,22925690;;10.1016/j.pharmthera.2012.08.012;;10.1007/s40263-015-0260-0;;26242477;;pmc2042938;;10.1038/sj.bjp.0707264;;17502850;;20859658;;10.1007/s11095-010-0283-7;;10.1038/nprot.2006.205;;17406415;;10.1016/s0169-328x(00)00031-0;;10762715;;17470445;;pmc2526144;;10.1093/schbul/sbm031;;10.1002/jps.2600541133;;pmc3116036;;10.1016/j.neuropharm.2011.01.044;;21288470;;3228475;;10.1016/0166-4328(88)90157-x;;10.1016/j.pneurobio.2004.09.006;;15649582;;10.1016/j.tips.2006.07.004;;16876883;;9862770;;10.1038/npp.2011.199;;pmc3238081;;21956443;;pmc3513881;;23251750;;10.1177/2040622310397691;;10.1007/s00213-005-0164-7;;16220335;;16678864;;10.1016/j.neuropharm.2006.03.012;;10.1016/s0166-4328(00)00196-0;;10942028;;12190310;;10.1021/jm010496a;;10.1126/science.1206606;;21885782;;pmc3210548;;15753976;;pmc4753586;;26071208;;10.1093/schbul/sbv072;;10.1517/17460441.2.9.1185;;23496128;;10.1021/jm2007672;;21919481,"Hurst; Pharmacology & Therapeutics 2013,137, 22-54. (Year: 2013).;;Beinat ;CNS Drugs 2015, 29, 529-542. (Year: 2015).;;De Jonge; British Journal of Pharmacology 2007, 151, 915-929. DOI: 10.1038/sj.bjp.0707264 (Year: 2007).;;Marrero; Pharm Res 2011, 28, 413-416. DOI: 10.1007/s11095-010-0283-7 (Year: 2011).;;Acker, et al. (2008) “Discovery of N-[(3R,5R)-1-zabicyclo[3.2.1]oct-3-yl]furo-[2,3-c]pyridine-5-carboxamide s an agonist of the α7 nicotinic acetylcholine receptor: In vitro and in vivo activity.”, Med. Chem. Lett., 18:3611-3615.;;Banerjee, et al. (2000), “Cellular expression of α7 nicotinic acetylcholine receptor protein in the temporal cortex in Alzheimer's and Parkinson's disease—astereological approach.” Neurobiol. Disease, 7:666-672.;;Bevins, et al. (2006) “Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study ‘recognition memory’.” Nat Protoc., 1(3):1306-1311.;;Bitner, et al. (2010) “In vivo pharmacological characterization of a novel selective α7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease.” J. Pharmacol. Exp. Ther., 334:875-886.;;Burghaus, et al. (2000) “Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients.” Mol. Brain Res., 76:385-388.;;Cannon, et al. (2007) “Editor's introduction: The empirical status of the ultra highrisk (prodromal) research paradigm.” Schizophrenia Bulletin, 33(3):661-664.;;Casola, et al. (1965) “2-pyridones: 1-(heterocyclic)-1,2-dihydro-2-oxopyridine-5-carboxylic acids and derivatives.” J. Pharm. Sci., 54:1686-1688.;;Castner, et al. (2011) “Immediate and sustained improvements in working memory after selective stimulation of α7 nicotinic acetylcholine receptors.” Biol. Psychiatry, 69:12-18.;;D'Souza, et al. (2012) “Scizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits.” Neuropharmacology, 62:1564-1573.;;Ennaceur, et al. (1988) “A new one-trial test for neurobiological studies of memory in rats.1: Behavioral data.” Behavioral Brain Res., 31:47-59.;;Gotti, et al. (2004) “Neuronal nicotinic receptors: from structure to pathology.” Prog.Neurobiol., 74:363-396.;;Gotti, et al. (2006) “Brain nicotinic acetylcholine receptors: native subtypes and their relevance.” Trends in Pharmacol., Sci. 27:482-491.;;Hong-Qi, et al., (2012) “Current advances in the treatment of Alzheimer's disease: focused on considerations targeting Aβ and tau.” Translational Neurodegeneration, 1:1-12.;;Hosford, et al. (2013) “TC-5619:7 agonist for potential treatment of negative symptoms and cognitive dysfunction in schizophrenia.” Presented by Society for Neuroscience Meeting, San Diego, CA Nov. 6, 2013.;;Jones, et al. (1999) “Subjective and physiological effects of intravenous nicotine and cocaine in cigarette smoking cocaine abusers1.” J. Pharmacol. Exp. Ther., 288:188-197.;;Jones, et al., (2012) “Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia”Neuropsychopharmacology 37:16-42.;;Kawamata, et al., (2011) “Enhancement of nicotinic receptors alleviates cytotoxicity in neurological disease models.” Ther. Adv. Chronic. Dis. 2:197-208.;;Levin, et al. (2006) “Nicotinic effects on cognitive function: behavioralcharacterization, pharmacological specification, and anatomic localization.” Psychopharmacology, 184:523-539.;;Marrero, et al. (2009) “Convergence of alpha 7 nicotinic acetylcholine receptoractivated pathways for anti-apoptosis and anti-inflammation: central role for JAK2 activation of STAT3 and NF-κB.” Brain Res., 1256:1-7.;;Oshikawa, et al. (2003) “Nicotinic acetylcholine receptor α7 regulates cAMP signal within lipid rafts.” Am. J. Physiol. Cell Physiol., 285:567-574.;;Ospina, et al. (1998) “Calcium regulation of agonist binding to α7-type nicotinic acetylcholine receptors in adult and fetal rat hippocampus.” J. Neurochem., 70:1061-1068.;;(2011) “Pipeline report—neuronal alpha 7 nicotinic receptors: candidates for the treatment of alzheimers disease and schizophrenia” Advances In Drug Discovery, LeadDiscovery.CO.UK online publication.;;Spinelli (2006) “Enhancing effects of nicotine and impairing effects of scopolamine on distinct aspects of performance in computerized attention and working memory tasks in marmoset monkeys.” Neuropharmacology, 51:238-250.;;Wallace et al. (2011) “RG3487, a novel nicotinic α7 receptor partial agonist, improves cognition and sensorimotor gating in rodents.” J. Pharmacol. Exp. Ther., 336:242-253.;;Woodruff-Pak, et al. (2000) “Nicotinic modulation in an animal model of a form of associative learning impaired in Alzheimer's disease.” Behav. Brain Res., 113:11-19.;;Wright, et al. (2002) “Anilinoquinazoline inhibitors of fructose 1,6-bisphosphatase bind at a novel allosteric site: synthesis, in vitro characterization, and X-ray crystallography.” J. Med. Chem., 45:3865-3877.;;International Search Report (ISR) in PCT/KR2012/000652, dated Jun. 21, 2012.;;Supplementary European Search Report dated Mar. 3, 2014, issued in European Patent Application No. 12739548.1.;;Office Action dated Apr. 20, 2015 in U.S. Appl. No. 14/581,482.;;Office Action dated Dec. 24, 2013 in U.S. Appl. No. 13/980,821.;;Office Action dated Aug. 1, 2014 in U.S. Appl. No. 13/980,821.;;Office Action dated Apr. 18, 2014 in U.S. Appl. No. 13/980,821.;;Mangus; “Chemical and Genetic Engineering of Selective Ion Channel-Ligand Interactions”, Science, New Series, 2011, vol. 33, No. 6047, 1292-1296.;;Palmer; “CNS Drug Discovery: Challenges and Solutions”, Drug News Perspect, 2005, 18, 51-57.;;Walling; “Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia”, Schizophrenia Bulletin 2016, 42, 335-343.;;Lippiello; “Nicotinic receptors as targets for therapeutic discovery”, Expert Opinion on Drug Discovery, 2007, 2, 1185-1203.;;Mazurov, “Discovery and Development of a7 Nicotinic Acetylcholine Receptor Modulators”, J. Med. Chem., 2011, 54, 7943-7961.;;Office Action dated Feb. 1, 2017 in U.S. Appl. No. 14/997,754.",ACTIVE
109,US,A1,US 2021/0085658 A1,102-040-318-042-150,2021-03-25,2021,US 202017108052 A,2020-12-01,US 202017108052 A;;KR 20110008962 A;;US 201916568400 A;;US 201815987550 A;;US 201614997754 A;;US 201414581482 A;;US 201313980821 A;;KR 2012000652 W,2011-01-28,PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDONE DERIVATIVES,"A pyridone derivative compound and a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof, and a preventive or therapeutic pharmaceutical composition for cognitive disorders that includes the pyridone derivative compound or a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof.",SK BIOPHARMACEUTICALS CO LTD,MAENG CHEOL YOUNG;;JANG YOUNG KOO;;CHA SU BONG;;SHIN HYE WON;;JOUNG CHAN MI;;YI EUN JUNG,SK BIOPHARMACEUTICALS CO. LTD (2013-06-28),https://lens.org/102-040-318-042-150,Patent Application,yes,12,0,38,160-480-516-887-544;;183-766-785-119-795;;160-096-087-153-799;;099-303-326-630-265;;051-707-988-629-545;;149-102-626-714-234;;101-580-233-424-02X;;044-324-660-024-436;;102-040-318-042-150;;007-323-109-150-557;;137-515-039-683-971;;189-311-118-248-822;;062-832-256-786-926;;050-248-377-994-31X;;088-227-008-969-940;;157-104-881-167-142;;152-586-696-716-747;;035-204-582-504-764;;161-532-728-723-347;;036-183-174-524-762;;107-439-176-766-714;;180-020-553-513-144;;048-244-289-031-230;;055-337-448-583-566;;078-468-980-971-420;;118-444-082-208-16X;;186-169-532-756-87X;;010-744-547-429-455;;018-173-814-634-256;;118-637-540-893-40X;;062-326-391-883-33X;;002-242-574-877-309;;122-108-042-351-860;;175-203-797-197-070;;043-935-753-398-011;;161-082-200-130-505;;143-337-255-827-237;;111-560-504-700-722,CA;;RU;;KR;;JP;;ZA;;CN;;PL;;CL;;ES;;AU;;BR;;MX;;WO;;US;;HK;;EP,38,160-480-516-887-544;;183-766-785-119-795;;160-096-087-153-799;;099-303-326-630-265;;051-707-988-629-545;;149-102-626-714-234;;101-580-233-424-02X;;044-324-660-024-436;;102-040-318-042-150;;007-323-109-150-557;;137-515-039-683-971;;189-311-118-248-822;;062-832-256-786-926;;050-248-377-994-31X;;088-227-008-969-940;;157-104-881-167-142;;152-586-696-716-747;;035-204-582-504-764;;161-532-728-723-347;;036-183-174-524-762;;107-439-176-766-714;;180-020-553-513-144;;048-244-289-031-230;;055-337-448-583-566;;078-468-980-971-420;;118-444-082-208-16X;;186-169-532-756-87X;;010-744-547-429-455;;018-173-814-634-256;;118-637-540-893-40X;;062-326-391-883-33X;;002-242-574-877-309;;122-108-042-351-860;;175-203-797-197-070;;043-935-753-398-011;;161-082-200-130-505;;143-337-255-827-237;;111-560-504-700-722,CA;;RU;;KR;;JP;;ZA;;CN;;PL;;CL;;ES;;AU;;BR;;MX;;WO;;US;;HK;;EP,0,A61K31/439;;A61K31/497;;C07D453/02;;A61K31/4709;;A61K31/4725;;A61P25/00;;A61P25/18;;A61P25/28;;A61P43/00;;A61P25/28;;A61K9/0053;;A61K31/439;;C07D453/02;;A61K31/444;;A61K31/4748;;C07D471/08;;C07D453/02;;A61K31/439;;A61K31/497;;A61K9/0053;;A61K31/4709;;A61K31/4725,A61K31/439;;A61K9/00;;A61K31/4709;;A61K31/4725;;A61K31/497;;C07D453/02,,0,0,,,,DISCONTINUED
110,US,A1,US 2018/0263965 A1,002-242-574-877-309,2018-09-20,2018,US 201815987550 A,2018-05-23,US 201815987550 A;;KR 20110008962 A;;US 201614997754 A;;US 201414581482 A;;US 201313980821 A;;KR 2012000652 W,2011-01-28,PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES,"A pyridone derivative compound and a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof, and a preventive or therapeutic pharmaceutical composition for cognitive disorders that includes the pyridone derivative compound or a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof.",SK BIOPHARMACEUTICALS CO LTD,MAENG CHEOL YOUNG;;JANG YOUNG KOO;;CHA SU BONG;;SHIN HYE WON;;JOUNG CHAN MI;;YI EUN JUNG,,https://lens.org/002-242-574-877-309,Patent Application,yes,0,0,38,160-480-516-887-544;;183-766-785-119-795;;160-096-087-153-799;;099-303-326-630-265;;051-707-988-629-545;;149-102-626-714-234;;101-580-233-424-02X;;044-324-660-024-436;;102-040-318-042-150;;007-323-109-150-557;;137-515-039-683-971;;189-311-118-248-822;;062-832-256-786-926;;050-248-377-994-31X;;088-227-008-969-940;;157-104-881-167-142;;152-586-696-716-747;;035-204-582-504-764;;161-532-728-723-347;;036-183-174-524-762;;107-439-176-766-714;;180-020-553-513-144;;048-244-289-031-230;;055-337-448-583-566;;078-468-980-971-420;;118-444-082-208-16X;;186-169-532-756-87X;;010-744-547-429-455;;018-173-814-634-256;;118-637-540-893-40X;;062-326-391-883-33X;;002-242-574-877-309;;122-108-042-351-860;;175-203-797-197-070;;043-935-753-398-011;;161-082-200-130-505;;143-337-255-827-237;;111-560-504-700-722,CA;;RU;;KR;;JP;;ZA;;CN;;PL;;CL;;ES;;AU;;BR;;MX;;WO;;US;;HK;;EP,38,160-480-516-887-544;;183-766-785-119-795;;160-096-087-153-799;;099-303-326-630-265;;051-707-988-629-545;;149-102-626-714-234;;101-580-233-424-02X;;044-324-660-024-436;;102-040-318-042-150;;007-323-109-150-557;;137-515-039-683-971;;189-311-118-248-822;;062-832-256-786-926;;050-248-377-994-31X;;088-227-008-969-940;;157-104-881-167-142;;152-586-696-716-747;;035-204-582-504-764;;161-532-728-723-347;;036-183-174-524-762;;107-439-176-766-714;;180-020-553-513-144;;048-244-289-031-230;;055-337-448-583-566;;078-468-980-971-420;;118-444-082-208-16X;;186-169-532-756-87X;;010-744-547-429-455;;018-173-814-634-256;;118-637-540-893-40X;;062-326-391-883-33X;;002-242-574-877-309;;122-108-042-351-860;;175-203-797-197-070;;043-935-753-398-011;;161-082-200-130-505;;143-337-255-827-237;;111-560-504-700-722,CA;;RU;;KR;;JP;;ZA;;CN;;PL;;CL;;ES;;AU;;BR;;MX;;WO;;US;;HK;;EP,0,A61K31/439;;A61K31/497;;C07D453/02;;A61K31/4709;;A61K31/4725;;A61P25/00;;A61P25/18;;A61P25/28;;A61P43/00;;A61P25/28;;A61K9/0053;;A61K31/439;;C07D453/02;;A61K31/444;;A61K31/4748;;C07D471/08;;C07D453/02;;A61K31/439;;A61K31/497;;A61K9/0053;;A61K31/4709;;A61K31/4725,A61K31/439;;A61K9/00;;A61K31/4709;;A61K31/4725;;A61K31/497;;C07D453/02,,0,0,,,,ACTIVE
111,US,B2,US 9987259 B2,078-468-980-971-420,2018-06-05,2018,US 201614997754 A,2016-01-18,US 201614997754 A;;KR 20110008962 A;;US 201414581482 A;;US 201313980821 A;;KR 2012000652 W,2011-01-28,Pharmaceutical composition comprising pyridone derivatives,"A pyridone derivative compound and a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof, and a preventive or therapeutic pharmaceutical composition for cognitive disorders that includes the pyridone derivative compound or a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof.",SK BIOPHARMACEUTICALS CO LTD,MAENG CHEOL YOUNG;;JANG YOUNG KOO;;CHA SU BONG;;SHIN HYE WON;;JOUNG CHAN MI;;YI EUN JUNG,,https://lens.org/078-468-980-971-420,Granted Patent,yes,9,1,38,160-480-516-887-544;;183-766-785-119-795;;160-096-087-153-799;;099-303-326-630-265;;051-707-988-629-545;;149-102-626-714-234;;101-580-233-424-02X;;044-324-660-024-436;;102-040-318-042-150;;007-323-109-150-557;;137-515-039-683-971;;189-311-118-248-822;;062-832-256-786-926;;050-248-377-994-31X;;088-227-008-969-940;;157-104-881-167-142;;152-586-696-716-747;;035-204-582-504-764;;161-532-728-723-347;;036-183-174-524-762;;107-439-176-766-714;;180-020-553-513-144;;048-244-289-031-230;;055-337-448-583-566;;078-468-980-971-420;;118-444-082-208-16X;;186-169-532-756-87X;;010-744-547-429-455;;018-173-814-634-256;;118-637-540-893-40X;;062-326-391-883-33X;;002-242-574-877-309;;122-108-042-351-860;;175-203-797-197-070;;043-935-753-398-011;;161-082-200-130-505;;143-337-255-827-237;;111-560-504-700-722,CA;;RU;;KR;;JP;;ZA;;CN;;PL;;CL;;ES;;AU;;BR;;MX;;WO;;US;;HK;;EP,38,160-480-516-887-544;;183-766-785-119-795;;160-096-087-153-799;;099-303-326-630-265;;051-707-988-629-545;;149-102-626-714-234;;101-580-233-424-02X;;044-324-660-024-436;;102-040-318-042-150;;007-323-109-150-557;;137-515-039-683-971;;189-311-118-248-822;;062-832-256-786-926;;050-248-377-994-31X;;088-227-008-969-940;;157-104-881-167-142;;152-586-696-716-747;;035-204-582-504-764;;161-532-728-723-347;;036-183-174-524-762;;107-439-176-766-714;;180-020-553-513-144;;048-244-289-031-230;;055-337-448-583-566;;078-468-980-971-420;;118-444-082-208-16X;;186-169-532-756-87X;;010-744-547-429-455;;018-173-814-634-256;;118-637-540-893-40X;;062-326-391-883-33X;;002-242-574-877-309;;122-108-042-351-860;;175-203-797-197-070;;043-935-753-398-011;;161-082-200-130-505;;143-337-255-827-237;;111-560-504-700-722,CA;;RU;;KR;;JP;;ZA;;CN;;PL;;CL;;ES;;AU;;BR;;MX;;WO;;US;;HK;;EP,0,A61K31/439;;A61K31/497;;C07D453/02;;A61K31/4709;;A61K31/4725;;A61P25/00;;A61P25/18;;A61P25/28;;A61P43/00;;A61P25/28;;A61K9/0053;;A61K31/439;;C07D453/02;;A61K31/444;;A61K31/4748;;C07D471/08;;C07D453/02;;A61K31/439;;A61K31/497;;A61K9/0053;;A61K31/4709;;A61K31/4725,A61K9/00;;A61K31/439;;A61K31/4709;;A61K31/4725;;A61K31/497;;C07D453/02,,37,20,040-507-343-438-914;;011-407-639-113-73X;;051-514-658-283-00X;;073-287-437-765-057;;045-698-625-863-798;;025-322-934-414-08X;;025-667-632-630-530;;024-690-242-284-803;;052-959-294-068-381;;044-334-094-970-696;;009-550-404-283-996;;085-851-440-777-139;;013-471-544-328-120;;102-675-895-745-525;;004-071-370-575-885;;025-899-980-994-317;;037-132-026-628-144;;001-736-805-176-66X;;026-235-388-838-897;;040-108-145-486-132,10.1517/17460441.2.9.1185;;23496128;;10.1021/jm2007672;;21919481;;15753976;;pmc4753586;;26071208;;10.1093/schbul/sbv072;;10.1126/science.1206606;;21885782;;pmc3210548;;10.1038/nprot.2006.205;;17406415;;10.1016/s0169-328x(00)00031-0;;10762715;;17470445;;pmc2526144;;10.1093/schbul/sbm031;;10.1002/jps.2600541133;;pmc3116036;;10.1016/j.neuropharm.2011.01.044;;21288470;;3228475;;10.1016/0166-4328(88)90157-x;;10.1016/j.pneurobio.2004.09.006;;15649582;;10.1016/j.tips.2006.07.004;;16876883;;9862770;;10.1038/npp.2011.199;;pmc3238081;;21956443;;pmc3513881;;23251750;;10.1177/2040622310397691;;10.1007/s00213-005-0164-7;;16220335;;16678864;;10.1016/j.neuropharm.2006.03.012;;10.1016/s0166-4328(00)00196-0;;10942028;;12190310;;10.1021/jm010496a,"Lippiello; Expert Opinion on Drug Discovery, 2007, 2, 1185-1203.;;Mazurov; J. Med. Chem. 2011, 54, 7943-7961.;;Palmer; Drug News Perspect 2005, 18, 51-57.;;Walling; Schizophrenia Bulletin 2016, 42, 335-343.;;Magnus; Science, New Series, 2011, vol. 333, No. 6047, 1292-1296. (Year: 2011).;;Acker, et al. (2008) “Discovery of N-[(3R,5R)-1-zabicyclo[3.2.1]oct-3-yl]furo-[2,3-c]pyridine-5-carboxamide s an agonist of the α7 nicotinic acetylcholine receptor: In vitro and in vivo activity.”, Med. Chem. Lett., 18:3611-3615.;;Banerjee, et al. (2000), “Cellular expression of α7 nicotinic acetylcholine receptor protein in the temporal cortex in Alzheimer's and Parkinson's disease—a stereological approach.” Neurobiol. Disease, 7:666-672.;;Bevins, et al. (2006) “Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study ‘recognition memory’.” Nat Protoc., 1(3):1306-1311.;;Bitner, et al. (2010) “In vivo pharmacological characterization of a novel selective α7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease.” J. Pharmacol. Exp. Ther., 334:875-886.;;Burghaus, et al. (2000) “Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients.” Mol. Brain Res., 76:385-388.;;Cannon, et al. (2007) “Editor's introduction: the empirical status of the ultra high-risk (prodromal) research paradigm.” Schizophrenia Bulletin, 33(3):661-664.;;Casola, et al. (1965) “2-pyridones: 1-(heterocyclic)-1,2-dihydro-2-oxopyridine-5-carboxylic acids and derivatives.” J. Pharm. Sci., 54:1686-1688.;;Castner, et al. (2011) “Immediate and sustained improvements in working memory after selective stimulation of α7 nicotinic acetylcholine receptors.” Biol. Psychiatry, 69:12-18.;;D'Souza, et al. (2012) “Scizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits.” Neuropharmacology, 62:1564-1573.;;Ennaceur, et al. (1988) “A new one-trial test for neurobiological studies of memory in rats.1: Behavioral data.” Behavioral Brain Res., 31:47-59.;;Gotti, et al. (2004) “Neuronal nicotinic receptors: from structure to pathology.” Prog.Neurobiol., 74:363-396.;;Gotti, et al. (2006) “Brain nicotinic acetylcholine receptors: native subtypes and their relevance.” Trends in Pharmacol., Sci. 27:482-491.;;Hong-Qi, et al., (2012) “Current advances in the treatment of Alzheimer's disease: focused on considerations targeting Aβ and tau.” Translational Neurodegeneration, 1:1-12.;;Hosford, et al. (2013) “TC-5619:7 agonist for potential treatment of negative symptoms and cognitive dysfunction in schizophrenia.” Presented by Society for Neuroscience Meeting, San Deigo, CA Nov. 6, 2013.;;Jones, et al. (1999) “Subjective and physiological effects of intravenous nicotine and cocaine in cigarette smoking cocaine abusers1.” J. PharmacoL Exp. Ther., 288:188-197.;;Jones, et al., (2012) “Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia” Neuropsychopharmacology 37:16-42.;;Kawamata, et al., (2011) “Enhancement of nicotinic receptors alleviates cytotoxicity in neurological disease models.” Ther. Adv. Chronic. Dis. 2:197-208.;;Levin, et al. (2006) “Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization.” Psychopharmacology, 184:523-539.;;Marrero, et al. (2009) “Convergence of alpha 7 nicotinic acetylcholine receptor-activated pathways for anti-apoptosis and anti-inflammation: central role for JAK2 activation of STAT3 and NF-κB.” Brain Res., 1256:1-7.;;Oshikawa, et al. (2003) “Nicotinic acetylcholine receptor α7 regulates cAMP signal within lipid rafts.” Am. J. Physiol. Cell Physiol., 285:567-574.;;Ospina, et al. (1998) “Calcium regulation of agonist binding to α7-type nicotinic acetylcholine receptors in adult and fetal rat hippocampus.” J. Neurochem., 70:1061-1068.;;(2011) “Pipeline report—neuronal alpha 7 nicotinic receptors: candidates for the treatment of alzheimers disease and schizophrenia” Advances in Drug Discovery, LeadDiscovery. CO. UK online publication.;;Spinelli (2006) “Enhancing effects of nicotine and impairing effects of scopolamine on distinct aspects of performance in computerized attention and working memory tasks in marmoset monkeys.” Neuropharmacology, 51:238-250.;;Wallace et al. (2011) “RG3487, a novel nicotinic α7 receptor partial agonist, improves cognition and sensorimotor gating in rodents.” J. Pharmacol. Exp. Ther., 336:242-253.;;Woodruff-Pak, et al. (2000) “Nicotinic modulation in an animal model of a form of associative learning impaired in Alzheimer's disease.” Behav. Brain Res., 113:11-19.;;Wright, et al. (2002) “Anilinoquinazoline inhibitors of fructose 1,6-bisphosphatase bind at a novel allosteric site: synthesis, in vitro characterization, and X-ray crystallography.” J. Med. Chem., 45:3865-3877.;;International Search Report (ISR) in PCT/KR2012/000652, dated Jun. 21, 2012.;;Supplementary European Search Report dated Mar. 3, 2014, issued in European Patent Application No. 12739548.1.;;Office Action dated Apr. 20, 2015 in U.S. Appl. No. 14/581,482.;;Office Action dated Dec. 24, 2014 in U.S. Appl. No. 13/980,821.;;Office Action dated Aug. 1, 2014 in U.S. Appl. No. 13/980,821.;;Office Action dated Apr. 18, 2014 in U.S. Appl. No. 13/980,821.",ACTIVE
112,US,A1,US 2016/0166552 A1,118-637-540-893-40X,2016-06-16,2016,US 201614997754 A,2016-01-18,US 201614997754 A;;KR 20110008962 A;;US 201414581482 A;;US 201313980821 A;;KR 2012000652 W,2011-01-28,PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES,"A pyridone derivative compound and a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof, and a preventive or therapeutic pharmaceutical composition for cognitive disorders that includes the pyridone derivative compound or a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof.",SK BIOPHARMACEUTICALS CO LTD,MAENG CHEOL YOUNG;;JANG YOUNG KOO;;CHA SU BONG;;SHIN HYE WON;;JOUNG CHAN MI;;YI EUN JUNG,,https://lens.org/118-637-540-893-40X,Patent Application,yes,1,0,38,160-480-516-887-544;;183-766-785-119-795;;160-096-087-153-799;;099-303-326-630-265;;051-707-988-629-545;;149-102-626-714-234;;101-580-233-424-02X;;044-324-660-024-436;;102-040-318-042-150;;007-323-109-150-557;;137-515-039-683-971;;189-311-118-248-822;;062-832-256-786-926;;050-248-377-994-31X;;088-227-008-969-940;;157-104-881-167-142;;152-586-696-716-747;;035-204-582-504-764;;161-532-728-723-347;;036-183-174-524-762;;107-439-176-766-714;;180-020-553-513-144;;048-244-289-031-230;;055-337-448-583-566;;078-468-980-971-420;;118-444-082-208-16X;;186-169-532-756-87X;;010-744-547-429-455;;018-173-814-634-256;;118-637-540-893-40X;;062-326-391-883-33X;;002-242-574-877-309;;122-108-042-351-860;;175-203-797-197-070;;043-935-753-398-011;;161-082-200-130-505;;143-337-255-827-237;;111-560-504-700-722,CA;;RU;;KR;;JP;;ZA;;CN;;PL;;CL;;ES;;AU;;BR;;MX;;WO;;US;;HK;;EP,38,160-480-516-887-544;;183-766-785-119-795;;160-096-087-153-799;;099-303-326-630-265;;051-707-988-629-545;;149-102-626-714-234;;101-580-233-424-02X;;044-324-660-024-436;;102-040-318-042-150;;007-323-109-150-557;;137-515-039-683-971;;189-311-118-248-822;;062-832-256-786-926;;050-248-377-994-31X;;088-227-008-969-940;;157-104-881-167-142;;152-586-696-716-747;;035-204-582-504-764;;161-532-728-723-347;;036-183-174-524-762;;107-439-176-766-714;;180-020-553-513-144;;048-244-289-031-230;;055-337-448-583-566;;078-468-980-971-420;;118-444-082-208-16X;;186-169-532-756-87X;;010-744-547-429-455;;018-173-814-634-256;;118-637-540-893-40X;;062-326-391-883-33X;;002-242-574-877-309;;122-108-042-351-860;;175-203-797-197-070;;043-935-753-398-011;;161-082-200-130-505;;143-337-255-827-237;;111-560-504-700-722,CA;;RU;;KR;;JP;;ZA;;CN;;PL;;CL;;ES;;AU;;BR;;MX;;WO;;US;;HK;;EP,0,A61K31/439;;A61K31/497;;C07D453/02;;A61K31/4709;;A61K31/4725;;A61P25/00;;A61P25/18;;A61P25/28;;A61P43/00;;A61P25/28;;A61K9/0053;;A61K31/439;;C07D453/02;;A61K31/444;;A61K31/4748;;C07D471/08;;C07D453/02;;A61K31/439;;A61K31/497;;A61K9/0053;;A61K31/4709;;A61K31/4725,A61K31/439;;A61K9/00;;A61K31/4709;;A61K31/4725;;A61K31/497,,2,2,040-507-343-438-914;;011-407-639-113-73X,10.1517/17460441.2.9.1185;;23496128;;10.1021/jm2007672;;21919481,"Lippiello; Expert Opinion on Drug Discovery, 2007, 2, 1185-1203.;;Mazurov; J. Med. Chem. 2011, 54, 7943-7961.",ACTIVE
113,US,A1,US 2023/0390259 A1,118-444-082-208-16X,2023-12-07,2023,US 202318236001 A,2023-08-21,US 202318236001 A;;KR 20110008962 A;;US 202017108052 A;;US 201916568400 A;;US 201815987550 A;;US 201614997754 A;;US 201414581482 A;;US 201313980821 A;;KR 2012000652 W,2011-01-28,PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES,"A pyridone derivative compound and a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof, and a preventive or therapeutic pharmaceutical composition for cognitive disorders that includes the pyridone derivative compound or a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof.",SK BIOPHARMACEUTICALS CO LTD,MAENG CHEOL YOUNG;;JANG YOUNG KOO;;CHA SU BONG;;SHIN HYE WON;;JOUNG CHAN MI;;YI EUN JUNG,SK BIOPHARMACEUTICALS CO. LTD (2013-06-28),https://lens.org/118-444-082-208-16X,Patent Application,yes,0,0,38,160-480-516-887-544;;183-766-785-119-795;;160-096-087-153-799;;099-303-326-630-265;;051-707-988-629-545;;149-102-626-714-234;;101-580-233-424-02X;;044-324-660-024-436;;102-040-318-042-150;;007-323-109-150-557;;137-515-039-683-971;;189-311-118-248-822;;062-832-256-786-926;;050-248-377-994-31X;;088-227-008-969-940;;157-104-881-167-142;;152-586-696-716-747;;035-204-582-504-764;;161-532-728-723-347;;036-183-174-524-762;;107-439-176-766-714;;180-020-553-513-144;;048-244-289-031-230;;055-337-448-583-566;;078-468-980-971-420;;118-444-082-208-16X;;186-169-532-756-87X;;010-744-547-429-455;;018-173-814-634-256;;118-637-540-893-40X;;062-326-391-883-33X;;002-242-574-877-309;;122-108-042-351-860;;175-203-797-197-070;;043-935-753-398-011;;161-082-200-130-505;;143-337-255-827-237;;111-560-504-700-722,CA;;RU;;KR;;JP;;ZA;;CN;;PL;;CL;;ES;;AU;;BR;;MX;;WO;;US;;HK;;EP,38,160-480-516-887-544;;183-766-785-119-795;;160-096-087-153-799;;099-303-326-630-265;;051-707-988-629-545;;149-102-626-714-234;;101-580-233-424-02X;;044-324-660-024-436;;102-040-318-042-150;;007-323-109-150-557;;137-515-039-683-971;;189-311-118-248-822;;062-832-256-786-926;;050-248-377-994-31X;;088-227-008-969-940;;157-104-881-167-142;;152-586-696-716-747;;035-204-582-504-764;;161-532-728-723-347;;036-183-174-524-762;;107-439-176-766-714;;180-020-553-513-144;;048-244-289-031-230;;055-337-448-583-566;;078-468-980-971-420;;118-444-082-208-16X;;186-169-532-756-87X;;010-744-547-429-455;;018-173-814-634-256;;118-637-540-893-40X;;062-326-391-883-33X;;002-242-574-877-309;;122-108-042-351-860;;175-203-797-197-070;;043-935-753-398-011;;161-082-200-130-505;;143-337-255-827-237;;111-560-504-700-722,CA;;RU;;KR;;JP;;ZA;;CN;;PL;;CL;;ES;;AU;;BR;;MX;;WO;;US;;HK;;EP,0,A61K31/439;;A61K31/497;;C07D453/02;;A61K31/4709;;A61K31/4725;;A61P25/00;;A61P25/18;;A61P25/28;;A61P43/00;;A61P25/28;;A61K9/0053;;A61K31/439;;C07D453/02;;A61K31/444;;A61K31/4748;;C07D471/08;;C07D453/02;;A61K31/439;;A61K31/497;;A61K9/0053;;A61K31/4709;;A61K31/4725,A61K31/439;;A61K9/00;;A61K31/4709;;A61K31/4725;;A61K31/497;;C07D453/02,,0,0,,,,PENDING
114,US,A1,US 2020/0000782 A1,152-586-696-716-747,2020-01-02,2020,US 201916568400 A,2019-09-12,US 201916568400 A;;KR 20110008962 A;;US 201815987550 A;;US 201614997754 A;;US 201414581482 A;;US 201313980821 A;;KR 2012000652 W,2011-01-28,PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES,"A pyridone derivative compound and a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof, and a preventive or therapeutic pharmaceutical composition for cognitive disorders that includes the pyridone derivative compound or a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof.",SK BIOPHARMACEUTICALS CO LTD,MAENG CHEOL YOUNG;;JANG YOUNG KOO;;CHA SU BONG;;SHIN HYE WON;;JOUNG CHAN MI;;YI EUN JUNG,SK BIOPHARMACEUTICALS CO. LTD (2013-06-28),https://lens.org/152-586-696-716-747,Patent Application,yes,1,0,38,160-480-516-887-544;;183-766-785-119-795;;160-096-087-153-799;;099-303-326-630-265;;051-707-988-629-545;;149-102-626-714-234;;101-580-233-424-02X;;044-324-660-024-436;;102-040-318-042-150;;007-323-109-150-557;;137-515-039-683-971;;189-311-118-248-822;;062-832-256-786-926;;050-248-377-994-31X;;088-227-008-969-940;;157-104-881-167-142;;152-586-696-716-747;;035-204-582-504-764;;161-532-728-723-347;;036-183-174-524-762;;107-439-176-766-714;;180-020-553-513-144;;048-244-289-031-230;;055-337-448-583-566;;078-468-980-971-420;;118-444-082-208-16X;;186-169-532-756-87X;;010-744-547-429-455;;018-173-814-634-256;;118-637-540-893-40X;;062-326-391-883-33X;;002-242-574-877-309;;122-108-042-351-860;;175-203-797-197-070;;043-935-753-398-011;;161-082-200-130-505;;143-337-255-827-237;;111-560-504-700-722,CA;;RU;;KR;;JP;;ZA;;CN;;PL;;CL;;ES;;AU;;BR;;MX;;WO;;US;;HK;;EP,38,160-480-516-887-544;;183-766-785-119-795;;160-096-087-153-799;;099-303-326-630-265;;051-707-988-629-545;;149-102-626-714-234;;101-580-233-424-02X;;044-324-660-024-436;;102-040-318-042-150;;007-323-109-150-557;;137-515-039-683-971;;189-311-118-248-822;;062-832-256-786-926;;050-248-377-994-31X;;088-227-008-969-940;;157-104-881-167-142;;152-586-696-716-747;;035-204-582-504-764;;161-532-728-723-347;;036-183-174-524-762;;107-439-176-766-714;;180-020-553-513-144;;048-244-289-031-230;;055-337-448-583-566;;078-468-980-971-420;;118-444-082-208-16X;;186-169-532-756-87X;;010-744-547-429-455;;018-173-814-634-256;;118-637-540-893-40X;;062-326-391-883-33X;;002-242-574-877-309;;122-108-042-351-860;;175-203-797-197-070;;043-935-753-398-011;;161-082-200-130-505;;143-337-255-827-237;;111-560-504-700-722,CA;;RU;;KR;;JP;;ZA;;CN;;PL;;CL;;ES;;AU;;BR;;MX;;WO;;US;;HK;;EP,0,A61K31/439;;A61K31/497;;C07D453/02;;A61K31/4709;;A61K31/4725;;A61P25/00;;A61P25/18;;A61P25/28;;A61P43/00;;A61P25/28;;A61K9/0053;;A61K31/439;;C07D453/02;;A61K31/444;;A61K31/4748;;C07D471/08;;C07D453/02;;A61K31/439;;A61K31/497;;A61K9/0053;;A61K31/4709;;A61K31/4725,A61K31/439;;A61K9/00;;A61K31/4709;;A61K31/4725;;A61K31/497;;C07D453/02,,0,0,,,,DISCONTINUED
115,WO,A1,WO 2023/211195 A1,176-854-247-257-089,2023-11-02,2023,KR 2023005773 W,2023-04-27,US 202263335779 P,2022-04-28,N-OXIDE COMPOUNDS AND USE THEREOF,The present disclosure provides a compound represented by Formula (I) or a pharmaceutically acceptable salt which are effective as a sodium channel blocker and a method of using the compound.,SK BIOPHARMACEUTICALS CO LTD,KANG YOUNG SOON;;KANG HO WON;;KIM YONG SOO;;KIM JIN SUNG;;PANG MIN HEE;;LEE KA EUN;;RHEE CHI YEON;;YI HAN JU;;CHAE SANG MI;;KWAK YONG DO;;MIN HYE KYUNG;;LEE JI WON;;JANG YOUNG KOO;;JO MIN JAE,,https://lens.org/176-854-247-257-089,Patent Application,yes,5,0,6,007-250-362-011-871;;038-832-967-661-396;;196-933-649-529-703;;028-639-766-093-487;;176-854-247-257-089;;050-137-361-952-965,KR;;WO;;CN;;AR;;TW;;EP,6,007-250-362-011-871;;038-832-967-661-396;;196-933-649-529-703;;028-639-766-093-487;;176-854-247-257-089;;050-137-361-952-965,KR;;WO;;CN;;AR;;TW;;EP,0,C07D213/89;;A61K45/06;;C07D213/89;;A61K31/4425;;A61P29/00;;A61P25/04,C07D213/89;;A61K31/4412;;A61P1/00;;A61P25/04;;A61P25/28;;A61P29/00,,0,0,,,,PENDING
116,EP,B1,EP 2668186 B1,049-437-063-991-308,2017-05-03,2017,EP 12740018 A,2012-01-30,KR 20110008960 A;;KR 2012000648 W,2011-01-28,PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES,,SK BIOPHARMACEUTICALS CO LTD,MAENG CHEOL YOUNG;;JANG YOUNG KOO;;CHA SU BONG;;SHIN HYE WON;;JOUNG CHAN MI;;CHA HWA RYUN;;YI EUN JUNG,,https://lens.org/049-437-063-991-308,Granted Patent,yes,3,0,15,151-644-212-820-203;;175-954-652-772-30X;;014-731-425-631-113;;168-892-686-372-924;;120-575-965-373-734;;049-437-063-991-308;;196-301-954-336-347;;130-530-671-851-052;;059-952-597-067-725;;025-079-555-229-08X;;120-028-708-027-029;;031-686-384-099-672;;102-525-593-616-003;;157-793-931-979-592;;022-413-198-484-518,CA;;JP;;KR;;WO;;CN;;US;;ES;;EP,15,151-644-212-820-203;;175-954-652-772-30X;;014-731-425-631-113;;168-892-686-372-924;;120-575-965-373-734;;049-437-063-991-308;;196-301-954-336-347;;130-530-671-851-052;;059-952-597-067-725;;025-079-555-229-08X;;120-028-708-027-029;;031-686-384-099-672;;102-525-593-616-003;;157-793-931-979-592;;022-413-198-484-518,CA;;JP;;KR;;WO;;CN;;US;;ES;;EP,0,C07D453/02;;A61P25/00;;A61P25/18;;A61P25/28;;A61P29/00;;A61P43/00;;C07D453/04;;A61K31/439;;C07D453/02,C07D471/08;;A61K31/439;;A61P25/00;;C07D453/02,,0,0,,,,ACTIVE
117,US,B2,US 9271976 B2,137-515-039-683-971,2016-03-01,2016,US 201414581482 A,2014-12-23,US 201414581482 A;;KR 20110008962 A;;US 201313980821 A;;KR 2012000652 W,2011-01-28,Pharmaceutical composition comprising pyridone derivatives,"A pyridone derivative compound and a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof, and a preventive or therapeutic pharmaceutical composition for cognitive disorders that includes the pyridone derivative compound or a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof.",SK BIOBPHARMACEUTICALS CO LTD;;SK BIOPHARMACEUTICALS CO LTD,MAENG CHEOL YOUNG;;JANG YOUNG KOO;;CHA SU BONG;;SHIN HYE WON;;JOUNG CHAN MI;;YI EUN JUNG,,https://lens.org/137-515-039-683-971,Granted Patent,yes,7,3,38,160-480-516-887-544;;183-766-785-119-795;;160-096-087-153-799;;099-303-326-630-265;;051-707-988-629-545;;149-102-626-714-234;;101-580-233-424-02X;;044-324-660-024-436;;102-040-318-042-150;;007-323-109-150-557;;137-515-039-683-971;;189-311-118-248-822;;062-832-256-786-926;;050-248-377-994-31X;;088-227-008-969-940;;157-104-881-167-142;;152-586-696-716-747;;035-204-582-504-764;;161-532-728-723-347;;036-183-174-524-762;;107-439-176-766-714;;180-020-553-513-144;;048-244-289-031-230;;055-337-448-583-566;;078-468-980-971-420;;118-444-082-208-16X;;186-169-532-756-87X;;010-744-547-429-455;;018-173-814-634-256;;118-637-540-893-40X;;062-326-391-883-33X;;002-242-574-877-309;;122-108-042-351-860;;175-203-797-197-070;;043-935-753-398-011;;161-082-200-130-505;;143-337-255-827-237;;111-560-504-700-722,CA;;RU;;KR;;JP;;ZA;;CN;;PL;;CL;;ES;;AU;;BR;;MX;;WO;;US;;HK;;EP,38,160-480-516-887-544;;183-766-785-119-795;;160-096-087-153-799;;099-303-326-630-265;;051-707-988-629-545;;149-102-626-714-234;;101-580-233-424-02X;;044-324-660-024-436;;102-040-318-042-150;;007-323-109-150-557;;137-515-039-683-971;;189-311-118-248-822;;062-832-256-786-926;;050-248-377-994-31X;;088-227-008-969-940;;157-104-881-167-142;;152-586-696-716-747;;035-204-582-504-764;;161-532-728-723-347;;036-183-174-524-762;;107-439-176-766-714;;180-020-553-513-144;;048-244-289-031-230;;055-337-448-583-566;;078-468-980-971-420;;118-444-082-208-16X;;186-169-532-756-87X;;010-744-547-429-455;;018-173-814-634-256;;118-637-540-893-40X;;062-326-391-883-33X;;002-242-574-877-309;;122-108-042-351-860;;175-203-797-197-070;;043-935-753-398-011;;161-082-200-130-505;;143-337-255-827-237;;111-560-504-700-722,CA;;RU;;KR;;JP;;ZA;;CN;;PL;;CL;;ES;;AU;;BR;;MX;;WO;;US;;HK;;EP,0,A61K31/439;;A61K31/497;;C07D453/02;;A61K31/4709;;A61K31/4725;;A61P25/00;;A61P25/18;;A61P25/28;;A61P43/00;;A61P25/28;;A61K9/0053;;A61K31/439;;C07D453/02;;A61K31/444;;A61K31/4748;;C07D471/08;;C07D453/02;;A61K31/439;;A61K31/497;;A61K9/0053;;A61K31/4709;;A61K31/4725,C07D453/02;;A61K31/439;;A61K31/4748;;A61K31/497;;C07D417/14;;C07D471/08,,31,23,025-899-980-994-317;;004-071-370-575-885;;071-002-379-380-460;;047-709-472-163-005;;025-322-934-414-08X;;010-393-402-623-554;;025-667-632-630-530;;024-690-242-284-803;;052-959-294-068-381;;023-441-299-629-661;;044-334-094-970-696;;009-550-404-283-996;;085-851-440-777-139;;013-471-544-328-120;;102-675-895-745-525;;037-132-026-628-144;;025-913-528-999-718;;036-990-235-751-362;;093-193-698-989-815;;001-736-805-176-66X;;117-414-545-065-721;;026-235-388-838-897;;040-108-145-486-132,23251750;;pmc3513881;;10.1177/2040622310397691;;pmc3238081;;21956443;;10.1038/npp.2011.199;;10.1016/j.bmcl.2008.04.070;;18490160;;10.1006/nbdi.2000.0317;;11114264;;10.1038/nprot.2006.205;;17406415;;20504913;;10.1124/jpet.110.167213;;10762715;;10.1016/s0169-328x(00)00031-0;;10.1093/schbul/sbm031;;pmc2526144;;17470445;;10.1002/jps.2600541133;;20965497;;10.1016/j.biopsych.2010.08.006;;pmc3116036;;21288470;;10.1016/j.neuropharm.2011.01.044;;3228475;;10.1016/0166-4328(88)90157-x;;10.1016/j.pneurobio.2004.09.006;;15649582;;10.1016/j.tips.2006.07.004;;16876883;;9862770;;16220335;;10.1007/s00213-005-0164-7;;19063868;;10.1016/j.brainres.2008.11.053;;10.1152/ajpcell.00422.2002;;12748066;;10.1046/j.1471-4159.1998.70031061.x;;9489726;;10.1016/j.neuropharm.2006.03.012;;16678864;;10.1124/jpet.110.171892;;20959364;;10942028;;10.1016/s0166-4328(00)00196-0;;10.1021/jm010496a;;12190310,"Hong-Qi; Translational Neurodegeneration, 2012, 1, 1-12.;;Kawamata; Ther. Adv. Chronic. Dis. 2011, 2, 197-208.;;Jones; Neuropsychopharmacology, 2012, 37, 16-42.;;""Pipeline Report-Neuronal alpha 7 nicotinic receptors: Candidates for the treatment of Alzheimers disease and Schizophrenia"", Advances in Drug Discovery, LeadDiscovery.CO.UK online publication dated Mar. 21, 2011.;;Acker, et al. (2008) ""Discovery of N-[(3R,5R)-1-zabicyclo[3.2.1]oct-3-yl]furo-[2,3-c]pyridine-5-carboxamide s an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activity."", Med. Chem. Lett, 18:3611-3615.;;Banerjee, et al. (2000), ""Cellular expression of alpha7 nicotinic acetylcholine receptor protein in the temporal cortex in Alzheimer's and Parkinson's disease-a stereological approach."" Neurobiol. Disease7:666-672.;;Bevins, et al. (2006) ""Object recognition in rats and mice: a one-trial non-matching-to-sample learnign task to study 'recognition memory'. "" Nat. Protoc., 1(3):1306-1311.;;Bitner, et al. (2010) ""In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease."" J. Pharmacol. Exp. Ther., 334:875-886.;;Burghaus, et al. (2000) ""Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients."" Mol. Brain Res., 76:385-388.;;Cannon, et al. (2007) ""Editor's introduction: The empirical status of the ultra high-risk (prodromal) research paradigm."" Schizophrenia Bulletin, 33(3):661-664.;;Casola, et al. (1965) ""2-pyridones: 1-(heterocyclic)-1,2-dihydro-2-oxopyridine-5-carboxylic acids and derivatives."" J. Pharm. Sci., 54:1686-1688.;;Castner, et al. (2011) ""Immediate and sustained improvements in working memory after selective stimulation of alpha7 nicotinic acetylcholine receptors."" Biol. Psychiatry, 69:12-18.;;D'Souza, et al. (2012) ""Scizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits."" Neuropharmacology, 62:1564-1573.;;Ennaceur, et al. (1988) ""A new one-trial test for neurobiological studies of memory in rats.1: Behavioral data."" Behavioral Brain Res., 31:47-59.;;Gotti, et al. (2004) ""Neuronal nicotinic receptors: from structure to pathology."" Prog.Neurobiol., 74:363-396.;;Gotti, et al. (2006) ""Brain nicotinic acetylcholine receptors: native subtypes and their relevance."" Trends in Pharmacol., Sci. 27:482-491.;;Hosford, et al. (2013) ""TC-5619:7 agonist for potential treatment of negative symptoms and cognitive dysfunction in schizophrenia."" Presented by Society for Neuroscience Meeting, San Deigo, CA Nov. 6, 2013.;;Jones, et al. (1999) ""Subjective and physiological effects of intravenous nicotine and cocaine in cigarette smoking cocaine abusers'."" J. Pharmacol. Exp. Ther., 288:188-197.;;Levin, et al. (2006) ""Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization."" Psychopharmacology, 184:523-539.;;Marrero, et al. (2009) ""Convergence of alpha 7 nicotinic acetylcholine receptor-activated pathways for anti-apoptosis and anti-inflammation: central role for JAK2 activation of STAT3 and NF-kappaB."" Brain Res., 1256:1-7.;;Oshikawa, et al. (2003) ""Nicotinic acetylcholine receptor alpha7 regulates cAMP signal within lipid rafts."" Am. J. Physiol. Cell Physiol., 285:567-574.;;Ospina, et al. (1998) ""Calcium regulation of agonist binding to alpha7-type nicotinic acetylcholine receptors in adult and fetal rat hippocampus."" J. Neurochem., 70:1061-1068.;;Spinelli (2006) ""Enhancing effects of nicotine and impairing effects of scopolamine on distinct aspects of performance in computerized attention and working memory tasks in marmoset monkeys."" Neuropharmacology, 51:238-250.;;Wallace et al. (2011) ""RG3487, a novel nicotinic alpha7 receptor partial agonist, improves cognition and sensorimotor gating in rodents."" J. Pharmacol. Exp. Ther., 336:242-253.;;Woodruff-Pak, et al. (2000) ""Nicotinic modulation in an animal model of a form of associative learning impaired in Alzheimer's disease."" Behav. Brain Res., 113:11-19.;;Wright, et al. (2002) ""Anilinoquinazoline inhibitors of fructose 1,6-bisphosphatase bind at a novel allosteric site: synthesis, in vitro characterization, and X-ray crystallography."" J. Med. Chem., 45:3865-3877.;;International Search Report (ISR) in PCT/KR2012/000652, dated Jun. 21, 2012.;;Supplementary European Search Report dated Mar. 3, 2014, issued in European Patent Application No. 12739548.1.;;Office Action dated Dec. 24, 2014 in U.S. Appl. No. 13/980,821.;;Office Action dated Apr. 18, 2014 in U.S. Appl. No. 13/980,821.;;Office Action dated Aug. 1, 2014 in U.S. Appl. No. 13/980,821.",ACTIVE
118,US,B2,US 8592406 B2,040-895-886-524-090,2013-11-26,2013,US 94056310 A,2010-11-05,KR 20080044481 A;;KR 2009002567 W,2008-05-14,Transnasal anticonvulsive pharmaceutical composition comprising poorly soluble anticonvulsant,"There is provided a transnasal anticonvulsive pharmaceutical composition including a poorly soluble anticonvulsant. The anticonvulsive pharmaceutical composition comprising a poorly soluble anticonvulsant as an active component, which is transnasally spray-administered, comprises diethylene glycol monoethyl ether and fatty acid ester, wherein the fatty acid ester is selected from the group consisting of caprylocaproyl polyoxylglyceride, isopropyl palmitate, oleoyl polyoxylglyceride, sorbitan monolaurate 20, methyl laurate, ethyl laurate, and polysorbate 20. Also, the anticonvulsive pharmaceutical composition comprising a poorly soluble anticonvulsant as an active component, which is transnasally spray-administered, comprises diethylene glycol monoethyl ether, fatty acid ester, methylpyrrolidone, water and alcohol. Therefore, the transnasal anticonvulsive pharmaceutical composition may be useful to highly enhance the bioavailability of the poorly soluble anticonvulsant. Also, the transnasal anticonvulsive pharmaceutical composition may be useful to allow the poorly soluble anticonvulsant to show the improved viscosity and/or enhanced solubility in order to effectively deliver the poorly soluble anticonvulsant at a therapeutic dose.",BAEK MYOUNG-KI;;JO JAE-HOON;;CHANG HYE-JIN;;SK BIOPHARMACEUTICALS CO LTD,BAEK MYOUNG-KI;;JO JAE-HOON;;CHANG HYE-JIN,SK HOLDINGS CO. LTD (2010-11-17);;SK BIOPHARMACEUTICALS CO. LTD (2011-10-04),https://lens.org/040-895-886-524-090,Granted Patent,yes,32,1,27,015-260-595-433-249;;175-803-753-292-77X;;083-887-966-342-967;;051-851-931-919-484;;195-187-617-647-635;;028-580-651-802-219;;137-926-056-618-190;;148-479-644-508-251;;108-289-621-162-448;;170-037-002-773-044;;120-564-706-346-359;;025-611-607-754-416;;040-895-886-524-090;;008-778-568-715-497;;052-871-813-367-118;;151-420-699-494-581;;000-082-259-582-671;;057-673-283-798-053;;025-300-968-868-330;;123-511-837-475-53X;;113-986-052-059-962;;097-083-913-770-591;;073-058-413-730-651;;088-077-507-443-969;;151-134-450-146-568;;141-156-788-913-116;;157-535-423-454-616,CA;;KR;;JP;;MX;;WO;;CN;;US;;ES;;EP;;AU,27,015-260-595-433-249;;175-803-753-292-77X;;083-887-966-342-967;;051-851-931-919-484;;195-187-617-647-635;;028-580-651-802-219;;137-926-056-618-190;;148-479-644-508-251;;108-289-621-162-448;;170-037-002-773-044;;120-564-706-346-359;;025-611-607-754-416;;040-895-886-524-090;;008-778-568-715-497;;052-871-813-367-118;;151-420-699-494-581;;000-082-259-582-671;;057-673-283-798-053;;025-300-968-868-330;;123-511-837-475-53X;;113-986-052-059-962;;097-083-913-770-591;;073-058-413-730-651;;088-077-507-443-969;;151-134-450-146-568;;141-156-788-913-116;;157-535-423-454-616,CA;;KR;;JP;;MX;;WO;;CN;;US;;ES;;EP;;AU,0,A61K9/0043;;A61K31/5513;;A61K47/08;;A61K47/14;;A61K47/26;;A61K31/5513;;A61K9/0043;;A61K47/26;;A61K47/44;;A61P25/08;;Y02A50/30;;A61K9/08;;A61K47/08;;A61K31/5513;;A61K9/0043;;A61K47/26;;A61K47/44;;Y02A50/30,A61K9/08,514/219;;514/218,8,6,000-118-339-456-327;;019-095-725-805-311;;054-365-565-010-646;;024-868-940-428-718;;029-810-493-102-90X;;019-477-232-707-725,10794928;;10.1016/s0378-5173(00)00373-2;;10.1016/0378-5173(80)90017-4;;10.1016/0378-5173(89)90337-2;;10.1016/s0378-5173(02)00029-7;;11955806;;16091994;;10.1007/s11095-005-7391-9;;11719015;;10.1016/s0378-5173(01)00872-9,"The International Search Report and Written Opinion by the International Searching Authority, issued on Dec. 22, 2009, in the PCT application No. PCT/KR2009/002567.;;Li et al., ""Rapid-onset intranasal delivery of anticonvulsants: pharmacokinetic and pharmacodynamic evaluation in rabbits,"" Int. J. Pharm. Apr. 10, 2000;199(1):65-76.;;Moolenaar et al., ""Biopharmaceutics of rectal administration of drugs in man IX. Comparative biopharmaceutics of diazepam after single rectal, oral, intramuscular and intravenous administration in man,"" International Journal of Pharmaceutics vol. 5, Issue 2, Apr. 1980, pp. 127-137.;;Lau et al., ""Absorption of diazepam and lorazepam following intranasal administration,"" International Journal of Pharmaceutics vol. 54, Issue 2, Sep. 1, 1989, pp. 171-174.;;Li et al., ""Development of an ethyl laurate-based microemulsion for rapid-onset intranasal delivery of diazepam,"" Int. J. Pharm. Apr 26, 2002;237(1-2):77-85.;;Guo et al., ""The effect of formulation variables and breathing patterns on the site of nasal deposition in an anatomically correct model,"" Pharmaceutical Research, vol. 22, No. 11, pp. 1871-1878.;;Lindhardt et al., ""Intranasal bioavailability of diazepam in sheep correlated to rabbit and man,"" Int. J. Pharm. 231:67-72 (2002).;;International Search Report and Written Opinion Corresponding to International Application No. PCT/US2012/031453; Dated Sep. 26, 2012.",ACTIVE
119,US,A1,US 2013/0046001 A1,033-176-141-122-359,2013-02-21,2013,US 201113695809 A,2011-05-03,KR 20100041436 A;;KR 2011003318 W,2010-05-03,PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURON OR NEURODEGENERATION,Provided is a pharmaceutical composition for inhibiting apoptosis of neurons or neurodegeneration. The pharmaceutical composition effectively prevents or treats diseases related to apoptosis of neurons or neurodegeneration.,SK BIOPHARMACEUTICALS CO LTD;;PARK CHEOL HYOUNG;;MIN HYE KYUNG;;PARK IN SUK;;LIM MI JUNG;;LEE JI WON;;CHUNG JIN YONG;;YOON YEO JIN;;PARK JOO YOUNG,PARK CHEOL HYOUNG;;MIN HYE KYUNG;;PARK IN SUK;;LIM MI JUNG;;LEE JI WON;;CHUNG JIN YONG;;YOON YEO JIN;;PARK JOO YOUNG,SK BIOPHARMACEUTICALS CO. LTD (2012-10-23),https://lens.org/033-176-141-122-359,Patent Application,yes,2,5,29,083-039-858-242-705;;112-978-299-565-262;;167-510-528-540-117;;030-396-572-256-67X;;005-606-654-973-855;;044-160-932-409-906;;179-167-967-243-034;;105-588-674-891-784;;083-927-741-654-410;;181-093-802-766-315;;115-475-254-140-257;;033-176-141-122-359;;001-137-200-928-772;;100-201-254-946-24X;;128-594-256-312-773;;034-852-710-631-338;;173-997-219-171-383;;030-774-362-450-39X;;077-722-933-911-999;;013-924-370-730-345;;191-530-673-964-029;;163-910-907-096-308;;013-649-920-355-110;;135-196-887-792-996;;054-286-540-912-656;;103-278-855-304-829;;056-912-353-242-800;;179-903-799-833-766;;137-947-736-509-345,CA;;RU;;KR;;JP;;BR;;WO;;MX;;CN;;US;;ES;;EP;;AU,29,083-039-858-242-705;;112-978-299-565-262;;167-510-528-540-117;;030-396-572-256-67X;;005-606-654-973-855;;044-160-932-409-906;;179-167-967-243-034;;105-588-674-891-784;;083-927-741-654-410;;181-093-802-766-315;;115-475-254-140-257;;033-176-141-122-359;;001-137-200-928-772;;100-201-254-946-24X;;128-594-256-312-773;;034-852-710-631-338;;173-997-219-171-383;;030-774-362-450-39X;;077-722-933-911-999;;013-924-370-730-345;;191-530-673-964-029;;163-910-907-096-308;;013-649-920-355-110;;135-196-887-792-996;;054-286-540-912-656;;103-278-855-304-829;;056-912-353-242-800;;179-903-799-833-766;;137-947-736-509-345,CA;;RU;;KR;;JP;;BR;;WO;;MX;;CN;;US;;ES;;EP;;AU,0,C07D261/08;;A61K31/4196;;A61K31/4245;;A61K31/433;;A61P9/10;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P27/02;;A61P31/00;;A61P43/00;;A61K31/4196;;A61K31/4245;;A61K31/433;;A61K2121/00;;A61K31/4196;;A61K31/42;;A61K31/4245;;A61K31/433;;A61P25/00;;A61P25/28;;C07D261/08;;A61K31/4196;;A61K31/4245;;A61K31/433,A61K31/42;;A61P9/10;;A61P25/00;;A61P25/08;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28,514/378,2,0,,,STN Printout WO2007150025A2 from 2007;;STN Printout WO2010039947A1 from 2010,ACTIVE
120,WO,A2,WO 2011/139079 A2,083-039-858-242-705,2011-11-10,2011,KR 2011003318 W,2011-05-03,KR 20100041436 A,2010-05-03,PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURON OR NEURODEGENERATION,Provided is a pharmaceutical composition for inhibiting apoptosis of neurons or neurodegeneration. The pharmaceutical composition effectively prevents or treats diseases related to apoptosis of neurons or neurodegeneration.,SK BIOPHARMACEUTICALS CO LTD;;PARK CHEOL HYOUNG;;MIN HYE KYUNG;;PARK IN SUK;;LIM MI JUNG;;LEE JI WON;;CHUNG JIN YONG;;YOON YEO JIN;;PARK JOO YOUNG,PARK CHEOL HYOUNG;;MIN HYE KYUNG;;PARK IN SUK;;LIM MI JUNG;;LEE JI WON;;CHUNG JIN YONG;;YOON YEO JIN;;PARK JOO YOUNG,,https://lens.org/083-039-858-242-705,Patent Application,yes,0,4,29,083-039-858-242-705;;112-978-299-565-262;;167-510-528-540-117;;030-396-572-256-67X;;005-606-654-973-855;;044-160-932-409-906;;179-167-967-243-034;;105-588-674-891-784;;083-927-741-654-410;;181-093-802-766-315;;115-475-254-140-257;;033-176-141-122-359;;001-137-200-928-772;;100-201-254-946-24X;;128-594-256-312-773;;034-852-710-631-338;;173-997-219-171-383;;030-774-362-450-39X;;077-722-933-911-999;;013-924-370-730-345;;191-530-673-964-029;;163-910-907-096-308;;013-649-920-355-110;;135-196-887-792-996;;054-286-540-912-656;;103-278-855-304-829;;056-912-353-242-800;;179-903-799-833-766;;137-947-736-509-345,CA;;RU;;KR;;JP;;BR;;WO;;MX;;CN;;US;;ES;;EP;;AU,29,083-039-858-242-705;;112-978-299-565-262;;167-510-528-540-117;;030-396-572-256-67X;;005-606-654-973-855;;044-160-932-409-906;;179-167-967-243-034;;105-588-674-891-784;;083-927-741-654-410;;181-093-802-766-315;;115-475-254-140-257;;033-176-141-122-359;;001-137-200-928-772;;100-201-254-946-24X;;128-594-256-312-773;;034-852-710-631-338;;173-997-219-171-383;;030-774-362-450-39X;;077-722-933-911-999;;013-924-370-730-345;;191-530-673-964-029;;163-910-907-096-308;;013-649-920-355-110;;135-196-887-792-996;;054-286-540-912-656;;103-278-855-304-829;;056-912-353-242-800;;179-903-799-833-766;;137-947-736-509-345,CA;;RU;;KR;;JP;;BR;;WO;;MX;;CN;;US;;ES;;EP;;AU,0,C07D261/08;;A61K31/4196;;A61K31/4245;;A61K31/433;;A61P9/10;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P27/02;;A61P31/00;;A61P43/00;;A61K31/4196;;A61K31/4245;;A61K31/433;;A61K2121/00;;A61K31/4196;;A61K31/42;;A61K31/4245;;A61K31/433;;A61P25/00;;A61P25/28;;C07D261/08;;A61K31/4196;;A61K31/4245;;A61K31/433,A61K31/4196;;A61K31/4245;;A61K31/433;;A61P25/00,,2,0,,,"""Remington's Pharmaceutical Sciences"", 1995;;See references of EP 2566475A4",PENDING
121,US,B2,US 8841335 B2,179-167-967-243-034,2014-09-23,2014,US 201113695809 A,2011-05-03,KR 20100041436 A;;KR 2011003318 W,2010-05-03,Pharmaceutical composition for inhibiting apoptosis of neuron or neurodegeneration,Provided is a pharmaceutical composition for inhibiting apoptosis of neurons or neurodegeneration. The pharmaceutical composition effectively prevents or treats diseases related to apoptosis of neurons or neurodegeneration.,PARK CHEOL HYOUNG;;MIN HYE KYUNG;;PARK IN SUK;;LIM MI JUNG;;LEE JI WON;;CHUNG JIN YONG;;YOON YEO JIN;;PARK JOO YOUNG;;SK BIOPHARMACEUTICALS CO LTD,PARK CHEOL HYOUNG;;MIN HYE KYUNG;;PARK IN SUK;;LIM MI JUNG;;LEE JI WON;;CHUNG JIN YONG;;YOON YEO JIN;;PARK JOO YOUNG,SK BIOPHARMACEUTICALS CO. LTD (2012-10-23),https://lens.org/179-167-967-243-034,Granted Patent,yes,16,0,29,083-039-858-242-705;;112-978-299-565-262;;167-510-528-540-117;;030-396-572-256-67X;;005-606-654-973-855;;044-160-932-409-906;;179-167-967-243-034;;105-588-674-891-784;;083-927-741-654-410;;181-093-802-766-315;;115-475-254-140-257;;033-176-141-122-359;;001-137-200-928-772;;100-201-254-946-24X;;128-594-256-312-773;;034-852-710-631-338;;173-997-219-171-383;;030-774-362-450-39X;;077-722-933-911-999;;013-924-370-730-345;;191-530-673-964-029;;163-910-907-096-308;;013-649-920-355-110;;135-196-887-792-996;;054-286-540-912-656;;103-278-855-304-829;;056-912-353-242-800;;179-903-799-833-766;;137-947-736-509-345,CA;;RU;;KR;;JP;;BR;;WO;;MX;;CN;;US;;ES;;EP;;AU,29,083-039-858-242-705;;112-978-299-565-262;;167-510-528-540-117;;030-396-572-256-67X;;005-606-654-973-855;;044-160-932-409-906;;179-167-967-243-034;;105-588-674-891-784;;083-927-741-654-410;;181-093-802-766-315;;115-475-254-140-257;;033-176-141-122-359;;001-137-200-928-772;;100-201-254-946-24X;;128-594-256-312-773;;034-852-710-631-338;;173-997-219-171-383;;030-774-362-450-39X;;077-722-933-911-999;;013-924-370-730-345;;191-530-673-964-029;;163-910-907-096-308;;013-649-920-355-110;;135-196-887-792-996;;054-286-540-912-656;;103-278-855-304-829;;056-912-353-242-800;;179-903-799-833-766;;137-947-736-509-345,CA;;RU;;KR;;JP;;BR;;WO;;MX;;CN;;US;;ES;;EP;;AU,0,C07D261/08;;A61K31/4196;;A61K31/4245;;A61K31/433;;A61P9/10;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P27/02;;A61P31/00;;A61P43/00;;A61K31/4196;;A61K31/4245;;A61K31/433;;A61K2121/00;;A61K31/4196;;A61K31/42;;A61K31/4245;;A61K31/433;;A61P25/00;;A61P25/28;;C07D261/08;;A61K31/4196;;A61K31/4245;;A61K31/433,A61K31/42;;A61K31/41;;A61K31/4196;;A61K31/4245;;A61K31/433,514/378;;514/360;;514/361;;514/364;;514/362;;514/363,45,40,026-023-618-909-247;;003-442-169-604-000;;062-784-033-080-439;;082-752-597-106-197;;000-592-134-863-138;;044-031-150-189-426;;079-487-506-039-265;;007-184-165-866-448;;005-962-605-901-91X;;023-664-658-989-49X;;053-881-431-566-061;;031-924-029-481-368;;002-642-713-148-310;;100-925-308-977-978;;018-052-409-408-975;;095-570-487-792-864;;125-442-892-352-782;;028-585-517-362-171;;039-899-380-419-069;;001-984-489-498-626;;019-425-317-169-116;;122-079-859-330-191;;087-509-537-522-158;;072-445-148-605-027;;097-453-736-173-440;;117-411-959-670-127;;019-121-815-747-473;;009-501-675-949-701;;004-366-945-590-823;;074-555-246-495-925;;014-531-661-219-036;;011-004-785-493-826;;022-437-410-146-855;;016-068-174-873-998;;025-601-771-249-260;;062-139-337-054-262;;023-338-367-652-578;;065-356-303-160-104;;019-755-188-269-314;;077-840-643-698-250,10.1007/s11094-006-0087-6;;11588183;;pmc6763865;;10.1523/jneurosci.21-20-08108.2001;;12031278;;10.1016/s0361-9230(01)00775-4;;10.1006/exnr.2002.8033;;12504889;;7689641;;10.1111/j.1471-4159.1993.tb03633.x;;16787833;;10.1007/bf03033786;;10.1002/ana.20624;;16178023;;10.1016/j.jns.2009.02.008;;10.1016/0361-9230(91)90242-c;;1826461;;10.1111/j.1582-4934.2003.tb00225.x;;pmc6741335;;14594549;;14964686;;10.1080/14734220310004289;;10.1016/s0165-0173(98)00046-0;;9974149;;pmc6762498;;10.1523/jneurosci.21-10-j0001.2001;;11319241;;10.1056/nejmra022366;;12672865;;9013391;;10.1007/bf01291788;;pmc4514105;;10.1111/j.1582-4934.2008.00402.x;;18624755;;10.1101/gad.13.15.1899;;10444588;;12729576;;10.1016/s0006-291x(03)00614-4;;9157311;;10.1016/0306-4522(95)00571-4;;17468299;;10.1124/jpet.106.118034;;pmc6786015;;9952406;;10.1523/jneurosci.19-04-01284.1999;;12200198;;10.1016/s0892-0362(02)00221-0;;10.1038/nrn1886;;16552414;;pmc3710114;;11253364;;10.1038/35040009;;9875735;;10.1097/00001756-199812010-00034;;19198615;;10.1038/nm.1912;;pmc2838375;;9581757;;10.1016/s0896-6273(00)81004-1;;10.1016/0306-4522(95)00066-r;;7675192;;9827592;;9613716;;10.1002/mds.870131306;;12671216;;10.1016/0306-4522(94)90605-x;;7516500;;10.1007/s10863-005-6590-8;;16167175;;pmc2570496;;9409726;;10.1016/s0006-8993(97)00941-4;;10.1016/s0892-0362(02)00222-2;;12200192;;10.1111/j.1471-4159.1993.tb13610.x;;8376979;;10.2165/00023210-200519090-00001;;16142989;;10.1038/nrn1883;;16552415;;10.1016/s0896-6273(03)00601-9;;14556717;;10683571;;10.1016/s0306-4522(99)00567-9;;17056129;;10.1016/j.tips.2006.10.004,"STN Printout WO2007150025A2 from 2007.;;STN Printout WO2010039947A1 from 2010.;;Velikorodov, A.V., et al., ""Synthesis and Cardiovascular Activity of Some Azaheterocycles with Carbamate Groups"", Pharmaceutical Chemistry Journal, vol. 40, No. 4, 2006, pp. 182-185.;;The extended European Search Report issued in EP 11777560.1, dated Feb. 13, 2014.;;Akerud et al., ""Neuroprotection through Delivery of Glial Cell Line-Derived Neurotrophic Factor by Neural Stem Cells in a Mouse Model of Parkinson's Disease"" The Journal of Neuroscience, 21:8108-8118(2001).;;Alberch et al., ""Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington's disease"" Brain Research Bulletin, 57:817-822(2002).;;Armentero et al., ""Dopamine Receptor Agonists Mediate Neuroprotection in Malonate-Induced Striatal Lesion in the Rat"" Experimental Neurology, 178:301-305 (2002).;;Beal et al., ""Age-Dependent Striatal Excitotoxic Lesions Produced by the Endogenous Mitochondrial Inhibitor Malonate"" J. Neurochem., 61:1147-1150(1993).;;Beal et al., ""Neuroprotective and Neurorestorative Strategies for Neuronal Injury"" Neurotoxicity Research, 2:71-84(2000).;;Beal, ""Mitochondria Take Center Stage in Aging and Neurodegeneration"" Ann. Neurol., 58:495-505(2005).;;Beal, ""Mitochondrial dysfunction in neurodegenerative diseases and stroke: Neuroprotective strategies"" Journal of Neurological Sciences, 283:240-320(2009).;;Behl et al., ""Serial Review: Causes and Consequences of Oxidative Stress in Alzheimer's Disease"" Free radical Biology & Medicine, 33(2):182-191(2002).;;Berger et al., ""Retrograde Degeneration of Nigrostriatal Neurons Induced by Intrastriatal 6-Hydroxydopamine Injection in Rats"" Brain Res., 26:301-307(1991).;;Burlacu, ""Regulation of apoptosis by Bc1-2 family proteins"" J. Cell Mol. Med., 7:249-257(2003).;;Canu et al., ""In vitro cultured neurons for molecular studies correlating apoptosis with events related to Alzheimer disease"" Cerebellum, 2:270-278(2003).;;Cassarino et al., ""An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration"" Brain Res Rev., 29(1):1-25(1999).;;Chen et al., ""Neuroprotection by Caffeine and A2A Adenosine Receptor Inactivation in a Model of Parkinson's Disease"" J. Neurosci.,21:RC143 (2001).;;Friedlander, ""Apoptosis and Caspases in Neurodegenerative Diseases"" The New England Journal of Medicine, 348(14):1365-1375(2003).;;Gerlach et al., ""Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man"" J. Neural Transm.,103:987-1041(1996).;;Gorman, ""Neuronal cell death in neurodegenerative diseases: recurring themes around protein handling"" Journal of Cellular and Molecular Medicine,12:2263-2280(2008).;;Gross et al., ""BCL-2 family members and the mitochondria in apoptosis"" Genes and Development, 13:1899-1911(1999).;;Kroemer, ""Mitochondrial control of apoptosis: an introduction"" Biochem Biophys Res Commun., 304(3):433-435(2003).;;Lee et al., ""Dopaminergic Neuronal Degeneration and Motor Impairments Following Axon Terminal Lesion by Intrastriatal 6-Hydroxydopamine in the Rat"" Neurosci.,72:641-653(1996).;;Lin et al., ""Neuroprotection by Small Molecule Activators of the Nerve Growth Factor Receptor"" The Journal of Pharmacology and Experimental Therapeutics, 322:59-69(2007).;;Lotharius et al., ""Distinct Mechanisms Underlie Neurotoxin-Mediated Cell Death in Cultured Dopaminergic Neurons"" J. Neurosci., 19:1284-1293(1999).;;Maruyama et al., ""Neuroprotection by propargylamines in Parkinson's disease Suppression of apoptosis and induction of prosurvival genes"" Neurotoxicology and Teratology,24:675-682(2002).;;Mattson et al., ""Ageing and neuronal vulnerability"" Nat. Rev. Neurosci., 7:278-294(2006).;;Mattson, ""Apoptosis in Neurodegenerative Disorders"" Nature Reviews Molecular Cell Biology,1:120-130(2000).;;Monopoli et al., ""Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats"" Neuro Report,9:3955-3959(1998).;;Nagahara et al., ""Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease"" Nature medicine, 15:331-337(2009).;;Pettmann et al., ""Neuronal Cell Death"" Neuron, 20:633-647(1998).;;Przedborski et al., ""Dose-Dependent Lesions of the Dopaminergic Nigrostriatal Pathway Induced by Intrastriatal Injection of 6-Hydroxydopamine"" Neurosci.,67:631-647(1995).;;Przedborski et al., ""Mechanisms of MPTP Toxicity"" Mov. Disord.,13:35-38(1998).;;Przedborski et al., ""The parkinsonian toxin MPTP: action and mechanism"" Restor. Neurol. Neurosci.,16:135-142(2000).;;Sauer et al., ""Progressive Degeneration of Nigrostriatal Dopamine Neurons Following Intrastriatal Terminal Lesions With 6-Hydroxydopamine: A Combined Retrograde Tracing and Immunocytochemical Study in the Rat"" Neurosci.,59:401-415(1994).;;Soane et al., ""Inhibition of Mitochondrial Neural Cell Death Pathways by Protein Transduction of Bc1-2 Family Proteins"" Journal of Bioenergetics and Biomembranes, 37:179-190(2005).;;Sonsalla et al , ""Inhibition of striatal energy metabolism produces cell loss in the ipsilateral substantia nigra"" Brain Res., 773:223-226(1997).;;Speciale, ""MPTP Insights into parkinsonian neurodegeneration"" Neurotoxicol. Teratol. 24:607-620(2002).;;Tipton et al., ""Advances in Our Understanding of the Mechanisms of the Neurotoxicity of MPTP and Related Compounds"" J.Neurochem.,61:1191-1206(1993).;;Wu et al., ""Treatment of Parkinson's Disease What's on the Horizon?"" CNS drugs, 19:723(2005).;;Youdim et al., ""The therapeutic potential of monoamine oxidase inhibitors"" Nat. Rev. Neurosci., 7:295-309(2006).;;Yuan et al., ""Diversity in the Mechanisms of Neuronal Cell Death"" Neuron, 40:401-413(2003).;;Zeevalk et al., ""Oxidative Stress During Energy Impairment in Mesencephalic Cultures is Not a Downstream Consequence of a Secondary Excitotoxicity"" Neuroscience, 96:309-316(2000).;;Zhang et al., ""Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease"" TRENDS in Pharmacological Sciences, 27:619-625(2006).;;PCT/KR2011/003318 International Search Report dated Jan. 10, 2012 (3 pages).",ACTIVE
122,US,B2,US 8501436 B2,046-065-801-072-546,2013-08-06,2013,US 57870909 A,2009-10-14,KR 20090055576 A,2009-06-22,Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester,"Disclosed is a method for the preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester, comprising the asymmetric reduction of arylketone and the carbamation of alcohol.",LIM SANG CHUL;;UHM MOO YONG;;CHO NAHM RYUNE;;LEE DAE WON;;LEE JU YOUNG;;KIM HUI HO;;LEE DONG HO;;LEE HYUN SEOK;;LEE SE IL;;SK BIOPHARMACEUTICALS CO LTD,LIM SANG CHUL;;UHM MOO YONG;;CHO NAHM RYUNE;;LEE DAE WON;;LEE JU YOUNG;;KIM HUI HO;;LEE DONG HO;;LEE HYUN SEOK;;LEE SE IL,SK HOLDINGS CO. LTD (2010-12-01);;SK BIOPHARMACEUTICALS CO. LTD (2011-07-01),https://lens.org/046-065-801-072-546,Granted Patent,yes,83,4,28,007-555-136-346-451;;158-653-493-805-69X;;168-903-366-391-350;;060-834-915-468-988;;054-191-736-617-817;;047-587-052-154-169;;146-543-770-179-090;;187-264-533-757-139;;090-700-469-438-627;;195-978-189-312-759;;133-378-285-197-342;;081-782-803-753-24X;;132-439-277-743-024;;057-725-855-822-461;;012-511-230-387-803;;072-608-951-910-067;;099-311-434-759-20X;;046-065-801-072-546;;184-576-115-196-504;;069-876-936-965-214;;084-572-481-959-985;;139-626-924-540-871;;123-980-927-505-01X;;162-862-772-618-366;;192-577-110-026-922;;084-186-970-132-131;;140-397-656-885-695;;001-508-602-639-922,RU;;CA;;JP;;KR;;ZA;;CN;;PL;;CL;;MY;;ES;;AU;;BR;;MX;;WO;;US;;EP;;IL,28,007-555-136-346-451;;158-653-493-805-69X;;168-903-366-391-350;;060-834-915-468-988;;054-191-736-617-817;;047-587-052-154-169;;146-543-770-179-090;;187-264-533-757-139;;090-700-469-438-627;;195-978-189-312-759;;133-378-285-197-342;;081-782-803-753-24X;;132-439-277-743-024;;057-725-855-822-461;;012-511-230-387-803;;072-608-951-910-067;;099-311-434-759-20X;;046-065-801-072-546;;184-576-115-196-504;;069-876-936-965-214;;084-572-481-959-985;;139-626-924-540-871;;123-980-927-505-01X;;162-862-772-618-366;;192-577-110-026-922;;084-186-970-132-131;;140-397-656-885-695;;001-508-602-639-922,RU;;CA;;JP;;KR;;ZA;;CN;;PL;;CL;;MY;;ES;;AU;;BR;;MX;;WO;;US;;EP;;IL,0,C07D257/04;;C12P17/10;;C07D257/06;;C07D413/12;;C12P17/12;;C07D257/04;;C12P17/10,C12P17/10;;C12P1/00,435/41;;435/25;;435/121;;435/135;;435/155,7,3,010-680-137-385-664;;005-903-507-321-057;;001-580-232-559-357,10.1016/j.tet.2007.12.020;;10.1016/s0957-4166(01)00020-9;;19251421;;10.1016/j.bmc.2009.02.004,"The European Search Opinion mailed Oct. 22, 2012 from the European Patent Office in the corresponding European Patent Application No. 09846577.6.;;D1: Hobub et al., ""Catalytic enantioselective borane reduction of arylketones with pinene-derived amino alcohols,"" Tetrahedron, vol. 64, Issue 8, Feb. 18, 2008, pp. 1635-1640.;;D2: Yadav et al., ""A facile synthesis of (R)-(-)-2-azido-1-arylethanols from 2-azido-1-arylketones using baker's yeast,"" Tetrahedron: Asymmetry (Feb. 2001), 12 (1), p. 63-67.;;The International Search Report and Written Opinion mailed on Apr. 28, 2010 in the corresponding PCT Application No. PCT/KR2009/005906.;;The International Search Report and Written Opinion mailed on Jul. 11, 2011 in the related PCT Application No. PCT/KR2010/007069.;;Rostom et al., ""Azole antimicrobial pharmacophore-based tetrazoles: Synthesis and biological evaluation as potential antimicrobial and anticonvulsant agents,"" Bioorganic & Medicinal Chemistry 17 (2009) 2410-2422.;;Office Actions mailed on Apr. 19, 2012, May 18, 2012 and Jan. 3, 2012, in related U.S. Appl. No. 12/904,267.",ACTIVE
123,US,B2,US 8952165 B2,107-439-176-766-714,2015-02-10,2015,US 201213980821 A,2012-01-30,KR 20110008962 A;;KR 2012000652 W,2011-01-28,Pharmaceutical composition comprising pyridone derivatives,"A pyridone derivative compound and a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof, and a preventive or therapeutic pharmaceutical composition for cognitive disorders that includes the pyridone derivative compound or a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof.",MAENG CHEOL YOUNG;;JANG YOUNG KOO;;CHA SU BONG;;SHIN HYE WON;;JOUNG CHAN MI;;YI EUN JUNG;;SK BIOPHARMACEUTICALS CO LTD,MAENG CHEOL YOUNG;;JANG YOUNG KOO;;CHA SU BONG;;SHIN HYE WON;;JOUNG CHAN MI;;YI EUN JUNG,SK BIOPHARMACEUTICAL CO. LTD (2013-06-28),https://lens.org/107-439-176-766-714,Granted Patent,yes,6,4,38,160-480-516-887-544;;183-766-785-119-795;;160-096-087-153-799;;099-303-326-630-265;;051-707-988-629-545;;149-102-626-714-234;;101-580-233-424-02X;;044-324-660-024-436;;102-040-318-042-150;;007-323-109-150-557;;137-515-039-683-971;;189-311-118-248-822;;062-832-256-786-926;;050-248-377-994-31X;;088-227-008-969-940;;157-104-881-167-142;;152-586-696-716-747;;035-204-582-504-764;;161-532-728-723-347;;036-183-174-524-762;;107-439-176-766-714;;180-020-553-513-144;;048-244-289-031-230;;055-337-448-583-566;;078-468-980-971-420;;118-444-082-208-16X;;186-169-532-756-87X;;010-744-547-429-455;;018-173-814-634-256;;118-637-540-893-40X;;062-326-391-883-33X;;002-242-574-877-309;;122-108-042-351-860;;175-203-797-197-070;;043-935-753-398-011;;161-082-200-130-505;;143-337-255-827-237;;111-560-504-700-722,CA;;RU;;KR;;JP;;ZA;;CN;;PL;;CL;;ES;;AU;;BR;;MX;;WO;;US;;HK;;EP,38,160-480-516-887-544;;183-766-785-119-795;;160-096-087-153-799;;099-303-326-630-265;;051-707-988-629-545;;149-102-626-714-234;;101-580-233-424-02X;;044-324-660-024-436;;102-040-318-042-150;;007-323-109-150-557;;137-515-039-683-971;;189-311-118-248-822;;062-832-256-786-926;;050-248-377-994-31X;;088-227-008-969-940;;157-104-881-167-142;;152-586-696-716-747;;035-204-582-504-764;;161-532-728-723-347;;036-183-174-524-762;;107-439-176-766-714;;180-020-553-513-144;;048-244-289-031-230;;055-337-448-583-566;;078-468-980-971-420;;118-444-082-208-16X;;186-169-532-756-87X;;010-744-547-429-455;;018-173-814-634-256;;118-637-540-893-40X;;062-326-391-883-33X;;002-242-574-877-309;;122-108-042-351-860;;175-203-797-197-070;;043-935-753-398-011;;161-082-200-130-505;;143-337-255-827-237;;111-560-504-700-722,CA;;RU;;KR;;JP;;ZA;;CN;;PL;;CL;;ES;;AU;;BR;;MX;;WO;;US;;HK;;EP,0,A61K31/439;;A61K31/497;;C07D453/02;;A61K31/4709;;A61K31/4725;;A61P25/00;;A61P25/18;;A61P25/28;;A61P43/00;;A61P25/28;;A61K9/0053;;A61K31/439;;C07D453/02;;A61K31/444;;A61K31/4748;;C07D471/08;;C07D453/02;;A61K31/439;;A61K31/497;;A61K9/0053;;A61K31/4709;;A61K31/4725,C07D453/02;;A61K31/4748;;C07D417/14;;C07D471/08,546/135;;514/255.05;;514/305;;546/133;;546/137,24,21,052-959-294-068-381;;071-002-379-380-460;;044-334-094-970-696;;024-690-242-284-803;;047-709-472-163-005;;025-322-934-414-08X;;010-393-402-623-554;;025-667-632-630-530;;023-441-299-629-661;;009-550-404-283-996;;085-851-440-777-139;;013-471-544-328-120;;102-675-895-745-525;;037-132-026-628-144;;025-913-528-999-718;;036-990-235-751-362;;093-193-698-989-815;;001-736-805-176-66X;;117-414-545-065-721;;026-235-388-838-897;;040-108-145-486-132,10.1002/jps.2600541133;;10.1016/j.bmcl.2008.04.070;;18490160;;pmc3116036;;21288470;;10.1016/j.neuropharm.2011.01.044;;10.1093/schbul/sbm031;;pmc2526144;;17470445;;10.1006/nbdi.2000.0317;;11114264;;10.1038/nprot.2006.205;;17406415;;20504913;;10.1124/jpet.110.167213;;10762715;;10.1016/s0169-328x(00)00031-0;;20965497;;10.1016/j.biopsych.2010.08.006;;3228475;;10.1016/0166-4328(88)90157-x;;10.1016/j.pneurobio.2004.09.006;;15649582;;10.1016/j.tips.2006.07.004;;16876883;;9862770;;16220335;;10.1007/s00213-005-0164-7;;19063868;;10.1016/j.brainres.2008.11.053;;10.1152/ajpcell.00422.2002;;12748066;;10.1046/j.1471-4159.1998.70031061.x;;9489726;;10.1016/j.neuropharm.2006.03.012;;16678864;;10.1124/jpet.110.171892;;20959364;;10942028;;10.1016/s0166-4328(00)00196-0;;10.1021/jm010496a;;12190310,"Casola; Journal of Pharmaceutical Sciences, 1965, 54, 1686-1688.;;Acker; Bioorg. Med. Chem. Lett. 18 (2008) 3611-3615.;;Hosford; ""TC-5619: -7 Agonist for Potential Treatment of Negative Symptoms and Cognitive Dysfunction in Schizophrenia"" Presented at Society for Neuroscience Meeting, San Diego, CA, Nov. 6, 2013.;;D'Souza; Neuropharmacology 2012, 62, 1564-1573.;;Cannon; Schizophrenia Bulletin, 2007, 33, 661-664.;;Banerjee, et al. (2000), ""Cellular expression of alpha7 nicotinic acetylcholine receptor protein in the temporal cortex in Alzheimer's and Parkinson's disease- a stereological approach."" Neurobiol. Disease, 7:666-672.;;Bevins, et al. (2006) ""Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study 'recognition memory'."" Nat Protoc., 1(3):1306-1311.;;Bitner, et al. (2010) ""In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease."" J. Pharmacol. Exp. Ther., 334:875-886.;;Burghaus, et al. (2000) ""Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients."" Mol. Brain Res., 76:385-388.;;Castner, et al. (2011) ""Immediate and sustained improvements in working memory after selective stimulation of alpha7 nicotinic acetylcholine receptors."" Biol. Psychiatry, 69:12-18.;;Ennaceur, et al. (1988) ""A new one-trial test for neurobiological studies of memory in rats.1: Behavioral data."" Behavioral Brain Res., 31:47-59.;;Gotti, et al. (2004) ""Neuronal nicotinic receptors: from structure to pathology."" Prog.Neurobiol., 74:363-396.;;Gotti, et al. (2006) ""Brain nicotinic acetylcholine receptors: native subtypes and their relevance."" Trends in Pharmacol., Sci. 27:482-491.;;Jones, et al. (1999) ""Subjective and physiological effects of intravenous nicotine and cocaine in cigarette smoking cocaine abusers1 ."" J. Pharmacol. Exp. Ther., 288:188-197.;;Levin, et al. (2006) ""Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization."" Psychopharmacology, 184:523-539.;;Marrero, et al. (2009) ""Convergence of alpha 7 nicotinic acetylcholine receptor-activated pathways for anti-apoptosis and anti-inflammation: central role for JAK2 activation of STAT3 and NF-kappaB."" Brain Res., 1256:1-7.;;Oshikawa, et al. (2003) ""Nicotinic acetylcholine receptor alpha7 regulates cAMP signal within lipid rafts."" Am. J. Physiol. Cell Physiol., 285:567-574.;;Ospina, et al. (1998) ""Calcium regulation of agonist binding to alpha7-type nicotinic acetylcholine receptors in adult and fetal rat hippocampus."" J. Neurochem., 70:1061-1068.;;Spinelli (2006) ""Enhancing effects of nicotine and impairing effects of scopolamine on distinct aspects of performance in computerized attention and working memory tasks in marmoset monkeys."" Neuropharmacology, 51:238-250.;;Wallace et al. (2011) ""RG3487, a novel nicotinic alpha7 receptor partial agonist, improves cognition and sensorimotor gating in rodents."" J. Pharmacol. Exp. Ther., 336:242-253.;;Woodruff-Pak, et al. (2000) ""Nicotinic modulation in an animal model of a form of associative learning impaired in Alzheimer's disease."" Behav. Brain Res., 113:11-19.;;International Search Report (ISR) in PCT/KR2012/000652, dated Jun. 21, 2012.;;Supplementary European Search Report dated Mar. 3, 2014, issued in European Patent Application No. 12739548.1.;;Wright, et al. (2002) ""Anilinoquinazoline inhibitors of fructose 1,6-bisphosphatase bind at a novel allosteric site: synthesis, in vitro characterization, and X-ray crystallography."" J. Med. Chem., 45:3865-3877.",ACTIVE
124,US,B2,US 8716309 B2,120-028-708-027-029,2014-05-06,2014,US 201213980819 A,2012-01-30,KR 20110008960 A;;KR 2012000648 W,2011-01-28,Pharmaceutical composition comprising pyridone derivatives,"A pyridone derivative compound and a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof, and a preventive or therapeutic pharmaceutical composition for cognitive disorders that includes the pyridone derivative compound or a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof.",MAENG CHEOL YOUNG;;JANG YOUNG KOO;;CHA SU BONG;;SHIN HYE WON;;JOUNG CHAN MI;;CHA HWA RYUN;;YI EUN JUNG;;SK BIOPHARMACEUTICALS CO LTD,MAENG CHEOL YOUNG;;JANG YOUNG KOO;;CHA SU BONG;;SHIN HYE WON;;JOUNG CHAN MI;;CHA HWA RYUN;;YI EUN JUNG,SK BIOPHARMACEUTICAL CO. LTD (2013-06-28),https://lens.org/120-028-708-027-029,Granted Patent,yes,4,8,15,151-644-212-820-203;;175-954-652-772-30X;;014-731-425-631-113;;168-892-686-372-924;;120-575-965-373-734;;049-437-063-991-308;;196-301-954-336-347;;130-530-671-851-052;;059-952-597-067-725;;025-079-555-229-08X;;120-028-708-027-029;;031-686-384-099-672;;102-525-593-616-003;;157-793-931-979-592;;022-413-198-484-518,CA;;JP;;KR;;WO;;CN;;US;;ES;;EP,15,151-644-212-820-203;;175-954-652-772-30X;;014-731-425-631-113;;168-892-686-372-924;;120-575-965-373-734;;049-437-063-991-308;;196-301-954-336-347;;130-530-671-851-052;;059-952-597-067-725;;025-079-555-229-08X;;120-028-708-027-029;;031-686-384-099-672;;102-525-593-616-003;;157-793-931-979-592;;022-413-198-484-518,CA;;JP;;KR;;WO;;CN;;US;;ES;;EP,0,C07D453/02;;A61P25/00;;A61P25/18;;A61P25/28;;A61P29/00;;A61P43/00;;C07D453/04;;A61K31/439;;C07D453/02,A01N43/90;;A61K31/44;;C07D453/02,514/305;;546/133;;546/137,17,16,047-709-472-163-005;;025-322-934-414-08X;;010-393-402-623-554;;025-667-632-630-530;;023-441-299-629-661;;009-550-404-283-996;;085-851-440-777-139;;013-471-544-328-120;;102-675-895-745-525;;037-132-026-628-144;;025-913-528-999-718;;036-990-235-751-362;;093-193-698-989-815;;001-736-805-176-66X;;117-414-545-065-721;;026-235-388-838-897,10.1006/nbdi.2000.0317;;11114264;;10.1038/nprot.2006.205;;17406415;;10.1124/jpet.110.167213;;20504913;;10.1016/s0169-328x(00)00031-0;;10762715;;20965497;;10.1016/j.biopsych.2010.08.006;;3228475;;10.1016/0166-4328(88)90157-x;;10.1016/j.pneurobio.2004.09.006;;15649582;;10.1016/j.tips.2006.07.004;;16876883;;9862770;;10.1007/s00213-005-0164-7;;16220335;;19063868;;10.1016/j.brainres.2008.11.053;;12748066;;10.1152/ajpcell.00422.2002;;10.1046/j.1471-4159.1998.70031061.x;;9489726;;16678864;;10.1016/j.neuropharm.2006.03.012;;10.1124/jpet.110.171892;;20959364;;10.1016/s0166-4328(00)00196-0;;10942028,"Banerjee, et al. (2000), ""Cellular expression of alpha7 nicotinic acetylcholine receptor protein in the temporal cortex in Alzheimer's and Parkinson's disease-a stereological approach."" Neurobiol. Disease, 7:666-672.;;Bevins, et al. (2006) ""Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study 'recognition memory'.""Nat Protoc., 1(3):1306-1311.;;Bitner, et al. (2010) ""In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease."" J. Pharmacol. Exp. Ther., 334:875-886.;;Burghaus, et al. (2000) ""Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients."" Mol. Brain Res., 76:385-388.;;Castner, et al. (2011) ""Immediate and sustained improvements in working memory after selective stimulation of alpha7 nicotinic acetylcholine receptors."" Biol. Psychiatry, 69:12-18.;;Ennaceur, et al. (1988) ""A new one-trial test for neurobiological studies of memory in rats.1: Behavioral data."" Behavioral Brain Res., 31:47-59.;;Gotti, et al. (2004) ""Neuronal nicotinic receptors: from structure to pathology."" Prog.Neurobiol., 74:363-396.;;Gotti, et al. (2006) ""Brain nicotinic acetylcholine receptors: native subtypes and their relevance."" Trends in Pharmacol., Sci. 27:482-491.;;Jones, et al. (1999) ""Subjective and physiological effects of intravenous nicotine and cocaine in cigarette smoking cocaine abusers1."" J. Pharmacol. Exp. Ther., 288:188-197.;;Levin, et al. (2006) ""Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization."" Psychopharmacology, 184:523-539.;;Marrero, et al. (2009) ""Convergence of alpha 7 nicotinic acetylcholine receptor-activated pathways for anti-apoptosis and anti-inflammation: central role for JAK2 activation of STAT3 and NF-kappaB."" Brain Res., 1256:1-7.;;Oshikawa, et al. (2003) ""Nicotinic acetylcholine receptor alpha7 regulates cAMP signal within lipid rafts."" Am. J. Physiol. Cell Physiol., 285:567-574.;;Ospina, et al. (1998) ""Calcium regulation of agonist binding to alpha7-type nicotinic acetylcholine receptors in adult and fetal rat hippocampus."" J. Neurochem., 70:1061-1068.;;Spinelli (2006) ""Enhancing effects of nicotine and impairing effects of scopolamine on distinct aspects of performance in computerized attention and working memory tasks in marmoset monkeys."" Neuropharmacology, 51:238-250.;;Wallace et al. (2011) ""RG3487, a novel nicotinic alpha7 receptor partial agonist, improves cognition and sensorimotor gating in rodents."" J. Pharmacol. Exp. Ther., 336:242-253.;;Woodruff-Pak, et al. (2000) ""Nicotinic modulation in an animal model of a form of associative learning impaired in Alzheimer's disease."" Behav. Brain Res., 113:11-19.;;International Search Report (ISR) in PCT/KR2012/000648, dated Jun. 21, 2012.",ACTIVE
125,US,A1,US 2013/0317059 A1,022-413-198-484-518,2013-11-28,2013,US 201213980819 A,2012-01-30,KR 20110008960 A;;KR 2012000648 W,2011-01-28,PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES,"A pyridone derivative compound and a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof, and a preventive or therapeutic pharmaceutical composition for cognitive disorders that includes the pyridone derivative compound or a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof.",MAENG CHEOL YOUNG;;JANG YOUNG KOO;;CHA SU BONG;;SHIN HYE WON;;JOUNG CHAN MI;;CHA HWA RYUN;;YI EUN JUNG;;SK BIOPHARMACEUTICALS CO LTD,MAENG CHEOL YOUNG;;JANG YOUNG KOO;;CHA SU BONG;;SHIN HYE WON;;JOUNG CHAN MI;;CHA HWA RYUN;;YI EUN JUNG,SK BIOPHARMACEUTICAL CO. LTD (2013-06-28),https://lens.org/022-413-198-484-518,Patent Application,yes,1,5,15,151-644-212-820-203;;175-954-652-772-30X;;014-731-425-631-113;;168-892-686-372-924;;120-575-965-373-734;;049-437-063-991-308;;196-301-954-336-347;;130-530-671-851-052;;059-952-597-067-725;;025-079-555-229-08X;;120-028-708-027-029;;031-686-384-099-672;;102-525-593-616-003;;157-793-931-979-592;;022-413-198-484-518,CA;;JP;;KR;;WO;;CN;;US;;ES;;EP,15,151-644-212-820-203;;175-954-652-772-30X;;014-731-425-631-113;;168-892-686-372-924;;120-575-965-373-734;;049-437-063-991-308;;196-301-954-336-347;;130-530-671-851-052;;059-952-597-067-725;;025-079-555-229-08X;;120-028-708-027-029;;031-686-384-099-672;;102-525-593-616-003;;157-793-931-979-592;;022-413-198-484-518,CA;;JP;;KR;;WO;;CN;;US;;ES;;EP,0,C07D453/02;;A61P25/00;;A61P25/18;;A61P25/28;;A61P29/00;;A61P43/00;;C07D453/04;;A61K31/439;;C07D453/02,C07D453/02,514/305;;546/133;;546/137,0,0,,,,ACTIVE
